hydroxyurea has been researched along with HbS Disease in 1272 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " SPHERE will prospectively determine the benefits of hydroxyurea at MTD for primary stroke prevention, anticipating expanded access to hydroxyurea treatment across Tanzania." | 9.69 | Stroke Prevention with Hydroxyurea Enabled through Research and Education: A Phase 2 Primary Stroke Prevention Trial in Sub-Saharan Africa. ( Adams, J; Ambrose, EE; Balyorugulu, G; Charles, M; Howard, TA; Komba, P; Lane, A; Latham, TS; Makubi, AN; McElhinney, KE; Nakafeero, M; O'Hara, SM; Odame, J; Shabani, I; Smart, LR; Songoro, P; Stuber, SE; Ware, RE, 2023) |
| "We tested the hypothesis that fixed oral moderate-dose hydroxyurea (20 mg/kg per day) for initial treatment of secondary stroke prevention results in an 80% relative risk reduction of stroke or death when compared with fixed oral low-dose hydroxyurea (10 mg/kg per day) in a phase 3 double-blind, parallel-group, randomized controlled trial in children with sickle cell anemia (SCA) living in Nigeria." | 9.69 | Hydroxyurea for secondary stroke prevention in children with sickle cell anemia in Nigeria: a randomized controlled trial. ( Abba, MS; Abdullahi, SU; Aliyu, MH; Ciobanu, M; Covert Greene, BV; DeBaun, MR; Gambo, A; Gambo, S; Hussaini, N; Inuwa, HA; Jordan, LC; Kassim, AA; Musa, B; Rodeghier, M; Sani, S; Sunusi, S, 2023) |
| "For children and adults with HbSC disease, PIVOT will determine the safety of hydroxyurea and identify measurable changes in laboratory and clinical parameters, suitable for future prospective testing in a definitive multi-centre phase III clinical trial." | 9.69 | Prospective identification of variables as outcomes for treatment (PIVOT): study protocol for a randomised, placebo-controlled trial of hydroxyurea for Ghanaian children and adults with haemoglobin SC disease. ( Amissah-Arthur, KN; Dei-Adomakoh, YA; Dzefi-Tettey, K; Lane, AC; Latham, TS; Segbefia, CI; Smart, LR; Stuber, SE; Ware, RE, 2023) |
| " In the low-dose hydroxyurea group, three (3%) of 109 participants had strokes, with an incidence rate of 1·19 per 100 person-years and in the moderate-dose hydroxyurea group five (5%) of 111 had strokes with an incidence rate of 1·92 per 100 person-years (incidence rate ratio 0·62 [95% CI 0·10-3·20], p=0·77)." | 9.51 | Hydroxyurea for primary stroke prevention in children with sickle cell anaemia in Nigeria (SPRING): a double-blind, multicentre, randomised, phase 3 trial. ( Abdullahi, SU; Aliyu, MH; Bello-Manga, H; Borodo, A; DeBaun, MR; Galadanci, A; Galadanci, N; Gambo, S; Ghafuri, DL; Greene, BC; Haliru, L; Hikima, MS; Ibrahim, J; Idris, N; Inuwa, H; Jibir, BW; Jordan, LC; Kassim, A; Kirkham, FJ; Neville, K; Rodeghier, M; Slaughter, JC; Suleiman, A; Tabari, AM; Tijjani, AG; Trevathan, E, 2022) |
| "Hydroxyurea treatment is recommended for children with sickle cell anemia (SCA) living in high-resource malaria-free regions, but its safety and efficacy in malaria-endemic sub-Saharan Africa, where the greatest sickle-cell burden exists, remain unknown." | 9.24 | Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. ( Hodges, JS; Hume, HA; John, CC; Kasirye, P; Lane, A; Latham, TS; Ndugwa, CM; Opoka, RO; Ware, RE, 2017) |
| "We compared daily pain, home analgesic use, and utilization among ambulatory adults in the randomized multicenter study of hydroxyurea in sickle cell anemia (MSH)." | 9.15 | The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. ( Ballas, SK; Bauserman, RL; McCarthy, WF; Smith, WR; Steinberg, MH; Swerdlow, PS; Waclawiw, MA, 2011) |
| "Stroke With Transfusions Changing to Hydroxyurea (SWiTCH) is an NHLBI-sponsored Phase III multicenter randomized controlled clinical trial for children with SCA, stroke, and iron overload (NCT00122980)." | 9.15 | Stroke With Transfusions Changing to Hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. ( Alvarez, O; Helms, RW; Hilliard, L; Iyer, RV; Miller, ST; Mortier, NA; Rogers, ZR; Schultz, WH; Scott, JP; Waclawiw, M; Ware, RE; Yovetich, N, 2011) |
| "In the past two decades, two landmark randomized controlled trials (RCT) have been completed among individuals with sickle cell disease (SCD), the Multi-center Study of Hydroxyurea (MSH) trial and the Stroke Prevention (STOP) trial." | 9.12 | Limitations of clinical trials in sickle cell disease: a case study of the Multi-center Study of Hydroxyurea (MSH) trial and the Stroke Prevention (STOP) trial. ( Debaun, MR; Field, JJ, 2007) |
| "The use of hydroxyurea for the prevention of sickle cell crises in patients with homozygous HbS disease is now well established." | 9.09 | Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece. ( Kalotychou, V; Loukopoulos, D; Loutradi, A; Schina, M; Theodoropoulos, I; Voskaridou, E, 2000) |
| "In a double-blind, randomized clinical trial, we tested the efficacy of hydroxyurea in reducing the frequency of painful crises in adults with a history of three or more such crises per year." | 9.08 | Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. ( Barton, FB; Bonds, DR; Charache, S; Dover, GJ; Eckert, SV; McMahon, RP; Moore, RD; Terrin, ML, 1995) |
| " As an ancillary study carried out during the recently completed Multicenter Study of Hydroxyurea, we examined the effect of hydroxyurea on the body weight, body composition and exercise capacity of adult patients with sickle-cell anaemia." | 9.08 | Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. ( Busby, M; Gulledge, TP; Hackney, AC; Hezier, W; Hoffman, E; Jones, S; Orringer, EP; Strayhorn, D, 1997) |
| "To evaluate the role of hydroxyurea in preventing silent strokes in a systematic review by adhering to the Cochrane guidelines." | 9.01 | The role of hydroxyurea to prevent silent stroke in sickle cell disease: Systematic review and meta-analysis. ( Hasson, C; Mhaskar, R; Rico, J; Veling, L, 2019) |
| "There have been significant changes in clinical guidelines for sickle cell disease (SCD) over the past two decades, including updated indications for hydroxyurea, transfusions, and iron overload management." | 8.31 | Trends in blood transfusion, hydroxyurea use, and iron overload among children with sickle cell disease enrolled in Medicaid, 2004-2019. ( Lai, KW; Lane, PA; Maillis, AN; Snyder, AB; Tang, AY; Zhou, M, 2023) |
| "In patients with sickle cell disease, hydroxyurea decreases the number of pain crises experienced." | 8.12 | Impact of Hydroxyurea Starting Dose on Pain Outcomes in Patients with Sickle Cell Disease. ( Dayer, LE; King, D; Lakkad, M; Montgomery, C; Painter, JT; Wagner, R; Wilson, LA, 2022) |
| "Sickle cell disease (SCD) children are frequent travellers to countries where yellow fever (YF) is endemic, but there are no data regarding the safety and immunogenicity of the vaccine in such children treated with hydroxyurea (HU)." | 8.02 | Tolerance and humoral immune response to the yellow fever vaccine in sickle cell disease children treated with hydroxyurea: a multicentre prospective study. ( Aupiais, C; Benkerrou, M; Brousse, V; Faye, A; Holvoet, L; Ithier, G; Koehl, B; Missud, F; Mornand, P; Niakate, A; Odièvre, MH; Schinckel, N; Sorge, F, 2021) |
| "Intravascular hemolysis (IH) contributes to the development of endothelial dysfunction (ED) in sickle cell anemia (SCA), and the effects of hydroxyurea (HU, the only approved drug that decreases the frequency and severity of vaso-oclussive crises) on IH and ED in SCA remain unclear." | 8.02 | Effect of hydroxyurea therapy on intravascular hemolysis and endothelial dysfunction markers in sickle cell anemia patients. ( Alagbe, AE; Araújo, ADS; Arcanjo, GDS; Batista, THC; Bezerra, MAC; Chenou, F; Costa, FF; De Paula, EV; Domingos, IF; Dos Santos, MNN; Hounkpe, BW; Lucena-Araújo, AR; Santana, RM; Sonati, MF; Tonassé, WV, 2021) |
| "What is the prevalence and incidence of congenital anomalies among babies born to women with sickle cell disease (SCD) and who have been exposed to hydroxyurea (HU) therapy at any time in their pregnancy?The objective of this review is to identify the proportion of babies born with congenital anomalies among babies born to mothers with SCD who have been exposed to HU therapy at any point during pregnancy and to describe the specific types of congenital anomalies encountered." | 7.88 | Prevalence and incidence of congenital anomalies amongst babies born to women with sickle cell disease and exposed to hydroxyurea during pregnancy: a systematic review protocol. ( Gwer, SO; Onyango, KO, 2018) |
| "We undertook a cost effectiveness analysis (CEA) of hydroxyurea (HU) in preventing stroke recurrence and/or death." | 7.81 | Hydroxyurea use in prevention of stroke recurrence in children with sickle cell disease in a developing country: A cost effectiveness analysis. ( Abdulkadri, A; Bortolusso Ali, S; Cunningham-Myrie, C; King, LG; Knight-Madden, J; Reid, M; Waugh, A, 2015) |
| "The prevalence of albuminuria was lower among patients on hydroxyurea (34." | 7.80 | Hydroxyurea is associated with lower prevalence of albuminuria in adults with sickle cell disease. ( Ataga, KI; Derebail, VK; Desai, PC; Laurin, LP; Nachman, PH, 2014) |
| " Hydroxyurea is a standard therapy in patients with history of acute chest syndrome and severe, recurrent, SCD-associated pain episodes, but has not been established for use with other sickle-associated morbidities." | 7.80 | Practice patterns of stroke screening and hydroxyurea use in children with sickle cell disease: a survey of health care providers. ( Jones, GL; Kalpatthi, R; Madden, NA; Woods, G, 2014) |
| " In this short communication, we describe a woman with sickle cell anemia responsive to hydroxyurea (HU) therapy who had primary stroke due to paradoxical embolization caused by a large atrial septal defect." | 7.80 | Primary stroke in a woman with sickle cell anemia responsive to hydroxyurea therapy. ( Ballas, SK; Martinez, U; Savage, M, 2014) |
| " The aim of this study was to characterize TG at the individual level and assess its relationship with age, hemolysis, transcranial Doppler velocity (TCD), and hydroxyurea treatment." | 7.79 | Thrombin generation in children with sickle cell disease: relationship with age, hemolysis, transcranial Doppler velocity, and hydroxyurea treatment. ( Demulder, A; Ferster, A; Lê, PQ; Noubouossie, DC; Rozen, L; Willems, D; Ziereisen, F, 2013) |
| "To compare the outcome after a first clinical stroke, following treatment with and without hydroxyurea (HU)." | 7.79 | Stroke recurrence in Nigerian children with sickle cell disease treated with hydroxyurea. ( Brown, BJ; Lagunju, IA; Sodeinde, OO, 2013) |
| " We previously reported the use of hydroxyurea/phlebotomy as an alternative to transfusions to reduce the risk of secondary stroke and improve management of iron overload in 35 children with SCA." | 7.77 | Long-term results using hydroxyurea/phlebotomy for reducing secondary stroke risk in children with sickle cell anemia and iron overload. ( Greenway, A; Thornburg, CD; Ware, RE, 2011) |
| "In a cohort of children with sickle cell disease (SCD) and vaso-occlusive pain visits served through South Carolina's Medicaid system over a 6-year period (N 5 523), we compared the number of vaso-occlusive pain or acute chest syndrome (ACS)/pneumonia episodes, and outpatient or acute service costs in those treated or not treated with hydroxyurea (HU)." | 7.76 | Cost-effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease. ( Jerrell, JM; Stallworth, JR; Tripathi, A, 2010) |
| "We describe a 28-year-old man treated with hydroxyurea for sickle cell anemia, who was admitted to the University Hospital with an acute myocardial infarction." | 7.73 | Acute myocardial infarction in sickle cell disease: a possible complication of hydroxyurea treatment. ( Costa, FF; de Souza, RA; Fattori, A; Saad, ST, 2005) |
| "For children with SCA and stroke, hydroxyurea effectively prevents secondary stroke and serial phlebotomy leads to complete resolution of transfusional iron overload." | 7.72 | Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy. ( Davis, JS; Mortier, NA; Schultz, WH; Sylvestre, PB; Treem, WR; Ware, RE; Zimmerman, SA, 2004) |
| " A possible alternative, the prophylactic use of hydroxyurea (HU), has not been tried to determine whether it may prevent recurrent stroke." | 7.71 | Hydroxyurea (HU) for prevention of recurrent stroke in sickle cell anemia (SCA). ( de Bisotti, R; Fairbanks, V; Sumoza, A; Sumoza, D, 2002) |
| "Hydroxyurea (HU), an inhibitor of DNA synthesis, has been shown to increase fetal hemoglobin (HbF) levels in patients with sickle cell anemia and in some patients with beta-thalassemia." | 7.68 | Hydroxyurea increases fetal hemoglobin in cultured erythroid cells derived from normal individuals and patients with sickle cell anemia or beta-thalassemia. ( Burke, LP; Fibach, E; Noguchi, CT; Rodgers, GP; Schechter, AN, 1993) |
| "Hydroxyurea is an alternative treatment to decrease stroke risk." | 7.30 | Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial. ( Ambrose, EE; Charles, M; Lane, AC; Latham, TS; Makubi, AN; Smart, LR; Songoro, P; Stuber, SE; Ware, RE, 2023) |
| "Children with sickle cell anemia (SCA) in areas of Africa with endemic malaria transmission are commonly prescribed malaria chemoprevention." | 7.11 | Monthly sulfadoxine/pyrimethamine-amodiaquine or dihydroartemisinin-piperaquine as malaria chemoprevention in young Kenyan children with sickle cell anemia: A randomized controlled trial. ( Clapp, S; Freedman, B; Green, CL; Kirui, JK; Korwa, S; Njuguna, FM; O'Meara, WP; Taylor, SM; Wu, A, 2022) |
| " Combined with animal data, research using these approaches might be able to define safe and effective hydroxyurea dosing regimens for pregnant and lactating women with SCA, when the benefits of continuing hydroxyurea treatment likely outweigh the risks of non-treatment, by avoiding substantial morbidity and even mortality for both mothers and infants." | 7.01 | Hydroxyurea treatment for sickle cell anemia during pregnancy and lactation: Current evidence and knowledge gaps. ( Dallmann, A; Dong, M; Vinks, AA; Ware, RE, 2023) |
| " The Fisher's Exact test was used to compare the frequency of subjects who experienced at least one SCA-related adverse event (AE) or serious adverse event (SAE) in each arm and to compare event rates." | 6.78 | Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. ( Alvarez, O; Aygun, B; Bonner, M; Flanagan, J; Lockhart, A; Miller, ST; Mueller, BU; Owen, W; Schultz, W; Scott, JP; Ware, RE; Yovetich, NA, 2013) |
| "Stroke is a devastating complication of sickle cell anemia (SCA) with high recurrence if untreated." | 6.77 | Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). ( Helms, RW; Ware, RE, 2012) |
| "The Multicenter Study of Hydroxyurea in Sickle Cell Anemia (MSH) was a randomized double-blind placebo-controlled trial to test whether hydroxyurea could reduce the rate of painful crises in adults who had at least 3 painful crises per year." | 6.74 | Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. ( Ballas, SK; Barton, BA; Bellevue, R; DeCastro, L; Guo, N; McCarthy, WF; Waclawiw, MA, 2009) |
| "Hydroxyurea was then introduced at the initial dose of 10 mg/kg, and as the hydroxyurea dosage increased, the number or length of priapism episodes decreased." | 6.71 | Follow-up of sickle cell disease patients with priapism treated by hydroxyurea. ( Arruda, VR; Costa, FF; Gilli, S; Lajolo, C; Lima, CS; Marques Júnior, JF; Saad, ST, 2004) |
| "A patient being treated for sickle cell disease with hydroxyurea (1 g/d) conceived, and drug treatment was discontinued at nine weeks gestational age." | 6.40 | Hydroxyurea use during pregnancy: a case report in sickle cell disease and review of the literature. ( Diav-Citrin, O; Hunnisett, L; Koren, G; Sher, GD, 1999) |
| "Splenomegaly is an unexplained risk factor for malaria infections among children with SCA in Africa." | 5.91 | Hydroxyurea treatment is associated with lower malaria incidence in children with sickle cell anemia in sub-Saharan Africa. ( Aygun, B; Howard, TA; Lane, A; Latham, TS; McElhinney, K; Olupot-Olupot, P; Santos, B; Smart, LR; Stuber, SE; Tomlinson, G; Tshilolo, L; Ware, RE; Williams, TN, 2023) |
| " To investigate the effect of hydroxyurea treatment on smooth muscle relaxation of corpus cavernosum induced by stimulation of the NO-cGMP pathway in SCD transgenic mice and endothelial NO synthase gene-deficient (eNOS-/-) mice, which are used as model of priapism associated with the low bioavailability of endothelial NO." | 5.91 | Hydroxyurea does not reverse functional alterations of the nitric oxide-cGMP pathway associated with priapism phenotype in corpus cavernosum from sickle cell mouse. ( Calmasini, FB; Costa, FF; da Silva Pereira, P; Pereira, DA; Reis, LO; Silva, FH; Silveira, THR, 2023) |
| " SPHERE will prospectively determine the benefits of hydroxyurea at MTD for primary stroke prevention, anticipating expanded access to hydroxyurea treatment across Tanzania." | 5.69 | Stroke Prevention with Hydroxyurea Enabled through Research and Education: A Phase 2 Primary Stroke Prevention Trial in Sub-Saharan Africa. ( Adams, J; Ambrose, EE; Balyorugulu, G; Charles, M; Howard, TA; Komba, P; Lane, A; Latham, TS; Makubi, AN; McElhinney, KE; Nakafeero, M; O'Hara, SM; Odame, J; Shabani, I; Smart, LR; Songoro, P; Stuber, SE; Ware, RE, 2023) |
| "We tested the hypothesis that fixed oral moderate-dose hydroxyurea (20 mg/kg per day) for initial treatment of secondary stroke prevention results in an 80% relative risk reduction of stroke or death when compared with fixed oral low-dose hydroxyurea (10 mg/kg per day) in a phase 3 double-blind, parallel-group, randomized controlled trial in children with sickle cell anemia (SCA) living in Nigeria." | 5.69 | Hydroxyurea for secondary stroke prevention in children with sickle cell anemia in Nigeria: a randomized controlled trial. ( Abba, MS; Abdullahi, SU; Aliyu, MH; Ciobanu, M; Covert Greene, BV; DeBaun, MR; Gambo, A; Gambo, S; Hussaini, N; Inuwa, HA; Jordan, LC; Kassim, AA; Musa, B; Rodeghier, M; Sani, S; Sunusi, S, 2023) |
| " We performed a secondary analysis of participants in the Primary Prevention of Stroke in Children with Sickle Cell Disease in Nigeria trial, a double-blind, parallel-group randomized controlled trial for low-dose or moderate-dose hydroxyurea in children with abnormal transcranial Doppler velocities and a comparison group of participants with nonelevated transcranial Doppler velocities in northern Nigeria." | 5.69 | Underweight children older than 5 years with sickle cell anemia are at risk for early mortality in a low-resource setting. ( Abdullahi, SU; Acra, S; DeBaun, MR; Gambo, S; Klein, LJ; Rodeghier, M; Stallings, VA, 2023) |
| "For children and adults with HbSC disease, PIVOT will determine the safety of hydroxyurea and identify measurable changes in laboratory and clinical parameters, suitable for future prospective testing in a definitive multi-centre phase III clinical trial." | 5.69 | Prospective identification of variables as outcomes for treatment (PIVOT): study protocol for a randomised, placebo-controlled trial of hydroxyurea for Ghanaian children and adults with haemoglobin SC disease. ( Amissah-Arthur, KN; Dei-Adomakoh, YA; Dzefi-Tettey, K; Lane, AC; Latham, TS; Segbefia, CI; Smart, LR; Stuber, SE; Ware, RE, 2023) |
| " In the low-dose hydroxyurea group, three (3%) of 109 participants had strokes, with an incidence rate of 1·19 per 100 person-years and in the moderate-dose hydroxyurea group five (5%) of 111 had strokes with an incidence rate of 1·92 per 100 person-years (incidence rate ratio 0·62 [95% CI 0·10-3·20], p=0·77)." | 5.51 | Hydroxyurea for primary stroke prevention in children with sickle cell anaemia in Nigeria (SPRING): a double-blind, multicentre, randomised, phase 3 trial. ( Abdullahi, SU; Aliyu, MH; Bello-Manga, H; Borodo, A; DeBaun, MR; Galadanci, A; Galadanci, N; Gambo, S; Ghafuri, DL; Greene, BC; Haliru, L; Hikima, MS; Ibrahim, J; Idris, N; Inuwa, H; Jibir, BW; Jordan, LC; Kassim, A; Kirkham, FJ; Neville, K; Rodeghier, M; Slaughter, JC; Suleiman, A; Tabari, AM; Tijjani, AG; Trevathan, E, 2022) |
| "Evidence-based practice for stroke prevention in high-income countries involves screening for abnormal transcranial Doppler (TCD) velocity and initiating regular blood transfusions for at least 1 year, followed by treatment with hydroxyurea." | 5.51 | Translating research to usual care of children with sickle cell disease in Northern Nigeria: lessons learned from the SPRING Trial Team. ( Bahago, GY; Bauman, AA; Bello-Manga, H; DeBaun, MR; Farouk, B; Haliru, L; King, AA; Sani, AM; Suleiman, A; Tabari, AM, 2022) |
| "Hydroxyurea (HU) has been shown to reduce elevated TCD velocities in children with SCD." | 5.51 | Annual stroke incidence in Nigerian children with sickle cell disease and elevated TCD velocities treated with hydroxyurea. ( Asinobi, A; Brown, BJ; Esione, A; Ibeh, J; Lagunju, I; Oyinlade, AO; Sodeinde, OO, 2019) |
| " Growing considerations for this population in the literature include cutaneous reactions to common treatments such as hydroxyurea and clinical management of the intersection between sickle cell disease and conditions like plaque psoriasis." | 5.41 | Cutaneous manifestations of sickle cell disease: an updated review. ( Dick, A; Khachemoune, A; Schwartzman, G, 2023) |
| " Sex, age, foetal haemoglobin (HbF), SCD type, painful vaso-occlusive crisis (PVO), blood parameters, flow-mediated vasodilation (FMV), and hydroxyurea use were all extracted." | 5.41 | Scoping Review of Predisposing Factors Associated with Sensorineural Hearing Loss in Sickle Cell Disease. ( Dagwa, I; Dahilo, E; Ibekwe, P; Ibekwe, T; Nnebe-Agumadu, U; Nnodu, O; Ramma, L; Rogers, C, 2023) |
| "We are unsure if hydroxyurea improves glomerular filtration rate or reduces hyperfiltration in children aged nine to 18 months, but it may improve their ability to concentrate urine and may make little or no difference to the incidence of acute chest syndrome, painful crises, and hospitalisations." | 5.41 | Interventions for chronic kidney disease in people with sickle cell disease. ( Carpenter, A; Dale-Harris, I; Dorée, C; Estcourt, LJ; Roy, NB, 2023) |
| "Hydroxyurea (HU) has been shown to reduce the frequency of vaso-occlusive manifestations in both adults and children with sickle cell disease (SCD), and the induction of hemoglobin F (HbF) is thought to be the underlying mechanism responsible for clinical improvement in some patients." | 5.32 | The effect of hydroxyurea on the coagulation system in sickle cell anemia and beta-thalassemia intermedia patients: a preliminary study. ( Gumruk, F; Gurgey, A; Koc, A, 2003) |
| "The standard care protocol requires that children with acute strokes be treated with hydroxyurea at a fixed dose of 20 mg/kg/day within two months of the stroke." | 5.30 | Stroke Recurrence in Nigerian Children With Sickle Cell Disease: Evidence for a Secondary Stroke Prevention Trial. ( Abdullahi, SU; DeBaun, MR; Galadanci, NA; Jordan, LC; Rodeghier, M, 2019) |
| "Among children and adults with sickle cell anemia, the median number of pain crises over 48 weeks was lower among those who received oral therapy with l-glutamine, administered alone or with hydroxyurea, than among those who received placebo, with or without hydroxyurea." | 5.27 | A Phase 3 Trial of l-Glutamine in Sickle Cell Disease. ( Bellevue, R; Blake, OA; Gordeuk, VR; Guillaume, E; Hsu, LL; Kanter, J; Lanzkron, S; Lasky, JL; Miller, ST; Neumayr, LD; New, TN; Niihara, Y; Osunkwo, I; Panosyan, EH; Razon, RL; Sadanandan, S; Sarnaik, S; Sieger, L; Smith, WR; Stark, CW; Tran, LT; Vichinsky, EP; Viswanathan, K, 2018) |
| " We hypothesized that transfusion would be associated with the development of acute chest syndrome (ACS), lower hemoglobin (Hb) concentration, and lack of hydroxyurea therapy." | 5.24 | Red blood cell transfusions during sickle cell anemia vaso-occlusive crises: a report from the magnesium in crisis (MAGiC) study. ( Brousseau, DC; Cook, LJ; Hulbert, ML; Liem, RI; Panepinto, JA; Scott, JP; Simmons, T, 2017) |
| "Hydroxyurea treatment is recommended for children with sickle cell anemia (SCA) living in high-resource malaria-free regions, but its safety and efficacy in malaria-endemic sub-Saharan Africa, where the greatest sickle-cell burden exists, remain unknown." | 5.24 | Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. ( Hodges, JS; Hume, HA; John, CC; Kasirye, P; Lane, A; Latham, TS; Ndugwa, CM; Opoka, RO; Ware, RE, 2017) |
| " Hydroxyurea (hydroxycarbamide), an oral chemotherapeutic drug, ameliorates some of the clinical problems of SCD, in particular that of pain, by raising foetal haemoglobin (HbF)." | 5.22 | Hydroxyurea (hydroxycarbamide) for sickle cell disease. ( Nevitt, SJ; Rankine-Mullings, AE, 2022) |
| "Transcranial Doppler (TCD) With Transfusions Changing to Hydroxyurea (TWiTCH) trial is a randomized, open-label comparison of hydroxycarbamide (also termed hydroxyurea) versus continued chronic transfusion therapy for primary stroke prevention in patients with sickle cell anaemia (SCA) and abnormal TCD." | 5.22 | Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial. ( Aygun, B; Cohen, AR; Davis, BR; Fuh, B; Imran, H; Luchtman-Jones, L; Pressel, SL; Schultz, WH; Thompson, AA; Ware, RE; Wood, JC, 2016) |
| " We report baseline LIC results from the TWiTCH trial, which compares hydroxyurea with blood transfusion treatment for primary stroke prophylaxis assessed by transcranial Doppler sonography in pediatric SCA patients." | 5.20 | Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial. ( Cohen, AR; Davis, BR; Heeney, MM; Kwiatkowski, JL; Lee, MT; Odame, I; Owen, WC; Pressel, S; Rogers, ZR; Schultz, WH; St Pierre, T; Ware, RE; Wood, JC, 2015) |
| "The Stroke With Transfusions Changing to Hydroxyurea (SWiTCH) trial compared standard (transfusions/chelation) to alternative (hydroxyurea/phlebotomy) treatment to prevent recurrent stroke and manage iron overload in children chronically transfused over 7 years before enrollment." | 5.19 | Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. ( Adams, RJ; Aygun, B; Driscoll, C; Heeney, MM; Helton, KJ; Jackson, SM; Kesler, KL; Krishnamurti, L; Lockhart, A; Miller, ST; Sarnaik, SA; Schultz, WH; Ware, RE, 2014) |
| " Higher Epo levels were seen in patients receiving hydroxyurea (HU), but no correlation with oxygenation, hemolysis, renal function, or inflammation was observed." | 5.19 | Erythropoietin levels in patients with sickle cell disease do not correlate with known inducers of erythropoietin. ( Ballas, SK; Caro, J; McKenzie, SE; Pulte, ED, 2014) |
| "We report a prospective, randomized, Phase II study of deferasirox and deferoxamine (DFO) in sickle cell disease patients with transfusional iron overload, with all patients continuing on deferasirox after 24 weeks, for up to 2 years." | 5.17 | Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea. ( Barrette, S; Files, B; Habr, D; Minniti, CP; Torres, M; Vichinsky, E; Zhang, Y, 2013) |
| "We compared daily pain, home analgesic use, and utilization among ambulatory adults in the randomized multicenter study of hydroxyurea in sickle cell anemia (MSH)." | 5.15 | The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. ( Ballas, SK; Bauserman, RL; McCarthy, WF; Smith, WR; Steinberg, MH; Swerdlow, PS; Waclawiw, MA, 2011) |
| "Stroke With Transfusions Changing to Hydroxyurea (SWiTCH) is an NHLBI-sponsored Phase III multicenter randomized controlled clinical trial for children with SCA, stroke, and iron overload (NCT00122980)." | 5.15 | Stroke With Transfusions Changing to Hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. ( Alvarez, O; Helms, RW; Hilliard, L; Iyer, RV; Miller, ST; Mortier, NA; Rogers, ZR; Schultz, WH; Scott, JP; Waclawiw, M; Ware, RE; Yovetich, N, 2011) |
| " Current treatment for SCD focuses on primary prevention of complications, such as hydroxyurea for prevention of pain and acute chest syndrome, and chronic transfusion therapy for children who are at high risk for strokes." | 5.12 | Neurologic and Cognitive Outcomes in Sickle Cell Disease from Infancy through Adolescence. ( Fields, ME; Hulbert, ML; Mayer, SL, 2021) |
| "The Multicenter Study of Hydroxyurea (HU) in Sickle Cell Anemia (MSH) previously showed that daily oral HU reduces painful sickle cell (SS) crises by 50% in patients with moderate to severe disease." | 5.12 | Hydroxyurea and sickle cell anemia: effect on quality of life. ( Ballas, SK; Barton, BA; Barton, FB; Bonds, DR; Eckman, JR; Koshy, M; Pegelow, CH; Swerdlow, P; Waclawiw, MA, 2006) |
| "In the past two decades, two landmark randomized controlled trials (RCT) have been completed among individuals with sickle cell disease (SCD), the Multi-center Study of Hydroxyurea (MSH) trial and the Stroke Prevention (STOP) trial." | 5.12 | Limitations of clinical trials in sickle cell disease: a case study of the Multi-center Study of Hydroxyurea (MSH) trial and the Stroke Prevention (STOP) trial. ( Debaun, MR; Field, JJ, 2007) |
| "The authors studied the long-term clinical and hematological response to hydroxyurea (HU) therapy in young patients, with either S/beta-thalassemia (beta(thal)) (8 patients) or SS (6 patients)." | 5.11 | Clinical response and adverse events in young patients with sickle cell disease treated with hydroxyurea. ( Kanavakis, E; Kattamis, A; Kattamis, C; Ladis, V; Lagona, E; Metaxotou-Mavrommati, A; Orfanou, I; Psichou, F, 2004) |
| "Hydroxyurea therapy reduces hemolysis and decreases serum bilirubin levels in children and adults with sickle cell anemia (SCA) and may therefore help prevent the development of cholelithiasis in this patient population." | 5.10 | UGT1A promoter polymorphisms influence bilirubin response to hydroxyurea therapy in sickle cell anemia. ( Heeney, MM; Howard, TA; Ware, RE; Zimmerman, SA, 2003) |
| "The use of hydroxyurea for the prevention of sickle cell crises in patients with homozygous HbS disease is now well established." | 5.09 | Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece. ( Kalotychou, V; Loukopoulos, D; Loutradi, A; Schina, M; Theodoropoulos, I; Voskaridou, E, 2000) |
| "In a double-blind, randomized clinical trial, we tested the efficacy of hydroxyurea in reducing the frequency of painful crises in adults with a history of three or more such crises per year." | 5.08 | Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. ( Barton, FB; Bonds, DR; Charache, S; Dover, GJ; Eckert, SV; McMahon, RP; Moore, RD; Terrin, ML, 1995) |
| " As an ancillary study carried out during the recently completed Multicenter Study of Hydroxyurea, we examined the effect of hydroxyurea on the body weight, body composition and exercise capacity of adult patients with sickle-cell anaemia." | 5.08 | Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. ( Busby, M; Gulledge, TP; Hackney, AC; Hezier, W; Hoffman, E; Jones, S; Orringer, EP; Strayhorn, D, 1997) |
| "To evaluate the role of hydroxyurea in preventing silent strokes in a systematic review by adhering to the Cochrane guidelines." | 5.01 | The role of hydroxyurea to prevent silent stroke in sickle cell disease: Systematic review and meta-analysis. ( Hasson, C; Mhaskar, R; Rico, J; Veling, L, 2019) |
| " Contraception is strongly recommended while on hydroxyurea therapy during reproductive years and discontinuing hydroxyurea for family planning and during pregnancy based on teratogenicity in animal studies." | 4.95 | Fertility challenges for women with sickle cell disease. ( Day, ME; DeBaun, MR; Ghafuri, DL; James, A; Sharma, D; Stimpson, SJ, 2017) |
| "An electronic search encompassing MEDLINE, PubMed, Cochrane Library, and Scopus was completed using the following search terms: rheumatoid arthritis; systemic sclerosis; systemic lupus erythematosus; antineutrophil cytoplasmic antibody-associated vasculitis; mixed connective tissue disease; antiphospholipid syndrome; pyoderma gangrenosum; thromboangiitis obliterans; cryoglobulinemia; hydroxyurea; sickle cell; atrophie blanche; livedoid vasculitis; cholesterol emboli; calciphylaxis; antiphospholipid antibodies; prothrombotic; combined with the terms: chronic wound and leg ulcer." | 4.95 | Vasculitic and autoimmune wounds. ( Angra, D; McNish, S; Rahimi, H; Shanmugam, VK, 2017) |
| "Despite Food and Drug Administration (FDA) approval of hydroxyurea to reduce the frequency of vaso-occlusive episodes, sickle cell disease (SCD) has continued to be treated primarily with analgesics for pain relief." | 4.93 | Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease. ( Telen, MJ, 2016) |
| " Vaso-occlusive painful crises are associated with recurrent and long-term use of analgesics/opioids and hydroxyurea (HU) by people living with SCD." | 4.93 | An Expert Review of Pharmacogenomics of Sickle Cell Disease Therapeutics: Not Yet Ready for Global Precision Medicine. ( Dandara, C; Mnika, K; Pule, GD; Wonkam, A, 2016) |
| " The introduction of penicillin prophylaxis, conjugated pneumococcal and Haemophilus influenzae type B vaccines have dramatically decreased the rate of life-threatening infections, while use of hydroxyurea in children has decreased pain and acute chest syndrome events." | 4.90 | The case for and against initiating either hydroxyurea therapy, blood transfusion therapy or hematopoietic stem cell transplant in asymptomatic children with sickle cell disease. ( DeBaun, MR; Kassim, AA, 2014) |
| " The first two trials addressed the use of chronic transfusion to prevent primary stroke; the third utilized the drug hydroxycarbamide (hydroxyurea) and phlebotomy to prevent both recurrent (secondary) stroke and iron overload in patients who had already experienced an initial stroke." | 4.89 | Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. ( Dwan, K; Wang, WC, 2013) |
| " Black pigment gallstones caused by elevated bilirubin excretion are common." | 4.86 | Gastrointestinal and hepatic complications of sickle cell disease. ( Ebert, EC; Hagspiel, KD; Nagar, M, 2010) |
| " Hydroxyurea, EPO preparations, sodium phenylbutyrate, arginine butyrate, and 5-azacytidine/decitabine have shown efficacy in approximately 40% to 70% of sickle cell and beta-thalassemia patients." | 4.84 | Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential. ( Perrine, SP, 2008) |
| " Pregnancy is a high-risk situation for the mother and child The efficacy and safety of hydroxyurea and long-term blood transfusions in adults with sickle cell disease are currently under investigation." | 4.84 | [New issues in adult sickle sell disease]. ( Girot, R; Lionnet, F; Stankovic, K, 2008) |
| " Improved understanding of the natural history of complications such as stroke and pulmonary hypertension, effects of treatments, such as hydroxyurea and blood transfusions, as well as the impact of transplantation on organ damage are likely to influence the timing and indication of transplantation." | 4.84 | Hematopoietic cell transplantation: a curative option for sickle cell disease. ( Krishnamurti, L, 2007) |
| " Whereas the orally administrable iron-chelating agent deferasirox is likely to increasingly take the place of desferioxamine (which can only be given parenterally), effective treatment of priapism in SCD remains a distressing challenge." | 4.83 | Investigational agents for sickle cell disease. ( Okpala, I, 2006) |
| " prevention of overwhelming bacterial infection, present indications and controversies regarding blood transfusion, prevention of stroke, acute chest syndrome, hydroxyurea therapy--probably the best disease modifying agent at the moment, stem cell transplantation--a cure and certain promising experimental therapies including gene therapy have been discussed in this review." | 4.82 | Advances in management of sickle cell disease. ( Agarwal, MB, 2003) |
| "There have been significant changes in clinical guidelines for sickle cell disease (SCD) over the past two decades, including updated indications for hydroxyurea, transfusions, and iron overload management." | 4.31 | Trends in blood transfusion, hydroxyurea use, and iron overload among children with sickle cell disease enrolled in Medicaid, 2004-2019. ( Lai, KW; Lane, PA; Maillis, AN; Snyder, AB; Tang, AY; Zhou, M, 2023) |
| " She was diagnosed with intracranial hypertension and began treatment with acetazolamide." | 4.31 | A Rare Report of the Coexistence of Sickle Cell Disease, Neurofibromatosis Type 1, and Intracranial Hypertension in a Pediatric Patient. ( Jain, A; Patel, A; Winter, T, 2023) |
| "Hydroxyurea lowers the incidence of vaso-occlusive pain crises (VOC) and acute chest syndrome (ACS) among children with sickle cell anemia (SCA)." | 4.31 | Adherence to hydroxyurea and clinical outcomes among children with sickle cell anemia. ( Creary, SE; Dombkowski, KJ; Kolenic, G; Lisabeth, LD; Madden, B; Peng, HK; Phan, H; Reeves, SL, 2023) |
| " Children were grouped according to serum levels of HbF, co-inheritance of alpha-thalassemia, and hydroxyurea therapy." | 4.12 | Growth Hormone/Insulin-like Growth Factor 1 Axis Associated with Modifier Factors in Children with Sickle Cell Anemia. ( Costa-Júnior, DAD; da Silva, CM; Santos, APP; Velloso-Rodrigues, C, 2022) |
| " The overall goals of this study were to evaluate the relationship between left ventricular hypertrophy (LVH) and laboratory markers of hemolysis and determine the association between LVH and SCD-specific therapies (hydroxyurea and chronic red cell transfusion)." | 4.12 | Factors associated with left ventricular hypertrophy in children with sickle cell disease: results from the DISPLACE study. ( Carson, A; Galadanci, NA; Hellemann, G; Howard, V; Johnson, W; Kanter, J, 2022) |
| "In patients with sickle cell disease, hydroxyurea decreases the number of pain crises experienced." | 4.12 | Impact of Hydroxyurea Starting Dose on Pain Outcomes in Patients with Sickle Cell Disease. ( Dayer, LE; King, D; Lakkad, M; Montgomery, C; Painter, JT; Wagner, R; Wilson, LA, 2022) |
| "Sickle cell disease (SCD) children are frequent travellers to countries where yellow fever (YF) is endemic, but there are no data regarding the safety and immunogenicity of the vaccine in such children treated with hydroxyurea (HU)." | 4.02 | Tolerance and humoral immune response to the yellow fever vaccine in sickle cell disease children treated with hydroxyurea: a multicentre prospective study. ( Aupiais, C; Benkerrou, M; Brousse, V; Faye, A; Holvoet, L; Ithier, G; Koehl, B; Missud, F; Mornand, P; Niakate, A; Odièvre, MH; Schinckel, N; Sorge, F, 2021) |
| " Most lesions were osteonecrosis and osteoarthritis and were statistically associated with the non-use of hydroxyurea." | 4.02 | Chronic osteo-articular changes in patients with sickle cell disease. ( de Araújo Pereira, G; Dos Santos, APT; Ferreira, TFA; Leal, AS; Moraes-Souza, H; Silva, SS, 2021) |
| "Intravascular hemolysis (IH) contributes to the development of endothelial dysfunction (ED) in sickle cell anemia (SCA), and the effects of hydroxyurea (HU, the only approved drug that decreases the frequency and severity of vaso-oclussive crises) on IH and ED in SCA remain unclear." | 4.02 | Effect of hydroxyurea therapy on intravascular hemolysis and endothelial dysfunction markers in sickle cell anemia patients. ( Alagbe, AE; Araújo, ADS; Arcanjo, GDS; Batista, THC; Bezerra, MAC; Chenou, F; Costa, FF; De Paula, EV; Domingos, IF; Dos Santos, MNN; Hounkpe, BW; Lucena-Araújo, AR; Santana, RM; Sonati, MF; Tonassé, WV, 2021) |
| " These recommendations include: use of transcranial Doppler ultrasound screening and hydroxyurea for primary stroke prevention in children with hemoglobin SS (HbSS) and hemoglobin Sβ0 (HbSβ0) thalassemia living in low-middle-income settings; surveillance for developmental delay, cognitive impairments, and neurodevelopmental disorders in children; and use of magnetic resonance imaging of the brain without sedation to detect silent cerebral infarcts at least once in early-school-age children and once in adults with HbSS or HbSβ0 thalassemia." | 3.96 | American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults. ( Daraz, L; DeBaun, MR; Fox, CK; Jordan, LC; King, AA; Kirkham, FJ; Kraut, MA; McKinstry, RC; Murad, MH; Schatz, J; Telfer, P; Vichinsky, E, 2020) |
| "What is the prevalence and incidence of congenital anomalies among babies born to women with sickle cell disease (SCD) and who have been exposed to hydroxyurea (HU) therapy at any time in their pregnancy?The objective of this review is to identify the proportion of babies born with congenital anomalies among babies born to mothers with SCD who have been exposed to HU therapy at any point during pregnancy and to describe the specific types of congenital anomalies encountered." | 3.88 | Prevalence and incidence of congenital anomalies amongst babies born to women with sickle cell disease and exposed to hydroxyurea during pregnancy: a systematic review protocol. ( Gwer, SO; Onyango, KO, 2018) |
| " ACE inhibition and hydroxyurea decrease proteinuria so they may limit progression of chronic kidney disease." | 3.88 | Sickle cell disease: a case report of renal amyloidosis. ( Blanco, P; Bugeja, A; Clark, EG; Sood, MM, 2018) |
| "Among Sickle cell disease patients without hydroxyurea therapy, 18% of patients developed oligospermia and 4% developed azoospermia." | 3.85 | Study of Seminal Fluid Parameters and Fertility of Male Sickle Cell Disease Patients and Potential Impact of Hydroxyurea Treatment. ( Kullu, BK; Meher, S; Patel, NK; Patel, S; Purohit, P; Rout, P; Sahoo, LK, 2017) |
| "SCD patients, in steady state and asymptomatic for pulmonary hypertension, were studied stressing on hydroxyurea therapy, serum ferritin, urinary albumin creatinine ratio (UACR), high-sensitivity C-reactive protein (hs-CRP) and sFas/sFasL levels." | 3.83 | Soluble Fas/FasL ratio as a marker of vasculopathy in children and adolescents with sickle cell disease. ( Adly, AA; Andrawes, NG; Eladawy, R; Ismail, EA; Mahmoud, MM, 2016) |
| "We undertook a cost effectiveness analysis (CEA) of hydroxyurea (HU) in preventing stroke recurrence and/or death." | 3.81 | Hydroxyurea use in prevention of stroke recurrence in children with sickle cell disease in a developing country: A cost effectiveness analysis. ( Abdulkadri, A; Bortolusso Ali, S; Cunningham-Myrie, C; King, LG; Knight-Madden, J; Reid, M; Waugh, A, 2015) |
| "The prevalence of albuminuria was lower among patients on hydroxyurea (34." | 3.80 | Hydroxyurea is associated with lower prevalence of albuminuria in adults with sickle cell disease. ( Ataga, KI; Derebail, VK; Desai, PC; Laurin, LP; Nachman, PH, 2014) |
| " Hydroxyurea is a standard therapy in patients with history of acute chest syndrome and severe, recurrent, SCD-associated pain episodes, but has not been established for use with other sickle-associated morbidities." | 3.80 | Practice patterns of stroke screening and hydroxyurea use in children with sickle cell disease: a survey of health care providers. ( Jones, GL; Kalpatthi, R; Madden, NA; Woods, G, 2014) |
| " In this short communication, we describe a woman with sickle cell anemia responsive to hydroxyurea (HU) therapy who had primary stroke due to paradoxical embolization caused by a large atrial septal defect." | 3.80 | Primary stroke in a woman with sickle cell anemia responsive to hydroxyurea therapy. ( Ballas, SK; Martinez, U; Savage, M, 2014) |
| " The aim of this study was to characterize TG at the individual level and assess its relationship with age, hemolysis, transcranial Doppler velocity (TCD), and hydroxyurea treatment." | 3.79 | Thrombin generation in children with sickle cell disease: relationship with age, hemolysis, transcranial Doppler velocity, and hydroxyurea treatment. ( Demulder, A; Ferster, A; Lê, PQ; Noubouossie, DC; Rozen, L; Willems, D; Ziereisen, F, 2013) |
| "To compare the outcome after a first clinical stroke, following treatment with and without hydroxyurea (HU)." | 3.79 | Stroke recurrence in Nigerian children with sickle cell disease treated with hydroxyurea. ( Brown, BJ; Lagunju, IA; Sodeinde, OO, 2013) |
| " We previously reported the use of hydroxyurea/phlebotomy as an alternative to transfusions to reduce the risk of secondary stroke and improve management of iron overload in 35 children with SCA." | 3.77 | Long-term results using hydroxyurea/phlebotomy for reducing secondary stroke risk in children with sickle cell anemia and iron overload. ( Greenway, A; Thornburg, CD; Ware, RE, 2011) |
| "In a cohort of children with sickle cell disease (SCD) and vaso-occlusive pain visits served through South Carolina's Medicaid system over a 6-year period (N 5 523), we compared the number of vaso-occlusive pain or acute chest syndrome (ACS)/pneumonia episodes, and outpatient or acute service costs in those treated or not treated with hydroxyurea (HU)." | 3.76 | Cost-effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease. ( Jerrell, JM; Stallworth, JR; Tripathi, A, 2010) |
| "Two experiments were conducted to determine: 1) whether the adult male transgenic sickle cell mouse (Tg58 x Tg98; TSCM), exhibits the patterns of reproductive endpoints (hypogonadism) characteristic of men with sickle cell disease (SCD) and 2) whether hydroxyurea (HU) exacerbates this condition." | 3.75 | Adverse effects of a clinically relevant dose of hydroxyurea used for the treatment of sickle cell disease on male fertility endpoints. ( Aguinaga, MP; Archibong, AE; Bourne, P; Brooks, CM; Bruce, D; Hills, ER; Jones, KM; Niaz, MS; Rice, VM; Roberson, SI, 2009) |
| "Hydroxyurea (HU) is not infrequently used in patients with sickle cell disease and myeloproliferative disorders." | 3.74 | Effect of hydroxyurea on sperm count, motility and morphology in adult men with sickle cell or myeloproliferative disease. ( Grigg, A, 2007) |
| "Failing codeine therapy for a pain crisis while taking hydroxyurea is associated with an increase in reduced-functioning CYP2D6 alleles." | 3.74 | The effect of CYP2D6 polymorphisms on the response to pain treatment for pediatric sickle cell pain crisis. ( Brousseau, DC; Divakaran, K; Drendel, AL; McCarver, DG; Panepinto, JA, 2007) |
| "Hydroxyurea represents a privileged choice of treatment in the severe forms of SCD in children, for homozygous SCD-SS as well as for double heterozygote SCD-S/beta thalassemia." | 3.74 | [The use of hydroxyurea in severe forms of sickle cell disease: study of 47 Tunisian paediatric cases]. ( Bejaoui, M; Mellouli, F, 2008) |
| "We describe a 28-year-old man treated with hydroxyurea for sickle cell anemia, who was admitted to the University Hospital with an acute myocardial infarction." | 3.73 | Acute myocardial infarction in sickle cell disease: a possible complication of hydroxyurea treatment. ( Costa, FF; de Souza, RA; Fattori, A; Saad, ST, 2005) |
| "A young Arab woman with sickle cell-beta0-thalassemia disease developed acute colonic pseudo-obstruction that became chronic but showed some response to hydroxyurea." | 3.72 | Colonic pseudo-obstruction in sickle cell disease. ( Ayyaril, M; Daar, A; Knox-Macaulay, H; Nusrat, N, 2003) |
| " We measured, and compared, the RBC deformability of 15 homozygous patients (HbSS) including five patients taking hydroxyurea (HU) for at least 6 months (HbSS/HU), 10 subjects with sickle cell trait (HbAS) and 35 normal controls." | 3.72 | Optical tweezers for measuring red blood cell elasticity: application to the study of drug response in sickle cell disease. ( Barbosa, LC; Barjas-Castro, ML; Brandão, MM; Cesar, CL; Costa, FF; Fontes, A; Saad, ST, 2003) |
| " It appears to be a complication of chronic hemolysis, is resistant to hydroxyurea therapy, and confers a high risk of death." | 3.72 | Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. ( Blackwelder, WC; Brown, B; Castro, O; Coles, WA; Ernst, I; Gladwin, MT; Hunter, LA; Jison, ML; Minter, K; Nichols, JS; Ognibene, FP; Plehn, JF; Rodgers, GP; Sachdev, V; Schechter, AN; Shizukuda, Y, 2004) |
| "For children with SCA and stroke, hydroxyurea effectively prevents secondary stroke and serial phlebotomy leads to complete resolution of transfusional iron overload." | 3.72 | Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy. ( Davis, JS; Mortier, NA; Schultz, WH; Sylvestre, PB; Treem, WR; Ware, RE; Zimmerman, SA, 2004) |
| " A possible alternative, the prophylactic use of hydroxyurea (HU), has not been tried to determine whether it may prevent recurrent stroke." | 3.71 | Hydroxyurea (HU) for prevention of recurrent stroke in sickle cell anemia (SCA). ( de Bisotti, R; Fairbanks, V; Sumoza, A; Sumoza, D, 2002) |
| "Our rate of hydroxyurea-induced leg ulcers (29%) is higher than that reported for patients with myeloproliferative syndromes (9%)." | 3.71 | Cutaneous adverse reactions to hydroxyurea in patients with sickle cell disease. ( Aractingi, S; Chaine, B; Girot, R; Neonato, MG, 2001) |
| "We have studied the effects of hydroxyurea on growth and differentiation of early erythroid progenitor cells (BFU-e) from peripheral blood of sickle cell disease patients (five SS and two Hb S/beta-thalassemia) in the presence or absence of exogenous stimulating factors." | 3.71 | Hydroxyurea promotes the reduction of spontaneous BFU-e to normal levels in SS and S/beta thalassemic patients. ( Bincoletto, C; Costa, FF; Perlingeiro, RC; Queiroz, ML; Saad, ST, 2001) |
| "Hydroxyurea was stopped for medical reasons in 11 patients: 6 failures, 1 pregnancy, 1 cutaneous rash, 1 leg ulcer, 1 lupus." | 3.70 | Preliminary report of a toxicity study of hydroxyurea in sickle cell disease. French Study Group on Sickle Cell Disease. ( Bachir, D; Bégué, P; Bernaudin, F; de Montalembert, M; Micheau, M; Thuret, I, 1999) |
| "Hydroxyurea is classified as an S-phase antineoplastic agent (pregnancy category D)." | 3.70 | Hydroxyurea in two pregnant women with sickle cell anemia. ( Alexander, CK; Byrd, DC; Pitts, SR, 1999) |
| "Hydroxyurea (HU) is an effective therapeutic agent for patients with myeloproliferative disorders (MPDs) or sickle cell disease (SCD)." | 3.70 | Acquired DNA mutations associated with in vivo hydroxyurea exposure. ( Fruchtman, SR; Hanft, VN; Howard, TA; Pickens, CV; Rosse, WF; Ware, RE, 2000) |
| "We report the response of three patients with homozygous sickle cell disease and 10 patients with compound HbS/beta-thalassemia (four with beta(o)thal/HbS and six with beta(+)thal/HbS respectively) to hydroxyurea treatment with regards to their serum erythropoietin levels (sEpo)." | 3.70 | Increased erythropoietin level induced by hydroxyurea treatment of sickle cell patients. ( Loukopoulos, D; Papassotiriou, I; Stamoulakatou, A; Voskaridou, E, 2000) |
| "Hydroxyurea (HU), an inhibitor of DNA synthesis, has been shown to increase fetal hemoglobin (HbF) levels in patients with sickle cell anemia and in some patients with beta-thalassemia." | 3.68 | Hydroxyurea increases fetal hemoglobin in cultured erythroid cells derived from normal individuals and patients with sickle cell anemia or beta-thalassemia. ( Burke, LP; Fibach, E; Noguchi, CT; Rodgers, GP; Schechter, AN, 1993) |
| "This study confirms that hydroxyurea therapy increases hemoglobin F production and provides objective evidence that hydroxyurea reduces the rate of hemolysis and intracellular polymerization of hemoglobin S." | 3.68 | Treatment of sickle cell anemia with hydroxyurea and erythropoietin. ( Brugnara, C; Bunn, HF; Charache, S; Dover, GJ; Goldberg, MA; Schapira, L, 1990) |
| "Sickle cell disease is an inherited haematological condition with life-threatening consequences." | 3.30 | Factors associated with health-related quality of life in children with sickle cell disease. ( Brecht, ML; Jacob, E; Lee, E; Mawali, AA; Nasiri, YA; Nyamathi, A; Omari, OA; Robbins, W, 2023) |
| " Optimal zinc dosing and the role of zinc in preventing stroke or death in SCA warrant further investigation." | 3.30 | Zinc for infection prevention in children with sickle cell anemia: a randomized double-blind placebo-controlled trial. ( Bond, C; Conroy, AL; Cusick, SE; Datta, D; Goings, MJ; Jang, JH; John, CC; Krebs, NF; Namazzi, R; Opoka, R; Ryu, MS; Tagoola, A; Tu, W; Ware, RE, 2023) |
| "Hydroxyurea is an alternative treatment to decrease stroke risk." | 3.30 | Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial. ( Ambrose, EE; Charles, M; Lane, AC; Latham, TS; Makubi, AN; Smart, LR; Songoro, P; Stuber, SE; Ware, RE, 2023) |
| "Children with sickle cell anemia (SCA) living in Nigeria are at an increased risk of malnutrition, which contributes to increased morbidity and mortality." | 3.30 | Feasibility trial for the management of severe acute malnutrition in older children with sickle cell anemia in Nigeria. ( Abdullahi, SU; Acra, S; DeBaun, MR; Gambo, S; Gwarzo, G; Kabir, H; Klein, LJ; Murtala, HA; Rodeghier, M; Shamsu, KA; Stallings, VA, 2023) |
| "Children with sickle cell anemia (SCA) in areas of Africa with endemic malaria transmission are commonly prescribed malaria chemoprevention." | 3.11 | Monthly sulfadoxine/pyrimethamine-amodiaquine or dihydroartemisinin-piperaquine as malaria chemoprevention in young Kenyan children with sickle cell anemia: A randomized controlled trial. ( Clapp, S; Freedman, B; Green, CL; Kirui, JK; Korwa, S; Njuguna, FM; O'Meara, WP; Taylor, SM; Wu, A, 2022) |
| "The only approved treatments for painful crises in many countries are hydroxyurea plus potent analgesics." | 3.11 | Cost-effectiveness analysis of adding omega-3 or vitamin D supplementation to standard therapy in treating painful crises of pediatric sickle cell disease patients. ( Abdelhalima, SM; Alshaeri, HK; Elberry, AA; Gamaleldin, MM; Hussein, RRS; Meabed, MH; Mohammad, BA; Murphy, JE, 2022) |
| " Here, we summarize what we know about SCD and hydroxyurea use in Africa and discuss a strategy to respond to what we consider to be a public health imperative to maximize access to and appropriate use of hydroxyurea for all individuals with SCD using innovative dosing and monitoring strategies." | 3.01 | Hydroxyurea for children with sickle cell disease in sub-Saharan Africa: A summary of the evidence, opportunities, and challenges. ( Dexter, D; McGann, PT, 2023) |
| " Therapies were overall considered safe; however, antiplatelets and sulfates may lead to more severe adverse events." | 3.01 | Efficacy and safety of pharmacological interventions for managing sickle cell disease complications in children and adolescents: Systematic review with network meta-analysis. ( Brito, M; Delgadinho, M; Fernandez-Llimos, F; Ferreira, J; Ginete, C; Santos, B; Tonin, FS, 2023) |
| " Combined with animal data, research using these approaches might be able to define safe and effective hydroxyurea dosing regimens for pregnant and lactating women with SCA, when the benefits of continuing hydroxyurea treatment likely outweigh the risks of non-treatment, by avoiding substantial morbidity and even mortality for both mothers and infants." | 3.01 | Hydroxyurea treatment for sickle cell anemia during pregnancy and lactation: Current evidence and knowledge gaps. ( Dallmann, A; Dong, M; Vinks, AA; Ware, RE, 2023) |
| "Sickle cell disease is the most common inherited pathological haemoglobinopathy." | 3.01 | The evolving treatment landscape for children with sickle cell disease. ( Jacob, SA; Kanter, J; Talati, R, 2023) |
| " However, there are few large-scale reports on its long-term use and certain caregivers and patients have concerns about its safety." | 3.01 | Real-Life experience with hydroxyurea in patients with sickle cell disease: Results from the prospective ESCORT-HU cohort study. ( Bartolucci, P; Brousse, V; Cannas, G; Colombatti, R; de Montalembert, M; Galactéros, F; Habibi, A; Joseph, L; Loko, G; Oevermann, L; Voskaridou, E, 2021) |
| " Conventional hydroxyurea dosing (e." | 3.01 | Early initiation of hydroxyurea (hydroxycarbamide) using individualised, pharmacokinetics-guided dosing can produce sustained and nearly pancellular expression of fetal haemoglobin in children with sickle cell anaemia. ( Bonar, H; Dong, M; Kalfa, TA; Korpik, J; Malik, P; McGann, PT; Niss, O; Pfeiffer, A; Quinn, CT; Reynaud, M; Smart, LR; Vinks, AA; Ware, RE, 2021) |
| "Hydroxyurea is a well-established disease-modifying medication for sickle cell disease (SCD)." | 2.94 | Inpatient Ordering of Home Hydroxyurea by Residents for Hospitalized Patients With Sickle Cell Disease. ( Kappa, S; Nickel, RS; Shaw, R, 2020) |
| "Hydroxyurea has proven safety, feasibility, and efficacy in children with sickle cell anemia in sub-Saharan Africa, with studies showing a reduced incidence of vaso-occlusive events and reduced mortality." | 2.94 | Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa. ( Hume, HA; John, CC; Kasirye, P; Lane, A; Latham, TS; Nabaggala, C; Ndugwa, CM; Opoka, RO; Ware, RE, 2020) |
| " Results from a single-center trial of individualized, PK-guided dosing of hydroxyurea for children with SCD suggest that individualized dosing achieves the optimal dose more rapidly and provides superior clinical and laboratory benefits than traditional dosing strategies." | 2.94 | Hydroxyurea Optimization through Precision Study (HOPS): study protocol for a randomized, multicenter trial in children with sickle cell anemia. ( Appiah-Kubi, AO; Creary, SE; Dong, M; Heeney, MM; Lane, A; Latham, TS; McGann, PT; Meier, ER; Nelson, SC; Niss, O; Pfeiffer, A; Piccone, C; Quarmyne, MO; Quinn, CT; Saving, KL; Scott, JP; Shook, LM; Talati, R; Vinks, AA, 2020) |
| "Hydroxyurea treatment was feasible and safe in children with sickle cell anemia living in sub-Saharan Africa." | 2.90 | Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa. ( Aygun, B; Lane, A; Latham, TS; McGann, PT; Olupot-Olupot, P; Santos, B; Stuber, SE; Tomlinson, G; Tshilolo, L; Ware, RE; Williams, TN, 2019) |
| "Hydroxyurea barriers were frequently reported but differed by dyad members' perspective." | 2.90 | Greater number of perceived barriers to hydroxyurea associated with poorer health-related quality of life in youth with sickle cell disease. ( Green, NS; Manwani, D; Smaldone, A, 2019) |
| " Accuracy of population-based dosing is sufficient to target AUCs in individual patients." | 2.87 | Hydroxycarbamide in children with sickle cell anaemia after first-dose vs. chronic therapy: pharmacokinetics and predictive models for drug exposure. ( Estepp, JH; Garg, U; Kang, G; Kearns, G; Liem, R; Mack, JM; Moen, J; Neville, KA; Panepinto, JA; Wiczling, P, 2018) |
| " The full enrollment to REACH confirms the feasibility of conducting high-quality SCA research in Africa; this study will provide vital information to guide safe and effective dosing of hydroxyurea for children with SCA living in Africa." | 2.87 | Realizing effectiveness across continents with hydroxyurea: Enrollment and baseline characteristics of the multicenter REACH study in Sub-Saharan Africa. ( Aygun, B; Howard, TA; Kitenge, R; Lane, A; Latham, T; Luís Reis da Fonseca, J; McElhinney, K; McGann, PT; Mochamah, G; Olupot-Olupot, P; Santos, B; Stuber, S; Tomlinson, GA; Tshilolo, L; Wabwire, H; Ware, RE; Williams, TN, 2018) |
| " The use of Filgrastim to mobilize large numbers of hematopoietic stem and progenitor cells into the circulation has been associated with severe adverse events in sickle cell patients." | 2.87 | Plerixafor enables safe, rapid, efficient mobilization of hematopoietic stem cells in sickle cell disease patients after exchange transfusion. ( André-Schmutz, I; Cavazzana, M; Couzin, C; Delville, M; Félix, T; Gabrion, A; Joseph, L; Lagresle-Peyrou, C; Lamhaut, L; Lefrère, F; Magnani, A; Magrin, E; Miccio, A; Plantier, C; Ribeil, JA; Romano, O; Sadek, H; Stanislas, A; Ternaux, B; Tréluyer, JM; Weber, L, 2018) |
| "Hydroxyurea (HU) has been suggested to act as a nitric oxide (NO) donor in sickle cell anemia (SCA)." | 2.87 | Hydroxyurea therapy modulates sickle cell anemia red blood cell physiology: Impact on RBC deformability, oxidative stress, nitrite levels and nitric oxide synthase signalling pathway. ( Bloch, W; Cannas, G; Collins, B; Connes, P; Fort, R; Gauthier, A; Grau, M; Guillot, N; Hot, A; Joly, P; Martin, C; Nader, E; Poutrel, S; Renoux, C; Romana, M; Thevis, M; Walpurgis, K, 2018) |
| "The vast majority of children with sickle cell anemia (SCA) live in Africa, where evidence-based guidelines for primary stroke prevention are lacking." | 2.84 | Feasibility trial for primary stroke prevention in children with sickle cell anemia in Nigeria (SPIN trial). ( Ali, S; Aliyu, MH; Amal Galadanci, A; Bello-Manga, H; Belonwu, R; Covert, BV; DeBaun, MR; Galadanci, NA; Jordan, LC; Kassim, AA; Kirkham, FJ; Musa Tabari, A; Neville, K; Phillips, S; Salihu, A; Shyr, Y; Umar Abdullahi, S; Vance, LD; Wudil Jibir, B, 2017) |
| "Acute and chronic pain as well as end-organ damage occur throughout the lifespan of individuals living with SCD resulting in significant disease morbidity and a median life expectancy of 43 years in the USA." | 2.82 | Advances in the diagnosis and treatment of sickle cell disease. ( Brandow, AM; Liem, RI, 2022) |
| "Hydroxyurea has been a gold standard for two decades, showing benefits in acute complications and overall survival in sickle cell anemia, although data is lacking for certain genotypes such as hemoglobin SC." | 2.82 | Emerging drugs for the treatment of sickle cell disease: a review of phase II/III trials. ( Forté, S; Ross, JM; Soulières, D, 2022) |
| "Sickle cell disease is an inherited blood disorder afflicting an estimated 100,000 individuals in the United States and over 20 million people worldwide." | 2.82 | Sickle cell disease in the new era: advances in drug treatment. ( Lee, MT; Ogu, UO, 2022) |
| "Hydroxyurea therapy was the main therapy in 15 studies and is efficacious." | 2.82 | Sickle cell disease treatment and management in India: a systematic review of interventional studies. ( Babu, BV; Balakrishna, SL; Sharma, Y; Sridevi, P, 2022) |
| "Throughout the Coronavirus Disease 2019 (COVID-19) pandemic, understanding the effects of COVID-19 on persons with Sickle Cell Disease (SCD) and Sickle Cell Trait (SCT) has garnered interest." | 2.82 | COVID-19 outcomes in sickle cell disease and sickle cell trait. ( Christian, J; Lanzkron, S; Naik, RP, 2022) |
| "Hydroxyurea (HU) is a crucial therapy for children with sickle cell anemia, but its off-label use is a barrier to widespread acceptance." | 2.82 | Pharmacokinetics and bioequivalence of a liquid formulation of hydroxyurea in children with sickle cell anemia. ( Brandow, AM; Crary, SE; Estepp, JH; Garg, U; Green, NS; Howard, TH; Jusko, WJ; Lewandowski, A; Liem, R; Melloni, C; Morris, MH; Neville, KA; Rogers, Z; Rothman, JA; Thornburg, CD; Wiczling, P, 2016) |
| "Stroke risk in sickle cell anemia (SCA), predicted by high transcranial Doppler (TCD) velocities, is prevented by transfusions." | 2.82 | Long-term treatment follow-up of children with sickle cell disease monitored with abnormal transcranial Doppler velocities. ( Arnaud, C; Bernaudin, F; Biscardi, S; Dalle, JH; Epaud, R; Fourmaux, C; Gluckman, E; Hau, I; Kamdem, A; Kasbi, F; Leveillé, E; Madhi, F; Pondarré, C; Socié, G; Vasile, M; Verlhac, S, 2016) |
| "We evaluated 10 patients with sickle cell anemia (SCA) treated with hydroxyurea (HU) and 13 SCA patients without this treatment." | 2.80 | Hydroxyurea increases plasma concentrations of microparticles and reduces coagulation activation and fibrinolysis in patients with sickle cell anemia. ( Brunetta, DM; Covas, DT; De Santis, GC; Oliveira de Oliveira, LC; Silva-Pinto, AC, 2015) |
| "Hydroxyurea treated group was on dosage more than 20 mg/kg/day." | 2.80 | Omega 3 (n-3) fatty acids down-regulate nuclear factor-kappa B (NF-κB) gene and blood cell adhesion molecule expression in patients with homozygous sickle cell disease. ( Daak, AA; Elbashir, LM; Elbashir, MI; Elderdery, AY; Ghebremeskel, K; Mariniello, K; Mills, J; Scarlett, G, 2015) |
| "Children with sickle cell anemia (SCA) and conditional transcranial Doppler (TCD) ultrasound velocities (170-199 cm/sec) may develop stroke." | 2.80 | Prevention of conversion to abnormal transcranial Doppler with hydroxyurea in sickle cell anemia: A Phase III international randomized clinical trial. ( Aldred, K; Ali, S; Aygun, B; Bennett, J; Boyett, JM; Goldsmith, JC; Hankins, JS; Jay, DW; Kang, G; Lobo, CL; McCarville, MB; Moura, PG; Rankine-Mullings, A; Reid, ME; Smeltzer, MP; Soares, DP; Ware, RE, 2015) |
| "Sickle cell disease was diagnosed in 54." | 2.79 | Challenge of managing sickle cell disease in a pediatric population living in kinshasa, democratic republic of congo: a sickle cell center experience. ( Aloni, MN; Nkee, L, 2014) |
| "The objective of this study was to develop a population pharmacokinetic (PK) model sufficient to describe hydroxyurea (HU) concentrations in serum and urine following oral drug administration in pediatric patients with sickle cell disease." | 2.79 | Population pharmacokinetics of hydroxyurea for children and adolescents with sickle cell disease. ( Abdel-Rahman, SM; Garg, U; Kearns, GL; Liem, RI; Neville, KA; Panepinto, JA; Wiczling, P, 2014) |
| "More than 90% of children with sickle cell anemia (SCA) lose splenic function by the age of 2 yrs." | 2.79 | Predictors of splenic function preservation in children with sickle cell anemia treated with hydroxyurea. ( Aygun, B; Dertinger, SD; Hankins, JS; Nottage, KA; Shulkin, B; Smeltzer, M; Wang, WC; Ware, RE; Winter, B, 2014) |
| "Hydroxyurea has proven efficacy in children and adults with sickle cell anemia (SCA), but with considerable inter-individual variability in the amount of fetal hemoglobin (HbF) produced." | 2.79 | Whole exome sequencing identifies novel genes for fetal hemoglobin response to hydroxyurea in children with sickle cell anemia. ( Aygun, B; Boerwinkle, E; Crosby, JR; Dugan-Perez, S; Flanagan, JM; Gibbs, RA; Howard, TA; Mortier, NA; Muzny, DM; Nottage, KA; Sabo, A; Sheehan, VA; Ware, RE, 2014) |
| "At study entry, infants with alpha thalassemia trait had significantly lower mean corpuscular volume, total bilirubin, and absolute reticulocyte count." | 2.78 | Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. ( Flanagan, JM; Howard, TA; Kutlar, A; Luo, Z; Sheehan, VA; Thompson, BW; Wang, WC; Ware, RE, 2013) |
| "Gastritis was graded as severe in three subjects at 40 mg/kg and was considered the dose-limiting toxicity." | 2.78 | A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease. ( Abboud, MR; Ataga, KI; Buchanan, GR; El-Beshlawy, A; Ghalie, RG; Inati, A; Kutlar, A; Perrine, SP; Reid, ME; Smith, H; Taher, AT, 2013) |
| " The Fisher's Exact test was used to compare the frequency of subjects who experienced at least one SCA-related adverse event (AE) or serious adverse event (SAE) in each arm and to compare event rates." | 2.78 | Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. ( Alvarez, O; Aygun, B; Bonner, M; Flanagan, J; Lockhart, A; Miller, ST; Mueller, BU; Owen, W; Schultz, W; Scott, JP; Ware, RE; Yovetich, NA, 2013) |
| "Clinical complications of sickle cell anemia begin in infancy." | 2.77 | Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. ( Brown, RC; Casella, JF; Howard, TH; Iyer, RV; Lebensburger, JD; Lu, M; Miller, ST; Rogers, ZR; Sarnaik, S; Wang, WC, 2012) |
| "Treatment with hydroxyurea for 24 months did not influence GFR in young children with SCA." | 2.77 | Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. ( Alvarez, O; Howard, T; Iyer, RV; Luo, Z; McCarville, MB; Miller, ST; Rana, SR; Rogers, ZR; Sarnaik, SA; Schwartz, GJ; Thompson, B; Thornburg, CD; Wang, WC; Ware, RE, 2012) |
| "Stroke is a devastating complication of sickle cell anemia (SCA) with high recurrence if untreated." | 2.77 | Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). ( Helms, RW; Ware, RE, 2012) |
| "Sixty sickle cell anemia children (5-18 years) with more than three episodes of vasoocclusive crises or blood transfusions per year were randomized to receive HU (n = 30) or placebo (n = 30) therapy." | 2.77 | Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease. ( Bhatnagar, M; Desai, S; Jain, DL; Lodha, A; Sarathi, V, 2012) |
| "Hydroxyurea was associated with statistically significantly lower rates of initial and recurrent episodes of pain, dactylitis, acute chest syndrome, and hospitalization; even infants who were asymptomatic at enrollment had less dactylitis as well as fewer hospitalizations and transfusions if treated with hydroxyurea." | 2.77 | Impact of hydroxyurea on clinical events in the BABY HUG trial. ( Alvarez, O; Files, BA; Iyer, R; Kalpatthi, R; Lebensburger, J; Luo, Z; Miller, ST; Seaman, P; Thompson, B; Thornburg, CD; Wang, WC; Ware, RE, 2012) |
| "In infants with sickle cell anemia, sonographic spleen volume does not reflect function, but increased renal volume correlates with GFR and is consistent with hyperfiltration." | 2.76 | Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: baseline data from the BABY HUG trial. ( Huang, X; Kalpatthi, R; Luo, Z; McCarville, MB; Miller, ST; Rees, RC; Rogers, ZR; Thompson, B; Wang, WC, 2011) |
| " The objectives of this study were to develop population pharmacokinetic(PK)-pharmacodynamic(PD) models for HU in order to characterize the exposure-efficacy relationships and their variability, compare two dosing regimens by simulations and develop some recommendations for monitoring the treatment." | 2.76 | Population pharmacokinetics and pharmacodynamics of hydroxyurea in sickle cell anemia patients, a basis for optimizing the dosing regimen. ( Bachir, D; Galactéros, F; Girard, P; Habibi, A; Hulin, A; Paule, I; Pham, KP; Sassi, H; Tod, M, 2011) |
| "Hydroxyurea therapy has proven laboratory and clinical efficacies for children with sickle cell anemia (SCA)." | 2.76 | Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia. ( Aygun, B; Despotovic, JM; Flanagan, JM; He, J; Howard, T; Kimble, AC; Mortier, NA; Smeltzer, MP; Sparreboom, A; Ware, RE; Wu, S, 2011) |
| "Hydroxyurea has been shown to be efficacious for the treatment of sickle cell anemia (SCA), primarily through the induction of fetal hemoglobin (HbF)." | 2.76 | Epigenetic and molecular profiles of erythroid cells after hydroxyurea treatment in sickle cell anemia. ( Howard, TA; Mortier, N; Smeltzer, M; Steward, S; Walker, AL; Wang, YD; Ware, RE, 2011) |
| "Thirty-four patients with sickle cell anemia (hemoglobin S [HbS]/HbS), 131 with HbS/beta(0)-thal, and 165 with HbS/beta(+)-thal participated in this trial." | 2.75 | The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). ( Balassopoulou, A; Bilalis, A; Christoulas, D; Loukopoulos, D; Plata, E; Sinopoulou, K; Stamatopoulos, G; Terpos, E; Varvagiannis, K; Voskaridou, E, 2010) |
| " Our results, while no longer the product of a randomized study because of the ethical concerns of withholding an efficacious treatment, suggest that long-term use of hydroxyurea is safe and might decrease mortality." | 2.75 | The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. ( Armstrong, FD; Ataga, K; Ballas, SK; Castro, O; DeCastro, L; Kutlar, A; McCarthy, WF; Smith, W; Steinberg, MH; Swerdlow, P; Waclawiw, MA, 2010) |
| "Treatment with hydroxyurea did not significantly (p > ." | 2.75 | The impact of hydroxyurea on career and employment of patients with sickle cell anemia. ( Ballas, SK; Bauserman, RL; McCarthy, WF; Waclawiw, MA, 2010) |
| "The Multicenter Study of Hydroxyurea in Sickle Cell Anemia (MSH) was a randomized double-blind placebo-controlled trial to test whether hydroxyurea could reduce the rate of painful crises in adults who had at least 3 painful crises per year." | 2.74 | Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. ( Ballas, SK; Barton, BA; Bellevue, R; DeCastro, L; Guo, N; McCarthy, WF; Waclawiw, MA, 2009) |
| "Hydroxyurea has hematologic and clinical efficacy in sickle cell anemia (SCA), but its effects on transcranial Doppler (TCD) flow velocities remain undefined." | 2.73 | Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia. ( Burgett, S; Mortier, NA; Schultz, WH; Ware, RE; Zimmerman, SA, 2007) |
| " The MTD for magnesium pidolate used in combination with hydroxycarbamide was 125 mg/kg/d." | 2.73 | Phase I study of magnesium pidolate in combination with hydroxycarbamide for children with sickle cell anaemia. ( Brugnara, C; Hankins, JS; Hillery, CA; Li, CS; Wang, WC; Wynn, LW, 2008) |
| " Recognizing this variability, using a precision medicine approach, we developed and prospectively evaluated an individualized dosing model for children with SCA, designed to optimize the hydroxyurea dose and clinical response." | 2.72 | Changing the Clinical Paradigm of Hydroxyurea Treatment for Sickle Cell Anemia Through Precision Medicine. ( Dong, M; McGann, PT, 2021) |
| "Hydroxyurea has proven clinical efficacy for SCA - treatment significantly reduces disease manifestations and prolongs survival." | 2.72 | Absence of hydroxyurea-induced mutational effects supports higher utilisation for the treatment of sickle cell anaemia. ( Dertinger, SD; Ware, RE, 2021) |
| "Hydroxyurea (HU) is an agent with important and effective role in the treatment of patients suffering from this disease." | 2.72 | Effect of hydroxyurea on the deformability of the red blood cell membrane in patients with sickle cell anemia. ( Athanassiou, G; Kourakli, A; Moutzouri, A; Zoumbos, N, 2006) |
| "Sickle cell anemia is the most common heritable hematological disease affecting humans." | 2.72 | Clinical response of patients with sickle cell anemia to cromolyn sodium nasal spray. ( Karimi, M; Mosavizadeh, K; Mousavizadeh, K; Sharifzadeh, S; Zekavat, OR, 2006) |
| " Our aims were to evaluate bioequivalence between standard hydroxyurea capsules and a new formulation of 1,000 mg coated breakable tablets in adults and to compare pharmacokinetic parameters in adults and children with SCD." | 2.72 | Pharmacokinetics of hydroxyurea 1,000 mg coated breakable tablets and 500 mg capsules in pediatric and adult patients with sickle cell disease. ( Astier, A; Bachir, D; Bresson, JL; de Montalembert, M; Galactéros, F; Gimeno, L; Hulin, A; Macquin-Mavier, I; Mogenet, A; Roudot-Thoraval, F, 2006) |
| "Although reduced endothelial nitric oxide (NO) bioavailability has been demonstrated in arteriosclerotic vascular disease, the integrity of this system in sickle cell disease remains uncertain." | 2.71 | Divergent nitric oxide bioavailability in men and women with sickle cell disease. ( Cannon, RO; Coles, WA; Csako, G; Gladwin, MT; Ognibene, FP; Panza, JA; Reiter, CD; Schechter, AN; Schenke, WH; Waclawiw, MA, 2003) |
| "Hydroxyurea was escalated to MTD, with an average dose of 25." | 2.71 | Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. ( Davis, JS; Howard, TA; Mortier, NA; Pickens, CV; Schultz, WH; Ware, RE; Zimmerman, SA, 2004) |
| "Hydroxyurea treatment of sickle cell anemia patients leads to clinical improvement and reduces the incidence of vaso-occlusive episodes." | 2.71 | Effects of hydroxyurea on the membrane of erythrocytes and platelets in sickle cell anemia. ( Covas, DT; de Lucena Angulo, I; Vianna Bonini Palma, P; Zago, MA, 2004) |
| "Hydroxyurea was then introduced at the initial dose of 10 mg/kg, and as the hydroxyurea dosage increased, the number or length of priapism episodes decreased." | 2.71 | Follow-up of sickle cell disease patients with priapism treated by hydroxyurea. ( Arruda, VR; Costa, FF; Gilli, S; Lajolo, C; Lima, CS; Marques Júnior, JF; Saad, ST, 2004) |
| " On the basis of the exposure and the apparent clearance from the current and 2 historical studies, the authors have proposed an initial dosing regimen of hydroxyurea (7." | 2.71 | The influence of renal function on hydroxyurea pharmacokinetics in adults with sickle cell disease. ( Ataga, K; Gothelf, S; Grasela, DM; Kaul, S; Kutlar, A; Olson, JS; Orringer, E; Yan, JH, 2005) |
| "In the Stroke Prevention Trial for Sickle Cell Anemia Study, patients were randomized to receive long-term transfusion (CTX) or standard care (STC)." | 2.71 | Effect of long-term transfusion on growth in children with sickle cell anemia: results of the STOP trial. ( Adams, R; Brambilla, D; Morales, KH; Olivieri, N; Scher, CD; Styles, L; Wang, WC, 2005) |
| "Hydroxyurea was temporarily discontinued for predefined toxicity." | 2.70 | A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia. ( Lane, PA; Rogers, ZR; Scott, JP; Wang, WC; Ware, RE; Wynn, LW, 2001) |
| "Hydroxyurea is a chemotherapeutic agent capable of increasing HbF levels in the red blood cells and its use has recently been proposed in the treatment of SCD." | 2.70 | Scintigraphic follow-up of the effects of therapy with hydroxyurea on splenic function in patients with sickle cell disease. ( Anjos, C; Brandalise, S; Camargo, EE; Etchebehere, E; Fahel, F; Lima, M; Pinheiro, V; Ramos, C; Santos, A, 2002) |
| " Patients were monitored by 2-week visits to assess compliance, toxicity, clinical adverse events, growth parameters, and laboratory efficacy associated with HU treatment." | 2.69 | Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. ( Daeschner, C; Gee, B; Helms, RW; Kinney, TR; O'Branski, EE; Ohene-Frempong, K; Platt, OS; Redding-Lallinger, R; Vichinsky, E; Wang, W; Ware, RE, 1999) |
| "The hydroxyurea arm was also associated with lower costs for emergency department visits, transfusion, and use of opiate analgesics." | 2.69 | Cost-effectiveness of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. ( Ballas, SK; Barton, FB; Charache, S; Moore, RD; Terrin, ML, 2000) |
| " Twenty-five patients (median age, 9 years) were randomized to receive either HU (at the initial dosage of 20 mg/kg/d) or a placebo for 6 months and were then switched to the other arm for the next 6 months." | 2.68 | Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. ( Buyse, M; Corazza, F; Cornu, G; Devalck, C; Ferster, A; Fondu, P; Sariban, E; Toppet, M; Vermylen, C, 1996) |
| " Dosage starts at 15 mg/kg/day and is titrated to the patient's maximum tolerated dose up to 35 mg/kg/day." | 2.68 | Design of the multicenter study of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea. ( Barton, FB; Charache, S; Dover, GJ; Eckert, SV; McMahon, RP; Moore, RD; Terrin, ML; Waclawiw, M, 1995) |
| "Painful crises in patients with sickle cell anemia are caused by vaso-occlusion and infarction." | 2.68 | Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia. ( Ballas, SK; Barton, FB; Castro, O; Charache, S; Dover, GJ; McMahon, RP; Moore, RD; Orringer, EP; Steinberg, MH; Terrin, ML, 1996) |
| "Hydroxyurea (HU) can increase fetal hemoglobin (HbF) in sickle cell anemia (HbSS)." | 2.68 | Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea. ( Barton, FB; Charache, S; Dover, GJ; Lu, ZH; Steinberg, MH; Terrin, ML, 1997) |
| "The Multicenter Study of Hydroxyurea in Sickle Cell Anemia (MSH), a double-blind randomized clinical trial, compared the frequency of acute vaso-occlusive (painful) crises during 2 yr of follow-up in 299 patients randomly assigned to hydroxyurea or placebo." | 2.68 | An extension of stochastic curtailment for incompletely reported and classified recurrent events: the Multicenter Study of Hydroxyurea in Sickle Cell Anemia (MSH). ( Barton, FB; Bonds, DR; Geller, NL; McMahon, RP; Terrin, ML; Waclawiw, MA, 1997) |
| "We have treated 9 patients with sickle cell anemia (SS) with hydroxyurea (HU)." | 2.68 | Hydroxyurea therapy in sickle cell anemia patients in Curaçao, The Netherlands Antilles. ( Gu, LH; Hillen, HF; Huisman, TH; Saleh, AW; Velvis, HJ, 1997) |
| "Patients with sickle cell anemia were treated with daily doses of hydroxyurea, to assess pharmacokinetics, toxicity, and increase in fetal hemoglobin (Hb) production in response to the drug." | 2.67 | Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. ( Ballas, SK; Charache, S; Dover, GJ; Eckert, S; Koshy, M; Milner, PF; Moore, RD; Orringer, EP; Phillips, G; Platt, OS, 1992) |
| "Hydroxyurea treatment also resulted in decreased numbers of irreversibly sickled cells and in decreased sickling at partial oxygen saturation, increased oxygen affinity, increased total RBC cation content, and diminished potassium:chloride co-transport." | 2.67 | Hydroxyurea and erythropoietin therapy in sickle cell anemia. ( Brugnara, C; Bunn, HF; Dover, GJ; Goldberg, MA; Lacroix, L; Schapira, L, 1992) |
| "Options for the treatment of sickle cell disease are increasing." | 2.66 | Sickle Cell Disease: A Primer for Primary Care Providers. ( Kimrey, S; Saving, KL, 2020) |
| "Hydroxyurea, indicated for managing sickle cell anemia (SCA), and L-glutamine, indicated for treating sickle cell disease (SCD), were the only pharmacotherapeutic options in this patient population before the approval of crizanlizumab by the U." | 2.66 | Systematic Review of Crizanlizumab: A New Parenteral Option to Reduce Vaso-occlusive Pain Crises in Patients with Sickle Cell Disease. ( Gordeuk, VR; Han, J; Saraf, SL, 2020) |
| "New drugs and novel treatment approaches such as gene therapy are currently being tested." | 2.66 | [Sickle cell disease]. ( Dickerhoff, R; Distelmaier, L; Dührsen, U, 2020) |
| "Stroke affects around 10% of children with sickle cell anaemia (HbSS)." | 2.66 | Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. ( Estcourt, LJ; Hopewell, S; Kohli, R; Trivella, M; Wang, WC, 2020) |
| "To determine its effect in sickle cell anemia, we treated two patients with a total of four, 5-d courses (50 mg/kg per d, divided into three oral doses)." | 2.65 | Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. ( Beardsley, GP; Dover, G; Miller, B; Nathan, DG; Orkin, SH; Platt, OS, 1984) |
| "To date, sickle cell disease has been cured by hematopoietic stem cell transplantation in approximately 1,000 people, most of whom were children, and significantly ameliorated by gene therapy in a handful of subjects who have only limited follow-up thus far." | 2.61 | Emerging disease-modifying therapies for sickle cell disease. ( Carden, MA; Little, J, 2019) |
| "Sickle cell disease is an autosomal recessive inherited haemoglobinopathy which causes painful vaso-occlusive crises due to sickle red blood cell dehydration." | 2.61 | Magnesium for treating sickle cell disease. ( Abas, AB; De Franceschi, L; Palaniappan, SK; Soe, HHK; Than, NN, 2019) |
| "Hydroxyurea treatment has become more widespread, whereas the number of evidence-based indications for erythrocyte transfusion is small." | 2.58 | Treatment Options for Sickle Cell Disease. ( Meier, ER, 2018) |
| "Hydroxyurea (HU) was approved to be used in the treatment of sickle cell disease (SCD) because of its anti-sickling potential." | 2.58 | Hydroxyurea in the management of sickle cell disease: pharmacogenomics and enzymatic metabolism. ( Adorno, EV; Aleluia, MM; Carvalho, SP; da Guarda, CC; de Oliveira, RM; Gonçalves, MS; Ndidi, US; Santiago, RP; Yahouédéhou, SCMA, 2018) |
| " The maximum tolerated dose (MTD) is the regimen recommended by guidelines from a panel of National Heart, Lung, and Blood Institute (NHLBI) experts, but other dosage regimens have been used in babies (BABY-HUG) 9 to 18 months old (20 mg/kg per day) and developing countries such as India (10 mg/kg per day); however, there has been no direct comparison of the efficacy, effectiveness, or cost-effectiveness of these different regimens." | 2.58 | Low-dose hydroxycarbamide therapy may offer similar benefit as maximum tolerated dose for children and young adults with sickle cell disease in low-middle-income settings. ( Anie, K; Dogara, L; Hassan, AA; Hsu, L; Idhate, T; Ijei, I; Inusa, BPD; Lawson, JO; Qin, Y; Wale, A, 2018) |
| "Sickle cell disease is an autosomal recessive inherited haemoglobinopathy which causes painful vaso-occlusive crises due to sickle red blood cell dehydration." | 2.55 | Magnesium for treating sickle cell disease. ( Abas, AB; De Franceschi, L; Palaniappan, SK; Soe, HHK; Than, NN, 2017) |
| " Opportunities exist for pharmacokinetics model-based precision dosing of hydroxyurea to quickly achieve individual MTD." | 2.55 | Opportunities for model-based precision dosing in the treatment of sickle cell anemia. ( Dong, M; Mizuno, T; Vinks, AA, 2017) |
| "Hydroxyurea is a potent disease-modifying therapeutic agent with efficacy for the treatment of sickle cell anemia." | 2.55 | Hydroxyurea: Analytical techniques and quantitative analysis. ( Marahatta, A; Ware, RE, 2017) |
| "Stroke affects around 10% of children with sickle cell anaemia (HbSS)." | 2.55 | Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. ( Estcourt, LJ; Fortin, PM; Hopewell, S; Trivella, M; Wang, WC, 2017) |
| "Sickle cell disease is a common and life-threatening haematological disorder that affects millions of people worldwide." | 2.55 | Sickle cell disease. ( Abboud, MR; de Montalembert, M; Tshilolo, L; Ware, RE, 2017) |
| "Sickle cell disease is a genetic haemoglobin disorder, which can cause severe pain, significant end-organ damage, pulmonary complications, and premature death." | 2.53 | Regular long-term red blood cell transfusions for managing chronic chest complications in sickle cell disease. ( Cho, G; Estcourt, LJ; Fortin, PM; Hambleton, IR; Hopewell, S; Trivella, M, 2016) |
| "Sickle cell disease is probably the first known assembly disease, and its mechanism has been extensively studied." | 2.53 | Sickle cell disease: Its molecular mechanism and the one drug that treats it. ( Ferrone, FA, 2016) |
| "Hydroxyurea treatment reduces haemolysis and anaemia by increasing foetal haemoglobin, which leads to lower hypoxic transcriptional responses in blood mononuclear cells but paradoxically further increases EPO." | 2.53 | A genetic variation associated with plasma erythropoietin and a non-coding transcript of PRKAR1A in sickle cell disease. ( Ammosova, T; Castro, O; Garcia, JG; Gladwin, MT; Gordeuk, VR; Machado, RF; Miasnikova, G; Nekhai, S; Niu, X; Nouraie, M; Prchal, JT; Saraf, SL; Sergueeva, A; Shah, BN; Zhang, W; Zhang, X, 2016) |
| "Approximately 25% of patients with sickle cell anemia (SCA), however, do not respond to HU and some patients experiencing serious side effects of this chemotherapeutic agent." | 2.52 | Emerging drugs for sickle cell anemia. ( Ballas, SK; Singh, PC, 2015) |
| "Low global arginine bioavailability (GAB) is associated with numerous complications of SCD including early mortality." | 2.50 | Alterations of the arginine metabolome in sickle cell disease: a growing rationale for arginine therapy. ( Morris, CR, 2014) |
| "In persons with sickle cell anemia, preoperative transfusion therapy to increase hemoglobin levels to 10 g/dL is strongly recommended with a moderate strength recommendation to maintain sickle hemoglobin levels of less than 30% prior to the next transfusion during long-term transfusion therapy." | 2.50 | Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. ( Afenyi-Annan, AN; Ballas, SK; Buchanan, GR; Fulwood, R; Goldsmith, JC; Hassell, KL; Horton, A; James, AH; John-Sowah, J; Jordan, L; Lanzkron, SM; Lottenberg, R; Murad, MH; Ortiz, E; Savage, WJ; Tanabe, PJ; Ware, RE; Yawn, BP, 2014) |
| "Hydroxyurea has documented laboratory efficacy with increases in Hb and HbF; treatment also significantly reduces the number of painful episodes, acute chest syndrome, transfusions, and hospitalizations." | 2.49 | Hydroxycarbamide: clinical aspects. ( Ware, RE, 2013) |
| "Stroke is a significant cause of morbidity and mortality in children and adults with sickle cell disease." | 2.49 | Stroke in patients with sickle cell disease. ( Kwiatkowski, JL; Webb, J, 2013) |
| "Because malaria is thought to be a significant cause of morbidity and mortality in patients with SCD, malaria chemoprophylaxis is often recommended for these patients." | 2.49 | Systematic review of current and emerging strategies for reducing morbidity from malaria in sickle cell disease. ( Aneni, EC; Gill, CJ; Hamer, DH, 2013) |
| "Hydroxyurea is a potent inducer of fetal hemoglobin, and evidence over the past 25 years has documented its laboratory and clinical efficacy for both adults and children with SCA." | 2.47 | Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain? ( McGann, PT; Ware, RE, 2011) |
| "Hydroxyurea is a prototypic therapeutic option; it can be administered with minimal side effects, has a relatively wide therapeutic window, and has mechanisms of action that address pathophysiologic pathways of sickling, vaso-occlusion, hemolysis, and organ damage." | 2.46 | Hydroxyurea for children with sickle cell disease. ( Heeney, MM; Ware, RE, 2010) |
| "Hydroxyurea has many characteristics of an ideal drug for sickle cell anemia (SCA) and provides therapeutic benefit through multiple mechanisms of action." | 2.46 | How I use hydroxyurea to treat young patients with sickle cell anemia. ( Ware, RE, 2010) |
| " Accordingly, we conclude that clinical trials in SCD designed to increase the bioavailability of NO or association studies in which SCD clinical manifestations are related to plasma hemoglobin via its surrogates should be viewed with caution." | 2.46 | Pulmonary hypertension and nitric oxide depletion in sickle cell disease. ( Bunn, HF; Dover, GJ; Hebbel, RP; Nathan, DG; Platt, OS; Rosse, WF; Ware, RE, 2010) |
| "Treatment with hydroxyurea is usually considered for patients with recurrent vaso-occlusive events, but additional indications for treatment may include laboratory markers of disease severity and evidence of chronic organ dysfunction." | 2.45 | Advances in the use of hydroxyurea. ( Aygun, B; Ware, RE, 2009) |
| "Hydroxyurea (HU) is an effective oral drug for the management of homozygous sickle cell anemia (SS) in part because it increases fetal hemoglobin (HbF) levels within sickle red blood cells (RBCs) and thus reduces sickling." | 2.44 | Pharmaco-proteomic study of hydroxyurea-induced modifications in the sickle red blood cell membrane proteome. ( Choudhary, PK; Ghatpande, SS; Goodman, SR; Quinn, CT, 2008) |
| " Common adverse events were reversible mild-to-moderate neutropenia, mild thrombocytopenia, severe anemia, rash or nail changes (10%), and headache (5%)." | 2.44 | Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children. ( Bass, EB; Beach, MC; Haywood, C; Lanzkron, S; Park, H; Segal, JB; Strouse, JJ; Wilson, RF; Witkop, C, 2008) |
| "The root cause of sickle cell disease is a single beta-globin gene mutation coding for the sickle beta-hemoglobin chain." | 2.44 | Sickle cell anemia, the first molecular disease: overview of molecular etiology, pathophysiology, and therapeutic approaches. ( Steinberg, MH, 2008) |
| "Stroke is one of the most devastating complications of sickle cell disease, but current research has led to improved understanding of its pathogenesis and to new approaches in the prevention of both primary and secondary stroke." | 2.44 | The pathophysiology, prevention, and treatment of stroke in sickle cell disease. ( Wang, WC, 2007) |
| "Cerebral vasculopathy in sickle cell anemia (HbSS) is manifest clinically as cerebral infarction and intracranial hemorrhage." | 2.44 | Overt and incomplete (silent) cerebral infarction in sickle cell anemia: diagnosis and management. ( Powars, DR; Wong, WY, 2007) |
| " The participation of nitric oxide (NO) in oxidative reactions causes a reduction in NO bioavailability and contributes to vascular dysfunction in SCD." | 2.44 | Redox-dependent impairment of vascular function in sickle cell disease. ( Aslan, M; Freeman, BA, 2007) |
| "Hydroxyurea is a prototypic therapeutic option; it can be administered with minimal side effects, has a relatively wide therapeutic window, and has mechanisms of action that address pathophysiologic pathways of sickling, vaso-occlusion, hemolysis, and organ damage." | 2.44 | Hydroxyurea for children with sickle cell disease. ( Heeney, MM; Ware, RE, 2008) |
| "Hydroxyurea has demonstrated efficacy in adults with sickle cell disease." | 2.44 | Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease. ( Bass, EB; Beach, MC; Haywood, C; Lanzkron, S; Park, H; Segal, JB; Strouse, JJ; Wilson, R; Witkop, C, 2008) |
| "Hydroxyurea has been shown to prevent vaso-occlusive crises by increasing the amount of foetal haemoglobin." | 2.43 | [Pathophysiology and treatment of sickle-cell disease]. ( Biemond, BJ; Peters, M; van Beers, EJ, 2005) |
| "Sickle cell disease is a systemic disorder that is caused by a mutation (Glu6Val) in the gene that encodes beta globin." | 2.43 | Pathophysiologically based drug treatment of sickle cell disease. ( Steinberg, MH, 2006) |
| "Hydroxyurea is a relatively new treatment for sickle cell disease." | 2.42 | Nitric oxide production from hydroxyurea. ( King, SB, 2004) |
| "Sickle cell disease is a serious and life threatening disease that affects approximately 1 in 600 African-Americans." | 2.41 | Sickle cell disease. ( Fixler, J; Styles, L, 2002) |
| "Hydroxyurea promotes HbF production by perturbing the maturation of erythroid precursors." | 2.41 | Hydroxyurea treatment for sickle cell disease. ( Steinberg, MH, 2002) |
| "Sickle cell disease is a recessively inherited condition in which synthesis of haemoglobin is abnormal." | 2.41 | Acute complications of sickle cell disease in children. ( , 2001) |
| "Poorly controlled postoperative pain also can worsen an impending painful crisis." | 2.41 | New advances in the treatment of sickle cell disease: focus on perioperative significance. ( Dix, HM, 2001) |
| "Children with sickle cell anemia provide the best opportunity to assess the efficacy of hydroxyurea (HU) in preventing complications and progressive organ damage." | 2.40 | Hydroxyurea in children: present and future. ( Vichinsky, EP, 1997) |
| " Guidelines regarding patient selection, dosing schedules, treatment goals, and short- and long-term monitoring parameters need to be established." | 2.40 | Use of hydroxyurea in children with sickle cell disease: what comes next? ( Ohene-Frempong, K; Smith-Whitley, K, 1997) |
| " However, application of these drugs at large is not yet justified because a series of questions concerning their long-term efficacy, the correct dosage and timing, their tolerance and toxicity, and the potential long-term dangers, including mutagenicity are still unresolved." | 2.40 | New therapies for the haemoglobinopathies. ( Loukopoulos, D, 1997) |
| "Hydroxyurea has been shown to stimulate Hb F synthesis, leading to a reduction in the incidence of hemolytic and vaso-occlusive manifestations; however, hydroxyurea has no role in the treatment of crises already in progress." | 2.40 | Hydroxyurea in the treatment of sickle-cell anemia. ( Howard, LW; Kennedy, LD, 1997) |
| "Only hydroxyurea has shown significant clinical effects in terms of reduction of pain-crises, chest syndrome and transfusions in sickle-cell patients." | 2.40 | Pharmacological induction of foetal haemoglobin synthesis in sickle-cell disease. ( Hillen, HF; Saleh, AW, 1997) |
| " The recent development of improved assays for hydroxyurea should have benefits for future pharmacokinetic studies." | 2.40 | Pharmacokinetics and pharmacodynamics of hydroxyurea. ( Gwilt, PR; Tracewell, WG, 1998) |
| "A patient being treated for sickle cell disease with hydroxyurea (1 g/d) conceived, and drug treatment was discontinued at nine weeks gestational age." | 2.40 | Hydroxyurea use during pregnancy: a case report in sickle cell disease and review of the literature. ( Diav-Citrin, O; Hunnisett, L; Koren, G; Sher, GD, 1999) |
| " The mean dosage associated with clinical benefits is 20 mg/kg/d; the HbF increase is not perfectly correlated with clinical benefits, so that a dosage increase should be considered based on the absence of a clinical improvement after three months." | 2.40 | [Hydroxyurea and other agents stimulating synthesis of fetal hemoglobin]. ( de Montalembert, M, 1999) |
| " Guidelines concerning patient selection, dosing schedules, and monitoring protocols as well as exhaustive registries for the detection of long-term side effects are necessary." | 2.40 | Long-term hydroxyurea treatment in young sickle cell patients. ( Elion, J; Labie, D; Maier-Redelsperger, M, 1999) |
| "The lower legs of homozygous sickle cell anemia patients are areas of marginal vascularity where minor abrasions become foci of inflammation." | 2.40 | [Falciform anemia and Plasmodium falciparum malaria: a threat to flap survival?]. ( Humbert, J; Loutan, L; Mariéthoz, S; Montandon, D; Pittet, B, 1999) |
| "Hydroxyurea (HU) has become the most widely used agent, although its effectiveness in increasing HbF levels and the number of F cells is highly variable." | 2.38 | Fetal hemoglobin reactivation in baboon and man: a short perspective. ( DeSimone, J; Heller, P; Lavelle, D, 1993) |
| "Hydroxyurea has now been shown to substantially increase HbF in patients with sickle cell anemia." | 2.38 | Hydroxyurea induction of fetal hemoglobin synthesis in sickle-cell disease. ( Charache, S; Dover, GJ, 1992) |
| " Chronic administration of the drug can lead to very impressive increases in Hb F synthesis and apparent clinical benefit." | 2.38 | Fetal hemoglobin, sickling, and sickle cell disease. ( Charache, S, 1990) |
| "Hydroxyurea treatment restores the abnormal immune parameters in children with sickle cell anemia." | 1.91 | Impact of hydroxyurea on lymphocyte subsets in children with sickle cell anemia. ( Abdel-Aziz, SM; Elhoufey, A; Elsayh, KI; Embaby, MM; Ghandour, AMA; Hetta, HF; Mohamed, IL; Saad, K; Youssef, MAM; Zahran, AM; Zahran, ZAM, 2023) |
| " We did not observe any significant adverse effects during the treatment period." | 1.91 | Evaluation of pharmacological efficacy and safety of hydroxyurea in sickle cell disease: Study of a pediatric cohort from Chhattisgarh, India. ( Chandak, GR; Lad, H; Nahrel, R; Naskar, S; Patra, PK; Punyasri Pasupuleti, SKDB; Sihare, P, 2023) |
| "Splenomegaly is an unexplained risk factor for malaria infections among children with SCA in Africa." | 1.91 | Hydroxyurea treatment is associated with lower malaria incidence in children with sickle cell anemia in sub-Saharan Africa. ( Aygun, B; Howard, TA; Lane, A; Latham, TS; McElhinney, K; Olupot-Olupot, P; Santos, B; Smart, LR; Stuber, SE; Tomlinson, G; Tshilolo, L; Ware, RE; Williams, TN, 2023) |
| "Hydroxyurea use was defined as at least one hospital admission with hydroxyurea listed as a medication." | 1.91 | Pediatric Sickle Cell Disease Patients on Hydroxyurea Have Higher Rates of Surgical Splenectomy. ( Beyene, TJ; Burdjalov, M; Menchaca, AD; Minneci, PC; Olutoye, OO; Style, CC; Villella, AD, 2023) |
| "Cardiac abnormalities seen in sickle cell anemia (SCA) include diastolic dysfunction, which has been shown to be associated with high morbidity and early mortality." | 1.91 | Longitudinal effect of disease-modifying therapy on left ventricular diastolic function in children with sickle cell anemia. ( Hankins, JS; Joshi, V; Kang, G; Martinez, HR; Okhomina, VI; Rai, P, 2023) |
| "Youths with sickle cell anemia (SCA) are at risk of pain crises, stroke, and early death." | 1.91 | Changes in Hydroxyurea Use Among Youths Enrolled in Medicaid With Sickle Cell Anemia After 2014 Revision of Clinical Guidelines. ( Anders, D; Cogan, LW; Dombkowski, KJ; Goel, A; Green, NS; Lisabeth, LD; Peng, HK; Reeves, SL; Wing, JJ, 2023) |
| "Hydroxyurea (HU) is an effective but underused disease-modifying therapy for patients with sickle cell anaemia (SCA)." | 1.91 | Successful quality improvement project to increase hydroxyurea prescriptions for children with sickle cell anaemia. ( Alvarez, OA; Buitrago-Mogollon, T; Clay, ELJ; Courtlandt, C; Echenique, S; Kanter, J; Noonan, L; Osunkwo, I; Rodriguez-Cortes, H; Strouse, JJ, 2023) |
| "Renal dysfunction is common in children with SCD and can be detected early using simple urine parameters and can be prevented with an early and appropriate dosage of HU with good compliance." | 1.91 | Early detection of glomerular dysfunction and renal tubulopathy in children with sickle cell disease in India. ( Ghildiyal, R; Karapurkar, S; Keshwani, R; Shah, N; Sharma, S, 2023) |
| "Both diagnosis and treatment of hemoglobinopathies have been associated with an increased risk of fertility impairment." | 1.91 | Desire for biological parenthood and patient counseling on the risk of infertility among adolescents and adults with hemoglobinopathies. ( Balcerek, M; Borgmann-Staudt, A; Diepold, M; Diesch-Furlanetto, T; Drexler, B; Dülberg, J; Eisenreich, B; Friedrich, LA; Hegemann, I; Infanti, L; Kager, L; Kroiss, S; Mandic, L; Merki, R; Njue, LM; Radauer-Plank, AC; Roll, S; Rovó, A; Salow, V; Scheinemann, K; Schilling, R; Schneider, M; Sommerhäuser, G, 2023) |
| " These data endorse broad, safe, and long-term use of HU for SCA in malaria-endemic countries and provide a novel biological model for the treatment of a genetic disorder with simultaneous, adjunct therapy of a life-threatening infection needed in a global health setting." | 1.91 | Simultaneous adjunctive treatment of malaria and its coevolved genetic disorder sickle cell anemia. ( Haldar, K; Mohandas, N; Safeukui, I; Ware, RE, 2023) |
| " We estimated the potential nonadherent days in individuals exhibiting a drop in biomarker levels by modifying the dosing profile using a probabilistic approach." | 1.91 | Leveraging mathematical modeling to analyze nonadherence for hydroxyurea therapy in sickle cell disease. ( Estepp, JH; Pandey, A; Raja, R; Ramkrishna, D, 2023) |
| "Hydroxyurea use was associated with increased pain severity (β, 1." | 1.91 | Examining Mental Health, Education, Employment, and Pain in Sickle Cell Disease. ( Bauer, A; Calhoun, CL; Gibson, R; Glassberg, J; Hankins, JS; Harris, KM; Hussain, FA; King, AA; Masese, R; Melvin, CL; Preiss, L; Treadwell, M; Varughese, T, 2023) |
| "DISEASE MODIFYING TREATMENTS FOR SICKLE CELL DISEASE." | 1.91 | [Disease modifying treatments for sickle cell disease]. ( Lionnet, F; Pondarré, C, 2023) |
| "Hydroxyurea treatment averted an expected 1." | 1.91 | Cost-Effectiveness of Hydroxyurea for Sickle Cell Anemia in a Low-Income African Setting: A Model-Based Evaluation of Two Dosing Regimens. ( Blomberg, B; Hume, HA; John, CC; Kasirye, P; Nabaggala, C; Opoka, RO; Robberstad, B; Teigen, D; Ware, RE, 2023) |
| " To investigate the effect of hydroxyurea treatment on smooth muscle relaxation of corpus cavernosum induced by stimulation of the NO-cGMP pathway in SCD transgenic mice and endothelial NO synthase gene-deficient (eNOS-/-) mice, which are used as model of priapism associated with the low bioavailability of endothelial NO." | 1.91 | Hydroxyurea does not reverse functional alterations of the nitric oxide-cGMP pathway associated with priapism phenotype in corpus cavernosum from sickle cell mouse. ( Calmasini, FB; Costa, FF; da Silva Pereira, P; Pereira, DA; Reis, LO; Silva, FH; Silveira, THR, 2023) |
| "Hydroxyurea treatment lowered TNF-induced VCAM1 and NOS3 expression but did not affect heme-induced HMOX1 expression." | 1.72 | VCAM1, HMOX1 and NOS3 differential endothelial expression may impact sickle cell anemia vasculopathy. ( Coelho, A; Faustino, P; Silva, M; Vargas, S, 2022) |
| "Although the prevalence of sickle cell anemia is high in Haiti, treatment with hydroxyurea (HU) is uncommon." | 1.72 | Introduction of Hydroxyurea Therapy to a Cohort of Sickle Cell Patients in Northern Haiti. ( Canarie, MF; Faustino, EVS; Joseph, W; Mondesir, W; Paul-Hanna, M, 2022) |
| "Hydroxyurea adherence was assessed by video directly observed therapy or electronic pill bottle and medication administration record." | 1.72 | Impact of hydroxyurea dose and adherence on hematologic outcomes for children with sickle cell anemia. ( Badawy, SM; Beeman, C; Creary, SE; Holl, J; King, K; Liem, RI; McGann, PT; O'Brien, SH; Stanek, J, 2022) |
| "Treatment with hydroxyurea and CTT were obtained from the chart review." | 1.72 | Evolution of Extracranial Internal Carotid Artery Disease in Children With Sickle Cell Anemia. ( Alison, M; Balandra, S; Belarbi, N; Bernaudin, F; Cussenot, I; Elmaleh, M; Ithier, G; Kheniche, A; Ntorkou, A; Oloukoi, C; Ouaziz, H; Sekkal, A; Tanase, A; Verlhac, S, 2022) |
| "Hydroxyurea (HU) is the key drug to treat Sickle cell anemia (SCA)." | 1.72 | Epicatechin exerts dual action to shield sickling and hydroxyurea-induced myelosuppression: Implication in sickle cell anemia management. ( Digra, SK; Dogra, A; Gour, A; Kour, D; Kumar, A; Manhas, D; Nandi, U; Wazir, P, 2022) |
| "Hydroxyurea (HU) has proven benefit in sickle cell anemia (SCA), but HU is still underutilized." | 1.72 | Ten-year longitudinal analysis of hydroxyurea implementation in a pediatric sickle cell program. ( Briere, N; Dulman, R; Lewis, A; Notarangelo, B; Park, JA; Phan, V; Yang, E, 2022) |
| "Although gallstones are a known complication, there is variability in estimates of disease burden and uncertainty in the association between sex and gall bladder disease (GBD)." | 1.72 | Age- and sex-specific rates of gall bladder disease in children with sickle cell disease. ( Agawu, A; Feudtner, C; Shults, J; Smith-Whitley, K, 2022) |
| "A total of 200 children with sickle cell anemia completed neurocognitive testing (109 males, 91 females; mean age 12." | 1.72 | Neurocognitive functioning in children with sickle cell anemia and history of abnormal transcranial doppler ultrasonography. ( Gossett, J; Hankins, JS; Heitzer, AM; Kang, G; King, AA; Krull, K; Longoria, JN; Raches, D; Schreiber, J; Wang, W, 2022) |
| "Given the complex pathology of sickle cell anemia (SCA) and low adherence to hydroxyurea (HU) treatment, there is a need to seek parameters that identify recent changes in patient status." | 1.72 | Advanced clinical parameters: A complementary hydroxyurea adherence evaluation in sickle cell anemia treatment. ( Fogliatto, LM; Jahnke, VS; Lessa, CLM; Moreira, ID; Rocha, GLG; Rotta, LN; Schmitz, LD; Werlang, MC, 2022) |
| "Splenomegaly was common in all age groups, with 28% of children overall having larger spleens than the average for their age." | 1.72 | The significance of spleen size in children with sickle cell anemia. ( Braunstein, TH; Brewin, JN; Glenthøj, A; Kurtzhals, JAL; Nardo-Marino, A; Petersen, J; Rees, DC; Williams, TN, 2022) |
| " Hydroxyurea, when combined with iron chelators such as DFX, provides an additional benefit of iron chelation in patients receiving chronic transfusion therapy." | 1.72 | Iron Chelators, Such as Deferasirox, When Combined With Hydroxyurea, Provide an Additional Benefit of Iron Chelation in Patients Receiving Chronic Transfusion Therapy. ( Delicou, S; Koskinas, J; Manganas, K; Xydaki, A, 2022) |
| " From dose-response measurements, 106 of the 12,657 compounds exhibit statistically significant antisickling at concentrations ranging from 31 nM to 10 μM." | 1.72 | Phenotypic screening of the ReFRAME drug repurposing library to discover new drugs for treating sickle cell disease. ( Cellmer, T; Chatterjee, AK; Conrey, AK; Dunkelberger, EB; Eaton, WA; Henry, ER; Hofrichter, J; Hsieh, MM; Li, Q; Metaferia, B; Staton, D; Thein, SL; Tisdale, JF, 2022) |
| "Hydroxyurea (HU) is an evidence-based therapy that is currently the most effective drug for sickle cell disease (SCD)." | 1.72 | Determinants of hydroxyurea use among doctors, nurses and sickle cell disease patients in Nigeria. ( Asala, SA; Brown, BJ; Chianumba, RI; Isa, HA; Nnebe-Agumadu, U; Nnodu, OE; Nwegbu, MM; Okocha, EC; Peprah, E, 2022) |
| "Hydroxyurea (HU) is an old and commonly used medication that demonstrated its effectiveness in reducing the risk of VOCs and the incidence of hospitalization." | 1.72 | The impact of Hydroxyurea on the rates of Vaso-occlusive crises in patients with sickle cell disease in Saudi Arabia: a single-center study. ( Al-Hazzaa, MS; Al-Malki, HS; Al-Mufarrij, SM; Al-Murdhi, FM; Alanazi, M; Albabtain, MA; Alkhalifah, SA; Almasaoud, MA; AlRuthia, Y; Alshiakh, AA, 2022) |
| "Hydroxyurea (HU) has been useful in preventing sickle cell vaso-occlusive crises (VOC)." | 1.72 | Impact of hydroxyurea on hospital stay & analgesic utilization in sickle cell anaemia with vaso-occlusive crises. ( Hiregoudar, M; Meher, S; Mohanty, PK; Soren, UK; Sukla, SK, 2022) |
| "Hydroxyurea (HU) alone has the potential to prevent one out of every three deaths due to sickle cell disease (SCD) and almost all forms of disabilities caused by SCD." | 1.72 | Promoting access of hydroxyurea to sickle cell disease individuals: Time to make it an essential medicine. ( Balandya, E; Chirande, L; Jonathan, A; Kida, I; Kilonzi, M; Makani, J; Mlyuka, H; Rugajo, P; Sirili, N; Tutuba, H, 2022) |
| "Hydroxyurea treatment revealed no impact on TL." | 1.72 | Telomere length and telomere repeat-binding protein in children with sickle cell disease. ( Al-Daghri, NM; Ansari, MGA; Hamza, MA; Mohammed, AK; Rayis, MA; Saeed, AA; Suliman, ME, 2022) |
| "Sickle beta+thalassemia is considered to be a mild form of sickle cell disease." | 1.72 | Multifocal Osteonecrosis in a 3-Year-old Child With Sickle Beta Plus Thalassemia. ( Bhasin, N; Desoky, SM; Price, N, 2022) |
| " However, this study found that the poor potency and oral bioavailability of compound 1 limits the development of this inducer for clinical use." | 1.62 | Potent and orally active purine-based fetal hemoglobin inducers for treating β-thalassemia and sickle cell disease. ( Chen, CT; Chou, YC; Hsieh, MY; Hsu, T; James Shen, CK; Jiaang, WT; Kung, FC; Lai, ZS; Lin, CH; Lu, CT; Yeh, TK, 2021) |
| "Data on a total of 100 patients with sickle cell anemia were analyzed; 60 (60%) were being treated with hydroxyurea." | 1.62 | Longitudinal analysis of cardiac abnormalities in pediatric patients with sickle cell anemia and effect of hydroxyurea therapy. ( Appiah-Kubi, A; Aygun, B; Dhar, A; Gruber, D; Leung, TM; Mitchell, E; Serigano, O, 2021) |
| " However, as compared with the university clinic, these satellite clinics do not offer immediate access to HU dosing laboratory results and a nurse clinician calls families with HU dose adjustments after the clinic visit." | 1.62 | Impact of telehealth visits on hydroxyurea response in sickle cell anemia. ( Bhatia, S; Hilliard, L; Howard, T; Lebensburger, J; Pernell, B; Shaner, S, 2021) |
| "Sickle cell anemia is a type of hemoglobinopathy characterized by a specific mutation in the beta globin gene with the consequent generation of an unstable hemoglobin that crystallizes in a state of hypoxia." | 1.62 | [Disease genotype, haplotypes, diagnosis and associated studies in sickle cell anemia]. ( Benavides-Benítez, E; Bernal, JE; Briceño-Balcázar, I; Díaz-Matallana, M; Márquez-Benítez, Y; Martínez-Lozano, JC, 2021) |
| " Computer program dosing recommendations were the same as manual dosing decisions made using the same algorithm for all patients and at all times." | 1.62 | Computer Algorithm-Based Hydroxyurea Dosing Facilitates Titration to Maximum Tolerated Dose in Sickle Cell Anemia. ( Conrey, A; Fisher, C; Fitzhugh, CD; Hargrett, S; Hsieh, MM; Jackson, M; Jeffries, N; Johnson, D; Kaplarevic, M; Martin, S; Oldham, M; Olkhanud, P; Pittman, C; West, K, 2021) |
| "Benserazide is used in the treatment of Parkinson's disease and was noticed to induce gamma globin in preclinical models." | 1.62 | Benserazide as a potential novel fetal hemoglobin inducer: an observational study in non-carriers of hemoglobin disorders. ( Costa, FF; de Azevedo, PC; Fertrin, KY; Leonardo, DP; Olops, L; Piovesana, LG; Santos, MEHP; Tavares, AHJ; Vendrame, F, 2021) |
| "Hydroxyurea treatment augmented plasma nitrite and attenuated plasma arginase in HbSS mice." | 1.62 | Hydroxyurea improves nitric oxide bioavailability in humanized sickle cell mice. ( Dunaway, LS; Kasztan, M; Molina, PA; Pollock, DM; Pollock, JS; Sedaka, R; Taylor, CM, 2021) |
| "Hydroxyurea is a safe and effective medication that reduces or prevents most SCA-related complications." | 1.62 | Implementation of near-universal hydroxyurea uptake among children with sickle cell anemia: A single-center experience. ( Clapp, K; Fenchel, L; Kalfa, TA; Karkoska, K; Malik, P; McGann, PT; Niss, O; Quinn, CT; Todd, K; Ware, RE, 2021) |
| "hydroxyurea was available at 41/188 (22%) participating pharmacies, but more frequently at those of a big city than at those of a small city (34/96 versus 7/92)." | 1.62 | [Sickle cell disease in the Democratic Republic of the Congo: what are the barriers to treatment using hydroxyurea?] ( Cibeyibeyi, GK; Gulbis, B; Mukinayi, BM; Tumba, GD, 2021) |
| "Pain was the most common clinical event observed among all patients." | 1.62 | Clinical Features and Outcome of Sickle Cell Disease in a Tertiary Center in Northern Lebanon: A Retrospective Cohort Study in a Local, Hospital-Associated Registry. ( Al Alam, C; El Ojaimi, C; Hamad, T; Inati, A; Kanakamedala, H; Pilipovic, V; Sabah, R, 2021) |
| "Hydroxyurea has been utilized extensively for management of SCA, but its effects on brain function have not been established." | 1.62 | Effects of hydroxyurea on brain function in children with sickle cell anemia. ( Ding, J; Hankins, JS; Heitzer, AM; Helton, K; Hwang, SN; Kang, G; Schreiber, JE; Wang, WC; Zou, P, 2021) |
| "Hydroxyurea has been shown to positively modify sickle cell disease pathogenesis, but its use is low among Nigerian sickle cell anaemia (SCA) patients because of effectiveness and safety concerns." | 1.56 | Effectiveness and Safety of Hydroxyurea in the Treatment of Sickle Cell Anaemia Children in Jos, North Central Nigeria. ( Adekola, K; Afolaranmi, TO; Diaku-Akinwumi, IN; Ofakunrin, AOD; Oguche, S; Okpe, ES; Sagay, AS; Zoakah, AI, 2020) |
| "Hydroxyurea (HU) has been shown to reduce the frequency and severity of vaso-occlusive episodes in SCD." | 1.56 | Higher oxygen saturation with hydroxyurea in paediatric sickle cell disease. ( Arigliani, M; Bossley, CJ; Chakravorty, S; Gupta, A; Inusa, B; Kozlowska, W; Rees, D; Ruiz, G; Singh, B; van Geyzel, L, 2020) |
| "This study showed that skin carcinogenesis did not occur in our series of SCD patients exposed to transforming events such as long term HU treatment or prolonged leg ulcers." | 1.56 | Sickle cell disease induces resistance to cutaneous carcinogenesis. ( Aractingi, S; Habibi, A; Lionnet, F; Senet, P; Soutou, B, 2020) |
| " In 16 women who were lactating volunteers, we documented hydroxyurea transferred into breastmilk with a relative infant dosage of 3." | 1.56 | Hydroxyurea Exposure in Lactation: a Pharmacokinetics Study (HELPS). ( Dong, M; Marahatta, A; McElhinney, K; Vinks, AA; Ware, JL; Ware, RE, 2020) |
| " Our results showed, for the first time, a significantly increased expression of HIF-1α and VEGF genes in patients with SCA and an inverse dose-response relationship with hydroxyurea therapy." | 1.56 | Gene expression of HIF-1α and VEGF in response to hypoxia in sickle cell anaemia: Influence of hydroxycarbamide. ( Lemes, RPG; Pedrosa, AM, 2020) |
| "Hydroxyurea is a US Food and Drug Administration-approved medication that reduces disease complications, acute health care utilization, and costs." | 1.56 | Development of the InCharge Health Mobile App to Improve Adherence to Hydroxyurea in Patients With Sickle Cell Disease: User-Centered Design Approach. ( Alberts, NM; Badawy, SM; Estepp, JH; Hankins, JS; Hodges, J; Homayouni, R; Khan, H; Klesges, L; Norell, S; Nwosu, C; Porter, JS; Smeltzer, MP, 2020) |
| "The complex pathophysiology of sickle cell anemia (SCA) involves intravascular hemolytic processes and recurrent vaso-occlusion, driven by chronic vascular inflammation, which result in the disease's severe clinical complications, including recurrent painful vaso-occlusive episodes." | 1.56 | Beneficial Effects of Soluble Guanylyl Cyclase Stimulation and Activation in Sickle Cell Disease Are Amplified by Hydroxyurea: In Vitro and In Vivo Studies. ( Almeida, CB; Brito, PL; Brockschnieder, D; Chweih, H; Conran, N; Costa, FF; Ferreira, WA; Franco-Penteado, CF; Frenette, PS; Garcia, F; Gotardo, EMF; Lanaro, C; Leonardo, FC; Miguel, LI; Saad, STO; Sandner, P; Stasch, JP; Torres, L, 2020) |
| "Hydroxyurea is an efficacious treatment for sickle cell disease (SCD), but adoption is low among individuals with SCD." | 1.56 | Intentional and unintentional nonadherence to hydroxyurea among people with sickle cell disease: a qualitative study. ( Badawy, SM; Calhoun, C; Hankins, JS; Hodges, JR; Khan, H; King, A; Luo, L; Norell, S; Nwosu, C; Phillips, SM; Porter, J; Rojas Smith, L; Tanabe, P; Treadwell, M, 2020) |
| "Hydroxyurea is an approved therapy in the management of children suffering from sickle cell disease (SCD)." | 1.56 | Blood pressure, hematologic and biochemical changes following L-arginine supplementation in children with sickle cell anaemia already on hydroxyurea therapy. ( Eimunjeze, OP; Jaja, SI; Ogungbemi, SI; Temiye, EO, 2020) |
| "Hydroxyurea has been proposed to mediate these effects through a mechanism of increasing cellular cGMP levels." | 1.56 | A novel, highly potent and selective phosphodiesterase-9 inhibitor for the treatment of sickle cell disease. ( Abdulla, F; Belcher, JD; Carvalho, C; Chen, C; Edwards, D; Fricot, A; Hermine, O; Maciel, TT; McArthur, JG; Nguyen, J; Nguyen, P; Parachikova, A; Ribeil, JA; Svenstrup, N; Vercellotti, GM, 2020) |
| "Hydroxyurea is a disease-modifying medication for patients with sickle cell disease (SCD)." | 1.51 | A Multidimensional Electronic Hydroxyurea Adherence Intervention for Children With Sickle Cell Disease: Single-Arm Before-After Study. ( Chisolm, D; Creary, S; Hankins, J; O'Brien, SH; Stanek, J, 2019) |
| "Hydroxyurea is a medication that can ameliorate risk but to benefit, adolescents must adhere to treatment." | 1.51 | Allocation of Treatment Responsibility and Adherence to Hydroxyurea Among Adolescents With Sickle Cell Disease. ( Chisolm, DJ; Creary, SE; Crosby, LE; Modi, AC; Nwankwo, C; O'Brien, SH; Stanek, JR, 2019) |
| "Hydroxyurea (HU) has been widely used in sickle cell disease." | 1.51 | Occurrence of acute myeloid leukemia in hydroxyurea-treated sickle cell disease patient. ( El-Deiry, WS; Finnberg, NK; Pu, JJ; Regan, S; Yang, X, 2019) |
| "Hydroxyurea (HU) is a well-known Hb F-inducing agent with proven clinical and laboratory efficacy for patients with sickle cell disease." | 1.51 | Barriers to the use of hydroxyurea in the management of sickle cell disease in Nigeria. ( Adekile, AD; Adeyemo, TA; Bolarinwa, AB; Diaku-Akinwunmi, IN; Ojewunmi, OO, 2019) |
| "The Stroke Prevention Trial in Sickle Cell Anemia (STOP) and Optimizing Primary Stroke Prevention in Sickle Cell Anemia (STOP 2) trials established routine transcranial Doppler ultrasound (TCD) screening, with indefinite chronic red cell transfusions (CRCT) for children with abnormal TCD as standard of care." | 1.51 | Ischemic stroke in children and young adults with sickle cell disease in the post-STOP era. ( Adams, RJ; Brown, L; Debenham, E; Fullerton, HJ; Kanter, J; Kwiatkowski, JL; Voeks, JH, 2019) |
| "sickle cell disease is a genetic disease with autosomal inheritance associated with haemoglobin structure abnormality which causes the formation of hemoglobin S." | 1.51 | [Digestives diseases associated to sickle cell anemia in Lubumbashi: epidemiological and clinical aspects]. ( Banza, MI; Cabala, VPK; Lire, LI; Mulefu, JP; N'dwala, YTB; Tshiamala, IB, 2019) |
| "Hydroxyurea was the only approved treatment for SCD for nearly 2 decades; in 2017, L-glutamine oral powder was approved for the prevention of the acute complications of SCD." | 1.51 | Sickle cell disease: current treatment and emerging therapies. ( Brown, C; Hoppe, CC; Neumayr, LD, 2019) |
| "Hydroxyurea (HU) has been shown to reduce elevated TCD velocities in children with SCD." | 1.51 | Annual stroke incidence in Nigerian children with sickle cell disease and elevated TCD velocities treated with hydroxyurea. ( Asinobi, A; Brown, BJ; Esione, A; Ibeh, J; Lagunju, I; Oyinlade, AO; Sodeinde, OO, 2019) |
| "Hydroxyurea is FDA-approved and now increasingly used for children with sickle cell anemia (SCA), but dosing strategies, pharmacokinetic (PK) profiles, and treatment responses for individual patients are highly variable." | 1.51 | Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia. ( Dong, M; Howard, TA; Kalfa, TA; Lane, A; Malik, P; Marahatta, A; McGann, PT; Mizuno, T; Niss, O; Quinn, CT; Vinks, AA; Ware, RE, 2019) |
| "Hydroxyurea use was defined as >30 days' supply of filled prescriptions." | 1.51 | Hydroxyurea Initiation Among Children With Sickle Cell Anemia. ( Dombkowski, KJ; Gondhi, JP; Jary, HK; Lisabeth, LD; Raphael, JL; Reeves, SL, 2019) |
| "Hydroxyurea (HU) was recently described as a substitute for chronic transfusion for children with sickle cell disease (SCD) and abnormal transcranial Doppler (TCD) velocities who have received at least 1 year of transfusions." | 1.48 | Changes in Transcranial Doppler Flow Velocities in Children with Sickle Cell Disease: The Impact of Hydroxyurea Therapy. ( Adegoke, SA; Braga, JAP; Figueiredo, MS; Macedo-Campos, RS; Silva, GS, 2018) |
| "Hydroxyurea (HU) has proven hematologic and clinical benefits, especially when escalated to the maximum tolerated dose (MTD)." | 1.48 | A Retrospective Analysis of Sociodemographic and Hematologic Characteristics Associated With Achieving Optimal Hydroxyurea Therapy in Children With Sickle Cell Disease. ( Bazo-Alvarez, JC; George, PE; Sheehan, VA, 2018) |
| " Optimal therapeutic dosing and adherence to HC treatment significantly reduces 30-day readmissions among patients with SCD." | 1.48 | Hydroxycarbamide adherence and cumulative dose associated with hospital readmission in sickle cell disease: a 6-year population-based cohort study. ( Calip, GS; Gordeuk, VR; Han, J; Nutescu, EA; Saraf, SL; Zhou, J, 2018) |
| "Boys facing cancer and cytotoxic therapies are regarded as the major group who will benefit from novel fertility preservation techniques." | 1.48 | Spermatogonial quantity in human prepubertal testicular tissue collected for fertility preservation prior to potentially sterilizing therapy. ( Albalushi, H; Alves-Lopes, JP; Bjarnason, R; Henningsohn, L; Jahnukainen, K; Keros, V; Kurek, M; Langenskiöld, C; Mitchell, RT; Norén Nyström, U; Petersen, C; Reda, A; Romerius, P; Söder, O; Stukenborg, JB; Sundin, M; Töhönen, V; Vogt, H, 2018) |
| "Hydroxyurea (HU) is a key drug therapy for individuals with sickle cell anemia (SCA), yet its clinical and hematologic responses can be variable." | 1.46 | An age dependent response to hydroxyurea in pediatric sickle cell anemia patients with alpha thalassemia trait. ( Cohen, HW; Driscoll, C; Figueiredo, L; Ireland, K; Manwani, D; Morrone, K; Wei, C, 2017) |
| "Hydroxyurea is a highly effective treatment for SCD but less so for β-thalassemia, and does not represent curative therapy." | 1.46 | Clinical Features of β-Thalassemia and Sickle Cell Disease. ( McGann, PT; Nero, AC; Ware, RE, 2017) |
| "Hydroxyurea has proven beneficial in the treatment of SCD and prevention of disease-related complications." | 1.43 | Hydroxyurea in Pediatric Patients With Sickle Cell Disease: What Nurses Need to Know. ( Rees, AL, 2016) |
| "Hydroxyurea has emerged as the primary disease-modifying therapy for patients with sickle cell anaemia (SCA)." | 1.43 | Development of a pharmacokinetic-guided dose individualization strategy for hydroxyurea treatment in children with sickle cell anaemia. ( Dong, M; McGann, PT; Mizuno, T; Vinks, AA; Ware, RE, 2016) |
| "Hydroxyurea treatment was associated with a stable hemoglobin concentration; increased fetal hemoglobin (HbF) and mean corpuscular volume (MCV); and reduced white blood cell count (WBC), absolute neutrophil count (ANC), and absolute reticulocyte count (ARC)." | 1.43 | Effects of hydroxyurea treatment for patients with hemoglobin SC disease. ( Alvarez, O; Aygun, B; Brown, RC; Davis, BR; Gauger, C; Hassell, K; Hilliard, L; Imran, H; Kalfa, T; Kwiatkowski, JL; Lee, MT; Luchtman-Jones, L; Nelson, S; Owen, W; Piccone, C; Pressel, S; Roberts, C; Rogers, ZR; Rothman, J; Smith, MG; Thompson, AA; Thornburg, C; Ware, RE, 2016) |
| "Hydroxyurea-treated patients had higher apelin levels than untreated ones (P=0." | 1.43 | Serum apelin as a novel non-invasive marker for subclinical cardiopulmonary complications in children and adolescents with sickle cell disease. ( Elbarbary, NS; Fahmy, E; Ismail, EA; Roushdy, A, 2016) |
| " These data nicely complement the recently published results from the phase 3 multicenter TCD With Transfusions Changing to Hydroxyurea (TWiTCH) study and suggest that it may be safe to carefully transition a subset of patients from chronic transfusions to hydroxyurea therapy." | 1.43 | Hydroxyurea for abnormal TCDs: safe to switch? ( McGann, PT, 2016) |
| " The hemolysis releases arginase I, an enzyme that decreases the bioavailability of nitric oxide, worsening the symptoms." | 1.43 | Influence of βS-Globin Haplotypes and Hydroxyurea on Arginase I Levels in Sickle Cell Disease. ( Bandeira, IC; Barbosa, MC; Laurentino, MR; Lemes, RP; Machado, RP; Martins, AM; Moreira, JA; Santos, TE, 2016) |
| "The cohort was 273 children with sickle cell anemia born in NYS in 2006-2009 and enrolled essentially continuously in Medicaid for the first 4 years of life." | 1.43 | Hydroxyurea Use in Young Children With Sickle Cell Anemia in New York State. ( Anders, DG; Caggana, M; Green, NS; Ledneva, T; Sturman, LS; Tang, F; Wang, Y, 2016) |
| "Hydroxyurea was associated with significantly shorter TSpO2 < 88 (P = 0." | 1.43 | Dense red blood cell and oxygen desaturation in sickle-cell disease. ( Bartolucci, P; Boyer, L; Conti, M; Di Liberto, G; Galacteros, F; Habibi, A; Khorgami, S; Kiger, L; Maitre, B; Marden, MC; Pirenne, F; Poitrine, FC; Rakotoson, MG; Vingert, B, 2016) |
| "Hydroxyurea (HU) has been used clinically to reduce the frequency of painful crisis and the need for blood transfusion in sickle cell disease (SCD) patients." | 1.43 | Cellular normoxic biophysical markers of hydroxyurea treatment in sickle cell disease. ( Abidi, SZ; Choi, Y; Dao, M; Du, E; Higgins, JM; Hosseini, P; Kato, GJ; Papageorgiou, DP; Park, Y; So, PT; Suresh, S; Yaqoob, Z, 2016) |
| " Decrease from PBest HbF of 20% or more at recent assessment despite stable dosing was designated as high deviation from PBest." | 1.43 | Decreased fetal hemoglobin over time among youth with sickle cell disease on hydroxyurea is associated with higher urgent hospital use. ( Green, NS; Ireland, K; Manwani, D; Qureshi, M; Sinha, A; Smaldone, AM, 2016) |
| "Hydroxyurea (HU) has been demonstrated to be efficacious in reducing complications in individuals with sickle cell anemia (SCA) but poor adherence is a barrier." | 1.43 | Rationale and design of mDOT-HuA study: a randomized trial to assess the effect of mobile-directly observed therapy on adherence to hydroxyurea in adults with sickle cell anemia in Tanzania. ( Gladwin, MT; Makani, J; Makubi, A; Mmbando, BP; Ngaeje, M; Novelli, EM; Sasi, P, 2016) |
| "Hydroxyurea (HU) is a drug that increases HbF." | 1.43 | The role of BCL11A and HMIP-2 polymorphisms on endogenous and hydroxyurea induced levels of fetal hemoglobin in sickle cell anemia patients from southern Brazil. ( Baldan, A; Bittar, CM; da Rocha Silla, LM; Daudt, LE; Flanagan, JM; Friedrisch, BK; Friedrisch, JR; Ribeiro, CB; Sheehan, V; Summarell, CC; Wilke, II, 2016) |
| "Hydroxyurea therapy was associated with significant reductions in plasma angiogenic factors and inhibition of endothelial cell-mediated angiogenic mechanisms and neovascularization." | 1.42 | Key endothelial cell angiogenic mechanisms are stimulated by the circulating milieu in sickle cell disease and attenuated by hydroxyurea. ( Almeida, CB; Colella, MP; Conran, N; Costa, FF; Franco-Penteado, CF; Garrido, VT; Leonardo, FC; Lopes, FC; Olalla-Saad, ST; Soares, R; Traina, F, 2015) |
| "Obstructive sleep apnea was diagnosed in 14 of 37 (38%) and 54 of 104 (52%) in the HU group and no-HU groups, respectively (P = 0." | 1.42 | Higher nocturnal and awake oxygen saturations in children with sickle cell disease receiving hydroxyurea therapy. ( Al-Saleh, S; Amin, R; Dhanju, S; Kadmon, G; Kirby-Allen, M; Lai, D; Lu, Z; Narang, I; Odame, I, 2015) |
| "Hemolysis and consequent release of cell-free hemoglobin (CFHb) impair vascular nitric oxide (NO) bioavailability and cause oxidative and inflammatory processes." | 1.42 | Acute hemolytic vascular inflammatory processes are prevented by nitric oxide replacement or a single dose of hydroxyurea. ( Almeida, CB; Conran, N; Costa, FF; Costa, FT; Covas, DT; Leonardo, FC; Souza, LE; Werneck, CC, 2015) |
| "Sickle cell anemia has many sequelae that result in emergency department (ED) use, but a minority of patients with sickle cell disease are frequent utilizers and make up the majority of ED visits." | 1.42 | Elevated Steady State WBC and Platelet Counts Are Associated with Frequent Emergency Room Use in Adults with Sickle Cell Anemia. ( Billett, HH; Cohen, HW; Curtis, SA; Danda, N; Etzion, Z, 2015) |
| "Hydroxyurea use was associated with improved survival (Hazard Ratio = 0." | 1.42 | Hydroxyurea-Increased Fetal Hemoglobin Is Associated with Less Organ Damage and Longer Survival in Adults with Sickle Cell Anemia. ( Allen, D; Coles, WA; Fitzhugh, CD; Hsieh, MM; Minniti, CP; Ring, M; Rodgers, GP; Schechter, AN; Seamon, C; Taylor, JG; Tisdale, JF; Zhao, X, 2015) |
| "Hydroxyurea has proven efficacy in numerous clinical trials as a disease-modifying treatment for patients with sickle cell anemia (SCA) but is currently under-used in clinical practice." | 1.42 | Optimizing hydroxyurea therapy for sickle cell anemia. ( Ware, RE, 2015) |
| "Pain is relatively infrequent in SCD infants and young children and commonly managed at home." | 1.40 | Pain characteristics and age-related pain trajectories in infants and young children with sickle cell disease. ( Aertker, L; Brodecki, D; Coleman, C; Dampier, C; Ely, B; Hyslop, T; Kesler, K; Leiby, B; Sendecki, JA; Stuart, M, 2014) |
| "Significantly more patients with neuropathic pain were taking hydroxyurea (90% vs." | 1.40 | Neuropathic pain in patients with sickle cell disease. ( Brandow, AM; Farley, RA; Panepinto, JA, 2014) |
| "The chronic inflammatory state in sickle cell anemia (SCA) is associated with several factors such as the following: endothelial damage; increased production of reactive oxygen species; hemolysis; increased expression of adhesion molecules by leukocytes, erythrocytes, and platelets; and increased production of proinflammatory cytokines." | 1.40 | Chronic inflammatory state in sickle cell anemia patients is associated with HBB(*)S haplotype. ( Bandeira, IC; Barbosa, MC; Elias, DB; Freitas, MV; Gonçalves, RP; Querioz, JA; Rocha, LB, 2014) |
| "This study included; 32 β-thalassemia major (β-TM) patients aged 14." | 1.40 | Serum angiogenin level in sickle cell disease and beta thalassemia patients. ( Abdelmaksoud, AA; Bebawy, EK; Matter, RM; Shams, MA, 2014) |
| " Children taking HU were more likely to take multiple daily medications, with more frequent dosing schedules." | 1.40 | Do difficulties in swallowing medication impede the use of hydroxyurea in children? ( Bekele, E; Brandow, AM; Green, NS; Jin, Z; Sharma, M; Smaldone, AM; Thornburg, CD, 2014) |
| "Hydroxyurea was approved by the FDA in 1998 to decrease the morbidity of SCD, but nationwide hospitalizations for SCD in the United States since 1998 have not been evaluated." | 1.40 | National trends in hospitalizations for sickle cell disease in the United States following the FDA approval of hydroxyurea, 1998-2008. ( Ayanian, JZ; Ebert, BL; Okam, MM; Shaykevich, S; Zaslavsky, AM, 2014) |
| "All patients <19 years of age with HbSS or HbSβ(0) thalassemia who were treated with hydroxyurea at a maximal tolerated dosage (MTD) at St." | 1.40 | Improved hydroxyurea effect with the use of text messaging in children with sickle cell anemia. ( Estepp, JH; Hankins, JS; Howard, SC; Johnson, M; Smeltzer, MP; Winter, B, 2014) |
| "Some sickle cell anemia (SCA) patients suffer significantly worse phenotypes than others." | 1.40 | Mast cell activation syndrome as a significant comorbidity in sickle cell disease. ( Afrin, LB, 2014) |
| "Hydroxyurea treatment was associated with a decrease in microparticles derived from erythrocytes and platelets." | 1.39 | Fetal hemoglobin and hydroxycarbamide moduate both plasma concentration and cellular origin of circulating microparticles in sickle cell anemia children. ( Benkerrou, M; Broquere, C; Chaar, V; Doumdo, L; Elion, J; Nébor, D; Odièvre, MH; Picot, J; Romana, M; Santiago, R; Vachiery, N, 2013) |
| "Proper management of sickle cell anemia (SCA) begins with establishing the correct diagnosis early in life, ideally during the newborn period." | 1.39 | Current management of sickle cell anemia. ( McGann, PT; Nero, AC; Ware, RE, 2013) |
| "Stroke is a common cause of morbidity and mortality in sickle cell disease (SCD) and silent cerebral infarction is the most common form of neurologic injury." | 1.39 | Cerebrovascular events in sickle cell-beta thalassemia treated with hydroxyurea: a single center prospective survey in adult Italians. ( Calvaruso, G; Iannello, S; Maggio, A; Pecoraro, A; Rigano, P; Steinberg, MH, 2013) |
| "Hydroxyurea (HU) is highly effective treatment for sickle cell disease (SCD)." | 1.39 | Parental and other factors associated with hydroxyurea use for pediatric sickle cell disease. ( Cohen, HW; Driscoll, MC; Giardina, PJ; Green, NS; Mullen, C; Oyeku, SO; Pashankar, F; Racine, AD; Trachtman, R; Velazco, N, 2013) |
| "Hydroxyurea therapy in sickle cell anemia patients maintains fungal species balance in oral cavity." | 1.39 | Hydroxyurea therapy in sickle cell anemia patients aids to maintain oral fungal colonization balance. ( Braga, JA; Brighenti, FL; Figueiredo, MS; Koga-Ito, CY; Pereira, DF; Salvia, AC, 2013) |
| "Hydroxyurea treatment decreased neutrophil extravasation into the infected lung coincident with significantly reduced levels of E-selectin in serum and on pulmonary epithelia." | 1.38 | Hydroxyurea therapy of a murine model of sickle cell anemia inhibits the progression of pneumococcal disease by down-modulating E-selectin. ( Gao, G; Howard, T; Hu, Y; Johnson, M; Lebensburger, JD; Persons, DA; Pestina, TI; Rosch, JW; Tuomanen, EI; Ware, RE; Zakharenko, SS, 2012) |
| "Hydroxyurea treatment of sickle cell mice improved their survival from pneumococcal pneumonia, counteracting the abnormally elevated inflammatory response and reducing invasion of bacteria into the bloodstream, through down regulation of E-selectin." | 1.38 | Hydroxyurea makes inflammation "just right"? ( Hsu, LL, 2012) |
| "Treatment with hydroxyurea, in addition to the regulation of haemolysis, lowers Ed-MPs and attenuates thrombin generation." | 1.38 | The acceleration of the propagation phase of thrombin generation in patients with steady-state sickle cell disease is associated with circulating erythrocyte-derived microparticles. ( Blanc-Brude, O; Chaari, M; Elalamy, I; Galea, V; Gerotziafas, GT; Girot, R; Hatmi, M; Khaterchi, A; Lionnet, F; Maier-Redelsperger, M; Stankovic-Stojanovic, K; Van Dreden, P; Woodhams, B, 2012) |
| "Sickle cell disease is a genetic disorder of hemoglobin synthesis leading to a deformation of the red blood cell." | 1.38 | Sickle cell disease and leg ulcers. ( Alavi, A; Bazakas, A; Ladizinski, B; Mistry, N; Salcido, R; Sibbald, RG, 2012) |
| "Our results show that DNA damage in sickle cell anemia is associated not only with treatment with HU but also with genotype." | 1.38 | DNA damage in leukocytes of sickle cell anemia patients is associated with hydroxyurea therapy and with HBB*S haplotype. ( Bandeira, IC; Barbosa, MC; da Silva Rocha, LB; Dias Elias, DB; Gonçalves, RP, 2012) |
| "Moreover, genotype analysis of β-thalassemia major and intermedia patients and an independent cohort of β-thalassemia/SCD compound heterozygous patients that do or do not respond to HU treatment showed that the homozygous mutant state of a tagSNP in the KLF10 3'UTR is not present in β-thalassemia intermedia patients and is underrepresented in β-thalassemia/SCD compound heterozygous patients that respond well to HU treatment." | 1.38 | KLF10 gene expression is associated with high fetal hemoglobin levels and with response to hydroxyurea treatment in β-hemoglobinopathy patients. ( Bartsakoulia, M; Borg, J; Christou, S; Felice, AE; Georgitsi, M; Grosveld, FG; Hou, J; Karkabouna, S; Kleanthous, M; Kourakli, A; Lappa-Manakou, C; Lederer, C; Ozgur, Z; Papachatzopoulou, A; Patrinos, GP; Philipsen, S; Phylactides, M; Stavrou, EF; Tafrali, C; van Ijcken, W; von Lindern, M, 2012) |
| "Hydroxyurea treatment improved the aerobic exercise tolerance and most of the physical fitness parameters in children with SCD." | 1.37 | Effect of hydroxyurea on physical fitness indices in children with sickle cell anemia. ( Moheeb, H; Wali, YA, 2011) |
| "Hydroxyurea is a safe and efficacious medication for children with sickle cell disease (SCD)." | 1.37 | Differences in health-related quality of life in children with sickle cell disease receiving hydroxyurea. ( Calatroni, A; Panepinto, JA; Thornburg, CD, 2011) |
| "Patients with sickle cell anemia are at risk for organ damage including kidney disease." | 1.37 | Protective role of hemoglobin and fetal hemoglobin in early kidney disease for children with sickle cell anemia. ( Askenazi, DJ; Hilliard, LM; Howard, TH; Johnson, SM; Lebensburger, J; Rozario, NL, 2011) |
| "Pomalidomide is a potent structural analog of thalidomide and member of a new class of immunomodulatory drugs." | 1.37 | Pomalidomide augments fetal hemoglobin production without the myelosuppressive effects of hydroxyurea in transgenic sickle cell mice. ( Corral, LG; Kutlar, A; Kutlar, F; Meiler, SE; Moutouh-de Parseval, LA; Swerdlow, PS; Wade, M; Xue, Y; Yerigenahally, SD, 2011) |
| "Hydroxyurea has enhanced the treatment for children with sickle cell anemia." | 1.37 | Impact of hydroxyurea on perioperative management and outcomes in children with sickle cell anemia. ( Calatroni, A; Hayashi, M; Herzberg, B; Rice, HE; Ross, AK; Thornburg, C, 2011) |
| "Sickle cell disease is characterized by phenotypic heterogeneity and many genetic modifiers have been identified with elevated Hb F being the most recognized ameliorating factor." | 1.37 | Limitations of Hb F as a phenotypic modifier in sickle cell disease: study of Kuwaiti Arab patients. ( Adekile, AD, 2011) |
| "Hydroxyurea (HU) is an effective drug for the treatment of sickle cell disease (SCD)." | 1.36 | In vivo pharmaco-proteomic analysis of hydroxyurea induced changes in the sickle red blood cell membrane proteome. ( Choudhary, PK; Ghatpande, SS; Goodman, SR; Quinn, CT, 2010) |
| "Hydroxyurea was underutilized in this patient population." | 1.36 | Examining the effectiveness of hydroxyurea in people with sickle cell disease. ( Fagan, PJ; Haywood, C; Lanzkron, S; Rand, CS, 2010) |
| "Hydroxyurea has proven clinical efficacy in patients with sickle cell disease." | 1.36 | Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model. ( Boyd, KL; Lebensburger, JD; Persons, DA; Pestina, TI; Ware, RE, 2010) |
| "Sickle cell anemia is the most common hemoglobinopathy worldwide; its musculoskeletal complications consist more often of medullary infarctions involving long bones." | 1.36 | [Orbital subperiosteal hematoma in child with sickle cell thalassemia. A case report]. ( Bellagha, I; Ben Hassine, L; Bouguila, H; Chebbi, A; Douira-Khomsi, W; Jarraya, M; Lahmar, L; Louati, H, 2010) |
| "Sickle cell disease is characterized by painful vaso-occlusive crises during which abnormal interactions between erythroid adhesion molecules and vessel-wall proteins are thought to play a critical role." | 1.36 | Decreased sickle red blood cell adhesion to laminin by hydroxyurea is associated with inhibition of Lu/BCAM protein phosphorylation. ( Bachir, D; Bartolucci, P; Chaar, V; Colin, Y; El Nemer, W; Fauroux, C; Galactéros, F; Habibi, A; Le Van Kim, C; Picot, J, 2010) |
| "Hydroxyurea therapy was used in 30 patients (31." | 1.36 | Sickle cell disease from Africa to Belgium, from neonatal screening to clinical management. ( Cotton, F; Dedeken, L; Dresse, MF; Ferster, A; Gulbis, B; Heijmans, C; Ketelslegers, O; Lê, PQ; Vanderfaeillie, A; Vermylen, C; Vertongen, F, 2010) |
| "Recent progress in the treatment of sickle cell disease, in particular the use of hydroxyurea, has considerably modified the prognosis of this disease." | 1.35 | Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males. ( Ancel, PY; Bachir, D; Berthaut, I; de Larouziere, V; Galactéros, F; Girot, R; Guignedoux, G; Jouannet, P; Kirsch-Noir, F; Kunstmann, JM; Levy, L; Mandelbaum, J; Ravel, C, 2008) |
| "Hydroxyurea has documented laboratory and clinical efficacy for children with sickle cell anemia (SCA), and has potential to become an effective and inexpensive treatment option for patients in countries with limited resources." | 1.35 | Chemical and functional analysis of generic hydroxyurea formulations. ( Abboud, MR; Hankins, J; Harrod, VL; Howard, T; Lobo, C; Ware, RE, 2008) |
| "Sickle cell disease is the most common inherited disease in the U." | 1.35 | The clinical care of adult patients with sickle cell disease. ( Howard, J; Olujohungbe, A, 2008) |
| "Ten male subjects affected by sickle cell anemia (SCA) were studied to evaluate the long-term effects of therapies on their fertility." | 1.35 | Bone marrow transplantation or hydroxyurea for sickle cell anemia: long-term effects on semen variables and hormone profiles. ( Brichard, B; Chantrain, C; Curaba, M; Dupont, S; Ferrant, A; Lukusa, AK; Vanabelle, B; Vermylen, C; Wyns, C, 2009) |
| "Hydroxyurea (HU) plays an important role in the treatment of patients with sickle cell disease (SCD)." | 1.35 | DNA damage in blood leukocytes of individuals with sickle cell disease treated with hydroxyurea. ( Bittar, CM; da Rocha Silla, LM; da Silva, MA; Friedrisch, JR; Henriques, JA; Kayser, M; Maluf, SW; Mergener, M; Pollo, T; Prá, D, 2008) |
| "Sickle-cell disease (SCD) and beta thalassemia constitute worldwide public health problems." | 1.35 | Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells. ( Brady, H; Chan, K; Corral, LG; Ferguson, GD; Glezer, E; Jensen-Pergakes, K; Morris, CL; Moutouh-de Parseval, LA; Muller, G; Verhelle, D, 2008) |
| "Chronic hypoxemia is a common manifestation among patients with sickle cell anemia (SCA) who develop chronic lung disease." | 1.35 | Resolution of chronic hypoxemia in pediatric sickle cell patients after treatment with hydroxyurea. ( Aygun, B; Koumbourlis, AC; Singh, SA, 2008) |
| "Pulmonary hypertension is common among Nigerian SCD patients." | 1.35 | Prevalence and risk factors for pulmonary artery systolic hypertension among sickle cell disease patients in Nigeria. ( Akpanpe, P; Aliyu, N; Aliyu, ZY; Attah, E; Babadoko, A; Gladwin, MT; Gordeuk, V; Kato, GJ; Mamman, AI; Mendelsohn, L; Sachdev, V; Suleiman, Y; Yusuf, J, 2008) |
| " Since nitric oxide bioavailability is decreased in sickle cell disease and nitric oxide may inhibit leukocyte adhesion, we investigated whether stimulation of NO-signaling pathways can reduce the adhesive properties of neutrophils from sickle cell disease individuals (sickle cell diseaseneu)." | 1.35 | Increased adhesive properties of neutrophils in sickle cell disease may be reversed by pharmacological nitric oxide donation. ( Canalli, AA; Conran, N; Costa, FF; Franco-Penteado, CF; Saad, ST, 2008) |
| "Patients with severe aplastic anemia fared poorly due to lack of availability and high cost of anti-thymocyte globulin and cyclosporine and lack of access to stem cell transplantation." | 1.34 | Treatment for children with severe aplastic anemia and sickle cell disease in low income countries in Latin America: a report on the recent meetings of the Monza International School of Pediatric Hematology/Oncology (MISPHO): Part III. ( de Reyes, G; Flores, A; Howard, SC; Machin, S; Masera, G; Navarrete, M; Nieves, R; Pacheco, C; Rodriguez, H; Svarch, E; Wilimas, JA, 2007) |
| "These data suggest a role of GM-CSF in leukocytosis of SCD." | 1.34 | Leukocyte numbers correlate with plasma levels of granulocyte-macrophage colony-stimulating factor in sickle cell disease. ( Conran, N; Costa, FF; Ikuta, T; Saad, ST, 2007) |
| "Hydroxyurea (HU) is useful for treating sickle cell anemia because of its ability to reduce some of the severe clinical events such as painful crises and acute chest syndrome." | 1.34 | Plasma and urine hydroxyurea levels might be useful in the management of adult sickle cell disease. ( Astier, A; Bachir, D; El Mahrab, M; Galacteros, F; Habibi, A; Huet, E; Hulin, A; Nzouakou, R, 2007) |
| "Enalapril treatment for 3." | 1.33 | Enalapril and hydroxyurea therapy for children with sickle nephropathy. ( Fitzhugh, CD; Ware, RE; Wigfall, DR, 2005) |
| " These assays are potentially useful to study hydroxyurea metabolism further, develop optimal dosing regimes and monitor compliance with treatment." | 1.33 | The measurement of urinary hydroxyurea in sickle cell anaemia. ( Awogbade, M; Dalton, RN; Dick, M; Height, SE; Inusa, B; O'Driscoll, S; Okpala, I; Rees, DC; Thein, SL; Turner, C, 2005) |
| "Hydroxyurea was started at 15 mg/kg/day and increased to a maximum dose of 25 mg/kg/day." | 1.33 | Clinical and laboratory effects of hydroxyurea in children and adolescents with sickle cell anemia: a Portuguese hospital study. ( Amaral, JM; Braga, LB; Ferreira, AC; Guimarães, M; Miranda, A; Nazário, C; Pacheco, P; Picanço, I; Rosado, L; Seixas, T, 2005) |
| "Pulmonary hypertension was associated with an increased risk of death (relative risk, 9." | 1.33 | Pulmonary hypertension in patients with sickle cell disease: a longitudinal study. ( Ataga, KI; Hinderliter, A; Jones, S; Moore, CG; Olajide, O; Orringer, EP; Strayhorn, D, 2006) |
| "Hydroxyurea treatment, as well as and long- and short-acting narcotics were given, with little improvement in symptoms." | 1.33 | Primary hyperparathyroidism mimicking vaso-occlusive crises in sickle cell disease. ( Abish, S; Albuquerque, P; Alyaarubi, S; Gale, M; Jabado, N; Krishnamoorthy, P, 2006) |
| " Hematologic responses, detailed herein, suggest that EPO therapy may allow more aggressive HU dosing in high-risk SCD patients and in the setting of mild renal insufficiency, common to the aging sickle cell population." | 1.33 | Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. ( Castro, O; Feld, JJ; Gladwin, MT; Heller, T; Kato, GJ; Little, JA; Machado, RF; Maric, I; Martyr, S; McGowan, VR; Partovi, KS; Taylor, JG, 2006) |
| "Using human in vitro models of cerebral malaria, we evaluated the interaction of HU with parasites and demonstrated that HU pretreatment increased the number of infected red blood cells adhering to the endothelium, but did not increase endothelial apoptosis." | 1.33 | Effects of hydroxyurea on malaria, parasite growth and adhesion in experimental models. ( Brun, M; Ciceron, L; Franetich, JF; Krishnamoorthy, R; Mazier, D; Pino, P; Taoufiq, Z; Tefit, M, 2006) |
| "Specific treatment of sickle cell disease with hydroxyurea should be considered in cases with significant abnormalities of myocardial perfusion." | 1.32 | [Abnormalities of myocardial perfusion in sickle cell disease in childhood: a study of myocardial scintigraphy]. ( Acar, P; de Montalembert, M; Dulac, Y; Maunoury, C, 2003) |
| "Hydroxyurea has been extensively used in patients with sickle cell anemia and severe sickle cell-hemoglobin C (SC) disease to reduce the severity of their diseases." | 1.32 | Hydroxyurea-induced splenic regrowth in an adult patient with severe hemoglobin SC disease. ( Ananthakrishnan, T; Eid, JE; Huang, Y, 2003) |
| "Hydroxyurea (HU) has been shown to reduce the frequency of vaso-occlusive manifestations in both adults and children with sickle cell disease (SCD), and the induction of hemoglobin F (HbF) is thought to be the underlying mechanism responsible for clinical improvement in some patients." | 1.32 | The effect of hydroxyurea on the coagulation system in sickle cell anemia and beta-thalassemia intermedia patients: a preliminary study. ( Gumruk, F; Gurgey, A; Koc, A, 2003) |
| "The median age at malignancy diagnosis was 34 years (range, 14 months-62 years)." | 1.32 | Malignancy in patients with sickle cell disease. ( Schultz, WH; Ware, RE, 2003) |
| " More frequent analgesic dosing was reported on days with more intense pain." | 1.31 | Home management of pain in sickle cell disease: a daily diary study in children and adolescents. ( Brodecki, D; Dampier, C; Ely, E; O'Neal, P, 2002) |
| "Hydroxyurea is an established drug that has been used for the treatment of myeloproliferative disorders and some solid tumors for some time." | 1.31 | Are we underestimating the leukemogenic risk of hydroxyurea. ( Al-Dabbous, IA; Al-Jam'a, AH; Al-Khatti, AA; Esan, FG, 2002) |
| "Hydroxyurea (HU) is a widely used cytotoxic agent that is known to induce fetal hemoglobin (HbF) production and is presently used to ameliorate the severity of pain episodes in patients with sickle cell anemia (HbSS)." | 1.31 | Mechanism for fetal hemoglobin induction by hydroxyurea in sickle cell erythroid progenitors. ( Baliga, BS; Chen, HH; Pace, BS; Shah, AK; Yang, YM, 2000) |
| "Hydroxyurea is a drug that is used to treat some patients with sickle cell disease." | 1.31 | In vitro exposure to hydroxyurea reduces sickle red blood cell deformability. ( Ballas, SK; Huang, Z; Kim-Shapiro, DB; King, SB; Louderback, JG, 2001) |
| "Hydroxyurea (HU) is an oral drug that ameliorates the clinical course of sickle cell anemia by increasing the levels of fetal hemoglobin and decreasing the adhesion of red cells to endothelium." | 1.31 | Hodgkin's disease in a child with sickle cell disease treated with hydroxyurea. ( Menegas, D; Moschovi, M; Nicolaidou, P; Nikolaidou, P; Psychou, F; Tsangaris, GT; Tzortzatou-Stathopoulou, F, 2001) |
| "Hydroxyurea treatment had no adverse effect on height or weight gain or pubertal development in school-aged children with SCA." | 1.31 | Effect of hydroxyurea on growth in children with sickle cell anemia: results of the HUG-KIDS Study. ( Gee, BE; Helms, RW; Kinney, TR; Lynn, HS; Ohene-Frempong, K; Redding-Lallinger, R; Smith-Whitley, K; Styles, LA; Vichinsky, EP; Waclawiw, MA; Wang, WC; Ware, RE, 2002) |
| "Use of hydroxyurea (HU) to treat sickle cell disease is usually associated with increments in fetal hemoglobin (Hb F) production; however, in vitro studies show that HU may also induce hemoglobin denaturation." | 1.30 | Hydroxyurea-induced denaturation of normal and sickle cell hemoglobins in vitro. ( Aguinaga, MP; Kopsombut, P; Roa, D; Turner, EA, 1997) |
| "Hydroxyurea (HU) has been shown to increase HbF production and therefore has the potential to prevent these crises in adult patients." | 1.30 | [Sickle cell anemia in children: value of hydroxyurea in severe forms]. ( Chantraine, JM; Dresse, MF; Hoyoux, C; Oury, AP, 1997) |
| "Hydroxyurea has been mixed with hemoglobin S and the reaction was studied using electronic absorption spectroscopy as a function of time and wavelength." | 1.30 | Time resolved absorption study of the reaction of hydroxyurea with sickle cell hemoglobin. ( Ballas, SK; Bonifant, CL; Kim-Shapiro, DB; King, SB; Kolibash, CP, 1998) |
| "The pathophysiology of sickle cell anemia is primarily explained in terms of the oxygen-dependent polymerization of sickle hemoglobin (HbS) followed by sickling of erythrocytes." | 1.30 | Sickling of nucleated erythroid precursors from patients with sickle cell anemia. ( Blanchette-Mackie, EJ; Dwyer, N; Fibach, E; Hasegawa, S; Noguchi, CT; Rodgers, GP; Schechter, AN; Uyesaka, N, 1998) |
| "BMT should be offered to sickle cell anemia patients with a history of stroke if a genoidentical donor is available." | 1.30 | [Results and current indications of bone marrow allograft in sickle cell disease]. ( Bernaudin, F, 1999) |
| "As recently as the 1970s, sickle cell anemia patients had little hope of living past their teen years and little relief from painful crises." | 1.30 | Sickle cell patients find a brand New World. ( Noonan, SS, 1999) |
| "Hydroxyurea can increase fetal hemoglobin (HbF) and improve the clinical course of sickle cell disease (SCD) patients." | 1.29 | A cautionary note regarding hydroxyurea in sickle cell disease. ( Lubin, BH; Vichinsky, EP, 1994) |
| " A reduced dosage of hydroxyurea alternating with erythropoietin may prove less myelotoxic than hydroxyurea given daily or in pulsed-dose regimens." | 1.29 | Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease. ( Dover, GJ; Nienhuis, AW; Noguchi, CT; Rodgers, GP; Schechter, AN; Uyesaka, N, 1993) |
| "From 295 individuals with sickle cell anemia, we chose for detailed studies 53 patients who had the highest or the lowest fetal hemoglobin levels and 7 patients whose fetal hemoglobin levels were atypical of their haplotype." | 1.29 | Fetal hemoglobin in sickle cell anemia: relation to regulatory sequences cis to the beta-globin gene. Multicenter Study of Hydroxyurea. ( Lu, ZH; Steinberg, MH, 1996) |
| "Treatment with hydroxyurea induced statistically significant increases in the total hemoglobin concentration, mean corpuscular volume, and percentage of hemoglobin F, and a decrease in the serum concentration of bilirubin." | 1.29 | Hydroxyurea therapy in children severely affected with sickle cell disease. ( Brown, ER; Hillery, CA; Labotka, RJ; Misiewicz, V; Scott, JP, 1996) |
| "Hydroxyurea (HU) has been shown to increase fetal hemoglobin (HbF) and decrease painful episodes in patients with this disease." | 1.29 | First report of reversal of organ dysfunction in sickle cell anemia by the use of hydroxyurea: splenic regeneration. ( Claster, S; Vichinsky, E, 1996) |
| "As concerns sickle cell anemia, we have underlined some particular aspects of the clinical expression of the disease." | 1.29 | [Study of hemoglobinopathies found in Belgium]. ( Fondu, P, 1995) |
| "Those sickle cell anemia subjects with minimal renal dysfunction (serum creatinine level, greater than 1." | 1.27 | Hydroxyurea induction of hemoglobin F production in sickle cell disease: relationship between cytotoxicity and F cell production. ( Charache, S; Dover, GJ; Humphries, RK; Ley, TJ; Moore, JG; Nienhuis, AW; Young, NS, 1986) |
| " Pharmacokinetic studies will probably be necessary to adjust individual dosage schedules so that cytotoxicity is avoided." | 1.27 | Hydroxyurea-induced augmentation of fetal hemoglobin production in patients with sickle cell anemia. ( Charache, S; Dover, GJ; Moore, JW; Moyer, MA, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 24 (1.89) | 18.7374 |
| 1990's | 120 (9.43) | 18.2507 |
| 2000's | 271 (21.31) | 29.6817 |
| 2010's | 547 (43.00) | 24.3611 |
| 2020's | 310 (24.37) | 2.80 |
| Authors | Studies |
|---|---|
| dos Santos, JL | 5 |
| Lanaro, C | 10 |
| Lima, LM | 2 |
| Gambero, S | 4 |
| Franco-Penteado, CF | 10 |
| Alexandre-Moreira, MS | 1 |
| Wade, M | 3 |
| Yerigenahally, S | 2 |
| Kutlar, A | 22 |
| Meiler, SE | 3 |
| Costa, FF | 35 |
| Chung, M | 1 |
| Chelucci, RC | 1 |
| Bosquesi, PL | 1 |
| Reis, JS | 1 |
| Cerecetto, H | 1 |
| González, M | 1 |
| Chung, MC | 1 |
| Lai, ZS | 2 |
| Yeh, TK | 1 |
| Chou, YC | 2 |
| Hsu, T | 1 |
| Lu, CT | 1 |
| Kung, FC | 1 |
| Hsieh, MY | 1 |
| Lin, CH | 1 |
| Chen, CT | 1 |
| James Shen, CK | 1 |
| Jiaang, WT | 1 |
| Soliman, AT | 1 |
| Alaaraj, N | 1 |
| Yassin, M | 1 |
| Patrinos, GP | 6 |
| Chui, DHK | 1 |
| Hardison, RC | 3 |
| Steinberg, MH | 29 |
| Dhar, A | 1 |
| Leung, TM | 1 |
| Appiah-Kubi, A | 1 |
| Gruber, D | 1 |
| Aygun, B | 28 |
| Serigano, O | 1 |
| Mitchell, E | 1 |
| Shaner, S | 1 |
| Hilliard, L | 4 |
| Howard, T | 7 |
| Pernell, B | 1 |
| Bhatia, S | 1 |
| Lebensburger, J | 5 |
| Karkoska, K | 5 |
| McGann, PT | 25 |
| Escobar Alvarez, SN | 1 |
| Myers, ER | 1 |
| Mathias, JG | 2 |
| Nolan, VG | 1 |
| Klesges, LM | 4 |
| Badawy, SM | 16 |
| Cooper, WO | 1 |
| Hankins, JS | 40 |
| Smeltzer, MP | 16 |
| Cyrus, C | 1 |
| Allard, P | 1 |
| Alhaj, N | 1 |
| Lobitz, S | 1 |
| Cario, H | 1 |
| Jarisch, A | 1 |
| Grosse, R | 1 |
| Oevermann, L | 2 |
| Hakimeh, D | 1 |
| Tagliaferri, L | 1 |
| Kohne, E | 1 |
| Kopp-Schneider, A | 1 |
| Kulozik, AE | 1 |
| Kunz, JB | 1 |
| Smith, WR | 9 |
| McClish, DK | 2 |
| Lottenberg, R | 9 |
| Sisler, IY | 1 |
| Sop, D | 1 |
| Johnson, S | 1 |
| Villella, A | 2 |
| Liles, D | 2 |
| Yang, E | 4 |
| Chen, I | 1 |
| Howell, KE | 1 |
| Treadwell, M | 7 |
| Preiss, L | 2 |
| King, AA | 9 |
| Glassberg, JA | 2 |
| Tanabe, P | 3 |
| DiMartino, L | 2 |
| Gibson, R | 5 |
| Kanter, J | 13 |
| Youssry, I | 1 |
| ElGhamrawy, M | 1 |
| Seif, H | 1 |
| Balsamo, L | 1 |
| Pashankar, F | 3 |
| Mahrous, M | 1 |
| Salama, N | 1 |
| Ofakunrin, AO | 1 |
| Okpe, ES | 2 |
| Afolaranmi, TO | 2 |
| Olaosebikan, RR | 1 |
| Kanhu, PU | 1 |
| Adekola, K | 2 |
| Dami, N | 1 |
| Sagay, AS | 2 |
| Elenga, N | 1 |
| Kayemba-Kay's, S | 1 |
| Nacher, M | 1 |
| Archer, N | 1 |
| Yurtsever, N | 1 |
| Nandi, V | 1 |
| Ziemba, Y | 1 |
| Shi, PA | 1 |
| Hoogenboom, WS | 1 |
| Alamuri, TT | 1 |
| McMahon, DM | 1 |
| Balanchivadze, N | 1 |
| Dabak, V | 1 |
| Mitchell, WB | 2 |
| Morrone, KB | 1 |
| Manwani, D | 17 |
| Duong, TQ | 1 |
| Adeniyi, OF | 1 |
| Akinsete, AM | 1 |
| Odeghe, EA | 1 |
| Okeke, OF | 1 |
| Mokwenyei, O | 1 |
| Kene-Udemezue, B | 1 |
| Seyi-Olajide, JO | 1 |
| Akinsulie, A | 2 |
| Adeniran, O | 2 |
| Oyeleke, G | 1 |
| Elsayh, KI | 1 |
| Saad, K | 1 |
| Hetta, HF | 1 |
| Youssef, MAM | 1 |
| Embaby, MM | 1 |
| Mohamed, IL | 1 |
| Abdel-Aziz, SM | 1 |
| Zahran, ZAM | 1 |
| Elhoufey, A | 1 |
| Ghandour, AMA | 1 |
| Zahran, AM | 1 |
| Bradford, C | 1 |
| Miodownik, H | 1 |
| Thomas, M | 1 |
| Ogu, UO | 3 |
| Minniti, CP | 17 |
| Kotwal, N | 1 |
| Pillai, DK | 1 |
| Darbari, DS | 7 |
| Sun, K | 1 |
| Koumbourlis, AC | 2 |
| Abdullahi, SU | 11 |
| Jibir, BW | 3 |
| Bello-Manga, H | 5 |
| Gambo, S | 8 |
| Inuwa, H | 2 |
| Tijjani, AG | 1 |
| Idris, N | 3 |
| Galadanci, A | 2 |
| Hikima, MS | 1 |
| Galadanci, N | 2 |
| Borodo, A | 1 |
| Tabari, AM | 2 |
| Haliru, L | 4 |
| Suleiman, A | 2 |
| Ibrahim, J | 1 |
| Greene, BC | 2 |
| Ghafuri, DL | 6 |
| Rodeghier, M | 12 |
| Slaughter, JC | 1 |
| Kirkham, FJ | 7 |
| Neville, K | 5 |
| Kassim, A | 1 |
| Trevathan, E | 2 |
| Jordan, LC | 10 |
| Aliyu, MH | 7 |
| DeBaun, MR | 31 |
| Farouk, B | 1 |
| Bahago, GY | 1 |
| Sani, AM | 1 |
| Bauman, AA | 1 |
| Silva, M | 1 |
| Coelho, A | 1 |
| Vargas, S | 1 |
| Faustino, P | 1 |
| Tolu, SS | 3 |
| Crouch, A | 1 |
| Choi, J | 1 |
| Gao, Q | 1 |
| Reyes-Gil, M | 1 |
| Vinces, G | 1 |
| Dela-Pena, JC | 1 |
| King, MA | 1 |
| Brown, J | 1 |
| Nachar, VR | 1 |
| Jiao, B | 1 |
| Basu, A | 1 |
| Ramsey, S | 1 |
| Roth, J | 1 |
| Bender, MA | 1 |
| Quach, D | 1 |
| Devine, B | 1 |
| Brito, PL | 2 |
| Dos Santos, AF | 2 |
| Chweih, H | 2 |
| Favero, ME | 1 |
| Gotardo, EMF | 2 |
| Silva, JAF | 1 |
| Leonardo, FC | 5 |
| de Oliveira, MG | 1 |
| Ferreira, WA | 2 |
| Zaidan, BC | 1 |
| Billis, A | 1 |
| Baldanzi, G | 1 |
| Mashima, DA | 1 |
| Antunes, E | 1 |
| Saad, STO | 2 |
| Conran, N | 25 |
| Kroner, BL | 1 |
| Pugh, N | 1 |
| Shah, NR | 1 |
| Glassberg, J | 4 |
| Gordeuk, VR | 22 |
| Çanak, B | 1 |
| Eşkazan, AE | 1 |
| Paul-Hanna, M | 1 |
| Joseph, W | 1 |
| Mondesir, W | 1 |
| Faustino, EVS | 1 |
| Canarie, MF | 1 |
| Costa-Júnior, DAD | 1 |
| Santos, APP | 2 |
| da Silva, CM | 1 |
| Velloso-Rodrigues, C | 2 |
| Brandow, AM | 11 |
| Liem, RI | 9 |
| Cai, J | 3 |
| Chen-Goodspeed, A | 1 |
| Idowu, M | 1 |
| Real, FJ | 1 |
| Hood, AM | 2 |
| Davis, D | 1 |
| Cruse, B | 1 |
| Klein, M | 1 |
| Johnson, Y | 2 |
| McTate, E | 2 |
| Brinkman, WB | 3 |
| Hackworth, R | 2 |
| Hackworth, K | 1 |
| Quinn, CT | 16 |
| Crosby, LE | 6 |
| Díaz-Matallana, M | 1 |
| Márquez-Benítez, Y | 1 |
| Martínez-Lozano, JC | 1 |
| Briceño-Balcázar, I | 1 |
| Benavides-Benítez, E | 1 |
| Bernal, JE | 1 |
| Creary, SE | 8 |
| Beeman, C | 1 |
| Stanek, J | 3 |
| King, K | 1 |
| O'Brien, SH | 8 |
| Holl, J | 1 |
| Verlhac, S | 2 |
| Ithier, G | 3 |
| Bernaudin, F | 10 |
| Oloukoi, C | 1 |
| Cussenot, I | 1 |
| Balandra, S | 1 |
| Kheniche, A | 1 |
| Ntorkou, A | 1 |
| Ouaziz, H | 1 |
| Tanase, A | 1 |
| Sekkal, A | 1 |
| Belarbi, N | 1 |
| Elmaleh, M | 1 |
| Alison, M | 1 |
| Galadanci, NA | 6 |
| Johnson, W | 1 |
| Carson, A | 1 |
| Hellemann, G | 2 |
| Howard, V | 1 |
| Muschick, K | 1 |
| Fuqua, T | 1 |
| Stoker-Postier, C | 1 |
| Anderson, AR | 1 |
| Walter, O | 4 |
| Cougoul, P | 4 |
| Maquet, J | 1 |
| Bartolucci, P | 15 |
| Lapeyre-Mestre, M | 1 |
| Lafaurie, M | 4 |
| Moulis, G | 4 |
| Hayat, A | 1 |
| Chaudhry, HUR | 1 |
| Ahmad, A | 2 |
| Sales, RR | 1 |
| Nogueira, BL | 1 |
| Luizon, MR | 1 |
| Binding, A | 1 |
| Starlard-Davenport, A | 2 |
| Gu, Q | 1 |
| Pace, BS | 4 |
| González-Pérez, C | 1 |
| Gómez-Carpintero García, A | 1 |
| Cervera Bravo, Á | 1 |
| Gour, A | 1 |
| Kour, D | 1 |
| Dogra, A | 1 |
| Manhas, D | 1 |
| Wazir, P | 1 |
| Digra, SK | 1 |
| Kumar, A | 1 |
| Nandi, U | 1 |
| Ataga, KI | 22 |
| Zhou, Q | 1 |
| Saraf, SL | 9 |
| Ciccone, EJ | 1 |
| Loehr, LR | 1 |
| Ashley-Koch, AE | 1 |
| Garrett, ME | 1 |
| Telen, MJ | 4 |
| Derebail, VK | 3 |
| Odame, I | 10 |
| Kavanagh, PL | 2 |
| Fasipe, TA | 1 |
| Wun, T | 1 |
| Phan, V | 1 |
| Park, JA | 1 |
| Dulman, R | 2 |
| Lewis, A | 3 |
| Briere, N | 1 |
| Notarangelo, B | 2 |
| de Alvarenga Maximo, C | 1 |
| Oliveira, T | 1 |
| Fertrin, KY | 5 |
| Lobo, C | 2 |
| Pfeiffer, A | 5 |
| Beebe, DW | 1 |
| Niss, O | 7 |
| Askew, MA | 1 |
| Smaldone, AM | 3 |
| Gold, MA | 1 |
| Smith-Whitley, K | 7 |
| Strouse, JJ | 10 |
| Jin, Z | 2 |
| Green, NS | 17 |
| Yang, M | 1 |
| Elmuti, L | 1 |
| Ross, JM | 1 |
| Forté, S | 1 |
| Soulières, D | 1 |
| Abdelhalim, SM | 1 |
| Murphy, JE | 2 |
| Meabed, MH | 2 |
| Elberry, AA | 2 |
| Gamaleldin, MM | 2 |
| Shaalan, MS | 1 |
| Hussein, RRS | 2 |
| Smart, LR | 5 |
| Ambrose, EE | 2 |
| Balyorugulu, G | 1 |
| Songoro, P | 2 |
| Shabani, I | 1 |
| Komba, P | 1 |
| Charles, M | 2 |
| Howard, TA | 17 |
| McElhinney, KE | 1 |
| O'Hara, SM | 1 |
| Odame, J | 1 |
| Nakafeero, M | 2 |
| Adams, J | 1 |
| Stuber, SE | 6 |
| Lane, A | 11 |
| Latham, TS | 9 |
| Makubi, AN | 2 |
| Ware, RE | 108 |
| Agawu, A | 1 |
| Shults, J | 1 |
| Feudtner, C | 1 |
| Delgadinho, M | 3 |
| Ginete, C | 3 |
| Santos, B | 7 |
| Fernandes, C | 1 |
| Silva, C | 2 |
| Miranda, A | 3 |
| Vasconcelos, JN | 1 |
| Brito, M | 3 |
| Longoria, JN | 2 |
| Wang, W | 5 |
| Kang, G | 13 |
| Gossett, J | 2 |
| Krull, K | 1 |
| Raches, D | 1 |
| Schreiber, J | 2 |
| Heitzer, AM | 3 |
| Rankine-Mullings, AE | 1 |
| Nevitt, SJ | 2 |
| Moreira, ID | 1 |
| Lessa, CLM | 1 |
| Rocha, GLG | 1 |
| Schmitz, LD | 1 |
| Jahnke, VS | 1 |
| Fogliatto, LM | 1 |
| Werlang, MC | 1 |
| Rotta, LN | 1 |
| Nardo-Marino, A | 1 |
| Glenthøj, A | 1 |
| Brewin, JN | 1 |
| Petersen, J | 1 |
| Braunstein, TH | 1 |
| Kurtzhals, JAL | 1 |
| Williams, TN | 6 |
| Rees, DC | 13 |
| Manganas, K | 1 |
| Delicou, S | 1 |
| Xydaki, A | 1 |
| Koskinas, J | 1 |
| Chan, KH | 2 |
| Rizvi, SH | 1 |
| De Jesus-Rojas, W | 1 |
| Stark, JM | 2 |
| Mosquera, RA | 2 |
| Prada-Ruiz, AC | 1 |
| Gonzales, T | 1 |
| Brown, DL | 2 |
| Menon, NM | 1 |
| Nguyen, TT | 2 |
| Jon, CK | 1 |
| Yadav, A | 2 |
| Lee, MT | 6 |
| Hsu, LL | 12 |
| Hooper, WC | 2 |
| Schieve, LA | 2 |
| Runge, A | 1 |
| Brazel, D | 1 |
| Pakbaz, Z | 1 |
| Sisler, I | 1 |
| Valrie, C | 1 |
| Metaferia, B | 1 |
| Cellmer, T | 1 |
| Dunkelberger, EB | 1 |
| Li, Q | 1 |
| Henry, ER | 1 |
| Hofrichter, J | 2 |
| Staton, D | 1 |
| Hsieh, MM | 5 |
| Conrey, AK | 1 |
| Tisdale, JF | 6 |
| Chatterjee, AK | 1 |
| Thein, SL | 12 |
| Eaton, WA | 3 |
| Simmons, GM | 1 |
| Payne, AB | 1 |
| Abe, K | 1 |
| Hulihan, M | 1 |
| Pope, S | 1 |
| Rhie, S | 1 |
| Dupervil, B | 1 |
| Taylor, SM | 1 |
| Korwa, S | 1 |
| Wu, A | 1 |
| Green, CL | 1 |
| Freedman, B | 1 |
| Clapp, S | 1 |
| Kirui, JK | 1 |
| O'Meara, WP | 1 |
| Njuguna, FM | 1 |
| de Oliveira Toledo, SL | 1 |
| Ladeira, VS | 2 |
| Nogueira, LS | 1 |
| Ferreira, LGR | 2 |
| Oliveira, MM | 2 |
| de Oliveira Renó, C | 2 |
| Dos Santos, HL | 2 |
| Coelho-Dos-Reis, JGA | 1 |
| Campi-Azevedo, AC | 1 |
| Teixeira-Carvalho, A | 1 |
| Martins-Filho, OA | 1 |
| Rios, DRA | 2 |
| Barros-Pinheiro, M | 1 |
| Lad, H | 1 |
| Naskar, S | 1 |
| Punyasri Pasupuleti, SKDB | 1 |
| Nahrel, R | 1 |
| Sihare, P | 1 |
| Chandak, GR | 1 |
| Patra, PK | 1 |
| Sridevi, P | 1 |
| Sharma, Y | 1 |
| Balakrishna, SL | 1 |
| Babu, BV | 1 |
| Kang, HA | 2 |
| Barner, JC | 2 |
| Lawson, KA | 1 |
| Rascati, K | 1 |
| Mignacca, RC | 1 |
| Abdelhalima, SM | 1 |
| Alshaeri, HK | 1 |
| Mohammad, BA | 1 |
| Sunusi, S | 1 |
| Abba, MS | 2 |
| Sani, S | 1 |
| Inuwa, HA | 1 |
| Gambo, A | 1 |
| Musa, B | 1 |
| Covert Greene, BV | 1 |
| Kassim, AA | 7 |
| Hussaini, N | 1 |
| Ciobanu, M | 1 |
| Cronin, RM | 2 |
| Wuichet, K | 1 |
| Hodges, B | 1 |
| Chopra, M | 1 |
| He, J | 5 |
| Niu, X | 4 |
| Wilkerson, K | 1 |
| Isa, HA | 1 |
| Nnebe-Agumadu, U | 4 |
| Nwegbu, MM | 1 |
| Okocha, EC | 1 |
| Chianumba, RI | 1 |
| Brown, BJ | 6 |
| Asala, SA | 1 |
| Peprah, E | 2 |
| Nnodu, OE | 2 |
| Lamont, AE | 1 |
| Jacobs, S | 2 |
| Chen, Y | 3 |
| Axelrod, K | 1 |
| Varughese, T | 3 |
| Melvin, C | 2 |
| Smith, S | 1 |
| Chukwudozie, IB | 1 |
| Olupot-Olupot, P | 4 |
| Tomlinson, G | 2 |
| Tshilolo, L | 6 |
| McElhinney, K | 3 |
| Klein, LJ | 4 |
| Stallings, VA | 5 |
| Acra, S | 4 |
| Rai, P | 6 |
| Desai, PC | 7 |
| Ferreira de Matos, C | 3 |
| Comont, T | 3 |
| Castex, MP | 3 |
| Dion, J | 3 |
| Dick, A | 3 |
| Schwartzman, G | 3 |
| Khachemoune, A | 3 |
| Alkhalifah, SA | 3 |
| Alanazi, M | 3 |
| Almasaoud, MA | 3 |
| Al-Malki, HS | 3 |
| Al-Murdhi, FM | 3 |
| Al-Hazzaa, MS | 3 |
| Al-Mufarrij, SM | 3 |
| Albabtain, MA | 3 |
| Alshiakh, AA | 3 |
| AlRuthia, Y | 3 |
| Menchaca, AD | 2 |
| Style, CC | 2 |
| Villella, AD | 2 |
| Burdjalov, M | 2 |
| Beyene, TJ | 2 |
| Minneci, PC | 2 |
| Olutoye, OO | 2 |
| Guarino, S | 2 |
| Lanzkron, S | 15 |
| Christian, J | 2 |
| Naik, RP | 2 |
| Soren, UK | 2 |
| Mohanty, PK | 2 |
| Meher, S | 4 |
| Sukla, SK | 2 |
| Hiregoudar, M | 2 |
| Lumbala, PK | 2 |
| Mbayabo, G | 2 |
| Ngole, MN | 2 |
| Lumaka, A | 2 |
| Race, V | 2 |
| Matthijs, G | 2 |
| Van Geet, C | 4 |
| Lukusa, PT | 2 |
| Devriendt, K | 2 |
| Mikobi, TM | 2 |
| Tang, AY | 1 |
| Zhou, M | 1 |
| Maillis, AN | 1 |
| Lai, KW | 1 |
| Lane, PA | 5 |
| Snyder, AB | 1 |
| Kargutkar, N | 1 |
| Sawant-Mulay, M | 1 |
| Hariharan, P | 1 |
| Chandrakala, S | 2 |
| Nadkarni, A | 2 |
| Sheppard, S | 1 |
| Nasiri, YA | 1 |
| Lee, E | 1 |
| Nyamathi, A | 1 |
| Brecht, ML | 1 |
| Robbins, W | 1 |
| Mawali, AA | 1 |
| Omari, OA | 1 |
| Jacob, E | 1 |
| Pandey, A | 2 |
| Kaur, H | 1 |
| Borah, S | 1 |
| Khargekar, N | 1 |
| Karra, VK | 1 |
| Adhikari, T | 1 |
| Jain, D | 2 |
| Madkaikar, M | 1 |
| Cheema, MRS | 1 |
| Dayer, LE | 1 |
| Wagner, R | 1 |
| King, D | 1 |
| Lakkad, M | 1 |
| Wilson, LA | 1 |
| Montgomery, C | 1 |
| Painter, JT | 1 |
| Namazzi, R | 1 |
| Opoka, R | 1 |
| Conroy, AL | 1 |
| Datta, D | 1 |
| Tagoola, A | 1 |
| Bond, C | 1 |
| Goings, MJ | 1 |
| Ryu, MS | 1 |
| Cusick, SE | 1 |
| Krebs, NF | 1 |
| Jang, JH | 1 |
| Tu, W | 1 |
| John, CC | 6 |
| Strong, H | 1 |
| Reed-Shackelford, M | 1 |
| Ramaswamy, R | 1 |
| Ghunney, WK | 1 |
| Asare, EV | 1 |
| Ayete-Nyampong, JB | 1 |
| Oppong, SA | 1 |
| Olayemi, E | 1 |
| Gibson, JS | 1 |
| Torous, DK | 1 |
| Avlasevich, S | 1 |
| Bemis, JC | 1 |
| Fung, C | 1 |
| Sahsrabudhe, D | 1 |
| MacGregor, JT | 1 |
| Dertinger, SD | 6 |
| Ibekwe, T | 1 |
| Nnodu, O | 5 |
| Dagwa, I | 1 |
| Dahilo, E | 1 |
| Ibekwe, P | 1 |
| Rogers, C | 1 |
| Ramma, L | 1 |
| Menon, N | 1 |
| Lane, AC | 2 |
| Diop, S | 1 |
| de Montalembert, M | 23 |
| Chen, CC | 1 |
| McGuiness, CB | 1 |
| Yasuda, M | 1 |
| Lee, S | 1 |
| Paulose, J | 2 |
| Yen, G | 1 |
| Okhomina, VI | 2 |
| Martinez, HR | 1 |
| Joshi, V | 1 |
| Patel, A | 1 |
| Winter, T | 1 |
| Jain, A | 1 |
| Dexter, D | 1 |
| Tonin, FS | 1 |
| Ferreira, J | 1 |
| Fernandez-Llimos, F | 1 |
| Brousse, V | 8 |
| Melaine, A | 1 |
| Goguillot, M | 1 |
| Gallagher, M | 1 |
| Benard, S | 2 |
| Habibi, A | 15 |
| Dong, M | 11 |
| Dallmann, A | 1 |
| Vinks, AA | 10 |
| Reeves, SL | 6 |
| Peng, HK | 3 |
| Wing, JJ | 1 |
| Cogan, LW | 1 |
| Goel, A | 1 |
| Anders, D | 1 |
| Lisabeth, LD | 4 |
| Dombkowski, KJ | 6 |
| Alvarez, OA | 4 |
| Rodriguez-Cortes, H | 1 |
| Clay, ELJ | 1 |
| Echenique, S | 1 |
| Buitrago-Mogollon, T | 1 |
| Courtlandt, C | 1 |
| Noonan, L | 1 |
| Osunkwo, I | 5 |
| Joseph, L | 5 |
| Manceau, S | 2 |
| Borderie, D | 1 |
| Patrat, C | 2 |
| Arlet, JB | 4 |
| Meunier, B | 1 |
| Cavazzana, M | 3 |
| Santulli, P | 1 |
| Barraud-Lange, V | 2 |
| Karapurkar, S | 1 |
| Ghildiyal, R | 1 |
| Shah, N | 4 |
| Keshwani, R | 1 |
| Sharma, S | 1 |
| Phan, H | 2 |
| Kolenic, G | 2 |
| Madden, B | 2 |
| Radauer-Plank, AC | 1 |
| Diesch-Furlanetto, T | 1 |
| Schneider, M | 1 |
| Sommerhäuser, G | 1 |
| Friedrich, LA | 1 |
| Salow, V | 1 |
| Dülberg, J | 1 |
| Diepold, M | 1 |
| Rovó, A | 1 |
| Njue, LM | 1 |
| Drexler, B | 1 |
| Infanti, L | 1 |
| Kroiss, S | 1 |
| Merki, R | 1 |
| Scheinemann, K | 1 |
| Eisenreich, B | 1 |
| Hegemann, I | 1 |
| Mandic, L | 1 |
| Kager, L | 1 |
| Borgmann-Staudt, A | 1 |
| Schilling, R | 1 |
| Roll, S | 1 |
| Balcerek, M | 1 |
| Safeukui, I | 1 |
| Mohandas, N | 2 |
| Haldar, K | 1 |
| Ribeil, JA | 4 |
| Pollock, G | 1 |
| Frangoul, H | 1 |
| Rankine-Mullings, A | 3 |
| Keenan, R | 2 |
| Chakravorty, S | 2 |
| Inusa, B | 7 |
| Telfer, P | 4 |
| Velangi, M | 1 |
| Moss, JJ | 1 |
| Lloyd, AL | 1 |
| Edwards, S | 2 |
| Mulla, H | 1 |
| Raja, R | 1 |
| Estepp, JH | 11 |
| Ramkrishna, D | 1 |
| Harris, KM | 1 |
| Bauer, A | 1 |
| Calhoun, CL | 1 |
| Masese, R | 1 |
| Hussain, FA | 1 |
| Melvin, CL | 2 |
| Jeon, WJ | 1 |
| Joung, B | 1 |
| Moon, JH | 1 |
| Hino, C | 1 |
| Park, D | 1 |
| Pham, B | 1 |
| Castillo, DR | 1 |
| Chong, E | 1 |
| Kaur, S | 1 |
| Grismore, C | 1 |
| Cao, H | 2 |
| Pinto, V | 3 |
| Pondarré, C | 5 |
| Lionnet, F | 8 |
| Dhédin, N | 2 |
| El Aissate, M | 1 |
| Ennaboulsi, Y | 1 |
| Bentaher, A | 1 |
| El Khader, SE | 1 |
| Dar, MS | 1 |
| Murtala, HA | 1 |
| Kabir, H | 1 |
| Shamsu, KA | 1 |
| Gwarzo, G | 1 |
| D'Alessandro, A | 1 |
| Nouraie, SM | 1 |
| Zhang, Y | 3 |
| Cendali, F | 1 |
| Gamboni, F | 1 |
| Reisz, JA | 1 |
| Zhang, X | 4 |
| Bartsch, KW | 1 |
| Galbraith, MD | 1 |
| Espinosa, JM | 1 |
| Gladwin, MT | 22 |
| Ladu, AI | 1 |
| Jeffery, C | 1 |
| Farate, A | 1 |
| Farouk, AG | 1 |
| Abba, AM | 1 |
| Adekile, A | 8 |
| Bates, I | 1 |
| Teigen, D | 1 |
| Opoka, RO | 5 |
| Kasirye, P | 4 |
| Nabaggala, C | 2 |
| Hume, HA | 4 |
| Blomberg, B | 1 |
| Robberstad, B | 1 |
| Roy, NB | 2 |
| Carpenter, A | 1 |
| Dale-Harris, I | 1 |
| Dorée, C | 4 |
| Estcourt, LJ | 8 |
| Lisabeth, L | 1 |
| Kilonzi, M | 1 |
| Mlyuka, H | 1 |
| Jonathan, A | 1 |
| Tutuba, H | 1 |
| Chirande, L | 1 |
| Rugajo, P | 1 |
| Kida, I | 1 |
| Balandya, E | 1 |
| Makani, J | 6 |
| Sirili, N | 1 |
| Karkoska, KA | 1 |
| Gollamudi, J | 1 |
| Hyacinth, HI | 2 |
| Pizzo, A | 1 |
| Porter, JS | 7 |
| Carroll, Y | 2 |
| Burcheri, A | 1 |
| Beestrum, M | 1 |
| Nwosu, C | 4 |
| Alberts, NM | 3 |
| Khater, D | 1 |
| Al-Mulaabed, S | 1 |
| Alomairi, A | 1 |
| Elshinawy, M | 2 |
| Soliman, A | 1 |
| Elshinawy, N | 1 |
| Wali, Y | 3 |
| Al Yaarubi, S | 1 |
| Wang, WC | 45 |
| Brown, RC | 9 |
| McNaull, MA | 1 |
| Rogers, ZR | 21 |
| Barton, M | 1 |
| Dua, MR | 1 |
| Richardson, J | 1 |
| Segbefia, CI | 1 |
| Amissah-Arthur, KN | 1 |
| Dzefi-Tettey, K | 1 |
| Dei-Adomakoh, YA | 1 |
| Brambilla, D | 2 |
| Potter, MB | 1 |
| Baumann, AA | 2 |
| Simon, J | 2 |
| Fernandez, ME | 1 |
| Bosworth, HB | 1 |
| Fogarty, H | 2 |
| Atiq, F | 1 |
| Doherty, D | 1 |
| Ward, S | 1 |
| Karampini, E | 1 |
| Rehill, A | 1 |
| Leon, G | 1 |
| Byrne, C | 1 |
| Geoghegan, R | 2 |
| Conroy, H | 2 |
| Byrne, M | 2 |
| Budde, U | 1 |
| Schneppenheim, S | 1 |
| Sheehan, C | 1 |
| Ngwenya, N | 2 |
| Baker, RI | 1 |
| Preston, RJS | 1 |
| Tuohy, E | 2 |
| McMahon, C | 2 |
| O'Donnell, JS | 1 |
| Chouhan, U | 1 |
| Janghel, T | 1 |
| Bhatt, S | 1 |
| Kurmi, S | 1 |
| Choudhari, JK | 1 |
| Beillat, M | 1 |
| Durand-Zaleski, I | 1 |
| Pirenne, F | 4 |
| Chillotti, L | 1 |
| Galacteros, F | 24 |
| Pereira, DA | 2 |
| da Silva Pereira, P | 1 |
| Silveira, THR | 1 |
| Calmasini, FB | 1 |
| Reis, LO | 1 |
| Silva, FH | 2 |
| Archer, NM | 1 |
| Notice, B | 1 |
| Soffer, E | 1 |
| Tickle, K | 1 |
| Xiang, Y | 1 |
| Gee, BE | 2 |
| Sidonio, RF | 2 |
| Sokkary, N | 1 |
| Batsuli, G | 1 |
| Jacob, SA | 1 |
| Talati, R | 2 |
| Soulié, A | 1 |
| Kamdem, A | 4 |
| Neumann, F | 1 |
| Hau, I | 2 |
| Madhi, F | 2 |
| Delestrain, C | 1 |
| Shum, M | 1 |
| Carlier-Gonod, A | 1 |
| Malterre, A | 1 |
| Lezeau, H | 2 |
| Khazem, B | 1 |
| Belozertseva, E | 1 |
| Guémas, E | 1 |
| Epaud, R | 2 |
| Pissard, S | 1 |
| Arnaud, C | 4 |
| Greppi Q, C | 1 |
| Fuentes G, MP | 1 |
| Sotomayor F, C | 1 |
| Verdugo L, P | 1 |
| Al Kahf, S | 1 |
| Roche, A | 1 |
| Baron, A | 1 |
| Chantalat-Auger, C | 1 |
| Savale, L | 1 |
| Newman, TV | 1 |
| Yang, J | 1 |
| Suh, K | 1 |
| Jonassaint, CR | 1 |
| Kane-Gill, SL | 1 |
| Novelli, EM | 3 |
| Meier, ER | 9 |
| Janson, IA | 2 |
| Hampton, K | 1 |
| Bloom, E | 1 |
| Duncan, N | 2 |
| Roberson, C | 1 |
| Rampersad, A | 2 |
| Mvalo, T | 2 |
| Topazian, HM | 1 |
| Kamthunzi, P | 2 |
| Chen, JS | 1 |
| Kambalame, I | 2 |
| Mafunga, P | 2 |
| Mumba, N | 2 |
| Chiume, M | 1 |
| Paseli, K | 2 |
| Tegha, G | 1 |
| Kumwenda, W | 1 |
| Heimlich, JB | 1 |
| Ellis, G | 1 |
| Key, N | 2 |
| Gopal, S | 2 |
| Hoffman, I | 2 |
| Westmoreland, KD | 1 |
| Creary, S | 3 |
| Chisolm, D | 2 |
| Hankins, J | 3 |
| Saunthararajah, Y | 2 |
| Modi, AC | 1 |
| Stanek, JR | 1 |
| Chisolm, DJ | 2 |
| Nwankwo, C | 2 |
| Wichlan, D | 2 |
| Elsherif, L | 2 |
| Wogu, AF | 1 |
| Maitra, P | 1 |
| Caughey, MC | 2 |
| Pollock, DM | 3 |
| Pollock, JS | 3 |
| Archer, DR | 2 |
| Hinderliter, AL | 2 |
| Jabour, SM | 1 |
| Beachy, S | 1 |
| Coburn, S | 1 |
| Eakin, MN | 1 |
| Carden, MA | 1 |
| Little, J | 1 |
| Galadanci, AA | 1 |
| Ali Abubakar, SA | 1 |
| Kabo, NA | 1 |
| Bashir, I | 1 |
| Galadanci, JA | 1 |
| Regan, S | 1 |
| Yang, X | 1 |
| Finnberg, NK | 1 |
| El-Deiry, WS | 1 |
| Pu, JJ | 1 |
| Monus, T | 1 |
| Howell, CM | 1 |
| Adeyemo, TA | 2 |
| Diaku-Akinwunmi, IN | 1 |
| Ojewunmi, OO | 2 |
| Bolarinwa, AB | 1 |
| Adekile, AD | 6 |
| Kwiatkowski, JL | 5 |
| Voeks, JH | 2 |
| Fullerton, HJ | 1 |
| Debenham, E | 2 |
| Brown, L | 1 |
| Adams, RJ | 6 |
| Than, NN | 2 |
| Soe, HHK | 2 |
| Palaniappan, SK | 2 |
| Abas, AB | 2 |
| De Franceschi, L | 5 |
| Oliveira, EAM | 1 |
| Boy, KA | 1 |
| Machado, CDS | 1 |
| Gerheim, PSAS | 1 |
| Mendonça, LM | 1 |
| Lim, SH | 1 |
| Dutta, D | 1 |
| Moore, J | 1 |
| Lance, EI | 1 |
| Ofakunrin, AOD | 1 |
| Oguche, S | 1 |
| Diaku-Akinwumi, IN | 2 |
| Zoakah, AI | 1 |
| Smaldone, A | 5 |
| Jia, H | 4 |
| Bruzzese, JM | 1 |
| Findley, S | 4 |
| Massei, J | 1 |
| Guarda, CC | 2 |
| Silveira-Mattos, PSM | 1 |
| Yahouédéhou, SCMA | 5 |
| Santiago, RP | 8 |
| Aleluia, MM | 5 |
| Figueiredo, CVB | 3 |
| Fiuza, LM | 3 |
| Carvalho, SP | 4 |
| Oliveira, RM | 4 |
| Nascimento, VML | 4 |
| Luz, NF | 1 |
| Borges, VM | 3 |
| Andrade, BB | 3 |
| Gonçalves, MS | 7 |
| Bhor, M | 1 |
| Xie, L | 1 |
| Halloway, R | 1 |
| Arcona, S | 1 |
| Yuce, H | 1 |
| Ndidi, US | 4 |
| Adanho, CSA | 1 |
| Santana, SS | 3 |
| Mafili, VV | 1 |
| Pitanga, TN | 3 |
| Fonseca, CA | 2 |
| Ferreira, JRD | 2 |
| Adorno, EV | 3 |
| Lyra, IM | 5 |
| Barbosa, CG | 2 |
| Williams, O | 1 |
| Tymon, J | 1 |
| Ndugwa, CM | 3 |
| Shaw, R | 1 |
| Kappa, S | 2 |
| Nickel, RS | 5 |
| Banza, MI | 1 |
| Mulefu, JP | 1 |
| Lire, LI | 1 |
| N'dwala, YTB | 1 |
| Tshiamala, IB | 1 |
| Cabala, VPK | 1 |
| Barbu, EA | 2 |
| Mendelsohn, L | 3 |
| Samsel, L | 2 |
| Adesina, OO | 1 |
| Neumayr, LD | 3 |
| Hoppe, CC | 2 |
| Brown, C | 2 |
| Alkindi, S | 2 |
| Almufargi, SS | 1 |
| Pathare, A | 2 |
| Matte, A | 1 |
| Cappellini, MD | 4 |
| Iolascon, A | 1 |
| Enrica, F | 1 |
| Hasson, C | 1 |
| Veling, L | 1 |
| Rico, J | 1 |
| Mhaskar, R | 1 |
| White, J | 2 |
| Lancelot, M | 1 |
| Gao, X | 2 |
| McGraw, BJ | 1 |
| Tabb, C | 1 |
| Hines, P | 1 |
| Dominical, VM | 3 |
| van Geyzel, L | 1 |
| Arigliani, M | 2 |
| Singh, B | 2 |
| Kozlowska, W | 1 |
| Bossley, CJ | 1 |
| Ruiz, G | 1 |
| Rees, D | 4 |
| Gupta, A | 3 |
| Azmet, FR | 1 |
| Al-Kasim, F | 1 |
| Alashram, WM | 1 |
| Siddique, K | 1 |
| Kimrey, S | 1 |
| Saving, KL | 4 |
| Cervi, A | 1 |
| Diamantouros, A | 1 |
| Azzam, M | 1 |
| Lane, SJ | 1 |
| Sapru, H | 1 |
| Verhovsek, M | 1 |
| Roumenina, LT | 1 |
| Chadebech, P | 2 |
| Bodivit, G | 2 |
| Vieira-Martins, P | 1 |
| Grunenwald, A | 1 |
| Boudhabhay, I | 1 |
| Poillerat, V | 1 |
| Pakdaman, S | 4 |
| Kiger, L | 3 |
| Jouard, A | 1 |
| Audureau, E | 4 |
| Frémeaux-Bacchi, V | 1 |
| da Guarda, CC | 5 |
| Neres, JSDS | 1 |
| Fernandes, CFL | 1 |
| Rocha, LC | 2 |
| Adepoju, P | 1 |
| Pecker, LH | 4 |
| Silver, EJ | 2 |
| Roth, M | 1 |
| Valadão Cardoso, A | 1 |
| Idris, IM | 1 |
| Soutou, B | 1 |
| Senet, P | 1 |
| Aractingi, S | 3 |
| Kayle, M | 2 |
| Valle, J | 1 |
| Paulukonis, S | 1 |
| Holl, JL | 1 |
| French, DD | 1 |
| Garg, R | 1 |
| Treadwell, MJ | 1 |
| Shah, F | 1 |
| Dwivedi, M | 1 |
| Renó, CO | 1 |
| Barbosa, AR | 2 |
| de Carvalho, SS | 1 |
| Pinheiro, MB | 1 |
| Rios, DR | 1 |
| Cortes, VF | 1 |
| Barbosa, LA | 1 |
| Santos, HL | 1 |
| Marahatta, A | 5 |
| Ware, JL | 1 |
| Power-Hays, A | 1 |
| Kimber, C | 1 |
| Hopewell, S | 7 |
| Trivella, M | 6 |
| Abboud, MR | 8 |
| Khandros, E | 2 |
| Huang, P | 2 |
| Peslak, SA | 2 |
| Sharma, M | 3 |
| Abdulmalik, O | 2 |
| Giardine, BM | 2 |
| Zhang, Z | 2 |
| Keller, CA | 2 |
| Blobel, GA | 2 |
| Garnier, Y | 3 |
| Ferdinand, S | 3 |
| Garnier, M | 2 |
| Cita, KC | 1 |
| Hierso, R | 2 |
| Claes, A | 1 |
| Connes, P | 10 |
| Hardy-Dessources, MD | 5 |
| Lapouméroulie, C | 10 |
| Lemonne, N | 7 |
| Etienne-Julan, M | 7 |
| El Nemer, W | 5 |
| Romana, M | 9 |
| Schatz, J | 2 |
| Vichinsky, E | 9 |
| Fox, CK | 1 |
| McKinstry, RC | 2 |
| Kraut, MA | 1 |
| Daraz, L | 1 |
| Murad, MH | 3 |
| Mwaiswelo, RO | 1 |
| Mawala, W | 1 |
| Iversen, PO | 1 |
| Luzzatto, L | 3 |
| Han, J | 7 |
| Pedrosa, AM | 1 |
| Lemes, RPG | 2 |
| Hodges, J | 1 |
| Khan, H | 2 |
| Homayouni, R | 1 |
| Norell, S | 2 |
| Klesges, L | 1 |
| Garg, U | 4 |
| Collins, AB | 1 |
| McTate-Acosta, EA | 1 |
| Williams, SE | 1 |
| Santos Neto, ATD | 1 |
| Silva, IS | 1 |
| Ivo, ML | 1 |
| Rodrigues, CT | 1 |
| Parisotto, EB | 1 |
| Ramalho, RT | 1 |
| Monteiro, GM | 1 |
| Margulies, S | 1 |
| Frazer, B | 1 |
| Luban, NLC | 2 |
| Webb, J | 2 |
| Shih, S | 1 |
| Cohen, LL | 1 |
| Gondhi, JP | 3 |
| Scott, EL | 1 |
| George, A | 4 |
| Dinu, B | 1 |
| Estrada, N | 1 |
| Minard, CG | 1 |
| Hurwitz, R | 1 |
| Mahoney, DH | 1 |
| Yates, AM | 2 |
| Vaughan, M | 1 |
| Carmouche, A | 1 |
| Airewele, G | 1 |
| Kirk, SE | 1 |
| Fasipe, T | 1 |
| Uwaezuoke, P | 1 |
| Ali Abubakar, S | 1 |
| Wudil Jibir, B | 2 |
| Aminu, H | 1 |
| Tijjani, A | 2 |
| Tabari, MA | 3 |
| Borodo, AM | 1 |
| Belonwu, R | 3 |
| Salihu, AS | 1 |
| Covert C Greene, BV | 1 |
| Distelmaier, L | 1 |
| Dührsen, U | 1 |
| Dickerhoff, R | 2 |
| Almeida, CB | 8 |
| Torres, L | 3 |
| Miguel, LI | 1 |
| Garcia, F | 1 |
| Frenette, PS | 4 |
| Brockschnieder, D | 1 |
| Stasch, JP | 1 |
| Sandner, P | 1 |
| Kato, GJ | 20 |
| Oldham, M | 1 |
| Conrey, A | 1 |
| Pittman, C | 1 |
| Fisher, C | 1 |
| Hargrett, S | 1 |
| West, K | 1 |
| Jackson, M | 2 |
| Martin, S | 2 |
| Jeffries, N | 1 |
| Kaplarevic, M | 1 |
| Johnson, D | 1 |
| Olkhanud, P | 1 |
| Fitzhugh, CD | 3 |
| Herity, LB | 1 |
| Vaughan, DM | 1 |
| Rodriguez, LR | 1 |
| Lowe, DK | 1 |
| Hebert, N | 1 |
| Rakotoson, MG | 6 |
| Bencheikh, L | 1 |
| Oubaya, N | 1 |
| Sakka, M | 1 |
| Di Liberto, G | 4 |
| Vingert, B | 2 |
| Cambot, M | 1 |
| Hussain, S | 1 |
| Christianson, MS | 1 |
| Kohli, R | 1 |
| Domingues-Hamdi, E | 2 |
| Vasseur, C | 2 |
| Moutereau, S | 2 |
| Baudin-Creuza, V | 2 |
| Adebayo, IA | 1 |
| Strader, MB | 2 |
| Jana, S | 2 |
| Meng, F | 2 |
| Heaven, MR | 2 |
| Shet, AS | 2 |
| Alayash, AI | 2 |
| Fan-Hsu, J | 1 |
| Liguoro, I | 1 |
| Inusa, BPD | 2 |
| Morrone, KA | 1 |
| Strumph, K | 1 |
| Liszewski, MJ | 1 |
| Jackson, J | 1 |
| Rinke, ML | 1 |
| Minniti, C | 2 |
| Davila, J | 1 |
| Hehre, RJ | 1 |
| Hodges, JR | 2 |
| Phillips, SM | 1 |
| Luo, L | 1 |
| King, A | 1 |
| Rojas Smith, L | 1 |
| Calhoun, C | 1 |
| Porter, J | 2 |
| Lan, X | 1 |
| Geronimo, CL | 1 |
| Grevet, JD | 1 |
| Shi, J | 2 |
| Costa, E | 1 |
| Tibalinda, P | 1 |
| Sterzi, E | 1 |
| Leufkens, HMG | 1 |
| Kaale, E | 1 |
| Jean, C | 2 |
| Chalas, C | 3 |
| Allali, S | 3 |
| Boutonnat-Faucher, B | 1 |
| Koehl, B | 2 |
| Berthaut, I | 3 |
| Wang, K | 2 |
| Yan, Z | 2 |
| Zhang, S | 2 |
| Roberts, K | 1 |
| Crouch, AS | 3 |
| Sebastian, G | 1 |
| Chaitowitz, M | 1 |
| Fornari, ED | 1 |
| Schwechter, EM | 1 |
| Uehlinger, J | 2 |
| Bouhassira, EE | 2 |
| Robert, K | 1 |
| Man, Y | 1 |
| Kucukal, E | 1 |
| An, R | 1 |
| Bode, A | 1 |
| Little, JA | 4 |
| Gurkan, UA | 1 |
| Boucher, AA | 1 |
| Nathan, JD | 1 |
| Abu-El-Haija, M | 1 |
| Luchtman-Jones, L | 9 |
| Li, J | 3 |
| Jeong, SY | 1 |
| Xiong, B | 1 |
| Tseng, A | 2 |
| Mahon, AB | 1 |
| Isaacman, S | 1 |
| Cho, J | 3 |
| Pittman, DD | 2 |
| Hines, PC | 1 |
| Beidler, D | 2 |
| Rybin, D | 2 |
| Frelinger, AL | 2 |
| Michelson, AD | 2 |
| Liu, K | 1 |
| Zaidi, AU | 2 |
| Charnigo, RJ | 2 |
| Callaghan, MU | 2 |
| Srivastava, K | 1 |
| Albasri, J | 1 |
| Alsuhaibani, OM | 1 |
| Aljasem, HA | 1 |
| Bueno, MU | 1 |
| Antonacci, T | 1 |
| Branch, DR | 1 |
| Denomme, GA | 1 |
| Flegel, WA | 1 |
| Vinhaes, CL | 1 |
| Teixeira, RS | 2 |
| Monteiro-Júnior, JAS | 1 |
| Tibúrcio, R | 1 |
| Cubillos-Angulo, JM | 1 |
| Arriaga, MB | 1 |
| Sabarin, AG | 1 |
| de Souza, AJ | 2 |
| Silva, JJ | 2 |
| Ladeia, AM | 2 |
| Ryan, N | 1 |
| Dike, L | 1 |
| Ojo, T | 1 |
| Vieira, D | 1 |
| Gyamfi, J | 1 |
| McCoy, B | 1 |
| Jaffe, RJ | 1 |
| Coffey, BJ | 1 |
| Santos, MEHP | 1 |
| Olops, L | 1 |
| Vendrame, F | 1 |
| Tavares, AHJ | 1 |
| Leonardo, DP | 1 |
| de Azevedo, PC | 1 |
| Piovesana, LG | 1 |
| Pressiat, C | 1 |
| Barau, C | 1 |
| Arrouasse, R | 1 |
| Stehlé, T | 3 |
| Audard, V | 3 |
| Hulin, A | 7 |
| Issa, F | 1 |
| Dang, BN | 1 |
| Buck, WC | 1 |
| Chicumbe, S | 1 |
| Nicolau, N | 1 |
| Virate, C | 1 |
| Cassamo, N | 1 |
| Dias, A | 1 |
| Amodo, F | 1 |
| Ingerski, LM | 2 |
| Loew, M | 1 |
| Su, Y | 1 |
| Zhang, H | 1 |
| Heeney, MM | 11 |
| Appiah-Kubi, AO | 1 |
| Nelson, SC | 3 |
| Piccone, C | 3 |
| Quarmyne, MO | 2 |
| Scott, JP | 9 |
| Shook, LM | 3 |
| Gille, AS | 1 |
| Dalle, JH | 2 |
| Fahd, M | 1 |
| Riou, L | 1 |
| Drouineaud, V | 1 |
| Paye-Jaouen, A | 1 |
| Neven, B | 1 |
| Azarnoush, S | 1 |
| Yakouben, K | 1 |
| Sarnacki, S | 1 |
| Comperat, EM | 1 |
| Lenaour, G | 1 |
| Sibony, M | 1 |
| Vaiman, D | 1 |
| Wolf, JP | 1 |
| Fouchet, P | 1 |
| Poirot, C | 1 |
| Neill, US | 1 |
| de Oliveira Júnior, WV | 1 |
| Reis, EA | 1 |
| Chaves, DG | 1 |
| Dusse, LMS | 1 |
| de Barros Pinheiro, M | 1 |
| Ribeiro, PR | 1 |
| Teixeira, RDS | 1 |
| Souza, AR | 1 |
| Pereira, TCS | 1 |
| Boffo, EF | 1 |
| Carosio, MGA | 1 |
| Ferreira, AG | 1 |
| Oliveira, RV | 1 |
| Rodrigues, LEA | 1 |
| Ladeia, AMT | 1 |
| Lagunju, IA | 2 |
| Labaeka, A | 1 |
| Ibeh, JN | 1 |
| Orimadegun, AE | 1 |
| Sodeinde, OO | 3 |
| Staffa, SJ | 1 |
| Brugnara, C | 10 |
| Stocker, JW | 2 |
| Aupiais, C | 1 |
| Schinckel, N | 1 |
| Mornand, P | 1 |
| Odièvre, MH | 8 |
| Niakate, A | 1 |
| Missud, F | 2 |
| Holvoet, L | 2 |
| Benkerrou, M | 7 |
| Sorge, F | 1 |
| Faye, A | 1 |
| Tauseef, U | 1 |
| Anjum, M | 1 |
| Ibrahim, M | 1 |
| Baqai, HS | 1 |
| Tauseef, A | 1 |
| Tauseef, M | 1 |
| Asghar, MS | 1 |
| Zafar, M | 1 |
| Rasheed, U | 1 |
| Shaikh, N | 1 |
| Joshi, VM | 1 |
| Goldberg, JF | 1 |
| Penkert, R | 1 |
| Nouraie, M | 8 |
| Crouch, GD | 1 |
| Carpenter, S | 1 |
| Jacobs, C | 1 |
| Klings, ES | 4 |
| Joice, GA | 1 |
| Liu, JL | 1 |
| Burnett, AL | 2 |
| Ferreira, TFA | 1 |
| Dos Santos, APT | 1 |
| Leal, AS | 1 |
| de Araújo Pereira, G | 1 |
| Silva, SS | 1 |
| Moraes-Souza, H | 1 |
| Stotesbury, H | 1 |
| Kawadler, JM | 1 |
| Saunders, DE | 1 |
| Taylor, CM | 1 |
| Kasztan, M | 2 |
| Sedaka, R | 1 |
| Molina, PA | 1 |
| Dunaway, LS | 1 |
| Taylor, M | 2 |
| Brice, J | 1 |
| Möckesch, B | 2 |
| Tudor Ngo Sock, E | 1 |
| Reminy, K | 1 |
| Skinner, S | 2 |
| Billaud, M | 1 |
| Nader, E | 3 |
| Tressieres, B | 2 |
| Guillot, N | 2 |
| Hue, O | 2 |
| Antoine-Jonville, S | 2 |
| Cunha, M | 1 |
| Simão, C | 1 |
| Ferrão, A | 1 |
| Palaré, MJ | 1 |
| Vick, L | 1 |
| Potts, M | 1 |
| Jaskowiak, M | 1 |
| Gibson, RW | 1 |
| Tarazi, RA | 1 |
| Patrick, KE | 1 |
| Iampietro, M | 1 |
| Apollonsky, N | 1 |
| Todd, K | 1 |
| Clapp, K | 1 |
| Fenchel, L | 1 |
| Kalfa, TA | 6 |
| Malik, P | 6 |
| Gaul, A | 1 |
| Syed, S | 1 |
| Aleksejenko, N | 1 |
| Crampton, E | 1 |
| Darshana, T | 1 |
| Premawardhena, A | 1 |
| Cavanaugh, R | 1 |
| Adebayo, I | 1 |
| Erigbuem, I | 1 |
| James, E | 1 |
| Kumode, E | 1 |
| Mohi, SM | 1 |
| Saadon, HL | 1 |
| Khalaf, AA | 1 |
| Suliman, ME | 1 |
| Ansari, MGA | 1 |
| Rayis, MA | 1 |
| Hamza, MA | 1 |
| Saeed, AA | 1 |
| Mohammed, AK | 1 |
| Al-Daghri, NM | 1 |
| Mukinayi, BM | 1 |
| Cibeyibeyi, GK | 1 |
| Tumba, GD | 1 |
| Gulbis, B | 6 |
| Bhasin, N | 1 |
| Price, N | 1 |
| Desoky, SM | 1 |
| Inati, A | 3 |
| Al Alam, C | 1 |
| El Ojaimi, C | 1 |
| Hamad, T | 1 |
| Kanakamedala, H | 1 |
| Pilipovic, V | 1 |
| Sabah, R | 1 |
| Dambatta, AH | 1 |
| Galadanci, J | 1 |
| Suleiman, AA | 1 |
| Gambo, AI | 1 |
| Khalifa, Y | 1 |
| Abdulrasheed, S | 1 |
| Zakari, MA | 1 |
| Temiye, EO | 1 |
| Eimunjeze, OP | 1 |
| Ogungbemi, SI | 1 |
| Jaja, SI | 1 |
| Sadaf, A | 1 |
| Korpik, JB | 1 |
| Reynaud, M | 2 |
| Dawson, A | 1 |
| Mullen, K | 1 |
| Henriksen, B | 1 |
| O'Brien, D | 1 |
| Bhattacharya, P | 1 |
| Sarmah, D | 1 |
| Dave, KR | 1 |
| Goswami, A | 1 |
| Watanabe, M | 1 |
| Wang, X | 1 |
| Kalia, K | 1 |
| Plesnila, N | 1 |
| Yavagal, DR | 1 |
| Alvarez, O | 7 |
| Ballas, SK | 31 |
| Kuypers, FA | 2 |
| Thompson, AA | 11 |
| Cong, Z | 1 |
| Agodoa, I | 1 |
| Ding, J | 2 |
| McCarville, MB | 5 |
| Weaver, SB | 1 |
| Rungkitwattanakul, D | 1 |
| Singh, D | 1 |
| Griesshammer, M | 1 |
| Wille, K | 1 |
| Sadjadian, P | 1 |
| Stegelmann, F | 1 |
| Döhner, K | 1 |
| Zanette, DL | 2 |
| Maffili, VV | 1 |
| Lima, JB | 1 |
| Carvalho, GQ | 1 |
| Filho, JR | 1 |
| Carvalho, MOS | 2 |
| Oliveira, RR | 1 |
| Voskaridou, E | 8 |
| Cannas, G | 3 |
| Loko, G | 1 |
| Colombatti, R | 3 |
| Korpik, J | 1 |
| Bonar, H | 1 |
| Scott, LC | 1 |
| Jones, SK | 2 |
| Shen, JH | 1 |
| Reid, M | 3 |
| Soares, D | 1 |
| Taylor-Bryan, C | 1 |
| Wisdom-Phipps, M | 1 |
| Aldred, K | 2 |
| Latham, T | 4 |
| Schultz, WH | 13 |
| Knight-Madden, J | 4 |
| Badaloo, A | 1 |
| Zou, P | 1 |
| Hwang, SN | 1 |
| Schreiber, JE | 2 |
| Helton, K | 1 |
| Mayer, SL | 1 |
| Fields, ME | 3 |
| Hulbert, ML | 4 |
| Pugh, NL | 1 |
| Gordeuk, V | 2 |
| Crego, N | 1 |
| Costa, SA | 1 |
| Ribeiro, CCC | 1 |
| Thomaz, EBAF | 1 |
| Costa, CPS | 1 |
| Souza, SFC | 1 |
| Freeman, M | 1 |
| Hamilton, L | 1 |
| Moen, J | 3 |
| Estepp, J | 1 |
| Chenou, F | 1 |
| Hounkpe, BW | 1 |
| Domingos, IF | 1 |
| Tonassé, WV | 1 |
| Batista, THC | 1 |
| Santana, RM | 1 |
| Arcanjo, GDS | 1 |
| Alagbe, AE | 1 |
| Araújo, ADS | 1 |
| Lucena-Araújo, AR | 1 |
| Bezerra, MAC | 1 |
| Sonati, MF | 1 |
| De Paula, EV | 2 |
| Dos Santos, MNN | 1 |
| Antunes, FD | 1 |
| Propheta, VGS | 1 |
| Vasconcelos, HA | 1 |
| Cipolotti, R | 1 |
| García-Morin, M | 1 |
| López-Sangüos, C | 1 |
| Vázquez, P | 1 |
| Alvárez, T | 1 |
| Marañón, R | 1 |
| Huerta, J | 1 |
| Cela, E | 1 |
| Jones, AP | 1 |
| Howard, J | 10 |
| Umar Abdullahi, S | 1 |
| Vance, LD | 1 |
| Musa Tabari, A | 1 |
| Ali, S | 2 |
| Salihu, A | 2 |
| Amal Galadanci, A | 1 |
| Shyr, Y | 2 |
| Phillips, S | 2 |
| Covert, BV | 2 |
| Uchida, N | 1 |
| Fujita, A | 1 |
| Bonifacino, AC | 1 |
| Krouse, AE | 1 |
| Metzger, ME | 1 |
| Donahue, RE | 1 |
| Parrow, NL | 1 |
| Tu, H | 1 |
| Nichols, J | 1 |
| Violet, PC | 1 |
| Pittman, CA | 1 |
| Fitzhugh, C | 2 |
| Fleming, RE | 1 |
| Levine, M | 1 |
| Kolliopoulou, A | 1 |
| Stratopoulos, A | 1 |
| Siamoglou, S | 2 |
| Sgourou, A | 4 |
| Ali, BR | 2 |
| Papachatzopoulou, A | 5 |
| Katsila, T | 3 |
| Panepinto, JA | 12 |
| Cook, LJ | 1 |
| Simmons, T | 1 |
| Brousseau, DC | 3 |
| Fortin, PM | 5 |
| Arnold, TL | 1 |
| Banks, G | 1 |
| Abraham, A | 1 |
| Cluster, A | 1 |
| Jacobsohn, D | 1 |
| Delgado, D | 1 |
| Kukadiya, D | 1 |
| Murray, L | 1 |
| Shenoy, S | 1 |
| Janakiram, M | 1 |
| Verma, A | 1 |
| Wang, Y | 4 |
| Budhathoki, A | 1 |
| Suarez Londono, J | 1 |
| Murakhovskaya, I | 1 |
| Braunschweig, I | 1 |
| Tehseen, S | 1 |
| Joiner, CH | 4 |
| Yee, ME | 1 |
| Matos, S | 2 |
| Hicks, A | 1 |
| Soto, L | 1 |
| Castillo, Y | 1 |
| Ireland, K | 3 |
| Stennett, Y | 1 |
| Bull, KR | 1 |
| Lai, JS | 3 |
| Penedo, FJ | 3 |
| Rychlik, K | 3 |
| Bakshi, N | 2 |
| Sinha, CB | 2 |
| Ross, D | 3 |
| Khemani, K | 1 |
| Loewenstein, G | 1 |
| Krishnamurti, L | 7 |
| Charlot, K | 2 |
| Waltz, X | 4 |
| Lamarre, Y | 4 |
| Sahoo, LK | 1 |
| Kullu, BK | 1 |
| Patel, S | 3 |
| Patel, NK | 1 |
| Rout, P | 1 |
| Purohit, P | 3 |
| Figueiredo, L | 1 |
| Morrone, K | 1 |
| Wei, C | 1 |
| Cohen, HW | 3 |
| Driscoll, C | 3 |
| Mizuno, T | 4 |
| Osemwota, O | 1 |
| Uhlemann, J | 1 |
| Rubin, A | 1 |
| Terse-Ramos, R | 1 |
| Ferreira, TA | 1 |
| Machado, VR | 1 |
| Perdiz, MI | 1 |
| Nascimento, VL | 1 |
| Boa-Sorte, N | 1 |
| Palazzi, G | 2 |
| Masera, N | 2 |
| Notarangelo, LD | 1 |
| Bonetti, E | 1 |
| Samperi, P | 1 |
| Barone, A | 1 |
| Perrotta, S | 2 |
| Facchini, E | 1 |
| Miano, M | 1 |
| Del Vecchio, GC | 1 |
| Guerzoni, ME | 1 |
| Corti, P | 1 |
| Menzato, F | 1 |
| Cesaro, S | 1 |
| Casale, M | 2 |
| Rigano, P | 6 |
| Forni, GL | 3 |
| Russo, G | 3 |
| Sainati, L | 2 |
| Sachdev, V | 3 |
| Sidenko, S | 1 |
| Wu, MD | 1 |
| Hannoush, H | 1 |
| Brenneman, CL | 1 |
| Waclawiw, MA | 16 |
| Arai, AE | 1 |
| Schechter, AN | 16 |
| Lindner, JR | 1 |
| Wiczling, P | 3 |
| Mack, JM | 1 |
| Liem, R | 2 |
| Kearns, G | 1 |
| Neville, KA | 4 |
| Stimpson, SJ | 2 |
| Day, ME | 1 |
| James, A | 1 |
| Sharma, D | 1 |
| Li, C | 2 |
| Abrams, C | 1 |
| Nottage, K | 3 |
| Legrand, T | 1 |
| Nahata, L | 1 |
| Caltabellotta, NM | 1 |
| Ball, K | 1 |
| Zhu, X | 1 |
| Hu, T | 1 |
| Ho, MH | 1 |
| Yu, M | 1 |
| Patel, N | 3 |
| Pi, W | 1 |
| Choi, JH | 1 |
| Xu, H | 1 |
| Ganapathy, V | 1 |
| Kutlar, F | 2 |
| Tuan, D | 1 |
| Bachir, D | 12 |
| Kotti, S | 1 |
| Stankovic, K | 2 |
| Eustache, F | 1 |
| Ravel, C | 2 |
| Brailly-Tabard, S | 1 |
| Lévy-Dutel, L | 1 |
| Bleibtreu, A | 1 |
| Simon, T | 1 |
| Mandelbaum, J | 2 |
| Adewoyin, AS | 1 |
| Oghuvwu, OS | 1 |
| Awodu, OA | 1 |
| Hodges, JS | 1 |
| Adegoke, SA | 3 |
| Macedo-Campos, RS | 1 |
| Braga, JAP | 2 |
| Figueiredo, MS | 5 |
| Silva, GS | 1 |
| Afifi, RA | 1 |
| Kamal, D | 1 |
| Sayed, RE | 1 |
| Ekladious, SMM | 1 |
| Shaheen, GH | 1 |
| Yousry, SM | 1 |
| Hussein, RE | 1 |
| de Melo, TR | 1 |
| Chin, CM | 3 |
| Nero, AC | 2 |
| Cui, S | 2 |
| Engel, JD | 1 |
| Penkert, RR | 2 |
| Hurwitz, JL | 2 |
| Thomas, P | 1 |
| Rosch, J | 1 |
| Dowdy, J | 1 |
| Sun, Y | 2 |
| Tang, L | 2 |
| D Adekile, A | 1 |
| Ansari, J | 1 |
| Moufarrej, YE | 1 |
| Pawlinski, R | 1 |
| Gavins, FNE | 1 |
| Tomlinson, GA | 2 |
| Luís Reis da Fonseca, J | 1 |
| Kitenge, R | 1 |
| Mochamah, G | 1 |
| Wabwire, H | 1 |
| Stuber, S | 3 |
| Hariri, E | 1 |
| Mansour, A | 1 |
| El Alam, A | 1 |
| Daaboul, Y | 1 |
| Korjian, S | 1 |
| Aoun Bahous, S | 1 |
| Chatterjee, T | 1 |
| Chakravarty, A | 1 |
| Chakravarty, S | 1 |
| Lagresle-Peyrou, C | 1 |
| Lefrère, F | 1 |
| Magrin, E | 1 |
| Romano, O | 1 |
| Weber, L | 1 |
| Magnani, A | 1 |
| Sadek, H | 1 |
| Plantier, C | 1 |
| Gabrion, A | 1 |
| Ternaux, B | 1 |
| Félix, T | 1 |
| Couzin, C | 1 |
| Stanislas, A | 1 |
| Tréluyer, JM | 1 |
| Lamhaut, L | 1 |
| Delville, M | 1 |
| Miccio, A | 1 |
| André-Schmutz, I | 1 |
| Di Maggio, R | 1 |
| Zhao, X | 2 |
| Calvaruso, G | 2 |
| Renda, D | 1 |
| Maggio, A | 5 |
| Rodriguez, A | 2 |
| Duez, P | 2 |
| Dedeken, L | 3 |
| Cotton, F | 3 |
| Ferster, A | 12 |
| George, PE | 1 |
| Bazo-Alvarez, JC | 1 |
| Sheehan, VA | 3 |
| Qureshi, A | 1 |
| Kaya, B | 1 |
| Pancham, S | 1 |
| Anderson, J | 1 |
| Akanni, M | 1 |
| Gwer, SO | 1 |
| Onyango, KO | 1 |
| Zhou, J | 1 |
| Nutescu, EA | 1 |
| Calip, GS | 1 |
| Lagunju, I | 2 |
| Oyinlade, AO | 1 |
| Asinobi, A | 1 |
| Ibeh, J | 1 |
| Esione, A | 1 |
| Villavicencio, MA | 1 |
| Robison, LL | 1 |
| Weiss, MJ | 1 |
| Kaste, SC | 2 |
| Bryant, PC | 1 |
| Deyo, JE | 1 |
| Nottage, KA | 6 |
| Lebensburger, JD | 5 |
| Adesina, O | 1 |
| Chou, ST | 1 |
| Zemel, BS | 2 |
| Gurney, JG | 2 |
| ElAlfy, MS | 2 |
| Adly, AAM | 1 |
| Ebeid, FSE | 1 |
| Eissa, DS | 1 |
| Ismail, EAR | 1 |
| Mohammed, YH | 1 |
| Ahmed, ME | 1 |
| Saad, AS | 1 |
| Niihara, Y | 1 |
| Miller, ST | 15 |
| Viswanathan, K | 1 |
| Sarnaik, S | 5 |
| Guillaume, E | 1 |
| Sadanandan, S | 1 |
| Sieger, L | 1 |
| Lasky, JL | 1 |
| Panosyan, EH | 1 |
| Blake, OA | 1 |
| New, TN | 1 |
| Bellevue, R | 4 |
| Tran, LT | 1 |
| Razon, RL | 1 |
| Stark, CW | 1 |
| Vichinsky, EP | 7 |
| Walton, A | 1 |
| Britto, M | 1 |
| Peugh, J | 1 |
| Oyeku, S | 2 |
| Stukenborg, JB | 1 |
| Alves-Lopes, JP | 1 |
| Kurek, M | 1 |
| Albalushi, H | 1 |
| Reda, A | 1 |
| Keros, V | 1 |
| Töhönen, V | 1 |
| Bjarnason, R | 1 |
| Romerius, P | 1 |
| Sundin, M | 1 |
| Norén Nyström, U | 1 |
| Langenskiöld, C | 1 |
| Vogt, H | 1 |
| Henningsohn, L | 1 |
| Mitchell, RT | 1 |
| Söder, O | 1 |
| Petersen, C | 1 |
| Jahnukainen, K | 1 |
| Barrera, L | 1 |
| Cai, S | 1 |
| Taylor, C | 1 |
| Tao, B | 1 |
| de Oliveira, RM | 1 |
| Wale, A | 1 |
| Hassan, AA | 1 |
| Idhate, T | 1 |
| Dogara, L | 1 |
| Ijei, I | 1 |
| Qin, Y | 1 |
| Anie, K | 1 |
| Lawson, JO | 1 |
| Hsu, L | 2 |
| Greenfest, A | 1 |
| Chondrou, V | 2 |
| Stavrou, EF | 2 |
| Markopoulos, G | 1 |
| Kouraklis-Symeonidis, A | 1 |
| Fotopoulos, V | 1 |
| Symeonidis, A | 2 |
| Vlachaki, E | 1 |
| Chalkia, P | 1 |
| Liles, DK | 1 |
| Cançado, RD | 1 |
| Friedrisch, JR | 3 |
| Knight-Madden, JM | 1 |
| Bruederle, A | 1 |
| Shi, M | 1 |
| Zhu, Z | 1 |
| Gowhari, M | 2 |
| Jain, S | 2 |
| Molokie, RE | 2 |
| Bugeja, A | 1 |
| Blanco, P | 1 |
| Clark, EG | 1 |
| Sood, MM | 1 |
| Smith, AW | 1 |
| Bodas, P | 1 |
| Sidebotham, L | 1 |
| Weilnau, J | 1 |
| Wildman, B | 1 |
| Dorner, TL | 1 |
| Utrankar, A | 1 |
| Allen, W | 1 |
| Jackson, GP | 1 |
| Grau, M | 1 |
| Fort, R | 1 |
| Collins, B | 1 |
| Gauthier, A | 2 |
| Walpurgis, K | 1 |
| Martin, C | 2 |
| Bloch, W | 1 |
| Poutrel, S | 1 |
| Hot, A | 2 |
| Renoux, C | 2 |
| Thevis, M | 1 |
| Joly, P | 2 |
| Gupta, R | 2 |
| Al-Khayat, A | 1 |
| Mohammed, A | 1 |
| Atyani, S | 1 |
| Thomas, D | 1 |
| Zahr, RS | 1 |
| Hicks, W | 1 |
| Kassa, T | 1 |
| Tarandovskiy, I | 1 |
| De Paoli, S | 1 |
| Simak, J | 1 |
| Belcher, JD | 2 |
| Vercellotti, GM | 2 |
| Al-Khatti, AA | 2 |
| Alkhunaizi, AM | 1 |
| Kapoor, S | 1 |
| Mian, UK | 1 |
| Tang, J | 1 |
| Allende, APM | 1 |
| Heo, M | 1 |
| Bernstein, N | 1 |
| Vattappally, L | 1 |
| Schoenfeld, D | 1 |
| Reid, ME | 3 |
| Casella, JF | 9 |
| Brambilla, DJ | 1 |
| Maier, P | 1 |
| Dlugash, R | 1 |
| Avadhani, R | 1 |
| Vermillion, K | 1 |
| Tonascia, J | 1 |
| Hanley, DF | 1 |
| Thompson, RE | 1 |
| Lehmann, HP | 1 |
| Hosseinzadeh, VA | 1 |
| Holt, RG | 1 |
| Topazian, H | 1 |
| Chen, J | 1 |
| Chiume-Chiphaliwali, M | 1 |
| Ataga, K | 4 |
| Westmoreland, K | 1 |
| Sánchez, LM | 1 |
| Nieves, RM | 2 |
| Luden, JR | 1 |
| Urcuyo, GS | 1 |
| Berges, ME | 1 |
| Florencio, C | 1 |
| Gonzalez, C | 1 |
| Del Villar, P | 1 |
| Schultz, W | 2 |
| Jeste, N | 1 |
| Mena, R | 1 |
| Olaniran, KO | 1 |
| Eneanya, ND | 1 |
| Nigwekar, SU | 1 |
| Vela-Parada, XF | 1 |
| Achebe, MM | 2 |
| Sharma, A | 1 |
| Thadhani, RI | 1 |
| Maia Filho, PA | 1 |
| Pereira, JF | 1 |
| Almeida Filho, TP | 1 |
| Cavalcanti, BC | 1 |
| Sousa, JC | 1 |
| Tan, B | 1 |
| Clarke, N | 1 |
| Núñez, RM | 1 |
| Figueroa, CAP | 1 |
| García-Perdomo, HA | 1 |
| Abraham, AA | 1 |
| Lang, H | 1 |
| Dean, M | 1 |
| Lawal, N | 1 |
| Speller-Brown, B | 2 |
| Kean, L | 1 |
| Bollard, CM | 1 |
| Al-Sawaf, O | 1 |
| Köhler, P | 1 |
| Eichenauer, DA | 1 |
| Böll, B | 1 |
| Kochanek, M | 1 |
| Shimabukuro-Vornhagen, A | 1 |
| Guilliams, KP | 2 |
| Dowling, MM | 1 |
| Akingbola, TS | 1 |
| Tayo, BO | 1 |
| Ezekekwu, CA | 1 |
| Sonubi, O | 1 |
| Molokie, R | 2 |
| Cooper, RS | 1 |
| Piccin, A | 1 |
| Murphy, C | 1 |
| Eakins, E | 1 |
| Rondinelli, MB | 1 |
| Daves, M | 1 |
| Vecchiato, C | 1 |
| Wolf, D | 1 |
| Mc Mahon, C | 1 |
| Smith, OP | 1 |
| Schuchard, SB | 1 |
| Lissick, JR | 1 |
| Nickel, A | 1 |
| Watson, D | 1 |
| Moquist, KL | 1 |
| Blaylark, RM | 1 |
| Walker, AL | 3 |
| Gaydos, LM | 1 |
| Farzan, R | 1 |
| De Castro, L | 1 |
| Jonassaint, C | 1 |
| Ragan, D | 1 |
| Binkley, MM | 1 |
| Mirro, A | 1 |
| Fellah, S | 1 |
| Blinder, M | 1 |
| Eldeniz, C | 1 |
| Vo, K | 1 |
| Shimony, JS | 1 |
| An, H | 1 |
| Lee, JM | 2 |
| Ford, AL | 1 |
| Jary, HK | 2 |
| Raphael, JL | 3 |
| Soya, E | 1 |
| Makowski, C | 1 |
| Blaise, S | 1 |
| Roderick, MC | 1 |
| Abel, C | 1 |
| Wolters, P | 1 |
| Toledo-Tamula, MA | 1 |
| Hsieh, M | 1 |
| Tisdale, J | 1 |
| Hirtz, D | 1 |
| Jit, BP | 1 |
| Bakr, S | 1 |
| Khorshied, M | 1 |
| Talha, N | 1 |
| Jaffer, KY | 1 |
| Soliman, N | 1 |
| Eid, K | 1 |
| El-Ghamrawy, M | 1 |
| Hoppe, C | 4 |
| Neumayr, L | 1 |
| Park, F | 1 |
| Soni, H | 1 |
| Pressly, JD | 1 |
| Adebiyi, A | 1 |
| Carman, AS | 1 |
| Sautter, C | 1 |
| Anyanwu, JN | 1 |
| Ssemata, AS | 1 |
| Rujumba, J | 1 |
| Brewin, J | 1 |
| Tewari, S | 1 |
| Menzel, S | 3 |
| Kirkham, F | 2 |
| Renney, G | 1 |
| Ward, M | 1 |
| Voi, V | 1 |
| Fidone, C | 2 |
| Quota, A | 1 |
| Graziadei, G | 1 |
| Pietrangelo, A | 1 |
| Ruffo, GB | 1 |
| Sorrentino, F | 1 |
| Venturelli, D | 1 |
| Ferrara, F | 1 |
| Piga, A | 1 |
| Wood, JC | 3 |
| McArthur, JG | 1 |
| Svenstrup, N | 1 |
| Chen, C | 1 |
| Fricot, A | 1 |
| Carvalho, C | 1 |
| Nguyen, J | 1 |
| Nguyen, P | 1 |
| Parachikova, A | 1 |
| Abdulla, F | 1 |
| Hermine, O | 1 |
| Edwards, D | 1 |
| Maciel, TT | 1 |
| Thomas, R | 1 |
| Ayinde, OC | 1 |
| Iwalokun, B | 1 |
| Nduba, V | 1 |
| El-Beshlawy, A | 2 |
| Hassab, H | 1 |
| Diuguid, DL | 1 |
| Tsitsikas, DA | 1 |
| Elghandour, A | 1 |
| Lehrer-Graiwer, J | 1 |
| Tonda, M | 1 |
| Intondi, A | 1 |
| Tong, B | 1 |
| El-Sherif, NH | 1 |
| Sakr, HM | 1 |
| El Ashkar, MNM | 1 |
| Kapustin, D | 1 |
| Leung, J | 1 |
| Williams, S | 1 |
| Shroff, M | 1 |
| Kassner, A | 1 |
| Singh, A | 1 |
| Yan, K | 1 |
| Richardson, T | 1 |
| Hall, M | 1 |
| Ellison, AM | 1 |
| Shah, SS | 1 |
| Bundy, DG | 2 |
| Arnold, S | 1 |
| Albinni, S | 1 |
| Amiranoff, D | 1 |
| Travis, K | 1 |
| Wood, A | 1 |
| Yeh, P | 1 |
| Allahabadi, S | 1 |
| Chien, LC | 1 |
| Curtis, S | 1 |
| Hammond, A | 1 |
| Kohn, J | 1 |
| Ogugbuaja, C | 1 |
| Rees, M | 1 |
| Shumway, J | 1 |
| Sheehan, V | 2 |
| Su, ZT | 1 |
| Segal, JB | 5 |
| Ogunsile, FJ | 1 |
| Racho, RG | 1 |
| Krishna, M | 1 |
| Canabal, JM | 1 |
| Keaveny, AP | 1 |
| Nébor, D | 1 |
| Santiago, R | 1 |
| Vachiery, N | 1 |
| Picot, J | 3 |
| Broquere, C | 1 |
| Chaar, V | 4 |
| Doumdo, L | 1 |
| Elion, J | 15 |
| Ender, KL | 2 |
| Giardina, PJ | 2 |
| Mullen, CA | 1 |
| Clark, LN | 1 |
| Crotty, J | 2 |
| Kisselev, S | 1 |
| Barral, S | 4 |
| Safford, MM | 1 |
| Howard, TH | 6 |
| Scarinci, IC | 1 |
| Ip, H | 1 |
| Kesse-Adu, R | 1 |
| Hart, N | 1 |
| Sharef, SW | 1 |
| Al-Hajri, M | 1 |
| Beshlawi, I | 1 |
| Al-Shahrabally, A | 1 |
| Zachariah, M | 1 |
| Mevada, ST | 1 |
| Bashir, W | 1 |
| Rawas, A | 1 |
| Taqi, A | 1 |
| Al-Lamki, Z | 1 |
| Noubouossie, DC | 1 |
| Lê, PQ | 6 |
| Rozen, L | 2 |
| Ziereisen, F | 1 |
| Willems, D | 1 |
| Demulder, A | 2 |
| Mukisi-Mukaza, M | 1 |
| Tarer, V | 1 |
| Mougenel, D | 1 |
| Lalanne-Mistrih, ML | 1 |
| Lobo, CL | 5 |
| Pinto, JF | 1 |
| Nascimento, EM | 1 |
| Moura, PG | 2 |
| Cardoso, GP | 1 |
| Kapetanaki, MG | 1 |
| Raghavachari, N | 1 |
| Woodhouse, K | 1 |
| Yu, G | 1 |
| Barge, S | 2 |
| Coronnello, C | 1 |
| Benos, PV | 1 |
| Kaminski, N | 1 |
| Vayá, A | 1 |
| Collado, S | 1 |
| Dasí, MA | 1 |
| Pérez, ML | 1 |
| Hernandez, JL | 1 |
| Barragán, E | 1 |
| Luo, Z | 6 |
| Flanagan, JM | 9 |
| Thompson, BW | 5 |
| Keikhaei, B | 2 |
| Mohseni, AR | 1 |
| Norouzirad, R | 1 |
| Alinejadi, M | 1 |
| Ghanbari, S | 1 |
| Shiravi, F | 1 |
| Solgi, G | 1 |
| Essack, M | 1 |
| Radovanovic, A | 1 |
| Bajic, VB | 1 |
| Sheth, S | 2 |
| Licursi, M | 2 |
| Bhatia, M | 1 |
| Jain, DL | 3 |
| Apte, M | 1 |
| Colah, R | 4 |
| Sarathi, V | 2 |
| Desai, S | 2 |
| Gokhale, A | 1 |
| Bhandarwar, A | 1 |
| Jain, HL | 1 |
| Ghosh, K | 5 |
| Pecoraro, A | 3 |
| Iannello, S | 1 |
| Taher, AT | 2 |
| Buchanan, GR | 6 |
| Smith, H | 1 |
| Perrine, SP | 3 |
| Ghalie, RG | 1 |
| May, RC | 1 |
| Strayhorn, D | 3 |
| Caughey, M | 1 |
| Hinderliter, A | 3 |
| Yovetich, NA | 1 |
| Owen, W | 3 |
| Lockhart, A | 2 |
| Flanagan, J | 2 |
| Bonner, M | 2 |
| Mueller, BU | 5 |
| Torres, M | 1 |
| Barrette, S | 1 |
| Habr, D | 1 |
| Files, B | 1 |
| Vermylen, C | 7 |
| Ukachi, N | 1 |
| Morrison, W | 1 |
| Vanhorn, S | 1 |
| Sundaram, R | 1 |
| Lantos, JD | 1 |
| Smeltzer, M | 4 |
| Mzayek, F | 1 |
| Mulaku, M | 1 |
| Opiyo, N | 1 |
| Karumbi, J | 1 |
| Kitonyi, G | 1 |
| Thoithi, G | 1 |
| English, M | 1 |
| Oyeku, SO | 2 |
| Boulet, SL | 1 |
| Fish, B | 2 |
| Grosse, SD | 1 |
| Verger, E | 2 |
| Schoëvaërt, D | 1 |
| Carrivain, P | 1 |
| Victor, JM | 1 |
| Page, C | 1 |
| Gardner, K | 1 |
| Height, S | 3 |
| Hampton, T | 2 |
| Apanah, S | 1 |
| Rizzolo, D | 1 |
| Nevin, J | 1 |
| Myers, L | 1 |
| Laurin, LP | 1 |
| Nachman, PH | 1 |
| Silva, DG | 4 |
| Belini Junior, E | 3 |
| Carrocini, GC | 2 |
| Torres, Lde S | 3 |
| Ricci Júnior, O | 2 |
| Bonini-Domingos, CR | 4 |
| de Almeida, EA | 2 |
| Troia, A | 2 |
| Calzolari, R | 2 |
| Scazzone, C | 2 |
| Di Marzo, R | 2 |
| Wudil, BJ | 1 |
| Balogun, TM | 1 |
| Ogunrinde, GO | 1 |
| Hasan-Hanga, F | 1 |
| Mohammed, AS | 1 |
| Kehinde, MO | 1 |
| Olaniyi, JA | 1 |
| Adeleke, S | 1 |
| Emodi, I | 1 |
| Ahmed, S | 1 |
| Osegbue, AO | 1 |
| Akinola, N | 1 |
| Opara, HI | 1 |
| Aneke, J | 1 |
| Dampier, C | 4 |
| Ely, B | 1 |
| Brodecki, D | 2 |
| Coleman, C | 1 |
| Aertker, L | 1 |
| Sendecki, JA | 1 |
| Leiby, B | 1 |
| Kesler, K | 1 |
| Hyslop, T | 1 |
| Stuart, M | 1 |
| Pollack, S | 4 |
| Silva-Pinto, AC | 3 |
| Angulo, IL | 1 |
| Brunetta, DM | 2 |
| Neves, FI | 2 |
| Bassi, SC | 1 |
| Santis, GC | 1 |
| Covas, DT | 5 |
| Farley, RA | 1 |
| Chui, DH | 2 |
| Dover, GJ | 28 |
| Sebastiani, P | 1 |
| Alsultan, A | 1 |
| Dwan, K | 1 |
| Kasar, M | 1 |
| Boğa, C | 1 |
| Yeral, M | 1 |
| Asma, S | 1 |
| Kozanoglu, I | 1 |
| Ozdogu, H | 1 |
| Bandeira, IC | 3 |
| Rocha, LB | 1 |
| Barbosa, MC | 3 |
| Elias, DB | 2 |
| Querioz, JA | 1 |
| Freitas, MV | 1 |
| Gonçalves, RP | 3 |
| Taylor, JG | 6 |
| Castro, O | 15 |
| Pallis, FR | 2 |
| Olalla Saad, ST | 1 |
| Hildesheim, M | 1 |
| Matter, RM | 1 |
| Abdelmaksoud, AA | 1 |
| Shams, MA | 1 |
| Bebawy, EK | 1 |
| Morris, CR | 4 |
| Ronzoni, L | 1 |
| Sonzogni, L | 1 |
| Fossati, G | 1 |
| Modena, D | 1 |
| Trombetta, E | 1 |
| Porretti, L | 1 |
| Laurance, S | 3 |
| Cochet, S | 1 |
| De Grandis, M | 1 |
| Colin, Y | 3 |
| Le Van Kim, C | 3 |
| Machado, RF | 5 |
| Barst, RJ | 1 |
| Mubarak, KK | 1 |
| Gibbs, JS | 1 |
| Rosenzweig, EB | 1 |
| Sood, N | 1 |
| Wilson, KC | 2 |
| Decastro, LM | 1 |
| Badesch, DB | 1 |
| Ngo, D | 1 |
| Steinberg, M | 2 |
| Aloni, MN | 1 |
| Nkee, L | 1 |
| Dias-Carlos, C | 1 |
| Saldanha-Araujo, F | 1 |
| Ferreira, FI | 1 |
| Palma, PV | 1 |
| Araujo, AG | 1 |
| Queiroz, RH | 1 |
| Zago, MA | 2 |
| Panepucci, RA | 1 |
| Madden, NA | 1 |
| Jones, GL | 1 |
| Kalpatthi, R | 5 |
| Woods, G | 2 |
| Mukherjee, M | 1 |
| Abdel-Rahman, SM | 1 |
| Kearns, GL | 1 |
| Bekele, E | 1 |
| Thornburg, CD | 11 |
| Winter, B | 2 |
| Shulkin, B | 1 |
| Amid, A | 1 |
| Anele, UA | 1 |
| Mack, AK | 1 |
| Resar, LMS | 1 |
| Helton, KJ | 5 |
| Kesler, KL | 1 |
| Jackson, SM | 1 |
| Sarnaik, SA | 4 |
| Lopes, FC | 2 |
| Ferreira, R | 1 |
| Albuquerque, DM | 3 |
| Silveira, AA | 1 |
| Costa, R | 1 |
| Soares, R | 2 |
| Okam, MM | 3 |
| Shaykevich, S | 1 |
| Ebert, BL | 3 |
| Zaslavsky, AM | 1 |
| Ayanian, JZ | 1 |
| Silva Junior, GB | 1 |
| Vieira, AP | 1 |
| Couto Bem, AX | 1 |
| Alves, MP | 1 |
| Meneses, GC | 1 |
| Martins, AM | 2 |
| Araújo, SM | 1 |
| Libório, AV | 1 |
| Daher, EF | 1 |
| Furlow, B | 1 |
| Vencato, E | 1 |
| Manfredi, R | 1 |
| Zamò, A | 1 |
| Chilosi, M | 1 |
| Beccari, S | 1 |
| Tantawy, AA | 1 |
| Adly, AA | 2 |
| Ismail, EA | 3 |
| Darwish, YW | 1 |
| Ali Zedan, M | 1 |
| Ferreira de Melo, TR | 1 |
| Nwenyi, E | 1 |
| Leafman, J | 1 |
| Mathieson, K | 1 |
| Ezeobah, N | 1 |
| Johnson, M | 2 |
| Howard, SC | 2 |
| Vazquez, B | 1 |
| Shah, B | 1 |
| Lash, JP | 1 |
| Ofori-Acquah, SF | 2 |
| Wonkam, A | 3 |
| Ohene-Frempong, K | 8 |
| Oneal, P | 2 |
| Gravia, A | 1 |
| Papantoni, I | 1 |
| Borg, J | 2 |
| Rana, S | 6 |
| Houston, PE | 1 |
| Iyer, RV | 7 |
| Goldsmith, J | 1 |
| Reed, CK | 1 |
| Thompson, B | 5 |
| Afrin, LB | 1 |
| Lederman, HM | 1 |
| Connolly, MA | 1 |
| Waclawiw, M | 4 |
| Goldsmith, JC | 5 |
| Swift, A | 1 |
| Yawn, BP | 3 |
| Afenyi-Annan, AN | 2 |
| Hassell, KL | 3 |
| James, AH | 3 |
| Jordan, L | 2 |
| Lanzkron, SM | 2 |
| Savage, WJ | 2 |
| Tanabe, PJ | 2 |
| Ortiz, E | 2 |
| Fulwood, R | 1 |
| Horton, A | 1 |
| John-Sowah, J | 2 |
| Brugnerotto, AF | 1 |
| Roversi, FM | 1 |
| Pashankar, FD | 1 |
| Martinez, U | 1 |
| Savage, M | 1 |
| Wong, TE | 2 |
| Lim, W | 1 |
| Crosby, JR | 1 |
| Sabo, A | 1 |
| Mortier, NA | 10 |
| Muzny, DM | 1 |
| Dugan-Perez, S | 1 |
| Boerwinkle, E | 1 |
| Gibbs, RA | 1 |
| Baird, JH | 1 |
| Tian, X | 1 |
| Wu, C | 1 |
| Alam, S | 1 |
| Abubakar, S | 1 |
| Walsh, KE | 1 |
| Cutrona, SL | 1 |
| Malone, C | 1 |
| Lobner, K | 1 |
| Pulte, ED | 1 |
| McKenzie, SE | 1 |
| Caro, J | 1 |
| Nichols, JS | 4 |
| McCoy, JP | 1 |
| Hayes, MM | 1 |
| Vedamurthy, A | 1 |
| George, G | 1 |
| Dweik, R | 1 |
| Thomson, CC | 1 |
| Singh, PC | 1 |
| Koch, KL | 1 |
| Karafin, MS | 1 |
| Simpson, P | 1 |
| Field, JJ | 3 |
| De Santis, GC | 1 |
| Oliveira de Oliveira, LC | 1 |
| Smith, TP | 1 |
| Schlenz, AM | 1 |
| Schatz, JC | 1 |
| Maitra, R | 1 |
| Sweitzer, SM | 1 |
| Thornburg, C | 3 |
| Nathan, DG | 8 |
| Buchanan, G | 1 |
| Hassell, K | 2 |
| Sarray, S | 1 |
| Saleh, LR | 1 |
| Lisa Saldanha, F | 1 |
| Al-Habboubi, HH | 1 |
| Mahdi, N | 1 |
| Almawi, WY | 1 |
| Ferrone, FA | 2 |
| Buckner, TW | 1 |
| Obaro, SK | 3 |
| Garrett, A | 1 |
| Robertson, J | 1 |
| Promislow, DE | 1 |
| Horan, JT | 1 |
| Hendrickson, JE | 1 |
| Kean, LS | 1 |
| Traina, F | 7 |
| Garrido, VT | 2 |
| Colella, MP | 4 |
| Olalla-Saad, ST | 1 |
| Aumont, C | 1 |
| Driss, F | 1 |
| Lazure, T | 1 |
| Picard, V | 1 |
| Creidy, R | 1 |
| De Botton, S | 1 |
| Saada, V | 1 |
| Lambotte, O | 1 |
| Bilhou-Nabera, C | 1 |
| Tertian, G | 1 |
| Michot, JM | 1 |
| Okumura, JV | 2 |
| Sodeinde, O | 1 |
| Al-Sharida, S | 1 |
| Farag, A | 1 |
| Haider, M | 1 |
| Akbulut, N | 1 |
| Mustafa, N | 1 |
| Poole, C | 1 |
| Stettler, N | 1 |
| McKiernan, CM | 1 |
| Melin, CQ | 1 |
| Adejoro, OO | 1 |
| Walczak, NB | 1 |
| Cunningham-Myrie, C | 1 |
| Abdulkadri, A | 1 |
| Waugh, A | 1 |
| Bortolusso Ali, S | 1 |
| King, LG | 1 |
| Rivers, A | 1 |
| Vaitkus, K | 1 |
| Ruiz, MA | 1 |
| Ibanez, V | 1 |
| Jagadeeswaran, R | 1 |
| Kouznetsova, T | 1 |
| DeSimone, J | 4 |
| Lavelle, D | 3 |
| Fauroux, C | 2 |
| Khorgami, S | 2 |
| Loric, S | 2 |
| Noizat-Pirenne, F | 1 |
| Narang, I | 1 |
| Kadmon, G | 1 |
| Lai, D | 1 |
| Dhanju, S | 1 |
| Kirby-Allen, M | 2 |
| Amin, R | 1 |
| Lu, Z | 1 |
| Al-Saleh, S | 1 |
| Elchuri, SV | 1 |
| Williamson, RS | 1 |
| Clark Brown, R | 1 |
| Haight, AE | 1 |
| Spencer, JB | 1 |
| Buchanan, I | 1 |
| Hassen-Schilling, L | 1 |
| Brown, MR | 1 |
| Mertens, AC | 1 |
| Meacham, LR | 1 |
| Daak, AA | 1 |
| Elderdery, AY | 1 |
| Elbashir, LM | 1 |
| Mariniello, K | 1 |
| Mills, J | 1 |
| Scarlett, G | 1 |
| Elbashir, MI | 1 |
| Ghebremeskel, K | 1 |
| Chen, RL | 1 |
| Song, JS | 1 |
| Chao, YS | 1 |
| Shen, CK | 1 |
| Martorana, A | 1 |
| Sacco, M | 1 |
| Souza, LE | 1 |
| Costa, FT | 1 |
| Werneck, CC | 1 |
| Esrick, EB | 1 |
| Mandell, E | 1 |
| Campigotto, F | 1 |
| Neuberg, DS | 1 |
| Mecabo, G | 1 |
| Yamamoto, M | 1 |
| Biassi, TP | 1 |
| Pressel, S | 3 |
| Owen, WC | 1 |
| Cohen, AR | 3 |
| St Pierre, T | 1 |
| Davis, BR | 5 |
| Lee, K | 2 |
| Connes, C | 1 |
| Quimby, KR | 1 |
| Hambleton, IR | 2 |
| Landis, RC | 1 |
| Dupont, S | 2 |
| Vanderfaeillie, A | 2 |
| Heijmans, C | 3 |
| Huybrechts, S | 1 |
| Devalck, C | 5 |
| Efira, A | 1 |
| Dresse, MF | 6 |
| Benghiat, FS | 1 |
| Melloni, C | 1 |
| Rogers, Z | 1 |
| Rothman, JA | 2 |
| Crary, SE | 1 |
| Morris, MH | 1 |
| Lewandowski, A | 1 |
| Jusko, WJ | 1 |
| Owusu-Ansah, A | 1 |
| Ihunnah, CA | 1 |
| Curtis, SA | 1 |
| Danda, N | 1 |
| Etzion, Z | 1 |
| Billett, HH | 1 |
| Barazia, A | 2 |
| Kim, K | 3 |
| Shabrani, N | 1 |
| Hampson, JP | 1 |
| Ichesco, E | 1 |
| Kadom, N | 1 |
| Vezina, G | 1 |
| Evangelou, I | 1 |
| Clauw, DJ | 1 |
| Taylor Vi, JG | 1 |
| Harris, RE | 1 |
| Zickmund, S | 1 |
| Bogen, DL | 1 |
| Pule, GD | 2 |
| Mowla, S | 1 |
| Novitzky, N | 1 |
| Wiysonge, CS | 1 |
| Nkashama, GM | 2 |
| Wakamb, GK | 1 |
| Mulangu, AM | 1 |
| Kupa, BK | 1 |
| Numbi, OL | 1 |
| Sawant, M | 1 |
| S, C | 1 |
| Soares, DP | 1 |
| Jay, DW | 1 |
| Bennett, J | 1 |
| Boyett, JM | 1 |
| Tun, AM | 1 |
| Naing, EE | 1 |
| Tun, NM | 1 |
| Guevara, E | 1 |
| Yousefi, H | 1 |
| Bahadoram, M | 1 |
| Durlak, M | 1 |
| Fugazza, C | 1 |
| Elangovan, S | 1 |
| Marini, MG | 1 |
| Marongiu, MF | 1 |
| Moi, P | 1 |
| Fraietta, I | 1 |
| Cappella, P | 1 |
| Barbarani, G | 1 |
| Font-Monclus, I | 1 |
| Mauri, M | 1 |
| Ottolenghi, S | 1 |
| Gasparri, F | 1 |
| Ronchi, A | 1 |
| Pressel, SL | 1 |
| Imran, H | 3 |
| Fuh, B | 2 |
| Chaturvedi, S | 2 |
| Allen, D | 1 |
| Coles, WA | 4 |
| Seamon, C | 1 |
| Ring, M | 1 |
| Rodgers, GP | 22 |
| Gellen-Dautremer, J | 1 |
| Sahali, D | 1 |
| Wagner-Ballon, O | 1 |
| Remy, P | 1 |
| Lang, P | 1 |
| Grimbert, P | 2 |
| Godeau, B | 2 |
| Fraser, DI | 1 |
| Liu, KT | 1 |
| Reid, BJ | 1 |
| Hawkins, E | 1 |
| Sevier, A | 1 |
| Pyle, M | 1 |
| Robinson, JW | 1 |
| Ouellette, PH | 1 |
| Ballantyne, JS | 1 |
| Rees, AL | 1 |
| Smith, MG | 1 |
| Rothman, J | 1 |
| Nelson, S | 2 |
| Roberts, C | 2 |
| Gauger, C | 3 |
| Kalfa, T | 1 |
| Jackson, S | 2 |
| Rhodes, M | 1 |
| Roberts, D | 1 |
| Coleman, J | 1 |
| Bonner, MJ | 1 |
| Wood, J | 1 |
| Piller, L | 1 |
| Wei, P | 1 |
| Luden, J | 1 |
| Eiymo Mwa Mpollo, MS | 1 |
| Brandt, EB | 1 |
| Shanmukhappa, SK | 1 |
| Arumugam, PI | 1 |
| Tiwari, S | 1 |
| Loberg, A | 1 |
| Pillis, D | 1 |
| Rizvi, T | 1 |
| Lindsey, M | 1 |
| Jonck, B | 1 |
| Carmeliet, P | 1 |
| Kalra, VK | 1 |
| Le Cras, TD | 1 |
| Ratner, N | 1 |
| Wills-Karp, M | 1 |
| Hershey, GK | 1 |
| Andrawes, NG | 1 |
| Mahmoud, MM | 1 |
| Eladawy, R | 1 |
| Upadhye, DS | 1 |
| Trivedi, YL | 1 |
| Nadkarni, AH | 2 |
| Colah, RB | 2 |
| Koch, TL | 1 |
| Zigmont, VA | 1 |
| Lu, B | 1 |
| Meremikwu, MM | 2 |
| Okomo, U | 2 |
| Leveillé, E | 1 |
| Vasile, M | 1 |
| Kasbi, F | 1 |
| Fourmaux, C | 1 |
| Biscardi, S | 1 |
| Gluckman, E | 1 |
| Socié, G | 1 |
| Elbarbary, NS | 1 |
| Roushdy, A | 1 |
| Fahmy, E | 1 |
| Chalikiopoulou, C | 1 |
| Tavianatou, AG | 1 |
| Kourakli, A | 3 |
| Kelepouri, D | 1 |
| Chrysanthakopoulou, M | 1 |
| Kanelaki, VK | 1 |
| Mourdoukoutas, E | 1 |
| John, A | 1 |
| Lavoie, P | 1 |
| Torres, LS | 1 |
| Belini-Junior, E | 1 |
| Barberino, WM | 1 |
| Oliveira, RG | 1 |
| Gelaleti, GB | 1 |
| Warthe, V | 1 |
| Dayama, P | 1 |
| Sarate, D | 1 |
| Mehta, P | 1 |
| Serjeant, G | 3 |
| Couque, N | 1 |
| Girard, D | 1 |
| Ducrocq, R | 4 |
| Boizeau, P | 1 |
| Haouari, Z | 1 |
| Belloy, M | 1 |
| Benemou, M | 1 |
| Benhaim, P | 1 |
| Retali, B | 1 |
| Bensaid, P | 1 |
| Monier, B | 1 |
| Amira, R | 1 |
| Orzechowski, C | 1 |
| Lesprit, E | 1 |
| Mangyanda, L | 1 |
| Garrec, N | 1 |
| Alberti, C | 2 |
| Baruchel, A | 1 |
| Goodman, SR | 3 |
| Cho, G | 2 |
| Ferreira, SB | 1 |
| Tavares, WL | 1 |
| Rosa, MA | 1 |
| Brito, LC | 1 |
| Vieira, LQ | 1 |
| Martelli, H | 1 |
| Ribeiro, AP | 1 |
| Inoue, S | 1 |
| Kodjebacheva, G | 1 |
| Scherrer, T | 1 |
| Rice, G | 1 |
| Grigorian, M | 1 |
| Blankenship, J | 1 |
| Onwuzurike, N | 1 |
| Moreira, JA | 1 |
| Machado, RP | 1 |
| Laurentino, MR | 1 |
| Lemes, RP | 1 |
| Santos, TE | 1 |
| Anders, DG | 1 |
| Tang, F | 1 |
| Ledneva, T | 1 |
| Caggana, M | 1 |
| Sturman, LS | 1 |
| Bakken, S | 1 |
| Matiz, LA | 1 |
| Rosenthal, SL | 1 |
| Faes, C | 1 |
| Garnier, N | 1 |
| Bertrand, Y | 1 |
| Petras, M | 1 |
| Divialle-Doumdo, L | 1 |
| Cuzzubbo, D | 1 |
| Kebaili, K | 1 |
| Pialoux, V | 1 |
| Marden, MC | 1 |
| Boyer, L | 1 |
| Poitrine, FC | 1 |
| Conti, M | 1 |
| Maitre, B | 1 |
| Hosseini, P | 1 |
| Abidi, SZ | 1 |
| Du, E | 1 |
| Papageorgiou, DP | 1 |
| Choi, Y | 1 |
| Park, Y | 1 |
| Higgins, JM | 1 |
| Suresh, S | 1 |
| Dao, M | 1 |
| Yaqoob, Z | 1 |
| So, PT | 1 |
| Wandersee, NJ | 1 |
| Dasgupta, M | 1 |
| Hoffmann, RG | 1 |
| Hillery, CA | 3 |
| Stucky, CL | 1 |
| Bouanane, M | 1 |
| Dudreuilh, C | 1 |
| Deux, JF | 1 |
| Nguyen, GT | 1 |
| Goldener, C | 1 |
| Reed, B | 1 |
| Dulman, RY | 1 |
| Kingwell, K | 1 |
| Qureshi, M | 1 |
| Sinha, A | 1 |
| Noronha, SA | 1 |
| Sadreameli, SC | 1 |
| Mnika, K | 1 |
| Dandara, C | 1 |
| Bhat, S | 1 |
| Megaraj, V | 1 |
| Setchell, KD | 1 |
| Schaefer, BA | 1 |
| Roberts, CW | 2 |
| Piccone, CM | 1 |
| Indik, JH | 1 |
| Nair, V | 1 |
| Rafikov, R | 1 |
| Nyotowidjojo, IS | 1 |
| Bisla, J | 1 |
| Kansal, M | 1 |
| Parikh, DS | 1 |
| Robinson, M | 1 |
| Desai, A | 1 |
| Oberoi, M | 1 |
| Abbasi, T | 1 |
| Khalpey, Z | 1 |
| Patel, AR | 1 |
| Lang, RM | 1 |
| Dudley, SC | 1 |
| Choi, BR | 1 |
| Garcia, JG | 2 |
| Desai, AA | 1 |
| Makubi, A | 1 |
| Sasi, P | 1 |
| Ngaeje, M | 1 |
| Mmbando, BP | 1 |
| Youn, SW | 1 |
| Abbadessa, G | 1 |
| Yu, Y | 1 |
| Schwartz, B | 1 |
| Andrews, RK | 1 |
| Dong, W | 1 |
| Theodore, R | 1 |
| Anand, S | 1 |
| Barry, V | 1 |
| Adisa, O | 1 |
| Buchanan, ID | 1 |
| Bost, J | 1 |
| Dai, Y | 1 |
| Sangerman, J | 1 |
| Faller, AD | 1 |
| Rock, A | 1 |
| Owoyemi, O | 1 |
| Nekhai, S | 3 |
| Maharaj, D | 1 |
| Taylor, R | 1 |
| Perrine, S | 2 |
| Baldan, A | 1 |
| Summarell, CC | 1 |
| Bittar, CM | 2 |
| Friedrisch, BK | 1 |
| Wilke, II | 1 |
| Ribeiro, CB | 1 |
| Daudt, LE | 1 |
| da Rocha Silla, LM | 2 |
| van Tuijn, CF | 1 |
| Sins, JW | 1 |
| Fijnvandraat, K | 1 |
| Biemond, BJ | 2 |
| Cancado, R | 1 |
| Friedrisch, J | 1 |
| Guthrie, TH | 1 |
| Gualandro, S | 1 |
| Rollins, SA | 1 |
| Rother, RP | 1 |
| McClain, B | 1 |
| Byrd, J | 1 |
| Grady, AJ | 1 |
| Haberman, B | 1 |
| Schoumacher, R | 1 |
| Stocks, RM | 1 |
| Shah, BN | 1 |
| Zhang, W | 1 |
| Miasnikova, G | 1 |
| Sergueeva, A | 1 |
| Ammosova, T | 2 |
| Prchal, JT | 2 |
| Azar, S | 1 |
| Fonseca, TC | 1 |
| Quinto, RS | 1 |
| Figueiredo, CV | 1 |
| Yahouédéhou, SC | 1 |
| Ferreira, JR | 1 |
| Cerqueira, BA | 1 |
| Milton, JN | 1 |
| de Souza Gonçalves, M | 1 |
| Shanmugam, VK | 1 |
| Angra, D | 1 |
| Rahimi, H | 1 |
| McNish, S | 1 |
| McLaren, A | 1 |
| Klingel, M | 1 |
| Behera, S | 1 |
| Grasemann, H | 1 |
| Guignedoux, G | 1 |
| Kirsch-Noir, F | 1 |
| de Larouziere, V | 1 |
| Ancel, PY | 1 |
| Kunstmann, JM | 1 |
| Levy, L | 1 |
| Jouannet, P | 1 |
| Girot, R | 7 |
| Koussa, S | 1 |
| Taher, A | 1 |
| Canalli, AA | 4 |
| Saad, ST | 18 |
| Harrod, VL | 1 |
| Nau, JY | 1 |
| Naina, HV | 1 |
| Harris, S | 1 |
| Bachmeyer, C | 1 |
| Ulug, P | 1 |
| Vasavda, N | 3 |
| Kumar, R | 1 |
| Keir, L | 1 |
| Awogbade, M | 3 |
| Cunningham, J | 2 |
| Ozsahin, H | 1 |
| Akar, NA | 1 |
| Haywood, C | 7 |
| Rand, C | 1 |
| Sidani, CA | 1 |
| Ballourah, W | 1 |
| El Dassouki, M | 1 |
| Muwakkit, S | 1 |
| Dabbous, I | 1 |
| Dahoui, H | 1 |
| Al-Kutoubi, A | 1 |
| Badiger, S | 1 |
| Ghatpande, SS | 2 |
| Choudhary, PK | 2 |
| Paydar, A | 1 |
| Glass, J | 1 |
| Weirich, EM | 1 |
| Li, CS | 3 |
| Ogg, RJ | 1 |
| Lukusa, AK | 2 |
| Couronné, L | 1 |
| Schneider, P | 1 |
| Dumesnil, C | 1 |
| Lahary, A | 2 |
| Vannier, JP | 1 |
| Khatib, R | 1 |
| Rabah, R | 1 |
| Albuqueque, DM | 1 |
| Furness, CL | 1 |
| O'Driscoll, S | 3 |
| Davenport, M | 1 |
| Morrison, G | 1 |
| Height, SE | 3 |
| Dick, MC | 3 |
| Trompeter, S | 1 |
| Roberts, I | 1 |
| Beach, MC | 4 |
| Park, H | 3 |
| Witkop, C | 3 |
| Wilson, RF | 2 |
| Bass, EB | 3 |
| Dixon, N | 1 |
| Burgett, S | 2 |
| Zimmerman, SA | 6 |
| Hardy, KK | 1 |
| Calatroni, A | 4 |
| Olujohungbe, A | 2 |
| Suliman, H | 1 |
| Al Saadoon, M | 1 |
| Zechariah, M | 1 |
| William, RR | 1 |
| Gujjar, A | 1 |
| Ding, X | 1 |
| Bishop, RJ | 1 |
| Herzlich, AA | 1 |
| Patel, M | 1 |
| Chan, CC | 1 |
| Fathallah, H | 3 |
| Hauser, KP | 1 |
| Martyr, SE | 1 |
| Harris, A | 1 |
| Maric, I | 3 |
| Suh, JH | 1 |
| Taylor, J | 2 |
| Machado, R | 2 |
| Kato, G | 1 |
| LaVista, JM | 1 |
| Treise, DM | 1 |
| Dunbar, LN | 1 |
| Ritho, J | 2 |
| Hartzema, AG | 2 |
| Vanabelle, B | 1 |
| Curaba, M | 1 |
| Brichard, B | 1 |
| Chantrain, C | 1 |
| Ferrant, A | 1 |
| Wyns, C | 1 |
| Jones, KM | 1 |
| Niaz, MS | 1 |
| Brooks, CM | 1 |
| Roberson, SI | 1 |
| Aguinaga, MP | 2 |
| Hills, ER | 1 |
| Rice, VM | 1 |
| Bourne, P | 1 |
| Bruce, D | 1 |
| Archibong, AE | 1 |
| Olnes, M | 1 |
| Chi, A | 1 |
| Haney, C | 1 |
| May, R | 1 |
| Bauserman, RL | 6 |
| McCarthy, WF | 8 |
| Swerdlow, PS | 3 |
| Barton, BA | 3 |
| Campbell, A | 2 |
| Sable, C | 1 |
| Darbari, D | 1 |
| Dham, N | 1 |
| Onyekwere, O | 1 |
| Castro, OL | 4 |
| Rees, RC | 3 |
| Kalpatthi, RV | 3 |
| Barredo, JC | 2 |
| Luck, L | 1 |
| Verduzco, LA | 1 |
| Italia, KY | 1 |
| Jijina, FF | 1 |
| Sawant, P | 1 |
| Dahoui, HA | 1 |
| Hayek, MN | 1 |
| Nietert, PJ | 1 |
| Arabi, MT | 1 |
| Muwakkit, SA | 1 |
| Saab, RH | 1 |
| Bissar, AN | 1 |
| Jumaa, NM | 1 |
| Farhat, FS | 1 |
| Dabbous, IA | 1 |
| Bitar, FF | 1 |
| Thom, GG | 1 |
| Kallanagowdar, C | 1 |
| Somjee, SS | 1 |
| Velez, MC | 1 |
| Yu, LC | 1 |
| Hempe, JM | 1 |
| Jeng, MR | 2 |
| Rana, SR | 3 |
| Faughnan, L | 2 |
| Hassen, L | 1 |
| Marshall, J | 1 |
| McDonald, RP | 1 |
| Huang, X | 3 |
| Guo, N | 2 |
| DeCastro, L | 3 |
| Wu, QQ | 1 |
| Qian, XH | 1 |
| Xu, MJ | 1 |
| Telen, M | 1 |
| Kemper, AR | 1 |
| Christoulas, D | 2 |
| Bilalis, A | 1 |
| Plata, E | 1 |
| Varvagiannis, K | 1 |
| Stamatopoulos, G | 1 |
| Sinopoulou, K | 1 |
| Balassopoulou, A | 1 |
| Loukopoulos, D | 7 |
| Terpos, E | 2 |
| Cho, CS | 1 |
| Yang, SH | 1 |
| Bae, SW | 1 |
| Lee, JS | 1 |
| Rhee, SG | 1 |
| Grace, RF | 1 |
| Su, H | 1 |
| Sena, L | 1 |
| Poussaint, TY | 1 |
| Gutierrez, A | 1 |
| Drotar, D | 1 |
| Fagan, PJ | 1 |
| Rand, CS | 1 |
| Ebert, EC | 1 |
| Nagar, M | 1 |
| Hagspiel, KD | 1 |
| Pellay, FX | 2 |
| Dossou-Yovo, OP | 1 |
| Krishnamoorthy, R | 5 |
| Benecke, A | 2 |
| Mortier, N | 2 |
| Avlasevich, SL | 1 |
| Wu, S | 2 |
| Carmel, R | 1 |
| Kelman, Z | 1 |
| Pestina, TI | 2 |
| Boyd, KL | 1 |
| Persons, DA | 2 |
| Bunn, HF | 6 |
| Hebbel, RP | 1 |
| Platt, OS | 8 |
| Rosse, WF | 3 |
| Douira-Khomsi, W | 1 |
| Jarraya, M | 1 |
| Ben Hassine, L | 1 |
| Louati, H | 1 |
| Chebbi, A | 1 |
| Lahmar, L | 1 |
| Bouguila, H | 1 |
| Bellagha, I | 1 |
| Reading, NS | 1 |
| Atweh, GF | 5 |
| Armstrong, FD | 4 |
| Smith, W | 2 |
| Swerdlow, P | 3 |
| Renaud, O | 1 |
| Nzouakou, R | 3 |
| Stallworth, JR | 2 |
| Jerrell, JM | 2 |
| Tripathi, A | 2 |
| Jirovec, DL | 1 |
| Patel, NG | 1 |
| Lindsey, T | 1 |
| Strunk, RC | 1 |
| Yannaki, E | 1 |
| Stamatoyannopoulos, G | 6 |
| Wynn, L | 2 |
| Miller, S | 1 |
| Adix, L | 1 |
| Hustace, T | 1 |
| Kelly, T | 1 |
| Macdermott, M | 1 |
| Marasciulo, J | 1 |
| Martin, B | 1 |
| McDuffie, J | 1 |
| Murphy, M | 1 |
| Rackoff, B | 1 |
| Reed, C | 1 |
| Seaman, P | 2 |
| Thomas, G | 1 |
| Kovacic, P | 1 |
| Kling, G | 1 |
| Baliga, BS | 6 |
| Haynes, J | 5 |
| Obiako, B | 4 |
| Mishra, N | 1 |
| Wali, YA | 1 |
| Moheeb, H | 1 |
| Carrara, P | 1 |
| Balocco, M | 1 |
| Olcese, F | 1 |
| Soldà, A | 1 |
| Strada, P | 1 |
| Byrnes, C | 1 |
| Weissman, M | 1 |
| Noel, P | 1 |
| Luban, NL | 1 |
| Miller, JL | 2 |
| Franco-Penteado, C | 1 |
| Bediako, S | 1 |
| Carroll, CP | 1 |
| Lattimer, L | 1 |
| Jarrett, D | 1 |
| Artz, N | 1 |
| Whelan, C | 1 |
| Feehan, S | 1 |
| Patterson, CA | 1 |
| Barakat, LP | 1 |
| Henderson, PK | 1 |
| Nall, F | 1 |
| Westin, A | 1 |
| Dampier, CD | 2 |
| Lavaud, A | 1 |
| Jouault, H | 1 |
| Préhu, C | 1 |
| Roudot-Thoraval, F | 2 |
| Lansiaux, P | 1 |
| Hauchecorne, M | 1 |
| Al-Nood, HA | 1 |
| Al-Khawlani, MM | 1 |
| Al-Akwa, A | 1 |
| Candrilli, SD | 1 |
| Nahata, MC | 1 |
| Seiber, EE | 1 |
| Balkrishnan, R | 1 |
| Moller, HJ | 1 |
| Nielsen, MJ | 1 |
| Bartram, J | 1 |
| Moestrup, SK | 1 |
| Benton, J | 1 |
| Pratt, J | 1 |
| Kim, MO | 1 |
| Kalinyak, KA | 1 |
| Greenway, A | 1 |
| Segel, GB | 1 |
| Simon, W | 1 |
| Lichtman, MA | 1 |
| Lobo, Cde C | 1 |
| Vertongen, F | 1 |
| Ketelslegers, O | 1 |
| Johnson, SM | 1 |
| Askenazi, DJ | 1 |
| Rozario, NL | 1 |
| Hilliard, LM | 1 |
| Yerigenahally, SD | 2 |
| Xue, Y | 1 |
| Moutouh-de Parseval, LA | 2 |
| Corral, LG | 2 |
| Lahti, JM | 1 |
| Weatherall, DJ | 2 |
| Wynn, LW | 5 |
| Files, BA | 2 |
| Coates, TD | 1 |
| Paule, I | 1 |
| Sassi, H | 1 |
| Pham, KP | 1 |
| Girard, P | 1 |
| Tod, M | 1 |
| Rey, K | 1 |
| Fish, BJ | 1 |
| Končić, MZ | 1 |
| Barbarić, M | 1 |
| Perković, I | 1 |
| Zorc, B | 1 |
| Yovetich, N | 1 |
| Helms, RW | 6 |
| Mahadeo, KM | 1 |
| Taragin, B | 1 |
| Rajpathak, SN | 1 |
| Moody, K | 1 |
| Santizo, R | 1 |
| Driscoll, MC | 4 |
| Despotovic, JM | 1 |
| Kimble, AC | 2 |
| Sparreboom, A | 1 |
| Ali, SB | 1 |
| Moosang, M | 1 |
| King, L | 1 |
| Magalhães, HI | 1 |
| de Souza, JH | 1 |
| Steward, S | 2 |
| Wang, YD | 1 |
| Liu, H | 1 |
| Hayashi, M | 1 |
| Herzberg, B | 1 |
| Ross, AK | 1 |
| Rice, HE | 1 |
| Ikuta, T | 2 |
| Gutsaeva, DR | 1 |
| Parkerson, JB | 1 |
| Clair, B | 2 |
| Odo, N | 1 |
| Head, CA | 1 |
| Gilmore, A | 2 |
| Layton, M | 1 |
| Afif, M | 1 |
| Hughes, RG | 1 |
| Philpott, NJ | 1 |
| Patankar, S | 1 |
| Davies, SC | 9 |
| Kulharya, AS | 1 |
| Woodley, C | 1 |
| Allman, M | 1 |
| Drašar, E | 1 |
| Darari, DS | 1 |
| McIver, Z | 1 |
| Arthur, DC | 1 |
| Takahashi, Y | 1 |
| Mori, J | 1 |
| Tsubokura, M | 1 |
| Matsumura, T | 1 |
| Kami, M | 1 |
| Hu, Y | 1 |
| Gao, G | 1 |
| Zakharenko, SS | 1 |
| Tuomanen, EI | 1 |
| Rosch, JW | 1 |
| Tsai, M | 1 |
| Kita, A | 1 |
| Leach, J | 1 |
| Rounsevell, R | 1 |
| Huang, JN | 1 |
| Moake, J | 1 |
| Fletcher, DA | 1 |
| Lam, WA | 1 |
| Lu, M | 2 |
| Reid, H | 1 |
| Kim, HY | 1 |
| Weiner, D | 1 |
| Wager, CG | 1 |
| Gallagher, D | 1 |
| Styles, L | 3 |
| Wruck, LM | 1 |
| Iyer, R | 2 |
| Schwartz, GJ | 1 |
| Ragni, MV | 1 |
| Hildesheim, ME | 1 |
| Meyer, MP | 1 |
| Hassett, AC | 1 |
| Isenberg, JS | 1 |
| Neale, GA | 1 |
| Malowany, JI | 1 |
| Butany, J | 1 |
| Gerotziafas, GT | 1 |
| Van Dreden, P | 1 |
| Chaari, M | 1 |
| Galea, V | 1 |
| Khaterchi, A | 1 |
| Stankovic-Stojanovic, K | 1 |
| Blanc-Brude, O | 1 |
| Woodhams, B | 1 |
| Maier-Redelsperger, M | 3 |
| Hatmi, M | 1 |
| Elalamy, I | 1 |
| McCavit, TL | 1 |
| Deal, AM | 1 |
| Brittain, JE | 1 |
| Jones, S | 3 |
| Bhatnagar, M | 1 |
| Lodha, A | 1 |
| Proença-Ferreira, R | 1 |
| Bezerra, MA | 1 |
| de Mello, MR | 1 |
| Araújo, AS | 1 |
| Machado-Neto, JA | 1 |
| Annicchino-Bizzacchi, JM | 1 |
| Scheiermann, C | 1 |
| Jang, JE | 1 |
| Prophete, C | 1 |
| Patel, DK | 1 |
| Mashon, RS | 1 |
| Das, BS | 1 |
| Bishwal, SC | 1 |
| Ladizinski, B | 1 |
| Bazakas, A | 1 |
| Mistry, N | 1 |
| Alavi, A | 1 |
| Sibbald, RG | 1 |
| Salcido, R | 1 |
| da Silva Rocha, LB | 1 |
| Dias Elias, DB | 1 |
| Kesen, MR | 1 |
| Goldberg, MF | 1 |
| Lutty, GA | 1 |
| Hagar, W | 2 |
| Wautier, JL | 1 |
| Wautier, MP | 1 |
| Kayinqo, G | 1 |
| Gregory, TB | 1 |
| Phylactides, M | 1 |
| Bartsakoulia, M | 1 |
| Tafrali, C | 1 |
| Lederer, C | 1 |
| Felice, AE | 1 |
| Christou, S | 1 |
| Hou, J | 1 |
| Karkabouna, S | 1 |
| Lappa-Manakou, C | 1 |
| Ozgur, Z | 1 |
| van Ijcken, W | 1 |
| von Lindern, M | 1 |
| Grosveld, FG | 1 |
| Georgitsi, M | 1 |
| Kleanthous, M | 1 |
| Philipsen, S | 1 |
| Kouegnigan, L | 1 |
| Gandhi, S | 1 |
| Abihsera, G | 1 |
| Trachtman, R | 1 |
| Mullen, C | 1 |
| Velazco, N | 1 |
| Racine, AD | 1 |
| Cherry, MG | 1 |
| Greenhalgh, J | 1 |
| Osipenko, L | 1 |
| Venkatachalam, M | 1 |
| Boland, A | 1 |
| Dundar, Y | 1 |
| Marsh, K | 1 |
| Dickson, R | 1 |
| Al-Ghazaly, J | 1 |
| Al-Dubai, W | 1 |
| Abdullah, M | 1 |
| Al-Mahagri, A | 1 |
| Al-Gharasi, L | 1 |
| Shulkin, BL | 1 |
| Salvia, AC | 1 |
| Braga, JA | 1 |
| Pereira, DF | 1 |
| Brighenti, FL | 1 |
| Koga-Ito, CY | 1 |
| Elkin, TD | 1 |
| Glass, P | 1 |
| Pavlakis, S | 1 |
| Mi, Z | 1 |
| Musallam, KM | 1 |
| Sankaran, VG | 1 |
| Aneni, EC | 1 |
| Hamer, DH | 1 |
| Gill, CJ | 1 |
| Schumacher, SN | 1 |
| Randolph, TR | 1 |
| Blinder, MA | 1 |
| Vekeman, F | 1 |
| Sasane, M | 1 |
| Trahey, A | 1 |
| Paley, C | 1 |
| Duh, MS | 1 |
| Hoehn, ME | 1 |
| Ferguson, RP | 1 |
| Arun, A | 1 |
| Carter, C | 1 |
| Walker, SD | 1 |
| Woodard, P | 1 |
| Jeng, M | 1 |
| Handgretinger, R | 1 |
| Sumoza, A | 1 |
| de Bisotti, R | 1 |
| Sumoza, D | 1 |
| Fairbanks, V | 1 |
| Nahavandi, M | 4 |
| Tavakkoli, F | 4 |
| Wyche, MQ | 4 |
| Perlin, E | 4 |
| Winter, WP | 1 |
| Ely, E | 1 |
| O'Neal, P | 1 |
| Al-Jam'a, AH | 2 |
| Al-Dabbous, IA | 2 |
| Esan, FG | 1 |
| Ognibene, FP | 3 |
| Reiter, CD | 1 |
| Schenke, WH | 1 |
| Csako, G | 1 |
| Panza, JA | 1 |
| Cannon, RO | 1 |
| Halsey, C | 2 |
| Roberts, IA | 4 |
| Koshy, M | 4 |
| Barton, F | 2 |
| Fixler, J | 1 |
| Knox-Macaulay, H | 1 |
| Ayyaril, M | 1 |
| Nusrat, N | 1 |
| Daar, A | 1 |
| Girgis, RE | 1 |
| Qureshi, MA | 1 |
| Abrams, J | 1 |
| Amrolia, PJ | 2 |
| Almeida, A | 2 |
| Rieman, MD | 1 |
| Naidu, PE | 1 |
| Jenkins, JJ | 1 |
| Prasad, R | 1 |
| Hasan, S | 1 |
| Borba, R | 1 |
| Lima, CS | 3 |
| Grotto, HZ | 2 |
| Brandão, MM | 1 |
| Fontes, A | 1 |
| Barjas-Castro, ML | 1 |
| Barbosa, LC | 1 |
| Cesar, CL | 1 |
| Pegelow, CH | 2 |
| Orringer, E | 2 |
| Olivieri, N | 2 |
| Eckman, J | 1 |
| Varma, M | 1 |
| Ramirez, G | 1 |
| Adler, B | 1 |
| Carlos, T | 1 |
| Bigelow, C | 1 |
| Telfer, M | 1 |
| Claster, S | 2 |
| Shurin, S | 1 |
| Bridges, K | 1 |
| Bonds, D | 1 |
| Terrin, M | 1 |
| Weiner, DL | 1 |
| Crawford, S | 1 |
| Torres, AF | 1 |
| Eberle, SE | 1 |
| Sciuccati, G | 1 |
| Bonduel, M | 1 |
| Acar, P | 1 |
| Maunoury, C | 1 |
| Dulac, Y | 1 |
| Ho, JA | 1 |
| Pickens, CV | 3 |
| Gamcsik, MP | 1 |
| Colvin, OM | 1 |
| Gamscik, MP | 1 |
| van Warmerdam, J | 1 |
| Machado, L | 1 |
| Kepka-Lenhart, D | 1 |
| Morris, SM | 1 |
| Spell, DW | 1 |
| Feldman, L | 3 |
| Allen, S | 2 |
| Westerman, M | 2 |
| Gilman-Sachs, A | 1 |
| Beaman, K | 1 |
| Lee, DA | 1 |
| Brun, M | 5 |
| Bourdoulous, S | 1 |
| Couraud, PO | 1 |
| Teixeira, SM | 1 |
| Cortellazzi, LC | 1 |
| Huang, Y | 1 |
| Ananthakrishnan, T | 1 |
| Eid, JE | 1 |
| Agarwal, MB | 1 |
| Sariban, E | 5 |
| Meuleman, N | 1 |
| La Spina, M | 1 |
| Davis, JS | 2 |
| Koc, A | 1 |
| Gumruk, F | 1 |
| Gurgey, A | 1 |
| Millis, RM | 2 |
| Ofori-Acquah, S | 2 |
| Pace, B | 2 |
| Brachet, C | 1 |
| Azzi, N | 1 |
| Gourdin, A | 1 |
| Klein, A | 2 |
| Loop, M | 2 |
| Oresco-Santos, C | 1 |
| Acosta, HC | 1 |
| Fattori, A | 4 |
| Jison, ML | 1 |
| Shizukuda, Y | 1 |
| Plehn, JF | 1 |
| Minter, K | 1 |
| Brown, B | 1 |
| Ernst, I | 1 |
| Hunter, LA | 2 |
| Blackwelder, WC | 2 |
| de Lucena Angulo, I | 1 |
| Vianna Bonini Palma, P | 1 |
| Makis, AC | 2 |
| Hatzimichael, EC | 2 |
| Kolios, G | 1 |
| Bourantas, KL | 1 |
| Whorton, MR | 1 |
| Johnson, CA | 1 |
| Elion, JE | 1 |
| Lapouméroulie, CL | 1 |
| Kattamis, A | 1 |
| Lagona, E | 1 |
| Orfanou, I | 1 |
| Psichou, F | 1 |
| Ladis, V | 1 |
| Kanavakis, E | 1 |
| Metaxotou-Mavrommati, A | 1 |
| Kattamis, C | 1 |
| King, SB | 3 |
| Lajolo, C | 1 |
| Gilli, S | 1 |
| Marques Júnior, JF | 1 |
| Arruda, VR | 2 |
| Sylvestre, PB | 1 |
| Treem, WR | 1 |
| Bakanay, SM | 1 |
| Dainer, E | 1 |
| Daitch, L | 1 |
| Wells, L | 1 |
| Holley, L | 1 |
| Smith, D | 1 |
| Williams, VL | 1 |
| Trent, JT | 1 |
| Kirsner, RS | 1 |
| Haberman, D | 1 |
| Dufour, D | 2 |
| Christophe, C | 1 |
| Kagambega, F | 1 |
| Corazza, F | 3 |
| Hunninck, K | 2 |
| Maes, P | 1 |
| Philippet, P | 2 |
| Schnog, JB | 1 |
| Duits, AJ | 3 |
| Muskiet, FA | 1 |
| ten Cate, H | 1 |
| Rojer, RA | 1 |
| Brandjes, DP | 1 |
| de Souza, RA | 1 |
| Wigfall, DR | 1 |
| Vicari, P | 1 |
| Barretto de Mello, A | 1 |
| Yan, JH | 1 |
| Kaul, S | 1 |
| Olson, JS | 1 |
| Grasela, DM | 1 |
| Gothelf, S | 1 |
| Meremikwu, M | 3 |
| Elira Dokekias, A | 1 |
| Okandze Elenga, JP | 1 |
| Ndinga, J | 1 |
| Sanogo, I | 1 |
| Sangare, A | 1 |
| Kuvibidila, S | 1 |
| Gardner, R | 1 |
| Yu, L | 1 |
| Warrier, R | 1 |
| Velez, M | 1 |
| Ode, D | 1 |
| Zumberg, MS | 1 |
| Reddy, S | 1 |
| Boyette, RL | 1 |
| Schwartz, RJ | 1 |
| Konrad, TR | 1 |
| van Beers, EJ | 1 |
| Peters, M | 1 |
| Dalton, RN | 1 |
| Turner, C | 1 |
| Dick, M | 1 |
| Okpala, I | 3 |
| Braga, LB | 1 |
| Ferreira, AC | 1 |
| Guimarães, M | 1 |
| Nazário, C | 1 |
| Pacheco, P | 1 |
| Picanço, I | 1 |
| Seixas, T | 1 |
| Rosado, L | 1 |
| Amaral, JM | 1 |
| Morales, KH | 1 |
| Scher, CD | 1 |
| Adams, R | 1 |
| Martyr, S | 2 |
| Brennan, ML | 1 |
| Hazen, SL | 1 |
| Wong, WY | 2 |
| Powars, DR | 3 |
| Okpala, IE | 1 |
| Iyamu, EW | 1 |
| Cecil, R | 1 |
| Parkin, L | 1 |
| Asakura, T | 1 |
| Giordano, PC | 1 |
| Perry, V | 1 |
| Sutton, M | 2 |
| Meyappan, JD | 1 |
| Lampl, M | 1 |
| Dorman, K | 1 |
| Aliyu, ZY | 2 |
| Tumblin, AR | 1 |
| Elie, C | 1 |
| Landais, P | 1 |
| Losada, R | 1 |
| Bravo, I | 1 |
| Capildeo, K | 1 |
| Charles, K | 1 |
| Kratovil, T | 1 |
| Bulas, D | 1 |
| McCarter, R | 1 |
| Khayat, AS | 1 |
| Antunes, LM | 1 |
| Guimarães, AC | 1 |
| Bahia, MO | 1 |
| Lemos, JA | 1 |
| Cabral, IR | 1 |
| Lima, PD | 1 |
| Amorim, MI | 1 |
| Cardoso, PC | 1 |
| Smith, MA | 1 |
| Santos, RA | 1 |
| Burbano, RR | 1 |
| Svarch, E | 2 |
| Machín, S | 2 |
| Mancia de Reyes, AG | 1 |
| Navarrete, M | 2 |
| Rodríguez, H | 2 |
| King, JA | 1 |
| Hester, RB | 2 |
| Moore, CG | 1 |
| Olajide, O | 1 |
| Orringer, EP | 7 |
| Rohrman, BA | 1 |
| Mazziotti, DA | 1 |
| Franco, RS | 1 |
| Yasin, Z | 1 |
| Palascak, MB | 1 |
| Ciraolo, P | 1 |
| Rucknagel, DL | 1 |
| Krishnamoorthy, P | 1 |
| Alyaarubi, S | 1 |
| Abish, S | 1 |
| Gale, M | 1 |
| Albuquerque, P | 1 |
| Jabado, N | 1 |
| Wilimas, JA | 1 |
| Flores, A | 1 |
| Pacheco, C | 1 |
| de Reyes, G | 1 |
| Nieves, R | 1 |
| Masera, G | 2 |
| McGowan, VR | 1 |
| Partovi, KS | 1 |
| Feld, JJ | 1 |
| Heller, T | 1 |
| Athanassiou, G | 1 |
| Moutzouri, A | 1 |
| Zoumbos, N | 1 |
| Shull, EP | 1 |
| Ahmad, N | 1 |
| Lee, NJ | 1 |
| Karimi, M | 1 |
| Zekavat, OR | 1 |
| Sharifzadeh, S | 1 |
| Mousavizadeh, K | 1 |
| Mosavizadeh, K | 1 |
| Barton, FB | 8 |
| Eckman, JR | 1 |
| Bonds, DR | 3 |
| Stebbing, J | 1 |
| Thorell, EA | 1 |
| Jackson, MA | 1 |
| Selvarangan, R | 1 |
| Woods, GM | 1 |
| Finnegan, EM | 1 |
| Turhan, A | 1 |
| Golan, DE | 1 |
| Barabino, GA | 1 |
| Pino, P | 1 |
| Taoufiq, Z | 1 |
| Tefit, M | 1 |
| Franetich, JF | 1 |
| Ciceron, L | 1 |
| Mazier, D | 1 |
| Gimeno, L | 1 |
| Mogenet, A | 1 |
| Bresson, JL | 1 |
| Macquin-Mavier, I | 1 |
| Astier, A | 2 |
| Costa, FC | 1 |
| da Cunha, AF | 1 |
| de Sousa Peres, T | 1 |
| Costa, GG | 1 |
| Machado, TF | 1 |
| de Albuquerque, DM | 1 |
| Habib, MJ | 1 |
| Tavakoli, N | 1 |
| Eggleston, B | 2 |
| Patience, M | 1 |
| Adamkiewicz, T | 1 |
| Donfield, S | 1 |
| Feig, SA | 1 |
| Giller, RH | 1 |
| Haight, A | 1 |
| Horan, J | 1 |
| Kamani, N | 1 |
| Lane, P | 1 |
| Levine, JE | 1 |
| Margolis, D | 1 |
| Moore, TB | 1 |
| Redding-Lallinger, R | 4 |
| Sanders, JE | 1 |
| Sleight, B | 1 |
| Sullivan, KM | 1 |
| Walters, MC | 1 |
| Ma, Q | 1 |
| Wyszynski, DF | 1 |
| Farrell, JJ | 1 |
| Farrer, LA | 1 |
| Baldwin, CT | 1 |
| Grigg, A | 1 |
| Adjaoud, D | 1 |
| Couillard, S | 1 |
| Bader-Meunier, B | 1 |
| Cueto González, AM | 1 |
| Díaz Conradi, A | 1 |
| Fábrega Sabaté, J | 1 |
| Mate García, MA | 1 |
| Solé Heuberger, E | 1 |
| Villalba Hernández, T | 1 |
| Tobeña Boada, L | 1 |
| McKie, KT | 1 |
| Hanevold, CD | 1 |
| Hernandez, C | 1 |
| Waller, JL | 1 |
| Ortiz, L | 1 |
| McKie, KM | 1 |
| Puffer, E | 1 |
| McCarver, DG | 1 |
| Drendel, AL | 1 |
| Divakaran, K | 1 |
| Tsetsos, G | 1 |
| Tsoutsias, A | 1 |
| Spyropoulou, E | 1 |
| Tubman, VN | 1 |
| Bennett, CM | 1 |
| Luo, HY | 1 |
| Coleman, E | 1 |
| Wood, KC | 1 |
| Granger, DN | 1 |
| Ferreira, RP | 1 |
| Solomon, LR | 1 |
| Aslan, M | 1 |
| Freeman, BA | 1 |
| Ware, R | 1 |
| Bagdasaryan, R | 1 |
| Glasser, L | 1 |
| Quillen, K | 1 |
| Chaves, F | 1 |
| Xu, D | 1 |
| Prá, D | 1 |
| Maluf, SW | 1 |
| Mergener, M | 1 |
| Pollo, T | 1 |
| Kayser, M | 1 |
| da Silva, MA | 1 |
| Henriques, JA | 1 |
| Stevens, T | 1 |
| Huet, E | 1 |
| El Mahrab, M | 1 |
| Tavecchia, L | 1 |
| Pozzi, L | 1 |
| Riva, F | 1 |
| Vimercati, C | 1 |
| Calabria, M | 1 |
| Ronzoni, S | 1 |
| Perseghin, P | 1 |
| Verhelle, D | 1 |
| Glezer, E | 1 |
| Jensen-Pergakes, K | 1 |
| Ferguson, GD | 1 |
| Morris, CL | 1 |
| Muller, G | 1 |
| Brady, H | 1 |
| Chan, K | 1 |
| Mellouli, F | 1 |
| Bejaoui, M | 1 |
| Michel, M | 1 |
| Fifi-Mah, A | 1 |
| Arfi, S | 1 |
| Lefèvre, N | 1 |
| Singh, SA | 1 |
| Babadoko, A | 1 |
| Mamman, AI | 1 |
| Akpanpe, P | 1 |
| Attah, E | 1 |
| Suleiman, Y | 1 |
| Aliyu, N | 1 |
| Yusuf, J | 1 |
| Kumkhaek, C | 1 |
| Zhu, J | 1 |
| Bony, V | 1 |
| Jacqz-Aigrain, E | 1 |
| Cartron, JP | 1 |
| Traynor, K | 1 |
| Johnson, C | 1 |
| Fawibe, AE | 1 |
| Brawley, OW | 1 |
| Cornelius, LJ | 1 |
| Edwards, LR | 1 |
| Gamble, VN | 1 |
| Green, BL | 1 |
| Inturrisi, C | 1 |
| Laraque, D | 1 |
| Mendez, M | 1 |
| Montoya, CJ | 1 |
| Pollock, BH | 1 |
| Robinson, L | 1 |
| Scholnik, AP | 1 |
| Schori, M | 1 |
| Wilson, R | 1 |
| Charache, S | 25 |
| Boyer, SH | 2 |
| Orkin, SH | 2 |
| Dover, G | 3 |
| Beardsley, GP | 2 |
| Miller, B | 2 |
| Kolata, G | 1 |
| Adamson, JW | 1 |
| el-Hazmi, MA | 3 |
| al-Momen, A | 3 |
| Kandaswamy, S | 2 |
| Huraib, S | 2 |
| Harakati, M | 3 |
| al-Mohareb, F | 2 |
| Warsy, AS | 3 |
| Lubin, BH | 1 |
| Mankad, VN | 1 |
| Baliga, S | 1 |
| Phillips, K | 1 |
| Shah, AK | 2 |
| Yang, YM | 3 |
| Kalotychou, V | 3 |
| Fibach, E | 5 |
| Kollia, P | 1 |
| Noguchi, CT | 7 |
| Saleh, AW | 5 |
| van Goethem, A | 1 |
| Jansen, R | 1 |
| Velvis, HJ | 2 |
| Gu, LH | 2 |
| Huisman, TH | 2 |
| Kinney, TR | 5 |
| Ho, PT | 1 |
| Murgo, AJ | 1 |
| Silver, RT | 1 |
| Heller, P | 1 |
| Uyesaka, N | 2 |
| Nienhuis, AW | 5 |
| Burke, LP | 1 |
| Prasanna, P | 1 |
| Samid, D | 1 |
| Terrin, ML | 6 |
| Moore, RD | 5 |
| Eckert, SV | 2 |
| McMahon, RP | 4 |
| Góra-Tybor, J | 1 |
| Robak, T | 1 |
| Marwick, C | 2 |
| Charatan, FB | 1 |
| Monsaingeon-Lion, A | 1 |
| Le Pennec, PY | 1 |
| Bridey, F | 1 |
| Girard, M | 1 |
| Ricard, R | 1 |
| Gross, E | 1 |
| Tchernia, G | 1 |
| Adams-Graves, P | 1 |
| Heltsley, C | 1 |
| Deitcher, S | 1 |
| Bevan, DH | 1 |
| Lu, ZH | 2 |
| Brown, ER | 1 |
| Misiewicz, V | 1 |
| Labotka, RJ | 1 |
| Embury, SH | 1 |
| Epstein, N | 1 |
| Epstein, M | 1 |
| Boulet, A | 1 |
| Pearson, HA | 1 |
| Cornu, G | 1 |
| Buyse, M | 1 |
| Fondu, P | 3 |
| Toppet, M | 2 |
| Jayabose, S | 1 |
| Tugal, O | 1 |
| Sandoval, C | 1 |
| Patel, P | 1 |
| Puder, D | 1 |
| Lin, T | 1 |
| Visintainer, P | 1 |
| Oury, AP | 2 |
| Hoyoux, CL | 1 |
| Chantraine, JM | 2 |
| Allen, A | 1 |
| Scoble, J | 1 |
| Snowden, S | 1 |
| Hambley, H | 1 |
| Bellingham, A | 1 |
| Styles, LA | 4 |
| Lubin, B | 1 |
| Lawrence, S | 1 |
| Hua, M | 1 |
| Test, S | 1 |
| Kuypers, F | 1 |
| Hackney, AC | 1 |
| Hezier, W | 1 |
| Gulledge, TP | 1 |
| Busby, M | 1 |
| Hoffman, E | 1 |
| Roa, D | 1 |
| Kopsombut, P | 1 |
| Turner, EA | 1 |
| Selby, R | 1 |
| Nisbet-Brown, E | 1 |
| Basran, RK | 1 |
| Chang, L | 1 |
| Olivieri, NF | 2 |
| Zelmanovic, D | 1 |
| Sorette, M | 1 |
| Platt, O | 2 |
| Geller, NL | 1 |
| Nagel, RL | 1 |
| Hoyoux, C | 1 |
| Hillen, HF | 4 |
| Howard, LW | 1 |
| Kennedy, LD | 1 |
| Kitchens, D | 1 |
| Shah, A | 1 |
| Kim-Shapiro, DB | 2 |
| Bonifant, CL | 1 |
| Kolibash, CP | 1 |
| Hasegawa, S | 1 |
| Dwyer, N | 1 |
| Blanchette-Mackie, EJ | 1 |
| Gwilt, PR | 1 |
| Tracewell, WG | 1 |
| Cinkotai, KI | 1 |
| Yardumian, A | 1 |
| Flahault, A | 1 |
| Neonato, MG | 2 |
| Masson, MP | 1 |
| Stamoulakatou, A | 2 |
| Papassotiriou, Y | 1 |
| Loutradi, A | 2 |
| Cozma, G | 1 |
| Tsiarta, H | 1 |
| Pavlides, N | 1 |
| Gerbers, A | 1 |
| de Vries, C | 1 |
| Roberts-Harwood, M | 1 |
| Udden, MM | 1 |
| Lo, MN | 1 |
| Sears, DA | 1 |
| Diav-Citrin, O | 1 |
| Hunnisett, L | 1 |
| Sher, GD | 1 |
| Koren, G | 1 |
| Nassif, I | 1 |
| Boosalis, V | 1 |
| Wallenstein, S | 1 |
| Wright, E | 1 |
| McMahon, L | 1 |
| Faller, DV | 1 |
| Labie, D | 1 |
| Schultz, JC | 1 |
| Mariéthoz, S | 1 |
| Pittet, B | 1 |
| Loutan, L | 1 |
| Humbert, J | 2 |
| Montandon, D | 1 |
| Marcolina, MJ | 1 |
| Glover, RE | 1 |
| Ivy, ED | 1 |
| Maeda, H | 1 |
| Mason, RP | 1 |
| Noonan, SS | 1 |
| O'Branski, EE | 2 |
| Daeschner, C | 2 |
| Gee, B | 2 |
| Bégué, P | 2 |
| Thuret, I | 1 |
| Micheau, M | 1 |
| Byrd, DC | 1 |
| Pitts, SR | 1 |
| Alexander, CK | 1 |
| Valafar, H | 1 |
| Valafar, F | 1 |
| Darvill, A | 1 |
| Albersheim, P | 1 |
| Woods, KF | 1 |
| Hardin, J | 1 |
| Hardeman, MR | 1 |
| Ince, C | 1 |
| Yale, SH | 1 |
| Nagib, N | 1 |
| Guthrie, T | 1 |
| Hanft, VN | 1 |
| Fruchtman, SR | 1 |
| Dorn, L | 1 |
| Bressler, L | 1 |
| Talischy, N | 1 |
| Hoffman, R | 1 |
| van Overveld, W | 1 |
| Garozzo, G | 1 |
| Disca, S | 1 |
| Bonomo, P | 1 |
| Chen, HH | 1 |
| Swaim, MW | 1 |
| Agarwal, S | 1 |
| Wilson, S | 1 |
| Day, SW | 1 |
| Schina, M | 1 |
| Theodoropoulos, I | 1 |
| Schmugge, M | 1 |
| Frischknecht, H | 1 |
| Yonekawa, Y | 1 |
| Baumgartner, RW | 1 |
| Boltshauser, E | 1 |
| Chaine, B | 1 |
| Bincoletto, C | 1 |
| Perlingeiro, RC | 1 |
| Queiroz, ML | 1 |
| Prose, NS | 1 |
| Tahriri, P | 1 |
| Sturbois, G | 1 |
| Feremans, W | 1 |
| Rodrigue, CM | 1 |
| Arous, N | 1 |
| Smith-Ravin, J | 1 |
| Romeo, PH | 1 |
| Garel, MC | 1 |
| Huang, Z | 1 |
| Louderback, JG | 1 |
| Chies, JA | 1 |
| Nardi, NB | 1 |
| Castello-Herbreteau, B | 1 |
| Mundee, Y | 1 |
| Bigelow, NC | 1 |
| Davis, BH | 1 |
| Porter, JB | 1 |
| Moschovi, M | 1 |
| Psychou, F | 1 |
| Menegas, D | 1 |
| Tsangaris, GT | 1 |
| Tzortzatou-Stathopoulou, F | 1 |
| Nicolaidou, P | 1 |
| Nikolaidou, P | 1 |
| Kersgard, C | 1 |
| Osswald, MB | 1 |
| Dix, HM | 1 |
| Rezaei Kalantari, H | 1 |
| Shelhamer, JH | 1 |
| Pease-Fye, ME | 1 |
| Link, B | 1 |
| Patel, DB | 1 |
| Jankowski, MA | 1 |
| Pannell, LK | 1 |
| Reed, W | 1 |
| Lynn, HS | 1 |
| Delarche, C | 1 |
| Brahimi, L | 1 |
| Fay, M | 1 |
| Vilmer, E | 1 |
| Gougerot-Pocidalo, MA | 1 |
| Elbim, C | 1 |
| Fung, EB | 1 |
| Barden, EM | 1 |
| Kawchak, DA | 1 |
| Santos, A | 1 |
| Pinheiro, V | 1 |
| Anjos, C | 1 |
| Brandalise, S | 1 |
| Fahel, F | 1 |
| Lima, M | 1 |
| Etchebehere, E | 1 |
| Ramos, C | 1 |
| Camargo, EE | 1 |
| Papassotiriou, I | 1 |
| Altura, RA | 1 |
| Altura, BM | 1 |
| Altura, BT | 1 |
| Venigalla, P | 1 |
| Motwani, B | 1 |
| Agarwal, M | 1 |
| Alva, M | 1 |
| Parker, JC | 2 |
| Ranney, HM | 1 |
| Stamatoyannopoulos, JA | 1 |
| Kaufman, RE | 1 |
| Eckert, S | 1 |
| Milner, PF | 1 |
| Phillips, G | 2 |
| Goldberg, MA | 2 |
| Schapira, L | 2 |
| Lacroix, L | 1 |
| Veith, R | 3 |
| al-Khatti, A | 2 |
| Papayannopoulou, T | 4 |
| Blythe, DS | 1 |
| Johnson, AE | 1 |
| Nora, R | 1 |
| Galanello, R | 2 |
| Humphries, RK | 2 |
| Young, N | 1 |
| Ley, T | 1 |
| Boyer, S | 1 |
| Nienhuis, A | 1 |
| Moore, JG | 1 |
| Ley, TJ | 1 |
| Young, NS | 1 |
| Moyer, MA | 1 |
| Moore, JW | 1 |
| Miller, BA | 1 |
| Hope, S | 1 |
| Umemura, T | 1 |
| Spadaccino, E | 1 |
| Abels, RI | 1 |
| Fritsch, EF | 1 |
| Merz, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Register Sichelzellkrankheit Der GPOH[NCT03327428] | 1,000 participants (Anticipated) | Observational [Patient Registry] | 2016-12-15 | Recruiting | |||
| Primary Prevention of Stroke in Children With Sickle Cell Disease in Sub-Saharan Africa II[NCT02560935] | Phase 3 | 440 participants (Actual) | Interventional | 2016-07-19 | Completed | ||
| Enhancing Preventive Therapy of Malaria In Children With Sickle Cell Anemia in East Africa (EPiTOMISE)[NCT03178643] | Phase 4 | 246 participants (Actual) | Interventional | 2018-01-23 | Completed | ||
| Hydroxyurea for Stroke Prevention in Children With Sickle Cell Disease in Sub-Saharan Africa[NCT02675790] | Phase 3 | 120 participants (Anticipated) | Interventional | 2017-01-31 | Completed | ||
| ENHANCE Study (ElectroNic Hydroxyurea AdhereNCE): A Strategy to Improve Hydroxyurea Adherence in Patients With Sickle Cell Disease[NCT02578017] | 71 participants (Actual) | Interventional | 2014-07-31 | Completed | |||
| Hydroxyurea Adherence for Personal Best in Sickle Cell Disease (HABIT): Efficacy Trial[NCT03462511] | 100 participants (Actual) | Interventional | 2018-08-15 | Completed | |||
| Optimizing Hydroxyurea Therapy in Children With Sickle Cell Anemia In Malaria Endemic Areas: The NOHARM Maximum Tolerated Dose (MTD) Study[NCT03128515] | Phase 3 | 187 participants (Actual) | Interventional | 2017-07-26 | Completed | ||
| Hydroxyurea Optimization Through Precision Study (HOPS): A Prospective, Multi-center, Randomized Trial of Personalized, Pharmacokinetics-guided Dosing of Hydroxyurea Versus Standard Weight-based Dosing for Children With Sickle Cell Anemia.[NCT03789591] | Phase 3 | 116 participants (Anticipated) | Interventional | 2019-01-17 | Recruiting | ||
| Therapeutic Response Evaluation and Adherence Trial (TREAT): A Prospective Study of Hydroxyurea for Children With Sickle Cell Anemia[NCT02286154] | 150 participants (Anticipated) | Interventional | 2014-10-31 | Recruiting | |||
| ESCORT-HU : European Sickle Cell Disease Cohort - Hydroxyurea[NCT02516579] | 1,906 participants (Actual) | Observational | 2009-01-31 | Completed | |||
| Safety and Feasibility of High-Dose Topical Capsaicin for the Treatment of Neuropathic Pain in Pediatric Sickle Cell Disease[NCT03899246] | Phase 1 | 10 participants (Actual) | Interventional | 2019-07-03 | Completed | ||
| "Hydroxyurea Therapy for Neurological and Cognitive Protection in Pediatric Sickle Cell Anemia in Uganda: A Single Arm Open Label Trial, BRAIN SAFE II"[NCT04750707] | Phase 3 | 270 participants (Actual) | Interventional | 2021-03-09 | Active, not recruiting | ||
| Hydroxyurea Adherence for Personal Best in Sickle Cell Treatment: HABIT[NCT02029742] | 60 participants (Actual) | Interventional | 2013-09-30 | Completed | |||
| Microvascular and Cardiac Dysfunction in Sickle Cell Disease[NCT01602809] | 65 participants (Actual) | Observational | 2012-04-30 | Completed | |||
| Pharmacokinetics and Relative Bioavailability of a Liquid Formulation of Hydroxyurea in Pediatric Patients With Sickle Cell Anemia[NCT01506544] | Phase 1 | 39 participants (Actual) | Interventional | 2011-12-31 | Completed | ||
| Novel Use Of Hydroxyurea in an African Region With Malaria[NCT01976416] | Phase 3 | 208 participants (Actual) | Interventional | 2014-09-30 | Completed | ||
| REALIZING EFFECTIVENESS ACROSS CONTINENTS WITH HYDROXYUREA (REACH): A PHASE I/II PILOT STUDY OF HYDROXYUREA FOR CHILDREN WITH SICKLE CELL ANEMIA[NCT01966731] | Phase 1/Phase 2 | 635 participants (Actual) | Interventional | 2014-06-30 | Active, not recruiting | ||
| Open Study of Phase I / II Evaluating Tolerance and Efficacy of Mobilization and Collection of Peripheral Hematopoietic Stem Cells Device After a Single Injection of 0.24mg/kg of Plerixafor in Sickle Cell Patients[NCT02212535] | Phase 1/Phase 2 | 3 participants (Actual) | Interventional | 2016-01-15 | Completed | ||
| A PHASE III, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY OF L GLUTAMINE THERAPY FOR SICKLE CELL ANEMIA AND SICKLE ß0-THALASSEMIA[NCT01179217] | Phase 3 | 230 participants (Actual) | Interventional | 2010-05-31 | Completed | ||
| Single-center Pilot Study: Nano-rheological Biomarkers for Patients With Sickle Cell Disease (SCD) Versus Control Subjects (Other Constitutional Red Blood Cell Diseases and Healthy Subjects)[NCT05530239] | 40 participants (Anticipated) | Observational | 2022-10-31 | Not yet recruiting | |||
| A Phase 1b Sequential Open Label Dose-Ranging Study of Safety, Pharmacokinetics, and Preliminary Activity of Benserazide in Subjects With Beta Thalassemia Intermedia and Sickle Cell Disease[NCT04432623] | Phase 1/Phase 2 | 36 participants (Anticipated) | Interventional | 2020-10-05 | Recruiting | ||
| A Phase 1b, Randomized, Double-blind (Sponsor Open), Placebo Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf 04447943, Co-administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Di[NCT02114203] | Phase 1 | 30 participants (Actual) | Interventional | 2014-12-31 | Completed | ||
| Risk Stratification for Clinical Severity of Sickle Cell Disease in Nigeria and Assessment of Efficacy and Safety During Treatment With Hydroxyurea[NCT02149537] | Phase 4 | 53 participants (Actual) | Interventional | 2014-12-31 | Completed | ||
| A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study of Voxelotor Administered Orally to Patients With Sickle Cell Disease[NCT03036813] | Phase 3 | 449 participants (Actual) | Interventional | 2016-12-31 | Completed | ||
| Assessing Functional Capacity in Sickle Cell Patients Receiving Voxelotor[NCT06023199] | 10 participants (Anticipated) | Observational | 2023-10-23 | Recruiting | |||
| Potential Role of Gum Arabic as Fetal Hemoglobin Agent in Sudanese Sickle Cell Anemia Patients[NCT02467257] | Phase 1/Phase 2 | 47 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
| A Randomized, Open-Label, Multi-Dose Study of HQK-1001 in Subjects With Sickle Cell Disease[NCT01322269] | Phase 2 | 52 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
| Stroke With Transfusions Changing to Hydroxyurea[NCT00122980] | Phase 3 | 134 participants (Actual) | Interventional | 2006-10-31 | Terminated (stopped due to The study has been stopped due to safety and futility concerns.) | ||
| Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG)[NCT00006400] | Phase 3 | 193 participants (Actual) | Interventional | 2000-08-31 | Completed | ||
| Phase 1-2 Trial of Gamunex (Intravenous Gammaglobulin) for Sickle Cell Acute Pain[NCT01757418] | Phase 1/Phase 2 | 300 participants (Anticipated) | Interventional | 2008-11-30 | Recruiting | ||
| Pilot Study to Assess Patients' and Health Workers' Needs Involved in Sickle Cell Disease Management[NCT04505969] | 196 participants (Actual) | Observational | 2020-11-11 | Completed | |||
| Nonpharmacological Approaches Used by Parents of Children With Sickle Cell Disease and the Effectiveness of Education Given to Nonpharmacological Approaches[NCT04121247] | 163 participants (Actual) | Interventional | 2015-09-01 | Completed | |||
| A Phase 1 Open-Label, Multiple-Dose Study to Evaluate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of FTX-6058 in Subjects With Sickle Cell Disease (SCD)[NCT05169580] | Phase 1 | 70 participants (Anticipated) | Interventional | 2021-12-13 | Recruiting | ||
| A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Single-and Multiple-Dose Study Evaluating Safety, Tolerability, and Pharmacokinetics, With an Open-Label Initial Food Effect and CYP3A Drug-Drug Interaction Study, of FTX-6058 in Healthy Adult Subjec[NCT04586985] | Phase 1 | 109 participants (Actual) | Interventional | 2020-10-26 | Completed | ||
| The Safety and Efficacy of Macitentan for Treatment of Pulmonary Hypertension in Sickle Cell Disease[NCT02651272] | Phase 2 | 4 participants (Actual) | Interventional | 2015-07-31 | Terminated (stopped due to Unable to enroll IRB approved sample of participants.) | ||
| Comparison of Sub-dissociative Intranasal Ketamine Plus Standard Pain Therapy Versus Standard Pain Therapy in the Treatment of Pediatric Sickle Cell Disease Vasoocclusive Crises in Resource-limited Settings: a Multi-centered, Randomized, Controlled Trial[NCT02573714] | 160 participants (Anticipated) | Interventional | 2015-12-31 | Recruiting | |||
| Monocytic Expression of Heme Oxidase-1 (HO-1) in Sickle Cell Patients and Correlation With the Humoral Immune Response to Vaccine and With Allo-immunization[NCT03111589] | 102 participants (Actual) | Interventional | 2016-10-31 | Completed | |||
| RH Genotype Matched Red Cells for Patients With Sickle Cell Disease and Anti-D[NCT04156906] | Early Phase 1 | 20 participants (Anticipated) | Interventional | 2020-07-08 | Recruiting | ||
| RH Genotype Matched Red Cell Transfusions for Patients With Sickle Cell Disease[NCT04156893] | Early Phase 1 | 35 participants (Anticipated) | Interventional | 2020-01-30 | Recruiting | ||
| Intranasal Sufentanil for Analgesia of Severe Sickle Cell Vaso-occlusive Pain Crisis in the Pediatric Emergency Department: a Double Blind Randomized Versus Placebo Controlled Trial[NCT06181695] | Phase 3 | 182 participants (Anticipated) | Interventional | 2024-05-02 | Not yet recruiting | ||
| Bone Marrow Transplantation HLA Haploidentical After a Reduced Intensity Conditioning and Prevention of GvHD Based on Post-transplant Cyclophosphamide Administration in Patients With Severe Sickle Cell Disease[NCT03240731] | Phase 2 | 18 participants (Anticipated) | Interventional | 2017-08-10 | Active, not recruiting | ||
| Health Literacy: A Randomized Controlled Trial to Investigate a Novel Feedback Tool for Neurocognitive Screening in Pediatric Sickle Cell Disease[NCT04917783] | 46 participants (Actual) | Interventional | 2019-09-25 | Completed | |||
| Quantitative and Prognostic Evaluation of Dense Red Blood Cells in Sickle Cell Children: Single-center Study From the Creteil (France) Pediatric Cohort[NCT02887118] | 82 participants (Actual) | Observational | 2015-12-31 | Terminated (stopped due to The recruiting centre was no longer presenting new patients for inclusion) | |||
| Low Dose Aspirin for Preventing Intrauterine Growth Restriction and Preeclampsia in Sickle Cell Pregnancy (PIPSICKLE): a Randomized Controlled Trial[NCT05253781] | Phase 3 | 476 participants (Anticipated) | Interventional | 2020-07-01 | Recruiting | ||
| Ketamine Infusion for Acute Sickle Cell crisiS in the Emergency Department[NCT02417298] | 12 participants (Actual) | Interventional | 2015-11-30 | Terminated (stopped due to Feasibility) | |||
| Prospective Clinical Study on Early Inflammatory, Cell Adhesion and Hemostatic Plasmatic Markers of Endothelial Dysfunction in Children With Sickle Cell Disease (SCD)[NCT04839159] | 41 participants (Anticipated) | Interventional | 2012-05-10 | Active, not recruiting | |||
| Sparing Conversion to Abnormal TCD Elevation (SCATE) - a Phase III Clinical Trial to Compare Standard Care (Observation) With Alternative Therapy (Hydroxyurea) for Reducing the Risk of Converting to an Abnormal TCD Velocity in Children With Sickle Cell An[NCT01531387] | Phase 3 | 38 participants (Actual) | Interventional | 2012-05-31 | Terminated (stopped due to inability to reach a satisfactory endpoint with respect to adequate recruitment) | ||
| Physical Rehabilitation in Adults With Sickle Cell Anemia: Effects on Muscle Function, Functional Capacity and Quality of Life[NCT04705792] | 40 participants (Anticipated) | Interventional | 2020-01-31 | Recruiting | |||
| Determining the Prevalence and Prognosis of Secondary Pulmonary Hypertension in Adult Patients With Sickle Cell Anemia[NCT00011648] | 986 participants (Actual) | Observational | 2008-02-19 | Completed | |||
| TCD With Transfusions Changing to Hydroxyurea (TWiTCH): A Phase III Randomized Trial to Compare Standard Therapy (Erythrocyte Transfusions) With Alternative Therapy (Hydroxyurea) for the Maintenance of Lowered TCD Velocities in Pediatric Subjects With Sic[NCT01425307] | Phase 3 | 159 participants (Actual) | Interventional | 2011-08-31 | Terminated (stopped due to The study was stopped early due to successfully meeting the primary endpoint) | ||
| Comparison of Efficacy Between Bilateral Superficial Cervical Plexus Block and Local Infiltration of Lidocaine 2% in Patients Undergoing Tracheostomy[NCT04006639] | 36 participants (Actual) | Interventional | 2019-08-01 | Completed | |||
| Effect of Mobile-Directly Observed Therapy (DOT) on Adherence to Hydroxyurea Treatment in Adult HbSS Patients at Muhimbili National Hospital (MNH) in Tanzania: a Pilot Study[NCT02844673] | Phase 4 | 100 participants (Anticipated) | Interventional | 2016-10-31 | Enrolling by invitation | ||
| Crizanlizumab for Treating COVID-19 Vasculopathy[NCT04435184] | Phase 2 | 54 participants (Actual) | Interventional | 2020-07-09 | Completed | ||
| A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Sickle Cell-Related Pain Crises[NCT01895361] | Phase 2 | 198 participants (Actual) | Interventional | 2013-07-31 | Completed | ||
| A Pilot Study of the Use of Oral Ketamine for Treatment of Vaso-Occlusive Pain in Adolescents and Young Adults[NCT05378555] | Phase 3 | 10 participants (Anticipated) | Interventional | 2023-05-01 | Recruiting | ||
| Evaluation of Sickle Cell Liver Disease[NCT01950429] | 42 participants (Actual) | Observational | 2013-10-16 | Completed | |||
| Studies of the Natural History of Sickle Cell Disease[NCT00081523] | 3,500 participants (Anticipated) | Observational | 2004-04-29 | Recruiting | |||
| Long Term Effects of Hydroxyurea Therapy in Children With Sickle Cell Disease[NCT00305175] | 260 participants (Actual) | Observational | 2006-03-03 | Completed | |||
| A Substudy of the CADRE Study: Determination of Clinical Markers in Patients With Extreme Sickle Cell Disease Phenotype[NCT03352986] | 300 participants (Anticipated) | Observational | 2017-05-15 | Recruiting | |||
| Sickle Cell Disease (SCD) Biochip': Towards a Simple and Reliable Way to Monitor Sickle Cell Disease[NCT02824471] | 100 participants (Anticipated) | Observational | 2014-10-31 | Recruiting | |||
| Aerobic Physical Fitness and Health-related Quality of Life in Children With Sickle Cell Disease.[NCT05995743] | 72 participants (Actual) | Observational | 2021-11-01 | Completed | |||
| Evaluation of the Hemostatic Potential in Sickle Cell Disease Patients[NCT02565082] | 64 participants (Actual) | Interventional | 2015-09-30 | Completed | |||
| Evaluation of Impact of Disease on Quality of Life, Education and Socio-professional Integration of Adults and Parents of Children Living With Sickle- Cell Disease in France[NCT04413539] | 1,088 participants (Actual) | Observational | 2020-06-02 | Completed | |||
| Treatment With Hydoxycarbamide and L-Carnitine in Adult Patients With Severe Forms of Sickle Cell Anemia: An Overview[NCT05081349] | Phase 4 | 91 participants (Actual) | Interventional | 2017-01-10 | Completed | ||
| National Transfusion Treatment Survey in Patients With Sickle Cell Disease (SCD)[NCT03397017] | 200 participants (Actual) | Observational | 2016-07-01 | Completed | |||
| Primary Prevention of Strokes in Nigerian Children With Sickle Cell Disease Affiliated Titles: Sickle Cell Disease - Stroke Prevention in Nigeria (SPIN) Trial[NCT01801423] | 29 participants (Actual) | Interventional | 2013-04-24 | Completed | |||
| Novel Dose Escalation to Predict Treatment With Hydroxyurea[NCT02042222] | Early Phase 1 | 70 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| Silent Cerebral Infarct Transfusion Multi-Center Clinical Trial[NCT00072761] | Phase 3 | 196 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| Preventing Acute Chest Syndrome by Transfusion Feasibility Study( PROACTIVE Feasibility Study)[NCT00951808] | 237 participants (Actual) | Interventional | 2009-07-31 | Completed | |||
| Comparison of Two Methods of Transfusion for Stroke Prevention in Sickle Cell[NCT02561312] | 9 participants (Actual) | Observational | 2015-09-30 | Completed | |||
| Obesity in Pediatric Sickle Cell Disease: A New Phenomenon[NCT04676113] | 100 participants (Actual) | Observational | 2021-03-01 | Completed | |||
| Multicenter Study of Hydroxyurea in Patients With Sickle Cell Anemia (MSH)[NCT00000586] | Phase 3 | 0 participants | Interventional | 1992-01-31 | Completed | ||
| Macrolide Therapy to Improve Forced Expiratory Volume in 1 Second in Adults With Sickle Cell Disease: a Feasibility Trial[NCT02960503] | Phase 1/Phase 2 | 0 participants (Actual) | Interventional | 2016-09-30 | Withdrawn (stopped due to Key personnel moved to new location. Therefore, we had insufficient resources to initiate the trial.) | ||
| Long-Term, Open-Label, Multicenter, Extension Study of Bosentan in Patients With Pulmonary Hypertension Associated With Sickle Cell Disease Completing a Double-Blind ASSET Study (AC-052-368 or AC 052-369)[NCT00360087] | Phase 3 | 236 participants | Interventional | 2006-03-31 | Terminated (stopped due to Slow enrollment) | ||
| Role of Nitric Oxide Scavenging by Plasma Hemoglobin and Identification of Hemolysis-Associated Pulmonary Hypertension in Malaria[NCT00527163] | 103 participants (Actual) | Observational | 2007-09-04 | Completed | |||
| Serum Brain Natriuretic Peptide Levels and Its Correlation With Echocardiographic Measurements Suggestive of Pulmonary Hypertension in Pediatric Patients With Sickle Cell Disease[NCT01023451] | 21 participants (Actual) | Observational | 2009-12-31 | Completed | |||
| Iron-mediated Vascular Disease in Sickle Cell Disease.[NCT01239901] | 150 participants (Actual) | Observational | 2009-12-31 | Completed | |||
| Erythrocyte Glutamine Level Relation to Pulmonary Hypertension Risk in Beta Thalassemia Major Children in Assiut University Children Hospital[NCT03133169] | 80 participants (Actual) | Observational | 2017-06-01 | Completed | |||
| Heart, Arteries and Sikle Cell Disease, a Multicentric Cohort of Cardiovascular Complications in Subsaharan Africa[NCT03114137] | 4,500 participants (Anticipated) | Observational [Patient Registry] | 2012-03-31 | Recruiting | |||
| An Evaluation of Tricuspid Regurgitant Jet Velocity as an Independent Marker for Mortality in Patients With Sickle Cell Anemia: A Retrospective Data Review[NCT01783093] | 209 participants (Actual) | Observational | 2009-12-31 | Completed | |||
| A Randomized Controlled Double-Blind Trial for Prevention of Recurrent Ischemic Priapism in Men With Sickle Cell Disease: A Pilot Study[NCT05142254] | Phase 2 | 64 participants (Actual) | Interventional | 2022-04-01 | Active, not recruiting | ||
| PINPOINT: Gaming Technology to Engage Adolescent Sickle Cell Patients in Precision Pain Management[NCT03291613] | 13 participants (Actual) | Interventional | 2017-01-15 | Completed | |||
| Interest of Nutritional Care of Children With Sickle Cell Disease on Bone Mineral Density and Body Composition[NCT04754711] | 70 participants (Anticipated) | Interventional | 2021-09-23 | Recruiting | |||
| [NCT00000592] | Phase 3 | 0 participants | Interventional | 1994-07-31 | Completed | ||
| [NCT00006182] | Phase 3 | 0 participants | Interventional | 2000-07-31 | Completed | ||
| Prevalence of Secondary Arterial Hypertension (PAH) in Patients With Sickle Cell Disease in Nigeria and the Role of HIV/AIDS and Endemic Parasitic Infections in the Natural History of Pulmonary Hypertension in Sickle Cell Disease[NCT00367523] | 308 participants (Actual) | Observational | 2006-06-15 | Completed | |||
| Exploratory Studies of Psychophysical Pain Phenotyping and Genetic Variability in Sickle Cell Disease[NCT01441141] | 67 participants (Actual) | Observational | 2012-06-17 | Completed | |||
| Hydroxyurea to Prevent Central Nervous System (CNS) Complications of Sickle Cell Disease in Children[NCT01389024] | Phase 2 | 28 participants (Actual) | Interventional | 2012-08-16 | Completed | ||
| Single-center Prospective Evaluation of Sickle Cell Patient Care in the CHU Brugmann Emergency Department[NCT02386657] | 104 participants (Actual) | Observational | 2012-11-30 | Completed | |||
| A Phase 1, Placebo-Controlled, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating, Single Oral Doses of Aes-103 in Subjects With Stable Sickle Cell Disease[NCT01597401] | Phase 1 | 19 participants (Actual) | Interventional | 2012-05-12 | Completed | ||
| A Phase 2, Open-Label, Multiple-Dose Study Investigating the Efficacy and Safety of Panhematin in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome[NCT00467610] | Phase 2 | 6 participants (Actual) | Interventional | 2007-05-31 | Terminated (stopped due to lack of efficacy.) | ||
| Effect of Hydroxyurea on Fetal Hemoglobin Synthesis in Patients With Sickle Cell Anemia[NCT00001197] | Phase 2 | 41 participants (Actual) | Interventional | 1984-02-07 | Completed | ||
| Nonmyeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease (SCD) and B-Thalassemia[NCT00061568] | Phase 1/Phase 2 | 150 participants (Anticipated) | Interventional | 2004-07-16 | Recruiting | ||
| Effect of Adenosine 2A Receptor Agonist Regadenoson on Microvascular Blood Flow in Sickle Cell Anemia[NCT01566890] | 200 participants (Anticipated) | Interventional | 2012-07-31 | Active, not recruiting | |||
| Abciximab (ReoPro) as a Therapeutic Intervention for Sickle Cell Vaso-Occlusive Pain Crisis[NCT01932554] | Phase 2 | 0 participants (Actual) | Interventional | 2013-11-30 | Withdrawn (stopped due to Insufficient recruitment) | ||
| Genomics and Personalized Medicine for All Though Artificial Intelligence in Haematological Diseases[NCT06019208] | 1,000 participants (Anticipated) | Observational | 2021-01-01 | Recruiting | |||
| Physiologic Effects of Inhaled Nitric Oxide, Nitroglycerin, and Placebo in Study Subjects With Sickle Cell Anemia[NCT00001716] | Phase 2 | 58 participants | Interventional | 1998-07-31 | Completed | ||
| [NCT00000602] | Phase 2 | 0 participants | Interventional | 1994-04-30 | Completed | ||
| Evaluation of Potential Synergy of Combining Hydroxyurea With Nitric Oxide Donors on Fetal Hemoglobin Synthesis in Patients With Sickle Cell Anemia[NCT00056433] | Phase 1 | 39 participants (Actual) | Interventional | 2003-03-10 | Completed | ||
| Crizanlizumab Improves Tissue Oxygen Supply Demand Matching in Patients With Sickle Cell Anemia[NCT05469828] | Phase 1/Phase 2 | 30 participants (Anticipated) | Interventional | 2024-07-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT02516579)
Timeframe: During the follow-up of participant, up to 10 years
| Intervention | % patient-years (Number) |
|---|---|
| Patients With Sickle Cell Disease Treated With Siklos® | 0.001 |
Patients with at least one myelosuppression (NCT02516579)
Timeframe: During the follow-up of participant, up to 10 years
| Intervention | % patient-years (Number) |
|---|---|
| Patients With Sickle Cell Disease Treated With Siklos® | 5.99 |
Patients with at least one skin ulceration (NCT02516579)
Timeframe: During the follow-up of participant, up to 10 years
| Intervention | % patient-years (Number) |
|---|---|
| Patients With Sickle Cell Disease Treated With Siklos® | 1.13 |
Malaria is defined as the presence of P. falciparum or P. malariae on the peripheral smear of any child brought in for medical evaluation of fever. P. vivax, P. ovale and P. knowlesi are not known to be present in this region, but if a child is seen with suspected infection with any of these malaria parasites, this will also be recorded as a case of malaria. Incidence will be reported in the number of cases per 100 patient years. (NCT01976416)
Timeframe: 12 months
| Intervention | malaria episodes (Number) |
|---|---|
| Hydroxyurea | 5 |
| Placebo | 7 |
An expected toxicity rate of 20% and acceptable toxicity rate of 30% were used for statistical calculations. After 53 participants at each site complete 3 months of therapy, if ≤ 15 participants have hematologic toxicity there is no early evidence against safety. If ≥ 15 of the initial participants experience toxicity, this is early evidence against safety. Future participants will begin at a lower dose of hydroxyurea (10 ± 2.5 mg/kg), with another 53 participants recruited of the same safety analysis. Upon final analysis of 133 participants at the same starting dose, safety for fixed-dose hydroxyurea can be concluded. (NCT01966731)
Timeframe: 3 months
| Intervention | percentage of participants (Number) |
|---|---|
| Hydroxyurea | 5.1 |
The number of emergency room visits or medical facility visits that occur from Week 0 to Week 48, will be used to evaluate the efficacy of oral L-glutamine as a treatment for sickle cell anemia and beta-0 thalassemia. (NCT01179217)
Timeframe: 48 weeks
| Intervention | Number of ER visits (Median) |
|---|---|
| L-glutamine | 1 |
| 100% Maltodextrin | 1 |
The number of hospitalizations that occur from Week 0 to Week 48, will be used to evaluate the efficacy of oral L-glutamine as a treatment for sickle cell anemia and beta-0 thalassemia. (NCT01179217)
Timeframe: 48 weeks
| Intervention | Number of hospitalizations (Median) |
|---|---|
| L-glutamine | 2 |
| 100% Maltodextrin | 3 |
The number of occurrences of protocol-defined sickle cell crises that occur from Week 0 to Week 48 will be used to evaluate the efficacy of oral L-glutamine as a treatment for sickle cell anemia and beta-0 thalassemia. (NCT01179217)
Timeframe: 48 weeks
| Intervention | Number of crises (Median) |
|---|---|
| L-glutamine | 3 |
| 100% Maltodextrin | 4 |
To assess the effect of oral L-glutamine on Vital signs (temperature). Change from Baseline will be reported at Weeks 4, 24, and 48. (NCT01179217)
Timeframe: Baseline, Week 4, Week 24 and Week 48
| Intervention | degree C (Mean) | |||
|---|---|---|---|---|
| Temperature at Baseline | Change in Temperature at Week 4 | Change in Temperature at Week 24 | Change in Temperature at Week 48 | |
| 100% Maltodextrin | 36.83 | -0.02 | 0.03 | 0.05 |
| L-glutamine | 36.85 | -0.06 | -0.05 | -0.09 |
To assess the effect of oral L-glutamine on hematological parameters (hemoglobin), Change from Baseline will be reported at Weeks 4, 24 and 48. (NCT01179217)
Timeframe: Baseline, Week 4, 24 and 48
| Intervention | g/dL (Mean) | |||
|---|---|---|---|---|
| Hemoglobin at Baseline | Change in Hemoglobin at week 4 | Change in Hemoglobin at Week 24 | Change in Hemoglobin at Week 48 | |
| L-glutamine | 8.82 | 0.04 | -0.17 | -0.12 |
| Placebo | 8.71 | 0.23 | -0.12 | -0.12 |
To assess the effect of oral L-glutamine on hematological parameters (hematocrit), Change from Baseline will be reported at Weeks 4, 24 and 48. (NCT01179217)
Timeframe: Baseline, Week 4, 24 and 48
| Intervention | % of red blood cells (Mean) | |||
|---|---|---|---|---|
| Hematocrit at Baseline | Change in Hematocrit at Week 4 | Change in Hematocrit Week 24 | Change in Hematocrit at Week 48 | |
| 100% Maltodextrin | 27.53 | 0.75 | -0.15 | 0.11 |
| L-glutamine | 27.67 | 0.16 | -0.26 | 0.16 |
To assess the effect of oral L-glutamine on hematological parameters (reticulocyte count), Change from Baseline will be reported at Weeks 4, 24 and 48. (NCT01179217)
Timeframe: Baseline, Week 4, 24 and 48
| Intervention | 1000 cells/uL (Mean) | |||
|---|---|---|---|---|
| Reticulocyte (Abs) | Change in Reticulocyte (Abs) at Week 4 | Change in Reticulocyte (Abs) at Week 24 | Change in Reticulocyte (Abs) at Week 48 | |
| 100% Maltodextrin | 295.03 | -23.09 | -1.93 | 26.27 |
| L-glutamine | 283.62 | -9.28 | 7.94 | 50.89 |
To assess the effect of oral L-glutamine on Vital signs (pulse rate). Change from Baseline will be reported at Weeks 4, 24, and 48. (NCT01179217)
Timeframe: Baseline, Week 4, Week 24 and Week 48
| Intervention | bpm (Mean) | |||
|---|---|---|---|---|
| Pulse Rate (bpm) at Baseline | Change in Pulse Rate (bpm) at Week 4 | Change in Pulse Rate (bpm) at Week 24 | Change in Pulse Rate (bpm) at 48 | |
| 100% Maltodextrin | 88.5 | -0.4 | -1.5 | 0.2 |
| L-glutamine | 85.6 | -0.1 | 3.0 | 1.1 |
To assess the effect of oral L-glutamine on Vital signs (respiration). Change from Baseline will be reported at Weeks 4, 24, and 48. (NCT01179217)
Timeframe: Baseline, Week 4, Week 24 and Week 48
| Intervention | breaths/min (Mean) | |||
|---|---|---|---|---|
| Respiration at Baseline | Change in Respiration at Week 4 | Change in Respiration at Week 24 | Change in Respiration at Week 48 | |
| 100% Maltodextrin | 19.1 | -0.2 | -0.6 | -0.6 |
| L-glutamine | 18.9 | -0.2 | -0.7 | -0.7 |
To assess the effect of oral L-glutamine on Vital signs (systolic and diastolic blood pressure). Change from Baseline will be reported at Weeks 4, 24, and 48. (NCT01179217)
Timeframe: Baseline, Week 4, 24, and 48
| Intervention | mm Hg (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Systolic blood pressure at Baseline | Change Systolic blood pressure at Week 4 | Change in Systolic blood pressure at Week 24 | Change in Systolic blood pressure at Week 48 | Diastolic blood pressure at Baseline | Change in Diastolic blood pressure at Week 4 | Change in Diastolic blood pressure at Week 24 | Change in Diastolic blood pressure at Week 48 | |
| 100% Maltodextrin | 114.6 | -0.2 | 0.5 | 2.6 | 66.2 | 0.3 | 0.6 | 2.0 |
| L-glutamine | 111.3 | 0.5 | 1.1 | 2.2 | 64.8 | -0.7 | -0.7 | 0.4 |
AUC(0-12h) referred to area under the plasma concentration-time curve from 0 to 12 hours post dose. (NCT02114203)
Timeframe: Prior to 0 hour, and 0.5, 1, 2, 4, 8, and 12 hours post dose on Day 1
| Intervention | nanogram*hour/milliliter (Geometric Mean) |
|---|---|
| PF-04447943 5 mg BID | 242.0 |
| PF-04447943 25 mg BID | 1170 |
(NCT02114203)
Timeframe: Prior to 0 hour, and 0.5, 1, 2, 4, 8, and 12 hours post dose on Day 1
| Intervention | ng/mL (Geometric Mean) |
|---|---|
| PF-04447943 5 mg BID | 45.83 |
| PF-04447943 25 mg BID | 248.2 |
The laboratory test included: hematology (hemoglobin, hematocrit, red blood cell count, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, platelet count, white blood cell count, absolute total neutrophils, eosinophils, monocytes, basophils, and lymphocytes), chemistry (blood urea nitrogen/urea, serum creatinine, fasting glucose, calcium, sodium, potassium, chloride, total carbon dioxide, aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, uric acid, albumin, total protein, and high sensitivity C-reactive protein), urinalysis (pH, qualitative glucose, qualitative protein, qualitative blood, ketones, nitrites, leukocyte esterase, urobilinogen, urine bilirubin, and microscopy), and other tests (follicle stimulating hormone and serum human chorionic gonadotropin, urine drug screening). Abnormality was determined by the investigator. (NCT02114203)
Timeframe: Baseline up to 30 days post last dose on Day 29
| Intervention | participants (Number) |
|---|---|
| PF-04447943 5 mg BID | 7 |
| PF-04447943 25 mg BID | 15 |
| Placebo | 7 |
Clinical assessment of neurologic functions included cranial nerve function, coordination, deep tendon reflexes, muscle strength, and reflexes (left and right ankles). Clinical importance of neurologic function changes was determined by the investigator. (NCT02114203)
Timeframe: Baseline up to Day 29
| Intervention | participants (Number) |
|---|---|
| PF-04447943 5 mg BID | 0 |
| PF-04447943 25 mg BID | 0 |
| Placebo | 0 |
The following symptoms were assessed: anemia; fatigue; chronic pain; acute pain; infections; fever; swelling hands; swelling feet; abdominal swelling; pale skin; pale nail beds; yellow tint to skin; whites of eyes turned yellow; stroke. Number of participants with changes from baseline deemed potentially clinically important by the investigator is presented. (NCT02114203)
Timeframe: Baseline up to 30 days post last dose on Day 29
| Intervention | participants (Number) |
|---|---|
| PF-04447943 5 mg BID | 0 |
| PF-04447943 25 mg BID | 0 |
| Placebo | 0 |
Physical examination included head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems. Clinical importance of physical examination changes was determined by the investigator. (NCT02114203)
Timeframe: Baseline up to 30 days post last dose on Day 29
| Intervention | participants (Number) |
|---|---|
| PF-04447943 5 mg BID | 0 |
| PF-04447943 25 mg BID | 0 |
| Placebo | 0 |
(NCT02114203)
Timeframe: Prior to 0 hour, and 0.5, 1, 2, 4, 8, and 12 hours post dose on Day 1
| Intervention | hours (Median) |
|---|---|
| PF-04447943 5 mg BID | 1.92 |
| PF-04447943 25 mg BID | 1.00 |
Maximum absolute values and increases from baseline were summarized for PR interval (time from the beginning of P wave to the start of QRS complex, corresponding to the end of atrial depolarization and onset of ventricular depolarization), QRS complex (time from Q wave to the end of S wave, corresponding to ventricle depolarization), and QTcF interval (time from the beginning of Q wave to the end of T wave corresponding to electrical systole corrected for heart rate using Fridericia's formula). Number of participants with ECG findings meeting the following criteria is presented: (1) PR interval >=300 msec; (2) QRS complex >=200 msec; (3) QTcF interval: 450 to <480 msec; (4) QTcF interval: 480 to <500 msec; (5) QTcF interval >=500 msec; (6) PR interval percent increase from baseline >=25/50 percent; (7) QRS complex percent increase from baseline >=25/50 percent; (8) QTcF interval increase from baseline: 30 to <60 msec; (9) QTcF interval increase from baseline >=60 msec. (NCT02114203)
Timeframe: Baseline up to 30 days post last dose on Day 29
| Intervention | participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Maximum PR interval >=300 msec | Maximum QRS complex >=200 msec | Maximum QTcF interval: 450 to <480 msec | Maximum QTcF interval: 480 to <500 msec | Maximum QTcF interval: >=500 msec | PR interval increase >=25/50 percent | QRS complex increase >=25/50 percent | QTcF interval increase: 30 to <60 msec | QTcF interval increase >=60 msec | |
| PF-04447943 25 mg BID | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 1 | 0 |
| PF-04447943 5 mg BID | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Placebo | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 0 |
Number of participants with changes from baseline in vital signs meeting the following criteria is presented: (1) maximum increase from baseline in supine systolic blood pressure (SBP) >=30 millimeters of mercury (mmHg); (2) maximum increase from baseline in supine diastolic blood pressure (DBP) >=20 mmHg; (3) maximum decrease from baseline in supine SBP >=30 mmHg; and (4) maximum decrease from baseline in supine DBP >=20 mmHg. (NCT02114203)
Timeframe: Baseline up to 30 days post last dose on Day 29
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Maximum increase in supine SBP >=30 mmHg | Maximum increase in supine DBP >=20 mmHg | Maximum decrease in supine SBP >=30 mmHg | Maximum decrease in supine DBP >=20 mmHg | |
| PF-04447943 25 mg BID | 0 | 0 | 1 | 0 |
| PF-04447943 5 mg BID | 0 | 2 | 0 | 2 |
| Placebo | 0 | 1 | 0 | 1 |
An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product or medical device, regardless of its causal relationship with study treatment. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; was life-threatening (immediate risk of death); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs are events between first dose of study drug and up to follow-up visit (30 days post last dose on Day 29) that were absent before treatment or that worsened after treatment. AEs included both serious and non-serious AEs. (NCT02114203)
Timeframe: Day 1 to 30 days post last dose on Day 29
| Intervention | participants (Number) | ||
|---|---|---|---|
| AEs | SAEs | Withdrawal due to TEAEs | |
| PF-04447943 25 mg BID | 13 | 1 | 1 |
| PF-04447943 5 mg BID | 7 | 2 | 0 |
| Placebo | 7 | 0 | 0 |
Number of Vaso-Occlusive Crisis (VOC) events averaged per year. (NCT03036813)
Timeframe: Baseline to Week 72
| Intervention | Events per year (Mean) |
|---|---|
| Voxelotor 900 mg | 2.4 |
| Voxelotor 1500 mg | 2.4 |
| Placebo | 2.8 |
Number of participants with increase in Hb >1 g/dL from Baseline to Week 24 (NCT03036813)
Timeframe: Baseline to Week 24
| Intervention | Participants (Count of Participants) |
|---|---|
| Voxelotor 900 mg | 30 |
| Voxelotor 1500 mg | 46 |
| Placebo | 6 |
Percentage change from Baseline to week 24 in Lactate Dehydrogenase (LDH) (NCT03036813)
Timeframe: Baseline to Week 24
| Intervention | Percentage Change (Least Squares Mean) |
|---|---|
| Voxelotor 900 mg | 1.6 |
| Voxelotor 1500 mg | -4.6 |
| Placebo | 3.0 |
Percentage change from Baseline to week 24 in reticulocytes % which is a % of total Red Blood Cells (RBCs). (NCT03036813)
Timeframe: Baseline to Week 24
| Intervention | Percentage Change (Least Squares Mean) |
|---|---|
| Voxelotor 900 mg | -1.4 |
| Voxelotor 1500 mg | -18.0 |
| Placebo | 6.8 |
Percentage change from Baseline to week 24 in the absolute reticulocyte which is used to estimate the degree of effective erythropoiesis. This values is important in Sickle Cell Disease and was reported by the central laboratory. (NCT03036813)
Timeframe: Baseline to Week 24
| Intervention | percentage change (Least Squares Mean) |
|---|---|
| Voxelotor 900 mg | 4.7 |
| Voxelotor 1500 mg | -6.4 |
| Placebo | 4.7 |
Percentage change from Baseline to week 24 in unconjugated bilirubin (NCT03036813)
Timeframe: Baseline to Week 24
| Intervention | percentage change (Least Squares Mean) |
|---|---|
| Voxelotor 900 mg | -20.1 |
| Voxelotor 1500 mg | -29.1 |
| Placebo | -2.8 |
The Barthel Index is a measure of activities of daily living (ADL) and assesses the degree of disability in a particular participant. The index records indicators of independence in terms of the disability caused by impairments, such as those that may be sequelae of stroke. The index was used as a record of what the participant did, not as a record of what the participant could do. Barthel scores range from 0 to 100, with higher scores indicating greater independence in daily living activities (caring for oneself). (NCT00122980)
Timeframe: Baseline and study exit after up to 30-month treatment period (due to study termination)
| Intervention | units on a scale (Mean) |
|---|---|
| Hydroxyurea/Phlebotomy | -0.33 |
| Transfusion/Chelation | -0.53 |
(NCT00122980)
Timeframe: Baseline to end of study participation (up to 136 weeks)
| Intervention | cm (Mean) |
|---|---|
| Hydroxyurea/Phlebotomy | 4.40 |
| Transfusion/Chelation | 6.61 |
(NCT00122980)
Timeframe: baseline to end of study participation (up to 136 weeks)
| Intervention | kg (Mean) |
|---|---|
| Hydroxyurea/Phlebotomy | 3.83 |
| Transfusion/Chelation | 6.36 |
LIC change-from-baseline is the second component of the composite primary endpoint. LIC was measured by quantitative liver biopsy at baseline and at 30 months or exit from the study.LIC values were transformed into Log10 values prior to computing the change from baseline. (NCT00122980)
Timeframe: Because the study was terminated early, time frame is from beginning of treatment until end of treatment (up to 30 Months)
| Intervention | mg ferritin/gram dry weight liver (Log Mean) |
|---|---|
| Hydroxyurea/Phlebotomy | -0.006 |
| Transfusion/Chelation | -0.120 |
This test is designed to assess both broad and narrow cognitive abilities in children age 4 years and above as well as to measure major aspects of academic achievement in persons aged 2-90 years. Higher scores mean better abilities/achievements. Scaled scores range from 0-100. (NCT00122980)
Timeframe: Baseline and study exit after up to 30-month treatment period (due to study termination)
| Intervention | units on a scale (Mean) |
|---|---|
| Hydroxyurea/Phlebotomy | 1.829 |
| Transfusion/Chelation | -2.487 |
Secondary stroke is the first component of the composite primary endpoint and considers the number of participants with recurrent secondary stroke events during 30 months of treatment. Stroke was defined as any clinical event with brain injury due to vascular disease. All neurological events underwent formal stroke adjudication. (NCT00122980)
Timeframe: Because the study was terminated early, time frame is from beginning of treatment until end of treatment (up to 30 Months)
| Intervention | participants (Number) | |
|---|---|---|
| Stroke | No Stroke | |
| Hydroxyurea/Phlebotomy | 7 | 60 |
| Transfusion/Chelation | 0 | 66 |
The PedsQLTM Measurement Model is a modular approach to measuring health-related quality of life (HRQOL) in healthy children and adolescents and those with acute and chronic health conditions. It has a Likert 5-points scale (never to almost always) which were transformed to a 0 to 100 scale based on the PedsQL scoring algorithms, higher scores indicating better quality of life characteristics. (NCT00122980)
Timeframe: Baseline, midpoint (week 64), and study exit (up to 30 months of treatment)
| Intervention | units on a scale (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Midpoint: Emotional Functioning Score (n=47, 57) | Exit: Emotional Functioning Score (n=55, 54) | Midpoint: Physical Functioning Score (n=47, 57) | Exit: Physical Functioning Score (n=55, 54) | Midpoint: School Functioning Score (n=47, 57) | Exit: School Functioning Score (n=55, 53) | Midpoint: Social Functioning Score (n=46, 57) | Exit: Social Functioning Score (n=54, 54) | Midpoint: Total Functioning Score (n=47, 57) | Exit: Total Functioning Score (n=55, 54) | Midpoint: Psychosocial Health Summary (n=47, 57) | Exit: Psychosocial Health Summary Score (n=57, 54) | |
| Hydroxyurea/Phlebotomy | 1.06 | 3.82 | 0.46 | 3.41 | -1.03 | 1.76 | 2.39 | 3.13 | 0.35 | 2.90 | 0.28 | 2.65 |
| Transfusion/Chelation | 3.51 | 3.80 | 3.18 | 2.03 | 4.56 | 2.74 | 1.84 | 2.87 | 3.26 | 2.62 | 3.30 | 2.93 |
The PedsQL(TM) Measurement Model is a modular approach to measuring health-related quality of life (HRQOL) in healthy children and adolescents and those with acute and chronic health conditions. It has a Likert 5-points scale (never to almost always) which were transformed to a 0 to 100 scale based on the PedsQL scoring algorithms, higher scores indicating better quality of life characteristics. (NCT00122980)
Timeframe: Baseline, mid-point (week 64), and study exit after up to 30-month treatment period (due to study termination)
| Intervention | units on a scale (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mid-point: Emotional Functioning Score (n=43,54) | Exit: Emotional Functioning Score (n=52, 54) | Mid-point: Physical Functioning Score (n=43,64) | Exit: Physical Functioning Score (n=53, 54) | Mid-point: School Functioning (n=43, 54) | Exit: School Functioning (n=51,53) | Mid-point : Social Functioning Score (n=42, 54) | Exit : Social Functioning Score (n=53, 54) | Mid-point: Total Functioning Score (n=43, 54) | Exit: Total Functioning Score (n=53, 54) | Mid-point: Psychosocial Health Summary (n=43,54) | Exit: Psychosocial Health Summary (n=53, 54) | |
| Hydroxyurea/Phlebotomy | -0.99 | -1.25 | -1.71 | 2.27 | 3.14 | -0.29 | 3.69 | 2.67 | 0.39 | 1.13 | 1.61 | 0.33 |
| Transfusion/Chelation | 5.56 | 5.65 | -0.57 | -0.98 | -3.34 | 2.83 | -0.35 | -1.11 | 0.20 | 1.09 | 0.59 | 2.11 |
This test is designed to assess both broad and narrow cognitive abilities in children age 4 years and above as well as to measure major aspects of academic achievement in persons aged 2-90 years. Scaled scores range from 0-100. Higher scores mean better abilities/achievements. (NCT00122980)
Timeframe: Baseline and study exit after up to 30-month treatment period (due to study termination)
| Intervention | units on a scale (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| General intellectual ability (n=33, 35) | Processing speed (n=35, 33) | Working memory (n=33, 34) | Broad attention (n=31, 33) | Executive processes (n=32, 33) | Broad reading (n=34, 33) | Broad math (n=34, 33) | |
| Hydroxyurea/Phlebotomy | -1.64 | -0.80 | -7.67 | -4.36 | -0.72 | -0.29 | -3.53 |
| Transfusion/Chelation | -3.00 | 2.06 | -2.65 | -0.49 | -1.15 | -0.94 | -5.76 |
DTPA GFR was originally a co-primary efficacy outcome for the study. Later in May 29, 2009, this measurement was discontinued because of statistical futility (an extremely small chance that the difference between treatment groups would be statistically significant for this outcome) and the small risk posed by the radiation exposure involved with performing the DTPA GFR test. Subjects who had missing data at baseline or 2 years measurement were excluded from the analysis (29 subjects from the hydroxurea, and 31 subjects from the placebo group excluded). (NCT00006400)
Timeframe: Before initiation of treatment and at 2 years
| Intervention | mL/min/1.73m^2 (Mean) |
|---|---|
| Hydroxyurea | 22.56 |
| Placebo | 20.74 |
GFR was calculated using new Schwartz formula: 39.1× [height (cm)/serum creatinine (mg/dL)]0.516 × [1.8/cystatin C]0.294 × [30/blood urea nitrogen]0.169 × [1.099]if male × [height(m)/1.4]0.188. Children with missing baseline or 2 years GFR were excluded from the analysis. (NCT00006400)
Timeframe: Before initiation of treatment and at 2 years
| Intervention | mL/min/1.73m^2 (Mean) |
|---|---|
| Hydroxyurea | 10.57 |
| Placebo | 14.33 |
Schwartz formula used to calculate GFR is: 0.55× height (cm)/serum creatinine (mg/dL). Where height is in cm and serum creatinine is in mg/dL. Children with missing baseline or 2 years GFR were excluded from the analysis. (NCT00006400)
Timeframe: Before initiation of treatment and at 2 years
| Intervention | mL/min/1.73m^2 (Mean) |
|---|---|
| Hydroxyurea | 28.65 |
| Placebo | 33.36 |
The Borg Dyspnea Index (BDI) is a 0 to 10 rated self reported numerical score used to measure dyspnea during submaximal exercise and will be administered immediately following the 6MWT. The higher the score, the more dyspnea. (NCT02651272)
Timeframe: Baseline, 16 weeks
| Intervention | score on a scale (Number) |
|---|---|
| Macitentan | 6 |
The 6 minute walk test (6MWT) assesses distance walked over 6 minutes (6MWD) as a sub-maximal test of aerobic capacity/endurance. Participants will walk at their normal pace for 6 minutes. (NCT02651272)
Timeframe: Baseline, 16 weeks
| Intervention | meters (Number) |
|---|---|
| Macitentan | -89 |
Cardiac index (CI) will be measured in L/min/m^2. The normal range for CI is 2.5 to 4 L/min/m^2. (NCT02651272)
Timeframe: Baseline to Week 16
| Intervention | L/min/m^2 (Number) |
|---|---|
| Macitentan | .23 |
Cardiac output (CO) will be measured in L/min/m^2. The normal range for CO is 4 to 8 L/min/m^2. (NCT02651272)
Timeframe: Baseline, Week 16
| Intervention | L/min/m^2 (Number) |
|---|---|
| Macitentan | .29 |
PADP will be assessed by right heart catheterization. Normal range is 8-15 mmHg. (NCT02651272)
Timeframe: Baseline, 16 weeks
| Intervention | mmHg (Number) |
|---|---|
| Macitentan | -5 |
The normal range for NT-pro-BNP is less than 300 picograms of BNP per milliliter (pg/ml) of blood; higher levels are less favorable. (NCT02651272)
Timeframe: Baseline, 16 weeks
| Intervention | pg/mL (Number) |
|---|---|
| Macitentan | 10528 |
RAP will be assessed by right heart catheterization. Normal range is 2-6 mmHg. (NCT02651272)
Timeframe: Baseline, 16 weeks
| Intervention | mmHg (Number) |
|---|---|
| Macitentan | -5 |
Systemic vascular resistance (SVR) will be assessed with this formula Systemic Vascular Resistance (SVR) = 80x(Mean Arterial Pressure - Mean Venous Pressure or CVP) / Cardiac Output. Normal range is 800 - 1200 dynes-sec/cm-5. (NCT02651272)
Timeframe: Baseline, Week 16
| Intervention | dynes-sec/cm-5. (Number) |
|---|---|
| Macitentan | -528 |
SPAP will be assessed by right heart catheterization. Normal range is 15-25 mm Hg. (NCT02651272)
Timeframe: Baseline, 16 weeks
| Intervention | mmHg (Number) |
|---|---|
| Macitentan | 7 |
RVSP will be assessed by right heart catheterization. Normal range is 15-25 mmHg. (NCT02651272)
Timeframe: Baseline, 16 weeks
| Intervention | mmHg (Number) |
|---|---|
| Macitentan | 3 |
The occurrence of treatment emergent AEs includes having any of the following: vaso-occlusive crises requiring hospitalization; acute congestive heart failure; hypotension (defined as a mean arterial pressure less than 60mmHg); decrease in hemoglobin concentration by greater than 1 g/dL. (NCT02651272)
Timeframe: 20 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Macitentan | 0 |
"The WHO functional classification will be assessed and documented with the WHO Class.~Class I Patients with pulmonary hypertension (PH) but without resulting limitation of physical activity. Ordinary physical activity does not cause undue dyspnea or fatigue, chest pain or near syncope.~Class II Patients with PH resulting in a slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity causes undue dyspnea or fatigue, chest pain or near syncope.~Class III Patients with PH resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes undue dyspnea or fatigue, chest pain or near syncope.~Class IV Patients with PH with inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnea and/or fatigue may even be present at rest. Discomfort is increased by any physical activity.~The Class is inversely related to function." (NCT02651272)
Timeframe: 16 weeks
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Class 1 | Class 2 | Class 3 | Class 4 | |
| Macitentan | 0 | 0 | 1 | 0 |
This secondary objective will compare standard to alternative therapy for hepatic iron overload. (NCT01425307)
Timeframe: Baseline and 24 months
| Intervention | mg FE per g dry weight liver (Mean) |
|---|---|
| Standard Therapy | 2.4 |
| Treatment Arm | -1.9 |
This secondary objective will compare standard to alternative therapy for hepatic iron overload. (NCT01425307)
Timeframe: Baseline and 24 months
| Intervention | ng per mL (Mean) |
|---|---|
| Standard Therapy | -38 |
| Treatment Arm | -1805 |
The primary endpoint for the TWiTCH trial was the difference between the treatment groups of the maximum TCD TAMV on the index side, calculated from a mixed model. The index side is the side with the higher mean (averaged over baseline evaluations) of the maximum (over arteries on that side) TCD time-averaged velocity. Values of the TAMV on the index site were obtained at clinic visits during baseline and during the treatment period. (NCT01425307)
Timeframe: Since the study was terminated early, time frame is from beginning of treatment until end of treatment (up to 24 Months).
| Intervention | cm/sec (Mean) |
|---|---|
| Treatment Arm | 138 |
| Standard Therapy | 143 |
Level of C-reactive protein (CRP) in mg/dL. (NCT04435184)
Timeframe: Day 14 after randomization
| Intervention | mg/dL (Median) |
|---|---|
| Crizanlizumab | 2.5 |
| Placebo Saline | 1.3 |
Level of C-reactive protein (CRP) in mg/dL. (NCT04435184)
Timeframe: Day 3 after randomization
| Intervention | mg/dL (Median) |
|---|---|
| Crizanlizumab | 4.4 |
| Placebo Saline | 4.5 |
Level of C-reactive protein (CRP) in mg/dL. (NCT04435184)
Timeframe: Day 7 after randomization
| Intervention | mg/dL (Median) |
|---|---|
| Crizanlizumab | 2.4 |
| Placebo Saline | 2.1 |
Level of D-dimer in mg/L. (NCT04435184)
Timeframe: Day 14 after randomization
| Intervention | mg/L (Median) |
|---|---|
| Crizanlizumab | 1.5 |
| Placebo Saline | 0.7 |
Level of D-dimer in mg/L. (NCT04435184)
Timeframe: Day 3 after randomization
| Intervention | mg/L (Median) |
|---|---|
| Crizanlizumab | 1.6 |
| Placebo Saline | 0.7 |
Level of D-dimer in mg/L. (NCT04435184)
Timeframe: Day 7 after randomization
| Intervention | mg/L (Median) |
|---|---|
| Crizanlizumab | 1.6 |
| Placebo Saline | 0.7 |
Safety of crizanlizumab will by assessed by adverse events, serious adverse events, and suspected unexpected serious adverse reactions. (NCT04435184)
Timeframe: Up to day 14 after randomization
| Intervention | total adverse events (Number) |
|---|---|
| Crizanlizumab | 7 |
| Placebo Saline | 6 |
Level of soluble P-selectin in ng/mL. (NCT04435184)
Timeframe: Day 14 after randomization
| Intervention | ng/mL (Mean) |
|---|---|
| Crizanlizumab | 12 |
| Placebo Saline | 48 |
Level of soluble P-selectin in ng/mL. (NCT04435184)
Timeframe: Day 3 after randomization or day of hospital discharge, whichever is earlier
| Intervention | ng/mL (Mean) |
|---|---|
| Crizanlizumab | 7 |
| Placebo Saline | 39 |
Level of soluble P-selectin in ng/mL. (NCT04435184)
Timeframe: Day 7 after randomization
| Intervention | ng/mL (Mean) |
|---|---|
| Crizanlizumab | 10 |
| Placebo Saline | 48 |
Time (days) to hospital discharge (NCT04435184)
Timeframe: Up to 30 days after randomization
| Intervention | days (Mean) |
|---|---|
| Crizanlizumab | 8.1 |
| Placebo Saline | 6.2 |
Level of von Willebrand Factor (VWF) antigen in IU/mL. (NCT04435184)
Timeframe: Day 3 after randomization
| Intervention | IU/mL (Median) |
|---|---|
| Crizanlizumab | 2.9 |
| Placebo Saline | 2.8 |
Level of VWF antigen in IU/mL. (NCT04435184)
Timeframe: Day 14 after randomization
| Intervention | IU/mL (Median) |
|---|---|
| Crizanlizumab | 2.7 |
| Placebo Saline | 4.6 |
Level of VWF antigen in IU/mL. (NCT04435184)
Timeframe: Day 7 after randomization
| Intervention | IU/mL (Median) |
|---|---|
| Crizanlizumab | 3.9 |
| Placebo Saline | 3.6 |
"Change in the clinical status over 14 days as measured by an ordinal scale that is the first assessment of the clinical status on a given study day. The scale is as follows:~0 = Uninfected; no viral RNA detected~= Ambulatory; asymptomatic; viral RNA detected~= Ambulatory; symptomatic; independent~= Ambulatory; symptomatic; assistance needed~= Hospitalized; no oxygen therapy~= Hospitalized; oxygen by mask or nasal prongs~= Hospitalized; oxygen by non-invasive ventilation (NIV) or high flow~= Hospitalized; intubation and mechanical ventilation, partial pressure of oxygen / fraction of inspired oxygen (pO2/FIO2) ≥ 150 or oxygen saturation / FIO2 (SpO2/FIO2) ≥ 200~= Hospitalized; intubation and mechanical ventilation, pO2/FIO2 < 150 or SpO2/FIO2 < 200 or vasopressors~= Hospitalized; intubation and mechanical ventilation, pO2/FIO2 < 150 or SpO2/FIO2 < 200 and vasopressors, dialysis, or extracorporeal membrane oxygenation (ECMO)~= Dead" (NCT04435184)
Timeframe: Days 3, 7 and 14 after randomization
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| WHO Clinical Status: Day 372489589 | WHO Clinical Status: Day 372489590 | WHO Clinical Status: Day 772489590 | WHO Clinical Status: Day 772489589 | WHO Clinical Status: Day 1472489589 | WHO Clinical Status: Day 1472489590 | |||||||||||||||||||||||||||||||||||||||||||
| 10 | 4 | 5 | 6 | 7 | 8 | 9 | ||||||||||||||||||||||||||||||||||||||||||
| Placebo Saline | 2 | |||||||||||||||||||||||||||||||||||||||||||||||
| Crizanlizumab | 3 | |||||||||||||||||||||||||||||||||||||||||||||||
| Crizanlizumab | 13 | |||||||||||||||||||||||||||||||||||||||||||||||
| Placebo Saline | 7 | |||||||||||||||||||||||||||||||||||||||||||||||
| Placebo Saline | 4 | |||||||||||||||||||||||||||||||||||||||||||||||
| Crizanlizumab | 9 | |||||||||||||||||||||||||||||||||||||||||||||||
| Placebo Saline | 13 | |||||||||||||||||||||||||||||||||||||||||||||||
| Crizanlizumab | 5 | |||||||||||||||||||||||||||||||||||||||||||||||
| Crizanlizumab | 6 | |||||||||||||||||||||||||||||||||||||||||||||||
| Placebo Saline | 3 | |||||||||||||||||||||||||||||||||||||||||||||||
| Crizanlizumab | 1 | |||||||||||||||||||||||||||||||||||||||||||||||
| Crizanlizumab | 0 | |||||||||||||||||||||||||||||||||||||||||||||||
| Crizanlizumab | 21 | |||||||||||||||||||||||||||||||||||||||||||||||
| Placebo Saline | 19 | |||||||||||||||||||||||||||||||||||||||||||||||
| Placebo Saline | 1 | |||||||||||||||||||||||||||||||||||||||||||||||
| Placebo Saline | 0 | |||||||||||||||||||||||||||||||||||||||||||||||
Acute Chest Syndrome (ACS) is defined on the basis of the finding of a new pulmonary infiltrate involving at least one complete lung segment that was consistent with alveolar consolidation, but excluding atelectasis (as indicated by chest X-ray). At least one of the following additional signs or symptoms needs to be present as well: a participant had to have reported chest pain, a temperature of more than 38.5oC, tachypnea, wheezing or cough. (NCT01895361)
Timeframe: One year
| Intervention | accute chest syndrome per year (Median) |
|---|---|
| High-dose SelG1 (Selg1 5.0 mg/kg) | 0.00 |
| Low-dose SelG1 (Selg1 2.5 mg/kg) | 0.00 |
| Placebo | 0.00 |
The annual rate of days hospitalized was calculated as the number of days hospitalized multiplied by 365 divided by the end date minus the date of randomization plus one where the end date is defined as the last dose date plus 14 days (for subjects never dosed, the end date equaled the end of study date, which was the last site contact for these patients). (NCT01895361)
Timeframe: One year
| Intervention | Days hospitalized per year (Median) |
|---|---|
| High-dose SelG1 (Selg1 5.0 mg/kg) | 4.00 |
| Low-dose SelG1 (Selg1 2.5 mg/kg) | 6.87 |
| Placebo | 6.87 |
An SCPC is defined as an acute episode of pain with no other medically determined cause than a vasoocclusive event that requires a medical facility visit and treatment with oral or parenteral narcotics, or parenteral non-steroidal anti-inflammatory drugs. The annual rate of SCPC is defined as the total number of pain crises for a patient occurring from the date of randomization to the end date multiplied by 365 divided by the number of days during that same time period. End date is defined as the last dose date plus 14 days. For participants never dosed, the end date was the end of study date. This calculation accounts for early dropouts or lost to follow-up by extrapolating the SCPC rate of every participant to one year. (NCT01895361)
Timeframe: One year
| Intervention | SCPC per year (Median) |
|---|---|
| High-dose SelG1 (Selg1 5.0 mg/kg) | 1.63 |
| Low-dose SelG1 (Selg1 2.5 mg/kg) | 2.01 |
| Placebo | 2.98 |
An SCPC is defined as an acute episode of pain with no other medically determined cause than a vasoocclusive event that requires a medical facility visit and treatment with oral or parenteral narcotics, or parenteral non-steroidal anti-inflammatory drugs. The annual rate of SCPC is defined as the total number of pain crises for a patient occurring from the date of randomization to the end date multiplied by 365 divided by the number of days during that same time period. End date is defined as the last dose date plus 14 days. For participants never dosed, the end date was the end of study date. This calculation accounts for early dropouts or lost to follow-up by extrapolating the SCPC rate of every participant to one year. (NCT01895361)
Timeframe: One year
| Intervention | SCPC per year (Median) |
|---|---|
| High-dose SelG1 (Selg1 5.0 mg/kg) | 1.63 |
| Low-dose SelG1 (Selg1 2.5 mg/kg) | 2.01 |
| Placebo | 2.98 |
Uncomplicated SCPC is defined as an acute episode of pain with no known cause for pain other than a vasoocclusive event; requiring a visit to a medical facility; and requiring treatment with a parenteral or oral narcotic (including opiates), or parenteral NSAIDs; but is NOT classified as an acute chest syndrome, hepatic sequestration, splenic sequestration or priapism. (NCT01895361)
Timeframe: Up to one year
| Intervention | Uncomplicated SCPC per year (Median) |
|---|---|
| High-dose SelG1 (Selg1 5.0 mg/kg) | 1.08 |
| Low-dose SelG1 (Selg1 2.5 mg/kg) | 2.00 |
| Placebo | 2.91 |
Time to first SCPC is defined as months from randomization to first SCPC. A participant without SCPC before withdrawal or completion of the study is considered censored at the time of the end date. End date is defined as the last dose plus 14 days. For participants never dosed, the end date is the end of study date. (NCT01895361)
Timeframe: Up to one year
| Intervention | months (Median) |
|---|---|
| High-dose SelG1 (Selg1 5.0 mg/kg) | 4.07 |
| Low-dose SelG1 (Selg1 2.5 mg/kg) | 2.20 |
| Placebo | 1.38 |
Time to second SCPC is defined as months from randomization to second SCPC. A patient with less than two SCPC before withdrawal or completion of the study is considered censored at the time of the end date. End date is defined as the last dose plus 14 days. For patients never dosed, the end date is the end of study date. (NCT01895361)
Timeframe: Up to one year
| Intervention | months (Median) |
|---|---|
| High-dose SelG1 (Selg1 5.0 mg/kg) | 10.32 |
| Low-dose SelG1 (Selg1 2.5 mg/kg) | 9.20 |
| Placebo | 5.09 |
The BPI instrument was completed by the patients at pre-specified study visits prior to & during the Treatment & Follow-Up Evaluation Phases. Patients completed the brief pain inventory long-form, 1-week recall at the indicated pre-specified study visits. The BPI is a standardized self-reported questionnaire developed to provide information on the intensity of pain (the sensory dimension) as well as the degree to which pain interferes with function (the reactive dimension). The BPI also asks questions about pain relief, pain quality, & the patient's perception of the cause of pain. Since pain can be quite variable over a day, the BPI asks patients to rate their pain at the time of responding to the questionnaire (pain now), & also at its worst, least, & average over the previous week. The scorings for pain & interference have a range from 0 (no pain/no interference) to 10 (worst pain/complete interference). The BPI scoring manual was used to calculate scores for each domain. (NCT01895361)
Timeframe: Baseline, Day 15, Week 14, Week 26, Week 38, Week 52, and Week 58, up to 58 weeks
| Intervention | score on a scale (Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pain Severity: Baseline (BL) (n=48,49,55) | Pain Severity: CFB to Day 15 (n=38,42,47) | Pain Severity: CFB to Week (Wk) 14 (n=32,33,33) | Pain Severity: CFB to Week 26 (n=27,31,32) | Pain Severity: CFB to Week 38 (n=25,29,29) | Pain Severity: CFB to Week 52 (n=18,23,22) | Pain Severity: CFB to Wk 58 follow up (n=27,33,30) | Pain Interference: BL (n=48,49,55) | Pain Interence: CFB to Day 15 (n=38,42,47) | Pain Interence: CFB to Wk 14 (n=32,33,33) | Pain Interference: CFB to Wk 26 (n=27,32,32) | Pain Interference: CFB to Wk 38 (n=25,29,29) | Pain Interference: CFB to Wk 52 (n=18,23,22) | Pain Interference: CFB to Wk 58 f/up (n=27,33,30) | |
| High-dose SelG1 (Selg1 5.0 mg/kg) | 4.363 | -0.123 | -0.146 | -0.377 | -0.267 | -0.634 | -0.145 | 4.643 | -0.674 | -0.213 | -0.583 | -0.866 | -1.014 | -0.476 |
| Low-dose SelG1 (Selg1 2.5 mg/kg) | 4.531 | 0.073 | -0.068 | -0.290 | 0.026 | 0.130 | 0.091 | 4.656 | -0.099 | -0.534 | -0.728 | -0.119 | -0.174 | -0.386 |
| Placebo | 4.129 | 0.355 | -0.152 | -0.563 | 0.333 | -0.310 | -0.444 | 4.995 | -0.816 | -0.039 | -0.821 | -0.221 | -0.819 | -0.802 |
The primary end point was the recurrence of infarct or hemorrhage as determined by neuroimaging, clinical evidence of permanent neurologic injury, or both. A new infarct had to meet the criteria for a silent cerebral infarction; an enlarged silent cerebral infarct was defined as a previously identified silent cerebral infarct that increased by at least 3 mm along any linear dimension in any plane on MRI. (NCT00072761)
Timeframe: From study entry to study exit
| Intervention | infarct recurrence per 100 person years (Number) |
|---|---|
| Transfusion Group | 2.0 |
| Observation Group | 4.8 |
First occurence of positive infiltrate on chest x-ray (NCT00951808)
Timeframe: Chest x-rays (CXR) were ordered for trial eligibility, as a result of clinical indications, or at discharge or 72 hours if no prior CXR.
| Intervention | participants (Number) | |
|---|---|---|
| Yes | No | |
| Adults | 11 | 85 |
| Children | 11 | 96 |
| Overall | 22 | 181 |
"Ten likert-type questions assessing user-friendliness of technology. Each question has five answer options that range from Strongly Agree to Strongly Disagree. Scores range from 0-100. A score of 68 or above is considered above average. All scores averaged." (NCT03291613)
Timeframe: After 1-hour usability session
| Intervention | units on a scale (Mean) |
|---|---|
| Pinpoint App | 86.67 |
We will evaluate the number of participants consented and fully screened that were randomized to hydroxyurea or placebo. (NCT01389024)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Participants Completing Screening Procedures | 12 |
A composite of abnormally elevated cerebral blood flow velocity as measured by transcranial Doppler ultrasound, silent cerebral infarct, or stroke. (NCT01389024)
Timeframe: 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Hydroxyurea | 1 |
| Placebo | 4 |
Number of sedated MRIs resulting in serious adverse events. Participants can have multiple MRIs performed. (NCT01389024)
Timeframe: 3 years
| Intervention | MRIs (Count of Units) |
|---|---|
| MRIs With Sedation. | 3 |
Number of MRIs resulting in serious adverse events. Participants can have multiple MRIs performed. (NCT01389024)
Timeframe: 3 years
| Intervention | MRIs (Count of Units) |
|---|---|
| Participants Undergoing MRIs | 3 |
(NCT00467610)
Timeframe: At 8 weeks from start of therapy
| Intervention | participants (Number) |
|---|---|
| Group 1 | 1 |
"Hematological improvement (HI)~Major:~HI-Erythroid:>2 g/dL rise in hemoglobin, or transfusion independence HI-Neutrophil: Absolute increase of >500/mm3, or >100% increase HI-Platelet: Absolute increase of >30,000, or transfusion independence~Minor:~HI-Erythroid:1 to 2 g/dL increase in hemoglobin or 50% decrease in transfusion dependence.~HI-P: For patients with pretreatment platelet count < 100,000/mm3, ≥ 50% increase with a net increase > 10,000/mm3 but < 30,000/mm3.~HI-N: For patients with pretreatment ANC < 1500/mm3, ≥ 100% increase, but < 500/mm3 increase." (NCT00467610)
Timeframe: 4 weeks after initiation of treatment with Panhematin
| Intervention | participants (Number) |
|---|---|
| Group 1 | 0 |
"Complete response(CR): <5% blasts in the bone marrow,with normal maturation of all cell lines, Hemoglobin >11 g/dL, neutrophils>1500/mm3 platelets>100,000/mm3.~Partial response (PR): >50% decrease in blasts, or less advanced IPSS than pretreatment value, same hematological parameters as in CR.~Stable disease (SD): No evidence of disease progression in bone marrow, stable peripheral blood counts failure: Increase in bone marrow blast percentage, progression to more advanced IPSS than pretreatment and worsening of cytopenias.~(Cheson, 2000)" (NCT00467610)
Timeframe: After 8 weeks of therapy with panhematin
| Intervention | Participants (Number) |
|---|---|
| Group 1 | 0 |
Number of patients with no adverse events. (NCT00467610)
Timeframe: participants were followed during therapy with panhematin, and up to six months post completion of therapy, average of 8 months.
| Intervention | participants (Number) |
|---|---|
| Group 1 | 6 |
277 reviews available for hydroxyurea and HbS Disease
| Article | Year |
|---|---|
The Effects of Treatment with Blood Transfusion, Iron Chelation and Hydroxyurea on Puberty, Growth and Spermatogenesis in Sickle Cell Disease (SCD): A short update.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Humans; Hydroxyurea; Iron C | 2021 |
How I approach disease-modifying therapy in children with sickle cell disease in an era of novel therapies.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Erythrocyte Transfusion; Humans; Hydrox | 2021 |
The Role of miRNAs as Therapeutic Tools in Sickle Cell Disease.
Topics: Anemia, Sickle Cell; Fetal Hemoglobin; gamma-Globins; Humans; Hydroxyurea; MicroRNAs | 2021 |
Clinical outcomes of COVID-19 in patients with sickle cell disease and sickle cell trait: A critical appraisal of the literature.
Topics: Adult; Anemia, Sickle Cell; Child; COVID-19; Humans; Hydroxyurea; SARS-CoV-2; Sickle Cell Trait | 2022 |
Incorporation of novel therapies for the management of sickle cell disease: A pharmacist's perspective.
Topics: Anemia, Sickle Cell; Humans; Hydroxyurea; Pain; Pharmacists | 2022 |
Health State Utilities for Sickle Cell Disease: A Catalog Prepared From a Systematic Review.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Child; Comorbidity; Cost-Benefit | 2022 |
Advances in the diagnosis and treatment of sickle cell disease.
Topics: Anemia, Sickle Cell; Chronic Pain; Graft vs Host Disease; Hemoglobin, Sickle; Humans; Hydroxyurea | 2022 |
Targeting Genetic Modifiers of HBG Gene Expression in Sickle Cell Disease: The miRNA Option.
Topics: Anemia, Sickle Cell; Fetal Hemoglobin; Gene Expression; Hemoglobinopathies; Humans; Hydroxyurea; Mic | 2022 |
Sickle cell disease in children: an update of the evidence in low- and middle-income settings.
Topics: Anemia, Sickle Cell; Blood Transfusion; Bone Marrow Transplantation; Child; Humans; Hydroxyurea; Inf | 2023 |
Sickle Cell Disease: A Review.
Topics: Adult; Anemia, Sickle Cell; Antibodies, Monoclonal, Humanized; Antisickling Agents; Benzaldehydes; C | 2022 |
Health-Related Quality of Life and Adherence to Hydroxyurea and Other Disease-Modifying Therapies among Individuals with Sickle Cell Disease: A Systematic Review.
Topics: Anemia, Sickle Cell; Humans; Hydroxyurea; Medication Adherence; Pain; Quality of Life | 2022 |
Emerging drugs for the treatment of sickle cell disease: a review of phase II/III trials.
Topics: Anemia, Sickle Cell; Clinical Trials, Phase III as Topic; Humans; Hydroxyurea | 2022 |
Hydroxyurea (hydroxycarbamide) for sickle cell disease.
Topics: Acute Chest Syndrome; Adult; Anemia, Sickle Cell; Antisickling Agents; Child; Hemoglobin, Sickle; Hu | 2022 |
Sickle cell disease in the new era: advances in drug treatment.
Topics: Anemia, Sickle Cell; Fetal Hemoglobin; Glutamine; Hemoglobin, Sickle; Hemoglobins; Humans; Hydroxyur | 2022 |
Stroke in sickle cell disease and the promise of recent disease modifying agents.
Topics: Adult; Anemia, Sickle Cell; Anticoagulants; Aspirin; Cerebral Infarction; Humans; Hydroxyurea; Strok | 2022 |
Sickle cell disease treatment and management in India: a systematic review of interventional studies.
Topics: Anemia, Sickle Cell; Humans; Hydroxyurea; India | 2022 |
The Evolving Landscape of Drug Therapies for Sickle Cell Disease.
Topics: Anemia, Sickle Cell; Genetic Therapy; Glutamine; Hematopoietic Stem Cell Transplantation; Humans; Hy | 2022 |
The Evolving Landscape of Drug Therapies for Sickle Cell Disease.
Topics: Anemia, Sickle Cell; Genetic Therapy; Glutamine; Hematopoietic Stem Cell Transplantation; Humans; Hy | 2022 |
The Evolving Landscape of Drug Therapies for Sickle Cell Disease.
Topics: Anemia, Sickle Cell; Genetic Therapy; Glutamine; Hematopoietic Stem Cell Transplantation; Humans; Hy | 2022 |
The Evolving Landscape of Drug Therapies for Sickle Cell Disease.
Topics: Anemia, Sickle Cell; Genetic Therapy; Glutamine; Hematopoietic Stem Cell Transplantation; Humans; Hy | 2022 |
The Evolving Landscape of Drug Therapies for Sickle Cell Disease.
Topics: Anemia, Sickle Cell; Genetic Therapy; Glutamine; Hematopoietic Stem Cell Transplantation; Humans; Hy | 2022 |
The Evolving Landscape of Drug Therapies for Sickle Cell Disease.
Topics: Anemia, Sickle Cell; Genetic Therapy; Glutamine; Hematopoietic Stem Cell Transplantation; Humans; Hy | 2022 |
The Evolving Landscape of Drug Therapies for Sickle Cell Disease.
Topics: Anemia, Sickle Cell; Genetic Therapy; Glutamine; Hematopoietic Stem Cell Transplantation; Humans; Hy | 2022 |
The Evolving Landscape of Drug Therapies for Sickle Cell Disease.
Topics: Anemia, Sickle Cell; Genetic Therapy; Glutamine; Hematopoietic Stem Cell Transplantation; Humans; Hy | 2022 |
The Evolving Landscape of Drug Therapies for Sickle Cell Disease.
Topics: Anemia, Sickle Cell; Genetic Therapy; Glutamine; Hematopoietic Stem Cell Transplantation; Humans; Hy | 2022 |
Risk of vaso-occlusive episodes in patients with sickle cell disease exposed to systemic corticosteroids: a comprehensive review.
Topics: Acute Chest Syndrome; Anemia, Sickle Cell; Erythrocyte Transfusion; Hospitalization; Humans; Hydroxy | 2022 |
Risk of vaso-occlusive episodes in patients with sickle cell disease exposed to systemic corticosteroids: a comprehensive review.
Topics: Acute Chest Syndrome; Anemia, Sickle Cell; Erythrocyte Transfusion; Hospitalization; Humans; Hydroxy | 2022 |
Risk of vaso-occlusive episodes in patients with sickle cell disease exposed to systemic corticosteroids: a comprehensive review.
Topics: Acute Chest Syndrome; Anemia, Sickle Cell; Erythrocyte Transfusion; Hospitalization; Humans; Hydroxy | 2022 |
Risk of vaso-occlusive episodes in patients with sickle cell disease exposed to systemic corticosteroids: a comprehensive review.
Topics: Acute Chest Syndrome; Anemia, Sickle Cell; Erythrocyte Transfusion; Hospitalization; Humans; Hydroxy | 2022 |
Risk of vaso-occlusive episodes in patients with sickle cell disease exposed to systemic corticosteroids: a comprehensive review.
Topics: Acute Chest Syndrome; Anemia, Sickle Cell; Erythrocyte Transfusion; Hospitalization; Humans; Hydroxy | 2022 |
Risk of vaso-occlusive episodes in patients with sickle cell disease exposed to systemic corticosteroids: a comprehensive review.
Topics: Acute Chest Syndrome; Anemia, Sickle Cell; Erythrocyte Transfusion; Hospitalization; Humans; Hydroxy | 2022 |
Risk of vaso-occlusive episodes in patients with sickle cell disease exposed to systemic corticosteroids: a comprehensive review.
Topics: Acute Chest Syndrome; Anemia, Sickle Cell; Erythrocyte Transfusion; Hospitalization; Humans; Hydroxy | 2022 |
Risk of vaso-occlusive episodes in patients with sickle cell disease exposed to systemic corticosteroids: a comprehensive review.
Topics: Acute Chest Syndrome; Anemia, Sickle Cell; Erythrocyte Transfusion; Hospitalization; Humans; Hydroxy | 2022 |
Risk of vaso-occlusive episodes in patients with sickle cell disease exposed to systemic corticosteroids: a comprehensive review.
Topics: Acute Chest Syndrome; Anemia, Sickle Cell; Erythrocyte Transfusion; Hospitalization; Humans; Hydroxy | 2022 |
Cutaneous manifestations of sickle cell disease: an updated review.
Topics: Anemia, Sickle Cell; Humans; Hydroxyurea; Leg Ulcer; Psoriasis; Vascular Diseases | 2023 |
Cutaneous manifestations of sickle cell disease: an updated review.
Topics: Anemia, Sickle Cell; Humans; Hydroxyurea; Leg Ulcer; Psoriasis; Vascular Diseases | 2023 |
Cutaneous manifestations of sickle cell disease: an updated review.
Topics: Anemia, Sickle Cell; Humans; Hydroxyurea; Leg Ulcer; Psoriasis; Vascular Diseases | 2023 |
Cutaneous manifestations of sickle cell disease: an updated review.
Topics: Anemia, Sickle Cell; Humans; Hydroxyurea; Leg Ulcer; Psoriasis; Vascular Diseases | 2023 |
Cutaneous manifestations of sickle cell disease: an updated review.
Topics: Anemia, Sickle Cell; Humans; Hydroxyurea; Leg Ulcer; Psoriasis; Vascular Diseases | 2023 |
Cutaneous manifestations of sickle cell disease: an updated review.
Topics: Anemia, Sickle Cell; Humans; Hydroxyurea; Leg Ulcer; Psoriasis; Vascular Diseases | 2023 |
Cutaneous manifestations of sickle cell disease: an updated review.
Topics: Anemia, Sickle Cell; Humans; Hydroxyurea; Leg Ulcer; Psoriasis; Vascular Diseases | 2023 |
Cutaneous manifestations of sickle cell disease: an updated review.
Topics: Anemia, Sickle Cell; Humans; Hydroxyurea; Leg Ulcer; Psoriasis; Vascular Diseases | 2023 |
Cutaneous manifestations of sickle cell disease: an updated review.
Topics: Anemia, Sickle Cell; Humans; Hydroxyurea; Leg Ulcer; Psoriasis; Vascular Diseases | 2023 |
COVID-19 outcomes in sickle cell disease and sickle cell trait.
Topics: Anemia, Sickle Cell; COVID-19; Humans; Hydroxyurea; Risk Factors; Sickle Cell Trait | 2022 |
COVID-19 outcomes in sickle cell disease and sickle cell trait.
Topics: Anemia, Sickle Cell; COVID-19; Humans; Hydroxyurea; Risk Factors; Sickle Cell Trait | 2022 |
COVID-19 outcomes in sickle cell disease and sickle cell trait.
Topics: Anemia, Sickle Cell; COVID-19; Humans; Hydroxyurea; Risk Factors; Sickle Cell Trait | 2022 |
COVID-19 outcomes in sickle cell disease and sickle cell trait.
Topics: Anemia, Sickle Cell; COVID-19; Humans; Hydroxyurea; Risk Factors; Sickle Cell Trait | 2022 |
A systematic review on hydroxyurea therapy for sickle cell disease in India.
Topics: Anemia, Sickle Cell; Antisickling Agents; Cross-Sectional Studies; Humans; Hydroxyurea; Prospective | 2022 |
Emerging drug targets for sickle cell disease: shedding light on new knowledge and advances at the molecular level.
Topics: Adult; Anemia, Sickle Cell; Humans; Hydroxyurea | 2023 |
Scoping Review of Predisposing Factors Associated with Sensorineural Hearing Loss in Sickle Cell Disease.
Topics: Anemia, Sickle Cell; Hearing Loss, Sensorineural; Humans; Hydroxyurea; Pain; Prospective Studies; Re | 2023 |
Hydroxyurea for children with sickle cell disease in sub-Saharan Africa: A summary of the evidence, opportunities, and challenges.
Topics: Africa South of the Sahara; Anemia, Sickle Cell; Child; Humans; Hydroxyurea; Infant; Infant, Newborn | 2023 |
Efficacy and safety of pharmacological interventions for managing sickle cell disease complications in children and adolescents: Systematic review with network meta-analysis.
Topics: Adolescent; Anemia, Sickle Cell; Antibodies, Monoclonal; Antisickling Agents; Child; Humans; Hydroxy | 2023 |
Hydroxyurea treatment for sickle cell anemia during pregnancy and lactation: Current evidence and knowledge gaps.
Topics: Adult; Anemia, Sickle Cell; Animals; Antisickling Agents; Child; Female; Humans; Hydroxyurea; Infant | 2023 |
An integrated therapeutic approach to sickle cell disease management beyond infancy.
Topics: Adult; Anemia, Sickle Cell; Child; Child, Preschool; Fetal Hemoglobin; Hemoglobin, Sickle; Humans; H | 2023 |
Interventions for chronic kidney disease in people with sickle cell disease.
Topics: Acute Chest Syndrome; Adolescent; Adult; Anemia, Sickle Cell; Angiotensin-Converting Enzyme Inhibito | 2023 |
Molecular and environmental contributors to neurological complications in sickle cell disease.
Topics: Anemia, Sickle Cell; Blood Transfusion; Cognitive Dysfunction; Humans; Hydroxyurea; Stroke | 2023 |
Provider prescription of hydroxyurea in youth and adults with sickle cell disease: A review of prescription barriers and facilitators.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Humans; Hydroxyurea; Prescriptions | 2023 |
The evolving treatment landscape for children with sickle cell disease.
Topics: Anemia, Sickle Cell; Child; Genetic Therapy; Hematopoietic Stem Cell Transplantation; Humans; Hydrox | 2023 |
Targeting sickle cell disease root-cause pathophysiology with small molecules.
Topics: Anemia, Sickle Cell; Antisickling Agents; DNA Methylation; Drug Design; Epigenesis, Genetic; Fetal H | 2019 |
Emerging disease-modifying therapies for sickle cell disease.
Topics: Anemia, Sickle Cell; Antioxidants; Antisickling Agents; Blood Coagulation; Clinical Trials as Topic; | 2019 |
Current and emerging treatments for sickle cell disease.
Topics: Acute Chest Syndrome; Acute Disease; Analgesics, Opioid; Anemia, Sickle Cell; Anti-Bacterial Agents; | 2019 |
Magnesium for treating sickle cell disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Female; Humans | 2019 |
Osteonecrosis in sickle cell disease: an update on risk factors, diagnosis, and management.
Topics: Adolescent; Anemia, Sickle Cell; Child; Female; Humans; Hydroxyurea; Middle Aged; Osteonecrosis; Pre | 2019 |
Emerging drugs in randomized controlled trials for sickle cell disease: are we on the brink of a new era in research and treatment?
Topics: Anemia, Sickle Cell; Animals; beta-Globins; Drug Development; Humans; Hydroxyurea; Mutation; Quality | 2020 |
The role of hydroxyurea to prevent silent stroke in sickle cell disease: Systematic review and meta-analysis.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Humans; Hydroxyurea; Stroke | 2019 |
Sickle Cell Disease: A Primer for Primary Care Providers.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Humans; Hydroxyurea; Primary Health Care | 2020 |
Pathophysiology and recent therapeutic insights of sickle cell disease.
Topics: Anemia, Sickle Cell; Erythrocytes, Abnormal; Fetal Hemoglobin; Humans; Hydroxyurea; Intermediate-Con | 2020 |
What is the place of hematopoietic stem cell transplantation in the management of cerebral vasculopathy in children with sickle cell anemia?
Topics: Allografts; Anemia, Sickle Cell; Cerebrovascular Disorders; Child; Hematopoietic Stem Cell Transplan | 2020 |
Effective use of hydroxyurea for sickle cell anemia in low-resource countries.
Topics: Africa South of the Sahara; Anemia, Sickle Cell; Caribbean Region; Developing Countries; Humans; Hyd | 2020 |
Interventions for preventing silent cerebral infarcts in people with sickle cell disease.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Brain Infarction; Cause of Death; Child; Cogni | 2020 |
Systematic Review of Crizanlizumab: A New Parenteral Option to Reduce Vaso-occlusive Pain Crises in Patients with Sickle Cell Disease.
Topics: Anemia, Sickle Cell; Animals; Antibodies, Monoclonal, Humanized; Glutamine; Humans; Hydroxyurea; P-S | 2020 |
A Systematic Review of Medication Adherence Interventions in Pediatric Sickle Cell Disease.
Topics: Anemia, Sickle Cell; Child; Humans; Hydroxyurea; Medication Adherence | 2020 |
[Sickle cell disease].
Topics: Anemia, Sickle Cell; Antineoplastic Agents; Erythrocytes; Erythrocytes, Abnormal; Humans; Hydroxyure | 2020 |
Voxelotor: A Novel Treatment for Sickle Cell Disease.
Topics: Anemia, Sickle Cell; Benzaldehydes; Female; Hematologic Agents; Hemoglobins; Humans; Hydroxyurea; Ma | 2021 |
Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Child; Child, Preschool; Ea | 2020 |
Drug Therapies for the Management of Sickle Cell Disease.
Topics: Anemia, Sickle Cell; Genetic Therapy; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; | 2020 |
Fetal hemoglobin in sickle cell anemia.
Topics: Anemia, Sickle Cell; beta-Globins; Fetal Hemoglobin; gamma-Globins; Gene Editing; Gene Expression Re | 2020 |
Evidence-based dental management in the new era of sickle cell disease: A scoping review.
Topics: Anemia, Sickle Cell; Brazil; Dental Care; Humans; Hydroxyurea | 2020 |
Changing the Clinical Paradigm of Hydroxyurea Treatment for Sickle Cell Anemia Through Precision Medicine.
Topics: Anemia, Sickle Cell; Dose-Response Relationship, Drug; Humans; Hydroxyurea; Maximum Tolerated Dose; | 2021 |
The Genetic and Clinical Significance of Fetal Hemoglobin Expression in Sickle Cell Disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; beta-Globins; Fetal Hemoglobin; Haplotypes; Humans; Hydrox | 2021 |
Managing patients with sickle cell disease in primary care.
Topics: Administration, Oral; Anemia, Sickle Cell; Antibodies, Monoclonal, Humanized; Antisickling Agents; B | 2020 |
Implementation of the therapeutic use of hydroxyurea for sickle cell disease management in resource-constrained settings: a systematic review of adoption, cost and acceptability.
Topics: Anemia, Sickle Cell; Cohort Studies; Cross-Sectional Studies; Humans; Hydroxyurea; Jamaica; Nigeria | 2020 |
Sickle cell disease: progress towards combination drug therapy.
Topics: Anemia, Sickle Cell; Animals; Antisickling Agents; Drug Development; Drug Therapy, Combination; Gene | 2021 |
Absence of hydroxyurea-induced mutational effects supports higher utilisation for the treatment of sickle cell anaemia.
Topics: Anemia, Sickle Cell; Animals; Antisickling Agents; DNA Damage; Humans; Hydroxyurea; Mutation; Neopla | 2021 |
Medical treatment of recurrent ischaemic priapism: a review of current molecular therapeutics and a new clinical management paradigm.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Agonists; Adrenergic beta-Agonists; Algori | 2021 |
Hydroxyurea Adherence Strategies for Persons with Sickle Cell Disease: A Systematic Review.
Topics: Anemia, Sickle Cell; Humans; Hydroxyurea; Medication Adherence; Prospective Studies; Retrospective S | 2021 |
Hydroxyurea and blood transfusion therapy for Sickle cell disease in South Asia: inconsistent treatment of a neglected disease.
Topics: Anemia, Sickle Cell; Bangladesh; Blood Transfusion; Humans; Hydroxyurea; India; Neglected Diseases; | 2021 |
Stroke and stroke prevention in sickle cell anemia in developed and selected developing countries.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Developing Countries; Humans; Hydroxyurea; Stroke; | 2021 |
Contemporary Management and Prevention of Vaso-Occlusive Crises (VOCs) in Adults With Sickle Cell Disease.
Topics: Adult; Anemia, Sickle Cell; Glutamine; Hospitalization; Humans; Hydroxyurea | 2023 |
A review of hydroxyurea-related cutaneous adverse events.
Topics: Anemia, Sickle Cell; Antineoplastic Agents; Humans; Hydroxyurea; Myeloproliferative Disorders; Skin | 2021 |
Neurologic and Cognitive Outcomes in Sickle Cell Disease from Infancy through Adolescence.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Cognition; Humans; Hy | 2021 |
Magnesium for treating sickle cell disease.
Topics: Administration, Oral; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Pre | 2017 |
Hydroxyurea (hydroxycarbamide) for sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Chelation Therapy; Child; Erythrocyte Transfusion; | 2017 |
Interventions for preventing silent cerebral infarcts in people with sickle cell disease.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Brain Infarction; Cause of Death; Child; Cogni | 2017 |
Interventions for chronic kidney disease in people with sickle cell disease.
Topics: Adult; Albuminuria; Anemia, Sickle Cell; Angiotensin-Converting Enzyme Inhibitors; Antisickling Agen | 2017 |
Opportunities for model-based precision dosing in the treatment of sickle cell anemia.
Topics: Anemia, Sickle Cell; Animals; Antisickling Agents; Bayes Theorem; Dose-Response Relationship, Drug; | 2017 |
Hydroxyurea: Analytical techniques and quantitative analysis.
Topics: Anemia, Sickle Cell; Animals; Antisickling Agents; Chromatography, High Pressure Liquid; Drug Monito | 2017 |
Fertility challenges for women with sickle cell disease.
Topics: Anemia, Sickle Cell; Blood Transfusion; Chronic Pain; Female; Fertility; Fertility Preservation; Gen | 2017 |
Sickle cell disease: a malady beyond a hemoglobin defect in cerebrovascular disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Cell Communication; Cerebrovascular Disorders; Disease Pro | 2018 |
Sickle cell nephropathy: an update on pathophysiology, diagnosis, and treatment.
Topics: Analgesics; Anemia, Sickle Cell; Biomarkers; Glomerular Filtration Rate; Hematuria; Humans; Hydroxyu | 2018 |
Guidelines for the use of hydroxycarbamide in children and adults with sickle cell disease: A British Society for Haematology Guideline.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Child; Child, Preschool; Female; Hematology; Humans; Hydroxy | 2018 |
Treatment Options for Sickle Cell Disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Erythrocyte Transfusion; Hematopoietic Stem Cell Transplan | 2018 |
l-Glutamine for sickle cell anemia: more questions than answers.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Child; Child, Preschool; Drug Approval; Female; Glutamine; H | 2018 |
Red blood cell transfusion to treat or prevent complications in sickle cell disease: an overview of Cochrane reviews.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Erythrocyte Transfusion; Humans; Hydrox | 2018 |
Hydroxyurea in the management of sickle cell disease: pharmacogenomics and enzymatic metabolism.
Topics: Anemia, Sickle Cell; Antisickling Agents; Enzymes; Humans; Hydroxyurea; Membrane Transport Proteins; | 2018 |
Low-dose hydroxycarbamide therapy may offer similar benefit as maximum tolerated dose for children and young adults with sickle cell disease in low-middle-income settings.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Child; Developing Countries; Dose-Response Relation | 2018 |
Advances in the Treatment of Sickle Cell Disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Erythrocyte Transfusion; Genetic Therapy; Glutathione; Hem | 2018 |
Emerging pharmacotherapeutic approaches for the management of sickle cell disease.
Topics: Anemia, Sickle Cell; Animals; Drug Development; Glycolipids; Humans; Hydroxyurea; P-Selectin; Platel | 2019 |
Sickle Cell Nephropathy in the Pediatric Population.
Topics: Adolescent; Adult; Albuminuria; Anemia, Sickle Cell; Angiotensin-Converting Enzyme Inhibitors; Bioma | 2019 |
Hydroxyurea can be used in children with sickle cell disease and cerebral vasculopathy for the prevention of chronic complications? A meta-analysis.
Topics: Anemia, Sickle Cell; Blood Transfusion; Child; Humans; Hydroxyurea; Stroke | 2020 |
Advances in Understanding Ischemic Stroke Physiology and the Impact of Vasculopathy in Children With Sickle Cell Disease.
Topics: Acute Disease; Anemia, Sickle Cell; Blood Transfusion; Brain Ischemia; Cerebral Arteries; Cerebrovas | 2019 |
Insight into the complex pathophysiology of sickle cell anaemia and possible treatment.
Topics: Anemia, Sickle Cell; Animals; Antisickling Agents; beta-Globins; Biomarkers; Blood Coagulation; Cell | 2019 |
cGMP modulation therapeutics for sickle cell disease.
Topics: Anemia, Sickle Cell; Cyclic GMP; Fetal Hemoglobin; Hemoglobin, Sickle; Humans; Hydroxyurea; Models, | 2019 |
Sickle Cell Disease and Stroke.
Topics: Anemia, Sickle Cell; Blood Transfusion; Cerebrovascular Circulation; Humans; Hydroxyurea; Stroke; Ul | 2019 |
Sickle Cell Disease: Monitoring, Current Treatment, and Therapeutics Under Development.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Clinical Trials as Topic; Erythrocyte Transfusion; | 2019 |
Current challenges in the management of patients with sickle cell disease - A report of the Italian experience.
Topics: Anemia, Sickle Cell; Disease Management; Hematologic Diseases; Hemoglobinopathies; Humans; Hydroxyur | 2019 |
Current perspectives of sickle cell disease in Nigeria: changing the narratives.
Topics: Anemia, Sickle Cell; Genetic Counseling; Hematopoietic Stem Cell Transplantation; Hemoglobins; Human | 2019 |
Transfusing children with hemoglobinopathies.
Topics: Allografts; Anemia, Sickle Cell; Child; Emergencies; Erythrocyte Transfusion; Exchange Transfusion, | 2019 |
Hydroxycarbamide: clinical aspects.
Topics: Agranulocytosis; Anemia, Sickle Cell; Antisickling Agents; Clinical Trials as Topic; Developing Coun | 2013 |
Sickle cell disease: time for a closer look at treatment options?
Topics: Africa; Anemia, Sickle Cell; Brain Damage, Chronic; Cardiovascular Diseases; Chelation Therapy; Chro | 2013 |
Stroke in patients with sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Vessels; Brain; Cerebral Infarction; Humans; Hydroxy | 2013 |
Sickle cell anaemia: current therapies.
Topics: Adolescent; Adult; Allografts; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Child; C | 2013 |
Evidence review of hydroxyurea for the prevention of sickle cell complications in low-income countries.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child, Preschool; Developing Countries; Evidence-Based Med | 2013 |
Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.
Topics: Anemia, Sickle Cell; Blood Transfusion; Child; Early Termination of Clinical Trials; Humans; Hydroxy | 2013 |
Emerging science of hydroxyurea therapy for pediatric sickle cell disease.
Topics: Age Factors; Anemia, Sickle Cell; Animals; Antisickling Agents; Child; Child, Preschool; Fetal Hemog | 2014 |
Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies.
Topics: Anemia, Sickle Cell; Antisickling Agents; Humans; Hydroxyurea; Vascular Diseases | 2013 |
The case for and against initiating either hydroxyurea therapy, blood transfusion therapy or hematopoietic stem cell transplant in asymptomatic children with sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Chest Pain; Child; Hematopoietic Stem C | 2014 |
Alterations of the arginine metabolome in sickle cell disease: a growing rationale for arginine therapy.
Topics: Anemia, Sickle Cell; Antisickling Agents; Arginine; Drug Therapy, Combination; Fetal Hemoglobin; Hum | 2014 |
Sickle cell disease in India.
Topics: Anemia, Sickle Cell; Fetal Hemoglobin; Hemoglobin, Sickle; Humans; Hydroxyurea; India; Prenatal Diag | 2014 |
Improving outcomes in children with sickle cell disease: treatment considerations and strategies.
Topics: Acute Chest Syndrome; Anemia, Sickle Cell; Antibiotic Prophylaxis; Child; Costs and Cost Analysis; H | 2014 |
Hydroxyurea therapy for priapism prevention and erectile function recovery in sickle cell disease: a case report and review of the literature.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Humans; Hydroxyurea; Male; Penile Erection; Pr | 2014 |
Sickle cell disease: new opportunities and challenges in Africa.
Topics: Africa; Anemia, Sickle Cell; Blood Transfusion; Humans; Hydroxyurea; Morbidity; Mortality; National | 2013 |
Individualizing fetal hemoglobin augmenting therapy for β-type hemoglobinopathies patients.
Topics: Anemia, Sickle Cell; beta-Thalassemia; Fetal Hemoglobin; Humans; Hydroxyurea; Pharmacogenetics; Poly | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusio | 2014 |
Hydroxyurea therapy contributes to infertility in adult men with sickle cell disease: a review.
Topics: Anemia, Sickle Cell; Animals; Antisickling Agents; Humans; Hydroxyurea; Hypogonadism; Infertility, M | 2014 |
Update on the use of hydroxyurea therapy in sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Anti-Inflammatory Agents, Non-Steroidal; Antisickling Agents; beta-Thala | 2014 |
Medication adherence among pediatric patients with sickle cell disease: a systematic review.
Topics: Adolescent; Anemia, Sickle Cell; Antibiotic Prophylaxis; Child; Drug Monitoring; Drug Substitution; | 2014 |
Emerging drugs for sickle cell anemia.
Topics: Anemia, Sickle Cell; Animals; Antisickling Agents; Blood Transfusion; Drug Design; Humans; Hydroxyur | 2015 |
Reproductive issues in sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Female; Fertility; Humans; Hydroxyurea; Infertility, Femal | 2014 |
Advances in sickle cell therapies in the hydroxyurea era.
Topics: Anemia, Sickle Cell; Animals; Cell Adhesion; Genetic Therapy; Hematopoietic Stem Cell Transplantatio | 2014 |
The delay time in sickle cell disease after 40 years: A paradigm assessed.
Topics: Anemia, Sickle Cell; Antisickling Agents; Cell Movement; Erythrocyte Deformability; Erythrocytes, Ab | 2015 |
Does hydroxyurea prevent pulmonary complications of sickle cell disease?
Topics: Anemia, Sickle Cell; Humans; Hydroxyurea; Lung Diseases; Practice Guidelines as Topic; Publications | 2014 |
Estimated pulmonary artery systolic pressure and sickle cell disease: a meta-analysis and systematic review.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Arterial Pressure; Echocardiography; Female; Humans | 2015 |
Inflammatory targets of therapy in sickle cell disease.
Topics: Anemia, Sickle Cell; Animals; Anti-Inflammatory Agents; Humans; Hydroxyurea; Inflammation; Signal Tr | 2016 |
Critical Reviews: How we treat sickle cell patients with leg ulcers.
Topics: Anemia, Sickle Cell; Drug Therapy, Combination; Erythropoietin; Humans; Hydroxyurea; Leg Ulcer; Recu | 2016 |
A systematic review of known mechanisms of hydroxyurea-induced fetal hemoglobin for treatment of sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Cyclic AMP; Cyclic GMP; Epigenesis, Genetic; Fetal Hemoglo | 2015 |
[From Hemoglobin SS to SF: interest of hydroxyurea in the management of sickle cell disease in two Congolese children and review of the literature].
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Democratic Republic of the Congo; | 2015 |
Hydroxyurea therapy for sickle cell anemia.
Topics: Administration, Oral; Anemia, Sickle Cell; Animals; Antisickling Agents; Humans; Hydroxyurea | 2015 |
Evolution of sickle cell disease from a life-threatening disease of children to a chronic disease of adults: The last 40 years.
Topics: Adult; Anemia, Sickle Cell; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antisickling Agents; Bloo | 2016 |
Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease.
Topics: Analgesics; Anemia, Sickle Cell; Animals; Antisickling Agents; Blood Coagulation; Cell Adhesion; Dru | 2016 |
Sickle cell disease.
Topics: Anemia, Sickle Cell; Antibiotic Prophylaxis; Blood Transfusion; Humans; Hydroxyurea; Pneumococcal Va | 2016 |
Minireview: Prognostic factors and the response to hydroxurea treatment in sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Fetal Hemoglobin; Humans; Hydroxyurea; Prognosis; Severity | 2016 |
New insights into sickle cell disease: mechanisms and investigational therapies.
Topics: Anemia, Sickle Cell; Humans; Hydroxyurea | 2016 |
Regular long-term red blood cell transfusions for managing chronic chest complications in sickle cell disease.
Topics: Acute Chest Syndrome; Anemia, Sickle Cell; Antisickling Agents; Erythrocyte Transfusion; Female; Hum | 2016 |
Management of Sickle Cell Disease in Children.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Gastrointestinal Diseases; Heart Diseases; Humans; | 2016 |
An Expert Review of Pharmacogenomics of Sickle Cell Disease Therapeutics: Not Yet Ready for Global Precision Medicine.
Topics: Analgesics; Analgesics, Opioid; Anemia, Sickle Cell; Humans; Hydroxyurea; Pain; Pain Management; Pha | 2016 |
Sickle cell disease: Its molecular mechanism and the one drug that treats it.
Topics: Anemia, Sickle Cell; Hemoglobins; Humans; Hydroxyurea; Protein Multimerization; Protein Structure, S | 2016 |
Pediatric sickle cell disease: past successes and future challenges.
Topics: Adolescent; Anemia, Sickle Cell; Blood Flow Velocity; Cerebrovascular Circulation; Child; Child, Pre | 2017 |
Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Child; Child, Preschool; Ea | 2017 |
Sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Cerebrovascular Disorders; Chronic Dise | 2017 |
Sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Cerebrovascular Disorders; Chronic Dise | 2017 |
Sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Cerebrovascular Disorders; Chronic Dise | 2017 |
Sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Cerebrovascular Disorders; Chronic Dise | 2017 |
A genetic variation associated with plasma erythropoietin and a non-coding transcript of PRKAR1A in sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Cyclic AMP-Dependent Protein Kinase RIalpha Subunit; Eryth | 2016 |
Sickle Cell Disease: A Brief Update.
Topics: Anemia, Sickle Cell; Erythrocyte Transfusion; Hematopoietic Stem Cell Transplantation; Hemoglobin, S | 2017 |
Vasculitic and autoimmune wounds.
Topics: Anemia, Sickle Cell; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antiphospholipid Sy | 2017 |
Sickle cell disease: new insights into pathophysiology and treatment.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Chelation Therapy; Diagnosis, Different | 2008 |
Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential.
Topics: Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Erythropoiesis; Erythropoietin; Fatty Ac | 2008 |
MRI abnormalities in infants with sickle cell anemia-indication for preemptive therapy?
Topics: Anemia, Sickle Cell; Antisickling Agents; Brain; Clinical Trials as Topic; Humans; Hydroxyurea; Infa | 2008 |
Pharmaco-proteomic study of hydroxyurea-induced modifications in the sickle red blood cell membrane proteome.
Topics: Anemia, Sickle Cell; Antisickling Agents; Catalase; Enzyme Activation; Erythrocyte Membrane; Erythro | 2008 |
The spleen in the sickling disorders: an update.
Topics: Anemia, Sickle Cell; Child; Child, Preschool; Diagnostic Imaging; Humans; Hydroxyurea; Infant; Infan | 2009 |
Haemoglobin F modulation in childhood sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Azacitidine; Butyrates; Child; Clinical Trials as T | 2009 |
Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Dose-Response Relatio | 2008 |
Sickle cell anemia, the first molecular disease: overview of molecular etiology, pathophysiology, and therapeutic approaches.
Topics: alpha-Thalassemia; Anemia, Sickle Cell; Erythrocyte Membrane; Female; Hemoglobin, Sickle; Humans; Hy | 2008 |
[Advances in sickle cell disease].
Topics: Anemia, Sickle Cell; Animals; Bone Marrow Transplantation; Endothelium, Vascular; Erythrocytes; Gene | 2008 |
[New issues in adult sickle sell disease].
Topics: Adult; Anemia, Sickle Cell; Blood Transfusion; Cardiomyopathies; Combined Modality Therapy; Female; | 2008 |
Sickle cell disease and stroke.
Topics: Anemia, Sickle Cell; Anti-Inflammatory Agents; Antisickling Agents; Blood Transfusion; Bone Marrow T | 2009 |
Advances in the use of hydroxyurea.
Topics: Adult; Anemia, Sickle Cell; Animals; Arterial Occlusive Diseases; Bone Marrow Diseases; Child; Clini | 2009 |
Hydroxyurea for children with sickle cell disease.
Topics: Anemia, Sickle Cell; Child; Humans; Hydroxyurea; Maximum Tolerated Dose; Risk Assessment | 2010 |
Gastrointestinal and hepatic complications of sickle cell disease.
Topics: Anemia; Anemia, Sickle Cell; Antisickling Agents; Bilirubin; Blood Transfusion; Gallstones; Humans; | 2010 |
How I use hydroxyurea to treat young patients with sickle cell anemia.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Clinical Trials as Topic; Humans; Hydro | 2010 |
Pulmonary hypertension and nitric oxide depletion in sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Animals; Child; Clinical Trials as Topic; Disease Models, Animal; Echoca | 2010 |
Hematopoietic stem cell mobilization strategies for gene therapy of beta thalassemia and sickle cell disease.
Topics: Anemia, Sickle Cell; beta-Thalassemia; Clinical Trials as Topic; Genetic Therapy; Granulocyte Colony | 2010 |
Genetic modifiers of HbF and response to hydroxyurea in sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Carrier Proteins; Fetal Hemoglobin; Gene Expression; Gene | 2011 |
Hydroxyurea for children with sickle cell disease: are we starting too late?
Topics: Anemia, Sickle Cell; Antisickling Agents; Caregivers; Child; Child Health Services; Humans; Hydroxyu | 2011 |
Current strategies for the management of children with sickle cell disease.
Topics: Adolescent; Anemia, Sickle Cell; Blood Transfusion; Child; Child, Preschool; Humans; Hydroxyurea; Ul | 2009 |
Genomic polymorphisms in sickle cell disease: implications for clinical diversity and treatment.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Fetal Hemoglobin; Genome-Wide Associati | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain?
Topics: Anemia, Sickle Cell; Humans; Hydroxyurea | 2011 |
Advances in sickle cell disease treatment: from drug discovery until the patient monitoring.
Topics: Anemia, Sickle Cell; Animals; Antisickling Agents; Chelating Agents; Drug Discovery; Erythrocytes; H | 2011 |
Sickle cell disease.
Topics: Acute Disease; Analgesia, Patient-Controlled; Anemia, Sickle Cell; Blood Transfusion; Humans; Hydrox | 2011 |
Exercise limitation, exercise testing and exercise recommendations in sickle cell anemia.
Topics: Adaptation, Physiological; Anemia, Sickle Cell; Arterial Occlusive Diseases; Bronchial Hyperreactivi | 2011 |
Prospects for primary stroke prevention in children with sickle cell anaemia.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Bacterial Infections; Blood Transfusion; Brain | 2012 |
Clinical management of adult sickle-cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Humans; Hydroxyurea; Hypertension, Pulmonary; Kidney Disea | 2012 |
Pathology of sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Death, Sudden; Humans; Hydroxyurea; Mortality, Premature; | 2012 |
Hydroxyurea for the treatment of sickle cell disease: efficacy, barriers, toxicity, and management in children.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Child; Disease Management; Humans; Hydroxyurea; Tre | 2012 |
Sickle cell disease in children.
Topics: Anemia, Sickle Cell; Blood Transfusion; Child; Child, Preschool; Genetic Predisposition to Disease; | 2012 |
Sickle cell disease.
Topics: Acute Pain; Anemia, Sickle Cell; Antisickling Agents; Bone Marrow Transplantation; Erythrocyte Trans | 2012 |
Novel approaches to the treatment of sickle cell disease: the potential of histone deacetylase inhibitors.
Topics: Anemia, Sickle Cell; Animals; Antisickling Agents; Fetal Hemoglobin; Hemoglobin, Sickle; Histone Dea | 2012 |
Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management.
Topics: Anemia, Sickle Cell; Blood Transfusion; Clinical Trials as Topic; Disease Management; Gastrointestin | 2012 |
Molecular basis of erythrocyte adhesion to endothelial cells in diseases.
Topics: Anemia, Sickle Cell; Animals; Cell Adhesion; Cell Adhesion Molecules; Diabetes Mellitus; Erythrocyte | 2013 |
Chronic pain perspectives: Sickle cell disease: Gaining control over the pain.
Topics: Adaptation, Psychological; Adult; Analgesia, Patient-Controlled; Analgesics, Opioid; Anemia, Sickle | 2012 |
The clinical effectiveness and cost-effectiveness of primary stroke prevention in children with sickle cell disease: a systematic review and economic evaluation.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Bone Marrow Transplantation; Cerebrovas | 2012 |
What is the evidence that hydroxyurea improves health-related quality of life in patients with sickle cell disease?
Topics: Acute Disease; Adult; Affect; Anemia, Sickle Cell; Child; Cognitive Behavioral Therapy; Cohort Studi | 2012 |
Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia.
Topics: Anemia, Sickle Cell; Antisickling Agents; Azacitidine; beta-Thalassemia; DNA Methylation; Fetal Hemo | 2013 |
Systematic review of current and emerging strategies for reducing morbidity from malaria in sickle cell disease.
Topics: Africa South of the Sahara; Anemia, Sickle Cell; Antimalarials; Antisickling Agents; Comorbidity; Dr | 2013 |
The role of hydroxyurea in sickle cell disease.
Topics: Adolescent; Adult; Aged; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Cell Communicat | 2003 |
Sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Child; Humans; Hydroxyurea; Stem Cell T | 2002 |
Therapeutic challenges in childhood sickle cell disease. Part 1: current and future treatment options.
Topics: Anemia, Sickle Cell; Antisickling Agents; Bone Marrow Transplantation; Cell Adhesion Molecules; Chil | 2003 |
Therapeutic challenges in childhood sickle cell disease. Part 2: a problem-orientated approach.
Topics: Anemia, Sickle Cell; Antisickling Agents; Bone Marrow Transplantation; Central Nervous System Diseas | 2003 |
The role of hydroxyurea in the management of sickle cell disease.
Topics: Anemia, Sickle Cell; Animals; Antisickling Agents; Dose-Response Relationship, Drug; Follow-Up Studi | 2003 |
Hydroxyurea information for children and parents.
Topics: Anemia, Sickle Cell; Child; Child, Preschool; Communication; Dose-Response Relationship, Drug; Femal | 2003 |
Hydroxyurea treatment for sickle cell disease.
Topics: Anemia, Sickle Cell; Animals; Humans; Hydroxyurea | 2002 |
Therapies to increase fetal hemoglobin in sickle cell disease.
Topics: Anemia, Sickle Cell; Azacitidine; Butyrates; Cytokines; Decitabine; Drug Therapy, Combination; Fetal | 2003 |
Advances in management of sickle cell disease.
Topics: Acute Disease; Adolescent; Anemia, Sickle Cell; Antisickling Agents; Bacterial Infections; Blood Tra | 2003 |
New drugs for childhood anemia.
Topics: Adult; Age Factors; Anemia; Anemia, Hemolytic, Autoimmune; Anemia, Sickle Cell; Antibodies, Monoclon | 2003 |
Vaso-occlusion in sickle cell anemia: role of interactions between blood cells and endothelium.
Topics: Anemia, Sickle Cell; Arterial Occlusive Diseases; Blood Proteins; Cell Adhesion; Cell Adhesion Molec | 2004 |
Pharmacological induction of fetal hemoglobin synthesis using histone deacetylase inhibitors.
Topics: Anemia, Sickle Cell; Azacitidine; beta-Thalassemia; Enzyme Inhibitors; Fetal Hemoglobin; Histone Dea | 2004 |
Nitric oxide production from hydroxyurea.
Topics: Anemia, Sickle Cell; Free Radicals; Hemoglobins; Humans; Hydroxylamine; Hydroxyurea; Iron; Models, C | 2004 |
Leg ulcers in sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Bandages; Blood Transfusion; Carnitine; Debridement; Drug | 2004 |
[Management of sickle cell disease].
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Bone Marrow Transplantation; Humans; Hy | 2004 |
Sickle cell disease; a general overview.
Topics: Anemia, Sickle Cell; Blood Transfusion; Constriction, Pathologic; Hemoglobin, Sickle; Hemolysis; Hum | 2004 |
Sickle cell disease; a general overview.
Topics: Anemia, Sickle Cell; Blood Transfusion; Constriction, Pathologic; Hemoglobin, Sickle; Hemolysis; Hum | 2004 |
Sickle cell disease; a general overview.
Topics: Anemia, Sickle Cell; Blood Transfusion; Constriction, Pathologic; Hemoglobin, Sickle; Hemolysis; Hum | 2004 |
Sickle cell disease; a general overview.
Topics: Anemia, Sickle Cell; Blood Transfusion; Constriction, Pathologic; Hemoglobin, Sickle; Hemolysis; Hum | 2004 |
Sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Child, Preschool; Humans; Hydroxyurea; Penicillins | 2004 |
Predicting clinical severity in sickle cell anaemia.
Topics: alpha-Thalassemia; Anemia, Sickle Cell; Antisickling Agents; Female; Fetal Hemoglobin; Genetic Predi | 2005 |
[Pathophysiology and treatment of sickle-cell disease].
Topics: Anemia, Sickle Cell; Antisickling Agents; Cell Adhesion; Combined Modality Therapy; Erythrocytes; Hu | 2005 |
Overt and incomplete (silent) cerebral infarction in sickle cell anemia: diagnosis and management.
Topics: Age Factors; Anemia, Sickle Cell; Blood Transfusion; Cerebral Infarction; Humans; Hydroxyurea; Risk | 2005 |
New therapies for sickle cell disease.
Topics: Acetamides; Anemia, Sickle Cell; Calcium Channel Blockers; Cell Adhesion; Fatty Acids, Omega-3; Huma | 2005 |
Leukocyte adhesion and the pathophysiology of sickle cell disease.
Topics: Anemia, Sickle Cell; Antibodies, Monoclonal; Antisickling Agents; Cell Adhesion; Cell Adhesion Molec | 2006 |
Pharmacological induction of fetal hemoglobin: Why haven't we been more successful in thalassemia?
Topics: Anemia, Sickle Cell; Animals; Azacitidine; Combined Modality Therapy; Drug Approval; Drug Evaluation | 2005 |
Sickle cell crisis! Managing the pain.
Topics: Adaptation, Psychological; Adult; Analgesics; Anemia, Sickle Cell; Bone Marrow Transplantation; Flui | 2005 |
Pathophysiologically based drug treatment of sickle cell disease.
Topics: Anemia, Sickle Cell; Animals; Anti-Inflammatory Agents; Antisickling Agents; Azacitidine; Cell Adhes | 2006 |
Sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Child, Preschool; Humans; Hydroxyurea; Penicillins | 2005 |
Investigational agents for sickle cell disease.
Topics: Acetamides; Anemia, Sickle Cell; Animals; Antihypertensive Agents; Antisickling Agents; Benzaldehyde | 2006 |
Sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Child, Preschool; Humans; Hydroxyurea; Pain; Penicillins | 2006 |
The genomics of new drugs in sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Azacitidine; Butyrates; Decitabine; Drug Resistance; Human | 2006 |
Review: clinical transfusion management in sickle cell disease.
Topics: Anemia, Sickle Cell; Blood Transfusion; Disease Management; Erythrocyte Transfusion; Female; Humans; | 2006 |
Induction of fetal hemoglobin in the treatment of sickle cell disease.
Topics: Anemia, Sickle Cell; Azacitidine; Butyrates; Decitabine; Fetal Hemoglobin; Gene Expression Regulatio | 2006 |
Sickle cell disease in North Europe.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Child; Europe; Humans; Hydroxyurea; Inf | 2007 |
The pathophysiology, prevention, and treatment of stroke in sickle cell disease.
Topics: Anemia, Sickle Cell; Blood Transfusion; Humans; Hydroxyurea; Stroke; Ultrasonography, Doppler, Trans | 2007 |
Sickle cell anemia: targeting the role of fetal hemoglobin in therapy.
Topics: Anemia, Sickle Cell; Fetal Hemoglobin; Gene Silencing; Genetic Therapy; Humans; Hydroxyurea; RNA, An | 2007 |
Sickle cell disease.
Topics: Adolescent; Age Distribution; Anemia, Sickle Cell; Blood Transfusion; Cause of Death; Child; Child, | 2007 |
Sickle cell disease: role of reactive oxygen and nitrogen metabolites.
Topics: Anemia, Sickle Cell; Animals; Antioxidants; Antisickling Agents; Endothelium, Vascular; Enzyme Inhib | 2007 |
Overt and incomplete (silent) cerebral infarction in sickle cell anemia: diagnosis and management.
Topics: Anemia, Sickle Cell; Blood Transfusion; Cerebral Infarction; Humans; Hydroxyurea | 2007 |
Redox-dependent impairment of vascular function in sickle cell disease.
Topics: Anemia, Sickle Cell; Anti-Inflammatory Agents; Anticoagulants; Antioxidants; Biological Availability | 2007 |
Principles and indications of chronic transfusion therapy for children with sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Child; Child, Preschool; Female; Humans | 2007 |
Hematopoietic cell transplantation: a curative option for sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Child; Child, Preschool; Female; Hemato | 2007 |
[Is therapeutic progress in the management of sickle cell disease applicable in sub-Saharan Africa?].
Topics: Africa South of the Sahara; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Hematopoiet | 2007 |
Hydroxyurea for the treatment of sickle cell anemia.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Female; Humans; Hydroxyurea; Practice Guidelin | 2008 |
Hydroxyurea for children with sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Humans; Hydroxyurea | 2008 |
Managing acute chest syndrome of sickle cell disease in an African setting.
Topics: Acute Disease; Anemia, Sickle Cell; Antisickling Agents; Diagnosis, Differential; Humans; Hydroxyure | 2008 |
Hydroxyurea for the treatment of sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Child; Health Services Accessibility; Humans; Hydro | 2008 |
Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Fetal Hemoglobin; Hemoglobins; Humans; Hydroxyurea; | 2008 |
The biophysics of sickle cell hydroxyurea therapy.
Topics: Anemia, Sickle Cell; Biopolymers; Fetal Hemoglobin; Hemoglobin, Sickle; Humans; Hydroxyurea | 1995 |
Fetal hemoglobin reactivation in baboon and man: a short perspective.
Topics: Anemia, Sickle Cell; Animals; Azacitidine; Butyrates; Butyric Acid; Erythropoietin; Fetal Hemoglobin | 1993 |
Pharmacological modification of hemoglobin F expression in sickle cell anemia: an update on hydroxyurea studies.
Topics: Anemia, Sickle Cell; Animals; Azacitidine; Erythrocytes; Fetal Hemoglobin; Gene Expression; Humans; | 1993 |
[Clinical pharmacology of hydroxyurea].
Topics: Anemia, Sickle Cell; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myelopro | 1995 |
[Potential alternatives to erythrocyte transfusion in hemoglobinopathies: hydroxyurea (HU), erythropoietin (EPO), butyrate derivatives, blood substitutes].
Topics: Adolescent; Adult; Anemia, Sickle Cell; Blood Substitutes; Butyrates; Child; Erythrocyte Transfusion | 1994 |
[Stimulation of fetal hemoglobin production in children with sickle cell anemia].
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Fetal Hemoglobin; Humans; Hydroxyurea | 1996 |
Pharmacologic manipulation of fetal hemoglobin levels in sickle cell diseases and thalassemia: promise and reality.
Topics: Anemia, Sickle Cell; Antineoplastic Agents; Antisickling Agents; Azacitidine; beta-Thalassemia; Eryt | 1996 |
Experimental therapy.
Topics: Anemia, Sickle Cell; Antisickling Agents; Bone Marrow Transplantation; Clinical Trials as Topic; Ery | 1996 |
New therapies and approaches to transfusion in sickle cell disease in children.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Bone Marrow Transplantation; Child; Fet | 1997 |
Pathogenesis and treatment of sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Fetal Hemoglobin; Hemoglobin, Sickle; Humans; Hydroxyurea | 1997 |
Pathogenesis and treatment of sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Fetal Hemoglobin; Hemoglobin, Sickle; Humans; Hydroxyurea | 1997 |
Pathogenesis and treatment of sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Fetal Hemoglobin; Hemoglobin, Sickle; Humans; Hydroxyurea | 1997 |
Pathogenesis and treatment of sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Fetal Hemoglobin; Hemoglobin, Sickle; Humans; Hydroxyurea | 1997 |
Pathogenesis and treatment of sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Fetal Hemoglobin; Hemoglobin, Sickle; Humans; Hydroxyurea | 1997 |
Pathogenesis and treatment of sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Fetal Hemoglobin; Hemoglobin, Sickle; Humans; Hydroxyurea | 1997 |
Pathogenesis and treatment of sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Fetal Hemoglobin; Hemoglobin, Sickle; Humans; Hydroxyurea | 1997 |
Pathogenesis and treatment of sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Fetal Hemoglobin; Hemoglobin, Sickle; Humans; Hydroxyurea | 1997 |
Pathogenesis and treatment of sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Fetal Hemoglobin; Hemoglobin, Sickle; Humans; Hydroxyurea | 1997 |
Pathogenesis and treatment of sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Fetal Hemoglobin; Hemoglobin, Sickle; Humans; Hydroxyurea | 1997 |
Pathogenesis and treatment of sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Fetal Hemoglobin; Hemoglobin, Sickle; Humans; Hydroxyurea | 1997 |
Pathogenesis and treatment of sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Fetal Hemoglobin; Hemoglobin, Sickle; Humans; Hydroxyurea | 1997 |
Pathogenesis and treatment of sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Fetal Hemoglobin; Hemoglobin, Sickle; Humans; Hydroxyurea | 1997 |
Pathogenesis and treatment of sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Fetal Hemoglobin; Hemoglobin, Sickle; Humans; Hydroxyurea | 1997 |
Pathogenesis and treatment of sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Fetal Hemoglobin; Hemoglobin, Sickle; Humans; Hydroxyurea | 1997 |
Pathogenesis and treatment of sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Fetal Hemoglobin; Hemoglobin, Sickle; Humans; Hydroxyurea | 1997 |
Pathogenesis and treatment of sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Fetal Hemoglobin; Hemoglobin, Sickle; Humans; Hydroxyurea | 1997 |
Pathogenesis and treatment of sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Fetal Hemoglobin; Hemoglobin, Sickle; Humans; Hydroxyurea | 1997 |
Pathogenesis and treatment of sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Fetal Hemoglobin; Hemoglobin, Sickle; Humans; Hydroxyurea | 1997 |
Pathogenesis and treatment of sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Fetal Hemoglobin; Hemoglobin, Sickle; Humans; Hydroxyurea | 1997 |
Pathogenesis and treatment of sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Fetal Hemoglobin; Hemoglobin, Sickle; Humans; Hydroxyurea | 1997 |
Pathogenesis and treatment of sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Fetal Hemoglobin; Hemoglobin, Sickle; Humans; Hydroxyurea | 1997 |
Pathogenesis and treatment of sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Fetal Hemoglobin; Hemoglobin, Sickle; Humans; Hydroxyurea | 1997 |
Pathogenesis and treatment of sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Fetal Hemoglobin; Hemoglobin, Sickle; Humans; Hydroxyurea | 1997 |
Pathogenesis and treatment of sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Fetal Hemoglobin; Hemoglobin, Sickle; Humans; Hydroxyurea | 1997 |
Overview of pathophysiology and rationale for treatment of sickle cell anemia.
Topics: Anemia, Sickle Cell; Antineoplastic Agents; Antisickling Agents; Fetal Hemoglobin; Globins; Hemoglob | 1997 |
Determinants of fetal hemoglobin response to hydroxyurea.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Bone Marrow; Fetal Hemoglobin; Globins; Haplotypes; | 1997 |
Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Erythrocyte Indices; Fetal Hemoglobin; Humans; Hydr | 1997 |
Hydroxyurea in children: present and future.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Clinical Trials as Topic; Fetal Hemoglobin; Humans; | 1997 |
Use of hydroxyurea in children with sickle cell disease: what comes next?
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Child; Contraindications; Female; Fetal Hemoglobin; | 1997 |
New therapies for the haemoglobinopathies.
Topics: Anemia, Sickle Cell; Antisickling Agents; Butyrates; Butyric Acid; Drug Therapy, Combination; Erythr | 1997 |
Treatment of sickling disorders.
Topics: Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Blood Component Removal; Blood Transfusi | 1996 |
Hydroxyurea in the treatment of sickle-cell anemia.
Topics: Anemia, Sickle Cell; Antisickling Agents; Clinical Trials as Topic; Humans; Hydroxyurea | 1997 |
Pharmacological induction of foetal haemoglobin synthesis in sickle-cell disease.
Topics: Anemia, Sickle Cell; Animals; Butyrates; Butyric Acid; Erythropoietin; Fetal Hemoglobin; Humans; Hyd | 1997 |
Pharmacokinetics and pharmacodynamics of hydroxyurea.
Topics: Acquired Immunodeficiency Syndrome; Anemia, Sickle Cell; Anti-HIV Agents; Antineoplastic Agents; Ant | 1998 |
The therapeutic reactivation of fetal haemoglobin.
Topics: Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Butyrates; Clinical Trials as Topic; Fet | 1998 |
Complications of sickle cell anemia in adults: guidelines for effective management.
Topics: Adult; Analgesics, Opioid; Anemia, Sickle Cell; Brain Diseases; Chest Pain; Child; Child, Preschool; | 1999 |
Hydroxyurea use during pregnancy: a case report in sickle cell disease and review of the literature.
Topics: Adult; Anemia, Sickle Cell; Female; Gestational Age; Humans; Hydroxyurea; Infant, Newborn; Male; Pre | 1999 |
Induction of fetal hemoglobin in sickle cell disease.
Topics: Anemia, Sickle Cell; Animals; Butyrates; Fetal Hemoglobin; Humans; Hydroxyurea | 1999 |
[Hydroxyurea and other agents stimulating synthesis of fetal hemoglobin].
Topics: Anemia, Sickle Cell; Antisickling Agents; Dose-Response Relationship, Drug; Fetal Hemoglobin; Humans | 1999 |
Long-term hydroxyurea treatment in young sickle cell patients.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Double-Blind M | 1999 |
Management of sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Bone Marrow Transplantation; Fetal Hemo | 1999 |
[Falciform anemia and Plasmodium falciparum malaria: a threat to flap survival?].
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Humans; Hydroxyurea; Leg Ulcer; Malaria, Falciparum | 1999 |
Management of sickle cell disease: recent advances and controversies.
Topics: Anemia, Sickle Cell; Blood Transfusion; Cardiovascular Diseases; Humans; Hydroxyurea; Laser Coagulat | 1999 |
Approach to the vaso-occlusive crisis in adults with sickle cell disease.
Topics: Acute Disease; Adult; Analgesics; Analgesics, Opioid; Anemia, Sickle Cell; Antisickling Agents; Arte | 2000 |
Pharmacological therapy.
Topics: Anemia, Sickle Cell; Animals; Antisickling Agents; beta-Thalassemia; Child; Fatty Acids; Fetal Hemog | 1998 |
Sickle cell pain & hydroxyurea.
Topics: Adult; Algorithms; Anemia, Sickle Cell; Child; Decision Trees; Drug Monitoring; Fetal Hemoglobin; Hu | 2000 |
Pharmacologic induction of fetal hemoglobin: raising the therapeutic bar in sickle cell disease.
Topics: Anemia, Sickle Cell; Azacitidine; Butyrates; Decitabine; Fetal Hemoglobin; Humans; Hydroxyurea | 2001 |
Stroke prevention and treatment in sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Bone Marrow Transplantation; Humans; Hy | 2001 |
Acute complications of sickle cell disease in children.
Topics: Abdominal Pain; Acute Disease; Adolescent; Analgesics; Anemia, Aplastic; Anemia, Sickle Cell; Animal | 2001 |
[Sickle cell disease: from childhood to adolescence. Management in 2001].
Topics: Acute Disease; Adolescent; Anemia, Sickle Cell; Bacterial Infections; Child; Humans; Hydroxyurea; In | 2001 |
Pharmacologic modulation of fetal hemoglobin.
Topics: Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Child; Child, Preschool; Combined Modali | 2001 |
New advances in the treatment of sickle cell disease: focus on perioperative significance.
Topics: Anemia, Sickle Cell; Anesthesia; Antisickling Agents; Fructose-Bisphosphatase; Humans; Hydroxyurea; | 2001 |
[How I treat ... sickle cell anemia: current therapies].
Topics: Anemia, Sickle Cell; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Antisickling Agents; A | 2001 |
Transfusion therapy: a coming-of-age treatment for patients with sickle cell disease.
Topics: Adolescent; Adult; Aged; Anemia, Sickle Cell; Bacteremia; Blood Group Antigens; Blood Substitutes; B | 2001 |
Hydroxyurea and sickle cell disease.
Topics: Anemia, Sickle Cell; Cost of Illness; Fetal Hemoglobin; Humans; Hydroxyurea | 1992 |
The spectrum of sickle cell disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Azacitidine; Chromosomes, Human, Pair 11; Chromosomes, Human | 1992 |
Therapeutic approaches to hemoglobin switching in treatment of hemoglobinopathies.
Topics: Anemia, Sickle Cell; Animals; Azacitidine; Erythropoietin; Fetal Hemoglobin; Gene Expression Regulat | 1992 |
Hydroxyurea: specific therapy for sickle cell anemia?
Topics: Anemia, Sickle Cell; Fetal Hemoglobin; Humans; Hydroxyurea | 1992 |
Hydroxyurea induction of fetal hemoglobin synthesis in sickle-cell disease.
Topics: Anemia, Sickle Cell; Fetal Hemoglobin; Humans; Hydroxyurea | 1992 |
Induction of fetal hemoglobin by cell-cycle-specific drugs and recombinant erythropoietin.
Topics: Anemia, Sickle Cell; Animals; Cell Cycle; Erythroid Precursor Cells; Erythropoietin; Fetal Hemoglobi | 1990 |
Fetal hemoglobin, sickling, and sickle cell disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Animals; Azacitidine; Child; Fetal Hemoglobin; Humans; Hydro | 1990 |
Pharmacologic manipulation of fetal hemoglobin. Update on clinical trials with hydroxyurea.
Topics: Anemia, Sickle Cell; Erythropoietin; Fetal Hemoglobin; Humans; Hydroxyurea; Thalassemia | 1990 |
Hydroxyurea as treatment for sickle cell anemia.
Topics: Anemia, Sickle Cell; Animals; Azacitidine; Erythropoietin; Humans; Hydroxyurea | 1991 |
Pharmacologic stimulation of Hb F in patients with sickle cell anemia.
Topics: Anemia, Sickle Cell; Azacitidine; Cell Survival; Erythropoiesis; Fetal Hemoglobin; Homozygote; Human | 1985 |
Regulation of fetal hemoglobin synthesis by cell cycle specific drugs.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Animals; Cell Cycle; Colony-Forming Units Assay; DNA; DNA (C | 1985 |
Levels of fetal hemoglobin necessary for treatment of sickle cell disease.
Topics: Anemia, Sickle Cell; Azacitidine; Fetal Hemoglobin; Humans; Hydroxyurea; Polymers | 1988 |
Chemotherapy and hemoglobin F synthesis in sickle cell disease.
Topics: Anemia, Sickle Cell; Animals; Azacitidine; Clinical Trials as Topic; Erythropoietin; Fetal Hemoglobi | 1989 |
Modulation of HBF production by erythropoietin.
Topics: Anemia, Sickle Cell; Animals; Cell Count; Erythroid Precursor Cells; Erythropoietin; Fetal Hemoglobi | 1989 |
Stimulation of fetal hemoglobin production by hydroxyurea in sickle cell anemia.
Topics: Anemia, Sickle Cell; Caffeine; Fetal Hemoglobin; Humans; Hydroxyurea; In Vitro Techniques | 1989 |
191 trials available for hydroxyurea and HbS Disease
| Article | Year |
|---|---|
A randomised controlled provider-blinded trial of community health workers in sickle cell anaemia: effects on haematologic variables and hydroxyurea adherence.
Topics: Adult; Anemia, Sickle Cell; Community Health Workers; Erythrocyte Indices; Female; Humans; Hydroxyur | 2022 |
Hydroxyurea for primary stroke prevention in children with sickle cell anaemia in Nigeria (SPRING): a double-blind, multicentre, randomised, phase 3 trial.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child, Preschool; Double-Blind Method; Female; Humans; Hyd | 2022 |
Translating research to usual care of children with sickle cell disease in Northern Nigeria: lessons learned from the SPRING Trial Team.
Topics: Anemia, Sickle Cell; Antisickling Agents; Humans; Hydroxyurea; Nigeria; Stroke; Ultrasonography, Dop | 2022 |
Comparative effectiveness of adding Omega-3 or Vitamin D to standard therapy in preventing and treating episodes of painful crisis in pediatric sickle cell patients.
Topics: Anemia, Sickle Cell; Double-Blind Method; Fatty Acids, Omega-3; Humans; Hydroxyurea; Pain; Retrospec | 2022 |
Stroke Prevention with Hydroxyurea Enabled through Research and Education: A Phase 2 Primary Stroke Prevention Trial in Sub-Saharan Africa.
Topics: Adolescent; Africa South of the Sahara; Anemia, Sickle Cell; Child; Child, Preschool; Female; Humans | 2023 |
Satisfaction and access to care for adults and adolescents with sickle cell disease: ASCQ-Me quality of care and the SHIP-HU study.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Health Services Accessibility; Humans; Hydroxyurea; Personal | 2022 |
PRIMARY STROKE PREVENTION IN CHILDREN WITH SICKLE CELL ANEMIA LIVING IN AFRICA: THE FALSE CHOICE BETWEEN PATIENT-ORIENTED RESEARCH AND HUMANITARIAN SERVICE-PART II.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Humans; Hydroxyurea; Nigeria; Stroke | 2022 |
Monthly sulfadoxine/pyrimethamine-amodiaquine or dihydroartemisinin-piperaquine as malaria chemoprevention in young Kenyan children with sickle cell anemia: A randomized controlled trial.
Topics: Amodiaquine; Anemia, Sickle Cell; Antimalarials; Artemisinins; Chemoprevention; Child; Child, Presch | 2022 |
Cost-effectiveness analysis of adding omega-3 or vitamin D supplementation to standard therapy in treating painful crises of pediatric sickle cell disease patients.
Topics: Anemia, Sickle Cell; Child; Cost-Benefit Analysis; Dietary Supplements; Fatty Acids, Omega-3; Humans | 2022 |
Hydroxyurea for secondary stroke prevention in children with sickle cell anemia in Nigeria: a randomized controlled trial.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Humans; Hydroxyurea; Nigeria; Secondary Prevention; | 2023 |
Underweight children older than 5 years with sickle cell anemia are at risk for early mortality in a low-resource setting.
Topics: Anemia, Sickle Cell; Body Mass Index; Child; Child, Preschool; Growth Disorders; Humans; Hydroxyurea | 2023 |
Underweight children older than 5 years with sickle cell anemia are at risk for early mortality in a low-resource setting.
Topics: Anemia, Sickle Cell; Body Mass Index; Child; Child, Preschool; Growth Disorders; Humans; Hydroxyurea | 2023 |
Underweight children older than 5 years with sickle cell anemia are at risk for early mortality in a low-resource setting.
Topics: Anemia, Sickle Cell; Body Mass Index; Child; Child, Preschool; Growth Disorders; Humans; Hydroxyurea | 2023 |
Underweight children older than 5 years with sickle cell anemia are at risk for early mortality in a low-resource setting.
Topics: Anemia, Sickle Cell; Body Mass Index; Child; Child, Preschool; Growth Disorders; Humans; Hydroxyurea | 2023 |
Underweight children older than 5 years with sickle cell anemia are at risk for early mortality in a low-resource setting.
Topics: Anemia, Sickle Cell; Body Mass Index; Child; Child, Preschool; Growth Disorders; Humans; Hydroxyurea | 2023 |
Underweight children older than 5 years with sickle cell anemia are at risk for early mortality in a low-resource setting.
Topics: Anemia, Sickle Cell; Body Mass Index; Child; Child, Preschool; Growth Disorders; Humans; Hydroxyurea | 2023 |
Underweight children older than 5 years with sickle cell anemia are at risk for early mortality in a low-resource setting.
Topics: Anemia, Sickle Cell; Body Mass Index; Child; Child, Preschool; Growth Disorders; Humans; Hydroxyurea | 2023 |
Underweight children older than 5 years with sickle cell anemia are at risk for early mortality in a low-resource setting.
Topics: Anemia, Sickle Cell; Body Mass Index; Child; Child, Preschool; Growth Disorders; Humans; Hydroxyurea | 2023 |
Underweight children older than 5 years with sickle cell anemia are at risk for early mortality in a low-resource setting.
Topics: Anemia, Sickle Cell; Body Mass Index; Child; Child, Preschool; Growth Disorders; Humans; Hydroxyurea | 2023 |
Factors associated with health-related quality of life in children with sickle cell disease.
Topics: Anemia, Sickle Cell; Humans; Hydroxyurea; Parents; Quality of Life; Surveys and Questionnaires | 2023 |
Zinc for infection prevention in children with sickle cell anemia: a randomized double-blind placebo-controlled trial.
Topics: Adolescent; Adult; Africa; Anemia, Sickle Cell; Child; Humans; Hydroxyurea; Stroke; Zinc | 2023 |
Using the consolidated framework for implementation research to identify recruitment barriers and targeted strategies for a shared decision-making randomized clinical trial in pediatric sickle cell disease.
Topics: Anemia, Sickle Cell; Caregivers; Child; Child, Preschool; Female; Humans; Hydroxyurea; Surveys and Q | 2023 |
Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Female; Humans; Hydroxyurea; Male; Stroke; Tanzania | 2023 |
Feasibility trial for the management of severe acute malnutrition in older children with sickle cell anemia in Nigeria.
Topics: Anemia, Sickle Cell; Child; Feasibility Studies; Humans; Hydroxyurea; Malnutrition; Nigeria; Severe | 2023 |
Prospective identification of variables as outcomes for treatment (PIVOT): study protocol for a randomised, placebo-controlled trial of hydroxyurea for Ghanaian children and adults with haemoglobin SC disease.
Topics: Adult; Anemia, Sickle Cell; Child; Ghana; Hemoglobin SC Disease; Humans; Hydroxyurea; Quality of Lif | 2023 |
A multilevel mHealth intervention boosts adherence to hydroxyurea in individuals with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Female; Humans; Hydroxyurea; Male; Medication Adherence; Pain; Telemedic | 2023 |
A pilot study of the effect of atorvastatin on endothelial function and albuminuria in sickle cell disease.
Topics: Aged; Albuminuria; Anemia, Sickle Cell; Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; beta | 2019 |
Evaluation of hydroxyurea genotoxicity in patients with sickle cell disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Child; Child, Preschool; Cytokinesis; DNA Damage; Female; Hu | 2019 |
HABIT efficacy and sustainability trial, a multi-center randomized controlled trial to improve hydroxyurea adherence in youth with sickle cell disease: a study protocol.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Humans; Hydroxyurea; Medication Adheren | 2019 |
Inpatient Ordering of Home Hydroxyurea by Residents for Hospitalized Patients With Sickle Cell Disease.
Topics: Adolescent; Anemia, Sickle Cell; Child; Drug Prescriptions; Female; Hospitalization; Humans; Hydroxy | 2020 |
Oxidative stress assessment in sickle cell anemia patients treated with hydroxyurea.
Topics: Adult; Anemia, Sickle Cell; Cholesterol; Erythrocytes, Abnormal; Female; Humans; Hydroxyurea; Male; | 2020 |
Measuring hydroxyurea adherence by pharmacy and laboratory data compared with video observation in children with sickle cell disease.
Topics: Adolescent; Anemia, Sickle Cell; Child; Child, Preschool; Cross-Sectional Studies; Erythrocyte Indic | 2020 |
Combination dose-escalated hydroxyurea and transfusion: an approach to conserve blood during the COVID-19 pandemic.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Blood Donors; Blood Safety; Blood Transfusion; Chelation The | 2020 |
Novel dose escalation to predict treatment with hydroxyurea (NDEPTH): A randomized controlled trial of a dose-prediction equation to determine maximum tolerated dose of hydroxyurea in pediatric sickle cell disease.
Topics: Adolescent; Anemia, Sickle Cell; Child; Female; Humans; Hydroxyurea; Male; Maximum Tolerated Dose | 2020 |
Moderate fixed-dose hydroxyurea for primary prevention of strokes in Nigerian children with sickle cell disease: Final results of the SPIN trial.
Topics: Anemia, Sickle Cell; Child; Child, Preschool; Female; Humans; Hydroxyurea; Male; Nigeria; Stroke | 2020 |
Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child, Preschool; Dose-Response Relationship, Drug; Double | 2020 |
Individual red blood cell fetal hemoglobin quantification allows to determine protective thresholds in sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Erythrocytes, Abnormal; Female; Fetal Hemoglobin; Flow Cytometry; Humans | 2020 |
Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide.
Topics: Adult; Anemia, Sickle Cell; Anti-Mullerian Hormone; Female; Hemoglobin, Sickle; Humans; Hydroxyurea; | 2020 |
Hydroxycarbamide decreases the free alpha-hemoglobin pool in red blood cells of adult patients with sickle cell anemia.
Topics: Adult; alpha-Globins; Anemia, Sickle Cell; Erythrocytes, Abnormal; Female; Humans; Hydroxyurea; Male | 2020 |
Evaluation of Longitudinal Pain Study in Sickle Cell Disease (ELIPSIS) by patient-reported outcomes, actigraphy, and biomarkers.
Topics: Actigraphy; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Biomarkers; Female; Humans; | 2021 |
Hydroxyurea Optimization through Precision Study (HOPS): study protocol for a randomized, multicenter trial in children with sickle cell anemia.
Topics: Anemia, Sickle Cell; Antisickling Agents; Body Weight; Bone Marrow Diseases; Child; Humans; Hydroxyu | 2020 |
ADAMTS-13-VWF axis in sickle cell disease patients.
Topics: ADAMTS13 Protein; Adolescent; Adult; Anemia, Sickle Cell; Cross-Sectional Studies; Female; Humans; H | 2021 |
Oxidative stress, inflammation, blood rheology, and microcirculation in adults with sickle cell disease: Effects of hydroxyurea treatment and impact of sickle cell syndrome.
Topics: Adult; Anemia, Sickle Cell; Biomarkers; Blood Viscosity; Female; Humans; Hydroxyurea; Inflammation; | 2021 |
Establishing Sickle Cell Disease Stroke Prevention Teams in Africa is Feasible: Program Evaluation Using the RE-AIM Framework.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Female; Humans; Hydroxyurea; Male | 2022 |
Rapid and automated quantitation of dense red blood cells: A robust biomarker of hydroxyurea treatment response.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Biomarkers; Child; Child, Preschool; Erythrocy | 2021 |
What drives transcranial Doppler velocity improvement in paediatric sickle cell anaemia: analysis from the Sickle Cell Clinical Research and Intervention Program (SCCRIP) longitudinal cohort study.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Flow Velocity; Child; Child, Preschool; Female; Hemo | 2021 |
Real-Life experience with hydroxyurea in patients with sickle cell disease: Results from the prospective ESCORT-HU cohort study.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Child; Europe; Female; Humans; Hydroxyu | 2021 |
Early initiation of hydroxyurea (hydroxycarbamide) using individualised, pharmacokinetics-guided dosing can produce sustained and nearly pancellular expression of fetal haemoglobin in children with sickle cell anaemia.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Dose-Response Relatio | 2021 |
Hydroxycarbamide treatment reduces transcranial Doppler velocity in the absence of transfusion support in children with sickle cell anaemia, elevated transcranial Doppler velocity, and cerebral vasculopathy: the EXTEND trial.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Blood Flow Velocity; Cerebrovascular Circulati | 2021 |
Feasibility trial for primary stroke prevention in children with sickle cell anemia in Nigeria (SPIN trial).
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Female; Follow-Up Studies; Hospit | 2017 |
Red blood cell transfusions during sickle cell anemia vaso-occlusive crises: a report from the magnesium in crisis (MAGiC) study.
Topics: Acute Chest Syndrome; Adolescent; Anemia, Sickle Cell; Arterial Occlusive Diseases; Child; Child, Pr | 2017 |
Unrelated Umbilical Cord Blood Transplantation for Sickle Cell Disease Following Reduced-Intensity Conditioning: Results of a Phase I Trial.
Topics: Alemtuzumab; Anemia, Sickle Cell; Calcineurin Inhibitors; Child; Child, Preschool; Cord Blood Stem C | 2017 |
Randomized feasibility trial to improve hydroxyurea adherence in youth ages 10-18 years through community health workers: The HABIT study.
Topics: Adolescent; Anemia, Sickle Cell; Child; Community Health Workers; Feasibility Studies; Female; Fetal | 2017 |
Hydroxycarbamide in children with sickle cell anaemia after first-dose vs. chronic therapy: pharmacokinetics and predictive models for drug exposure.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Area Under Curve; Biological Availability; Chi | 2018 |
Desire for parenthood and reproductive health knowledge in adolescents and young adults with sickle cell disease and their caregivers.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Caregivers; Contraception; Female; Fertility; Humans; Hydrox | 2018 |
Adverse effect of hydroxyurea on spermatogenesis in patients with sickle cell anemia after 6 months of treatment.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Humans; Hydroxyurea; Male; Middle Aged; Sperm Count | 2017 |
Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Cell Count; Child, Preschool; Double-Blind Method; E | 2017 |
CD209-336A/G promotor polymorphism and its clinical associations in sickle cell disease Egyptian Pediatric patients.
Topics: Adolescent; Alleles; Anemia, Sickle Cell; Cell Adhesion Molecules; Child; Egypt; Female; Gene Freque | 2018 |
Impact of Hydroxyurea on Anthropometry and Serum 25-Hydroxyvitamin D Among Children With Sickle Cell Disease.
Topics: Anemia, Sickle Cell; Anthropometry; Child; Child, Preschool; Female; Humans; Hydroxyurea; Male; Vita | 2018 |
Realizing effectiveness across continents with hydroxyurea: Enrollment and baseline characteristics of the multicenter REACH study in Sub-Saharan Africa.
Topics: Africa South of the Sahara; alpha-Thalassemia; Anemia, Sickle Cell; Blood Transfusion; Child; Child, | 2018 |
Beliefs about hydroxyurea in youth with sickle cell disease.
Topics: Adolescent; Anemia, Sickle Cell; Child; Cross-Sectional Studies; Culture; Female; Humans; Hydroxyure | 2018 |
Plerixafor enables safe, rapid, efficient mobilization of hematopoietic stem cells in sickle cell disease patients after exchange transfusion.
Topics: Anemia, Sickle Cell; Anti-HIV Agents; Antigens, CD34; Antisickling Agents; Benzylamines; Blood Trans | 2018 |
HABIT, a Randomized Feasibility Trial to Increase Hydroxyurea Adherence, Suggests Improved Health-Related Quality of Life in Youths with Sickle Cell Disease.
Topics: Adolescent; Anemia, Sickle Cell; Behavior Therapy; Child; Community Health Workers; Feasibility Stud | 2018 |
A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
Topics: Administration, Oral; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; | 2018 |
A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
Topics: Administration, Oral; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; | 2018 |
A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
Topics: Administration, Oral; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; | 2018 |
A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
Topics: Administration, Oral; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; | 2018 |
A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
Topics: Administration, Oral; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; | 2018 |
A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
Topics: Administration, Oral; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; | 2018 |
A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
Topics: Administration, Oral; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; | 2018 |
A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
Topics: Administration, Oral; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; | 2018 |
A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
Topics: Administration, Oral; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; | 2018 |
Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: A SUSTAIN study analysis.
Topics: Adolescent; Adult; Aged; Anemia, Sickle Cell; Antibodies, Monoclonal; Antibodies, Monoclonal, Humani | 2019 |
Hydroxyurea therapy modulates sickle cell anemia red blood cell physiology: Impact on RBC deformability, oxidative stress, nitrite levels and nitric oxide synthase signalling pathway.
Topics: Adult; Anemia, Sickle Cell; Erythrocyte Deformability; Erythrocytes; Female; Humans; Hydroxyurea; Ma | 2018 |
Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa.
Topics: Africa South of the Sahara; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Dose- | 2019 |
Building capacity to reduce stroke in children with sickle cell anemia in the Dominican Republic: the SACRED trial.
Topics: Anemia, Sickle Cell; Antisickling Agents; Capacity Building; Child; Dominican Republic; Humans; Hydr | 2018 |
PF-04447943, a Phosphodiesterase 9A Inhibitor, in Stable Sickle Cell Disease Patients: A Phase Ib Randomized, Placebo-Controlled Study.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adolescent; Adult; Aged; Anemia, Sickle Cell; Biomarkers; Dose- | 2019 |
"Maximum tolerated dose" vs "fixed low-dose" hydroxyurea for treatment of adults with sickle cell anemia.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Female; Humans; Hydroxyurea; Male; Maximum Tolerated Dose | 2019 |
Hydroxyurea reduces cerebral metabolic stress in patients with sickle cell anemia.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Cerebrovascular Circulation; Child; Female; Humans; Hydroxyu | 2019 |
Neurocognitive functioning in symptomatic adults with sickle cell disease: A description and comparison with unaffected siblings.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Cognitive Dysfunction; Executive Function; Female; | 2020 |
Greater number of perceived barriers to hydroxyurea associated with poorer health-related quality of life in youth with sickle cell disease.
Topics: Adolescent; Anemia, Sickle Cell; Child; Cross-Sectional Studies; Female; Humans; Hydroxyurea; Male; | 2019 |
Stroke Recurrence in Nigerian Children With Sickle Cell Disease: Evidence for a Secondary Stroke Prevention Trial.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Female; Follow-Up Stu | 2019 |
Stroke Recurrence in Nigerian Children With Sickle Cell Disease: Evidence for a Secondary Stroke Prevention Trial.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Female; Follow-Up Stu | 2019 |
Stroke Recurrence in Nigerian Children With Sickle Cell Disease: Evidence for a Secondary Stroke Prevention Trial.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Female; Follow-Up Stu | 2019 |
Stroke Recurrence in Nigerian Children With Sickle Cell Disease: Evidence for a Secondary Stroke Prevention Trial.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Female; Follow-Up Stu | 2019 |
The effects of hydroxycarbamide on the plasma proteome of children with sickle cell anaemia.
Topics: Adolescent; Anemia, Sickle Cell; Biomarkers; Blood Proteins; Child; Female; Humans; Hydroxyurea; Mal | 2019 |
A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Benzaldehydes; Biomarkers; Child; Dose- | 2019 |
A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Benzaldehydes; Biomarkers; Child; Dose- | 2019 |
A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Benzaldehydes; Biomarkers; Child; Dose- | 2019 |
A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Benzaldehydes; Biomarkers; Child; Dose- | 2019 |
Hydroxycarbamide treatment in children with Sickle Cell Anaemia is associated with more intact white matter integrity: a quantitative MRI study.
Topics: Adolescent; Anemia, Sickle Cell; Child; Female; Humans; Hydroxyurea; Male; White Matter | 2019 |
Hydroxyurea alters hematological, biochemical and inflammatory biomarkers in Brazilian children with SCA: Investigating associations with βS haplotype and α-thalassemia.
Topics: alpha-Thalassemia; Anemia, Sickle Cell; Bilirubin; Biomarkers; Blood Glucose; Child; Child, Preschoo | 2019 |
Exploring barriers and facilitators to clinical trial enrollment in the context of sickle cell anemia and hydroxyurea.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Female; Humans; Hydroxyurea; Male; Medication Adher | 2013 |
Optimizing Hydroxyurea use in children with sickle cell disease: low dose regimen is effective.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Female; Hemoglobins; | 2013 |
The effect of hydroxcarbamide therapy on survival of children with sickle cell disease.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Cause of Death; Child; Child, Preschool; Femal | 2013 |
Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes.
Topics: alpha-Thalassemia; Anemia, Sickle Cell; Antisickling Agents; beta-Globins; Bilirubin; Carrier Protei | 2013 |
A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease.
Topics: Administration, Oral; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; | 2013 |
A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease.
Topics: Administration, Oral; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; | 2013 |
A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease.
Topics: Administration, Oral; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; | 2013 |
A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease.
Topics: Administration, Oral; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; | 2013 |
Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial.
Topics: Acute Chest Syndrome; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Benzoates; Chelat | 2013 |
Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.
Topics: Acute Kidney Injury; Adolescent; Adult; Anemia, Sickle Cell; Benzoates; Cellulitis; Chelation Therap | 2013 |
Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child, Preschool; Databases, Factual; Double-Blind Method; | 2013 |
Clinical significance of circulating blood and endothelial cell microparticles in sickle-cell disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antigens, Differentiation; Antisickling Agents; Blood Platel | 2014 |
A pilot study of electronic directly observed therapy to improve hydroxyurea adherence in pediatric patients with sickle-cell disease.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Cell Phone; Child; Child, Preschool; Directly | 2014 |
Challenge of managing sickle cell disease in a pediatric population living in kinshasa, democratic republic of congo: a sickle cell center experience.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Blood-Borne Pathogen | 2014 |
Population pharmacokinetics of hydroxyurea for children and adolescents with sickle cell disease.
Topics: Administration, Oral; Adolescent; Anemia, Sickle Cell; Antisickling Agents; Area Under Curve; Child; | 2014 |
Predictors of splenic function preservation in children with sickle cell anemia treated with hydroxyurea.
Topics: Adolescent; Age Factors; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Female; | 2014 |
Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial.
Topics: Adolescent; Anemia, Sickle Cell; Blood Flow Velocity; Blood Transfusion; Brain; Cerebrovascular Circ | 2014 |
Hydroxyurea and growth in young children with sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Body Size; Body Weight; Child, Preschool; Double-Blind Met | 2014 |
Immunologic effects of hydroxyurea in sickle cell anemia.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child, Preschool; Double-Blind Method; Female; Humans; Hyd | 2014 |
Whole exome sequencing identifies novel genes for fetal hemoglobin response to hydroxyurea in children with sickle cell anemia.
Topics: Anemia, Sickle Cell; Child; Cohort Studies; DNA-Binding Proteins; Dose-Response Relationship, Drug; | 2014 |
Oscillatory haematopoiesis in adults with sickle cell disease treated with hydroxycarbamide.
Topics: Adult; Aged; Anemia, Sickle Cell; Antisickling Agents; Biological Clocks; Blood Cell Count; Female; | 2015 |
Primary stroke prevention in Nigerian children with sickle cell disease (SPIN): challenges of conducting a feasibility trial.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Feasibility Studies; Female; Foll | 2015 |
Erythropoietin levels in patients with sickle cell disease do not correlate with known inducers of erythropoietin.
Topics: Adult; Aged; Anemia, Sickle Cell; Antisickling Agents; Biomarkers; Erythropoietin; Female; Hemoglobi | 2014 |
Hydroxyurea increases plasma concentrations of microparticles and reduces coagulation activation and fibrinolysis in patients with sickle cell anemia.
Topics: Adult; Anemia, Sickle Cell; Animals; Antisickling Agents; Antithrombins; Cell-Derived Microparticles | 2015 |
From infancy to adolescence: fifteen years of continuous treatment with hydroxyurea in sickle cell anemia.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Dose-Response Relatio | 2014 |
Immune parameter analysis of children with sickle cell disease on hydroxycarbamide or chronic transfusion therapy.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Black or African American; Blood Transfusion; | 2015 |
Omega 3 (n-3) fatty acids down-regulate nuclear factor-kappa B (NF-κB) gene and blood cell adhesion molecule expression in patients with homozygous sickle cell disease.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; C-Reactive Protein; Case-Control Studies; Cell | 2015 |
Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Female; Histone Deacetylase Inhibitors; Humans; Hyd | 2015 |
Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Benzoates; Biological Assay; Child; Child, Pre | 2015 |
Pharmacokinetics and bioequivalence of a liquid formulation of hydroxyurea in children with sickle cell anemia.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Capsules; Child; Child, Preschool; Female; Hum | 2016 |
Prevention of conversion to abnormal transcranial Doppler with hydroxyurea in sickle cell anemia: A Phase III international randomized clinical trial.
Topics: Anemia, Sickle Cell; Antineoplastic Agents; Child; Child, Preschool; Female; Humans; Hydroxyurea; Ma | 2015 |
Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Female; Ferritins; Humans; Hydroxyurea; Iron; Iron | 2016 |
Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Blood Flow Velocity; Blood Transfusion; Cerebr | 2016 |
Hydroxyurea use in Children with Sickle Cell Disease: Do Severely Affected Patients Use It and Does It Impact Hospitalization Outcomes?
Topics: Adolescent; Anemia, Sickle Cell; Blood Transfusion; Child; Child, Preschool; Female; Humans; Hydroxy | 2016 |
Long-term treatment follow-up of children with sickle cell disease monitored with abnormal transcranial Doppler velocities.
Topics: Anemia, Sickle Cell; Blood Flow Velocity; Blood Transfusion; Cerebrovascular Circulation; Female; Fo | 2016 |
Health-related quality of life and adherence to hydroxyurea in adolescents and young adults with sickle cell disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Child; Cross-Sectional Studies; Female; Humans; Hydroxyurea; | 2017 |
Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; D | 2017 |
Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; D | 2017 |
Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; D | 2017 |
Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; D | 2017 |
A pilot study of hydroxyurea to prevent chronic organ damage in young children with sickle cell anemia.
Topics: Anemia, Sickle Cell; Body Height; Body Weight; Child, Preschool; Chronic Disease; Cognition; Drug To | 2009 |
Improvement in hemolysis and pulmonary arterial systolic pressure in adult patients with sickle cell disease during treatment with hydroxyurea.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Arginase; Blood Pressure; Disease-Free Survival; Ec | 2009 |
Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia.
Topics: Anemia, Sickle Cell; Antisickling Agents; Female; Fetus; Humans; Hydroxyurea; Male; Pregnancy; Pregn | 2009 |
The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS).
Topics: Adult; Aged; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Female; Fetal Hemoglobin; | 2010 |
Assessment of genotoxicity associated with hydroxyurea therapy in children with sickle cell anemia.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; DNA Damage; Humans; H | 2010 |
The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up.
Topics: Adolescent; Adult; Anemia, Sickle Cell; DNA Damage; Drug Utilization; Early Termination of Clinical | 2010 |
Recruitment of infants with sickle cell anemia to a Phase III trial: data from the BABY HUG study.
Topics: Anemia, Sickle Cell; Antisickling Agents; Attitude to Health; Humans; Hydroxyurea; Infant; Infant, N | 2010 |
Early detection of response to hydroxyurea therapy in patients with sickle cell anemia.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Erythrocyte Indices; Erythrocytes; Female; Fetal He | 2010 |
Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antisickling Agents; Double-Blind Method | 2010 |
The impact of hydroxyurea on career and employment of patients with sickle cell anemia.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Canada; Career Mobility; Chi-Square Distribution; D | 2010 |
The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients.
Topics: Activities of Daily Living; Adolescent; Adult; Analgesics; Anemia, Sickle Cell; Chronic Disease; Fem | 2011 |
Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG).
Topics: Acute Chest Syndrome; Anemia, Sickle Cell; Antisickling Agents; Biomarkers; Blood Cell Count; Child | 2011 |
Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG).
Topics: Acute Chest Syndrome; Anemia, Sickle Cell; Antisickling Agents; Biomarkers; Blood Cell Count; Child | 2011 |
Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG).
Topics: Acute Chest Syndrome; Anemia, Sickle Cell; Antisickling Agents; Biomarkers; Blood Cell Count; Child | 2011 |
Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG).
Topics: Acute Chest Syndrome; Anemia, Sickle Cell; Antisickling Agents; Biomarkers; Blood Cell Count; Child | 2011 |
Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: baseline data from the BABY HUG trial.
Topics: Abdomen; Alanine Transaminase; Analysis of Variance; Anemia, Sickle Cell; Antisickling Agents; Bilir | 2011 |
Population pharmacokinetics and pharmacodynamics of hydroxyurea in sickle cell anemia patients, a basis for optimizing the dosing regimen.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Computer Simulation; Drug Administration Schedule; Female; H | 2011 |
Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child, Preschool; Drug Overdose; Female; Humans; Hydroxyur | 2012 |
Stroke With Transfusions Changing to Hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Chelation Therapy; Child; Child, Preschool; Erythrocyte Tran | 2011 |
Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia.
Topics: Adolescent; Anemia, Sickle Cell; Biomarkers, Pharmacological; Child; Child, Preschool; DNA Mutationa | 2011 |
Epigenetic and molecular profiles of erythroid cells after hydroxyurea treatment in sickle cell anemia.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Child; CpG Islands; DNA Methylation; Epigenesis, Ge | 2011 |
Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial.
Topics: Anemia, Sickle Cell; Antisickling Agents; DNA Damage; Double-Blind Method; Follow-Up Studies; Humans | 2012 |
Effects of co-existing α-thalassaemia in sickle cell disease on hydroxycarbamide therapy and circulating nucleic acids.
Topics: alpha-Thalassemia; Anemia, Sickle Cell; Antisickling Agents; Female; Humans; Hydroxyurea; Infant; Ma | 2012 |
Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study.
Topics: Acute Disease; Anemia, Sickle Cell; Antisickling Agents; Double-Blind Method; Fever; Hemoglobins; Hu | 2012 |
Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities.
Topics: Anemia, Sickle Cell; Autoantibodies; Blood Flow Velocity; Cerebrovascular Circulation; Child; Child, | 2012 |
Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia.
Topics: Anemia, Sickle Cell; Antisickling Agents; Creatinine; Cystatin C; Double-Blind Method; Female; Glome | 2012 |
Stroke With Transfusions Changing to Hydroxyurea (SWiTCH).
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Female; Humans; Hydroxyurea; Male; Maxi | 2012 |
Stroke With Transfusions Changing to Hydroxyurea (SWiTCH).
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Female; Humans; Hydroxyurea; Male; Maxi | 2012 |
Stroke With Transfusions Changing to Hydroxyurea (SWiTCH).
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Female; Humans; Hydroxyurea; Male; Maxi | 2012 |
Stroke With Transfusions Changing to Hydroxyurea (SWiTCH).
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Female; Humans; Hydroxyurea; Male; Maxi | 2012 |
Hydroxycarbamide alters erythroid gene expression in children with sickle cell anaemia.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Carrier Proteins; Child; Child, Preschool; Fem | 2012 |
Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Child; Female; Fetal Hemogl | 2012 |
Impact of hydroxyurea on clinical events in the BABY HUG trial.
Topics: Acute Chest Syndrome; Anemia, Sickle Cell; Antisickling Agents; Child, Preschool; Double-Blind Metho | 2012 |
Impact of hydroxyurea on clinical events in the BABY HUG trial.
Topics: Acute Chest Syndrome; Anemia, Sickle Cell; Antisickling Agents; Child, Preschool; Double-Blind Metho | 2012 |
Impact of hydroxyurea on clinical events in the BABY HUG trial.
Topics: Acute Chest Syndrome; Anemia, Sickle Cell; Antisickling Agents; Child, Preschool; Double-Blind Metho | 2012 |
Impact of hydroxyurea on clinical events in the BABY HUG trial.
Topics: Acute Chest Syndrome; Anemia, Sickle Cell; Antisickling Agents; Child, Preschool; Double-Blind Metho | 2012 |
Comparison of hematologic measurements between local and central laboratories: data from the BABY HUG trial.
Topics: Anemia, Sickle Cell; Blood Cell Count; Hematology; Humans; Hydroxyurea; Infant; Laboratories; Labora | 2013 |
Hydroxyurea treatment decreases glomerular hyperfiltration in children with sickle cell anemia.
Topics: Adolescent; Albuminuria; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Cohort S | 2013 |
Developmental function in toddlers with sickle cell anemia.
Topics: Activities of Daily Living; Adaptation, Psychological; Age Factors; Anemia, Sickle Cell; Antisicklin | 2013 |
Divergent nitric oxide bioavailability in men and women with sickle cell disease.
Topics: Acetylcholine; Adult; Anemia, Sickle Cell; Biological Availability; Biomarkers; Black People; Blood | 2003 |
Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Cell Count; Cause of Death; Double-Blind Meth | 2003 |
UGT1A promoter polymorphisms influence bilirubin response to hydroxyurea therapy in sickle cell anemia.
Topics: Anemia, Sickle Cell; Antisickling Agents; Bilirubin; Child; Dose-Response Relationship, Drug; Drug A | 2003 |
Hydroxyurea and arginine therapy: impact on nitric oxide production in sickle cell disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antineoplastic Agents; Arginine; Child; Drug Interactions; D | 2003 |
Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Cohort Studies | 2004 |
Effects of hydroxyurea on the membrane of erythrocytes and platelets in sickle cell anemia.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Platelets; Cell Adhesion Molecule | 2004 |
Clinical response and adverse events in young patients with sickle cell disease treated with hydroxyurea.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Child; Erythrocyte Indices; Erythrocyte Transfusion; Female; | 2004 |
Follow-up of sickle cell disease patients with priapism treated by hydroxyurea.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; | 2004 |
The influence of renal function on hydroxyurea pharmacokinetics in adults with sickle cell disease.
Topics: Adult; Aged; Anemia, Sickle Cell; Female; Humans; Hydroxyurea; Kidney; Kidney Failure, Chronic; Kidn | 2005 |
[Evaluation of clinical response by hydroxyurea in 132 patients with major sickle cell anemia].
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Female; Humans; Hydroxyurea; Male; Midd | 2005 |
Effect of long-term transfusion on growth in children with sickle cell anemia: results of the STOP trial.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Body Height; Body Weight; C | 2005 |
Effect of long-term transfusion on growth in children with sickle cell anemia: results of the STOP trial.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Body Height; Body Weight; C | 2005 |
Effect of long-term transfusion on growth in children with sickle cell anemia: results of the STOP trial.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Body Height; Body Weight; C | 2005 |
Effect of long-term transfusion on growth in children with sickle cell anemia: results of the STOP trial.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Body Height; Body Weight; C | 2005 |
Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study.
Topics: Anemia, Sickle Cell; Blood Platelets; Child; Child, Preschool; Clinical Trials as Topic; Dose-Respon | 2005 |
Long-term hydroxyurea treatment in children with sickle cell disease: tolerance and clinical outcomes.
Topics: Adolescent; Anemia, Sickle Cell; Child; Child, Preschool; Female; Humans; Hydroxyurea; Male; Time Fa | 2006 |
Effect of hydroxyurea on the deformability of the red blood cell membrane in patients with sickle cell anemia.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Cell Membrane; Erythrocyte Deformability; Female; H | 2006 |
Clinical response of patients with sickle cell anemia to cromolyn sodium nasal spray.
Topics: Administration, Intranasal; Adolescent; Anemia, Sickle Cell; Anti-Asthmatic Agents; Blood Transfusio | 2006 |
Hydroxyurea and sickle cell anemia: effect on quality of life.
Topics: Activities of Daily Living; Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Cell Count; Doubl | 2006 |
Pharmacokinetics of hydroxyurea 1,000 mg coated breakable tablets and 500 mg capsules in pediatric and adult patients with sickle cell disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Capsules; Chemistry, Pharmaceutical; Child; Child, Preschool | 2006 |
Effect of myeloablative bone marrow transplantation on growth in children with sickle cell anaemia: results of the multicenter study of haematopoietic cell transplantation for sickle cell anaemia.
Topics: Age Factors; Aging; Anemia, Sickle Cell; Antisickling Agents; Body Height; Bone Marrow Transplantati | 2007 |
Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea.
Topics: Alcohol Oxidoreductases; Anemia, Sickle Cell; Antisickling Agents; Arginase; Biotransformation; Chro | 2007 |
Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Flow Velocity; Blood Transfusion; Child; Child, Pres | 2007 |
Phase I study of magnesium pidolate in combination with hydroxycarbamide for children with sickle cell anaemia.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Drug Combinations; Hu | 2008 |
Limitations of clinical trials in sickle cell disease: a case study of the Multi-center Study of Hydroxyurea (MSH) trial and the Stroke Prevention (STOP) trial.
Topics: Anemia, Sickle Cell; Humans; Hydroxyurea; Multicenter Studies as Topic; Randomized Controlled Trials | 2007 |
Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Bone Marrow; Clinical Trials as Topic; DNA; Female; Fetal He | 1984 |
On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Drug Therapy, Combina | 1995 |
Experimental therapy of sickle cell disease. Use of hydroxyurea.
Topics: Anemia, Sickle Cell; Azacitidine; Bone Marrow Transplantation; Humans; Hydroxyurea | 1994 |
Clinical and laboratory effects of long-term administration of hydroxyurea to patients with sickle-cell/beta-thalassaemia.
Topics: Adult; Aged; Anemia, Sickle Cell; beta-Thalassemia; Cell Size; Drug Administration Schedule; Erythro | 1995 |
Isobutyramide therapy in patients with sickle cell anemia.
Topics: Adult; Amides; Anemia, Sickle Cell; Female; Fetal Hemoglobin; Globins; Humans; Hydroxyurea; L-Lactat | 1995 |
Pharmacological modification of hemoglobin F expression in sickle cell anemia: an update on hydroxyurea studies.
Topics: Anemia, Sickle Cell; Animals; Azacitidine; Erythrocytes; Fetal Hemoglobin; Gene Expression; Humans; | 1993 |
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Topics: Adult; Anemia, Sickle Cell; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydroxyurea; Mal | 1995 |
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Topics: Adult; Anemia, Sickle Cell; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydroxyurea; Mal | 1995 |
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Topics: Adult; Anemia, Sickle Cell; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydroxyurea; Mal | 1995 |
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Topics: Adult; Anemia, Sickle Cell; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydroxyurea; Mal | 1995 |
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Topics: Adult; Anemia, Sickle Cell; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydroxyurea; Mal | 1995 |
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Topics: Adult; Anemia, Sickle Cell; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydroxyurea; Mal | 1995 |
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Topics: Adult; Anemia, Sickle Cell; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydroxyurea; Mal | 1995 |
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Topics: Adult; Anemia, Sickle Cell; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydroxyurea; Mal | 1995 |
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Topics: Adult; Anemia, Sickle Cell; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydroxyurea; Mal | 1995 |
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Topics: Adult; Anemia, Sickle Cell; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydroxyurea; Mal | 1995 |
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Topics: Adult; Anemia, Sickle Cell; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydroxyurea; Mal | 1995 |
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Topics: Adult; Anemia, Sickle Cell; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydroxyurea; Mal | 1995 |
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Topics: Adult; Anemia, Sickle Cell; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydroxyurea; Mal | 1995 |
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Topics: Adult; Anemia, Sickle Cell; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydroxyurea; Mal | 1995 |
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Topics: Adult; Anemia, Sickle Cell; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydroxyurea; Mal | 1995 |
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Topics: Adult; Anemia, Sickle Cell; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydroxyurea; Mal | 1995 |
Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Child; Child, Preschool; Cross-Over Studies; Female; Humans; | 1996 |
Design of the multicenter study of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Double-Blind Method; Female; Fetal Hemoglobin; Huma | 1995 |
Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Cell Count; Double-Blind Method; | 1996 |
Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea.
Topics: Adult; Anemia, Sickle Cell; Blood Cell Count; Double-Blind Method; Female; Fetal Hemoglobin; Follow- | 1997 |
Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Body Composition; Body Weight; Double-Blind Method; | 1997 |
An extension of stochastic curtailment for incompletely reported and classified recurrent events: the Multicenter Study of Hydroxyurea in Sickle Cell Anemia (MSH).
Topics: Anemia, Sickle Cell; Antisickling Agents; Bias; Confidence Intervals; Data Collection; Double-Blind | 1997 |
Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Erythrocyte Indices; Fetal Hemoglobin; Humans; Hydr | 1997 |
Hydroxyurea therapy for diverse pediatric populations with sickle cell disease.
Topics: Adolescent; Anemia, Sickle Cell; Blood Transfusion; Child; Child, Preschool; Erythrocyte Indices; Fe | 1997 |
Hydroxyurea therapy in sickle cell anemia patients in Curaçao, The Netherlands Antilles.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Drug Administration Schedule; Female; Fetal Hemoglo | 1997 |
Hydroxyurea therapy in thalassemia.
Topics: Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Drug Therapy, Combination; Erythropoiesi | 1998 |
Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Blood Urea Nitrogen; Butyrates; Cell Division; Erythrocyte C | 1999 |
Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Cell Survival; Double-Blind Method; Erythrocytes; E | 1999 |
Levels of endothelial, neutrophil and platelet-specific factors in sickle cell anemia patients during hydroxyurea therapy.
Topics: Adolescent; Adult; Aged; Anemia, Sickle Cell; Antisickling Agents; Blood Platelets; Endothelium, Vas | 1999 |
Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Drug Monitorin | 1999 |
Cost-effectiveness of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Cost-Benefit Analysis; Double-Blind Method; Female; | 2000 |
Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.
Topics: Acute Disease; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Erythr | 2000 |
A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia.
Topics: Age Factors; Anemia, Sickle Cell; Antisickling Agents; Blood Cell Count; Child, Preschool; Feasibili | 2001 |
Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Fetal Hemoglobin; Hemoglobins; Humans; Hydroxyurea; | 2002 |
Scintigraphic follow-up of the effects of therapy with hydroxyurea on splenic function in patients with sickle cell disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Blood Transfusion; Child; Child, Preschool; Female; Fetal He | 2002 |
Hydroxyurea in sickle cell disease patients from Eastern Saudi Arabia.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Child; Female; Hemolysis; Humans; Hydro | 2002 |
Hydroxyurea therapy associated with declining serum levels of magnesium in children with sickle cell anemia.
Topics: Adolescent; Analysis of Variance; Anemia, Sickle Cell; Antisickling Agents; Child; Dose-Response Rel | 2002 |
Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia.
Topics: Adult; Alanine Transaminase; Anemia, Sickle Cell; Chromosome Aberrations; Chromosome Disorders; Dose | 1992 |
Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia.
Topics: Adult; Alanine Transaminase; Anemia, Sickle Cell; Chromosome Aberrations; Chromosome Disorders; Dose | 1992 |
Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia.
Topics: Adult; Alanine Transaminase; Anemia, Sickle Cell; Chromosome Aberrations; Chromosome Disorders; Dose | 1992 |
Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia.
Topics: Adult; Alanine Transaminase; Anemia, Sickle Cell; Chromosome Aberrations; Chromosome Disorders; Dose | 1992 |
Hydroxyurea and erythropoietin therapy in sickle cell anemia.
Topics: Administration, Oral; Anemia, Sickle Cell; Drug Administration Schedule; Drug Combinations; Erythroc | 1992 |
Pharmacologic manipulation of fetal hemoglobin. Update on clinical trials with hydroxyurea.
Topics: Anemia, Sickle Cell; Erythropoietin; Fetal Hemoglobin; Humans; Hydroxyurea; Thalassemia | 1990 |
Recent approaches to the treatment of sickle cell anemia.
Topics: Adult; Anemia, Sickle Cell; Cell Count; Fetal Hemoglobin; Humans; Hydroxyurea; Male; Reticulocytes | 1991 |
Hydroxyurea as treatment for sickle cell anemia.
Topics: Anemia, Sickle Cell; Animals; Azacitidine; Erythropoietin; Humans; Hydroxyurea | 1991 |
Progress toward increasing fetal hemoglobin production in man: experience with 5-azacytidine and hydroxyurea.
Topics: Anemia, Sickle Cell; Animals; Azacitidine; Bone Marrow; Cells, Cultured; Clinical Trials as Topic; E | 1985 |
Chemotherapy and hemoglobin F synthesis in sickle cell disease.
Topics: Anemia, Sickle Cell; Animals; Azacitidine; Clinical Trials as Topic; Erythropoietin; Fetal Hemoglobi | 1989 |
809 other studies available for hydroxyurea and HbS Disease
| Article | Year |
|---|---|
Design, synthesis, and pharmacological evaluation of novel hybrid compounds to treat sickle cell disease symptoms.
Topics: Acetic Acid; Analgesics; Anemia, Sickle Cell; Animals; Anti-Inflammatory Agents; Antisickling Agents | 2011 |
Design, synthesis, and pharmacological evaluation of novel hybrid compounds to treat sickle cell disease symptoms. part II: furoxan derivatives.
Topics: Anemia, Sickle Cell; Drug Design; Drug Evaluation, Preclinical; Humans; Nitric Oxide Donors; Oxadiaz | 2012 |
Potent and orally active purine-based fetal hemoglobin inducers for treating β-thalassemia and sickle cell disease.
Topics: Administration, Oral; Anemia, Sickle Cell; Animals; Antisickling Agents; beta-Thalassemia; Cell Memb | 2021 |
Strategies to improve pharmacogenomic-guided treatment options for patients with β-hemoglobinopathies.
Topics: Anemia, Sickle Cell; beta-Thalassemia; Hemoglobinopathies; Humans; Hydroxyurea; Pharmacogenetics | 2021 |
Longitudinal analysis of cardiac abnormalities in pediatric patients with sickle cell anemia and effect of hydroxyurea therapy.
Topics: Anemia, Sickle Cell; Child; Cohort Studies; Echocardiography; Humans; Hydroxyurea; Retrospective Stu | 2021 |
Impact of telehealth visits on hydroxyurea response in sickle cell anemia.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Fetal Hemoglobin; Humans; Hydroxyurea; | 2021 |
Impact of a grant program to spur advances in sickle cell disease research.
Topics: Anemia, Sickle Cell; Financing, Organized; Hematopoietic Stem Cell Mobilization; Heterocyclic Compou | 2021 |
Hydroxyurea Use After Transitions of Care Among Young Adults With Sickle Cell Disease and Tennessee Medicaid Insurance.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Cohort Studies; Female; Humans; Hydroxy | 2021 |
Genetic modifiers of fetal hemoglobin affect the course of sickle cell disease in patients treated with hydroxyurea.
Topics: Anemia, Sickle Cell; Child, Preschool; Fetal Hemoglobin; gamma-Globins; Humans; Hydroxyurea; Metallo | 2022 |
Identifying barriers to evidence-based care for sickle cell disease: results from the Sickle Cell Disease Implementation Consortium cross-sectional survey of healthcare providers in the USA.
Topics: Anemia, Sickle Cell; Child; Cross-Sectional Studies; Evidence-Based Medicine; Health Personnel; Huma | 2021 |
Prevalence and risk factors of cognitive impairment in children with sickle cell disease in Egypt.
Topics: Adolescent; Adult; Age Factors; Anemia, Sickle Cell; Biomarkers; Brain; Child; Cognition; Cognitive | 2022 |
Level of utilization and provider-related barriers to the use of hydroxyurea in the treatment of sickle cell disease patients in Jos, North-Central Nigeria.
Topics: Anemia, Sickle Cell; Antisickling Agents; Cross-Sectional Studies; Female; Health Care Surveys; Huma | 2021 |
A call to start hydroxyurea by 6 months of age and before the advent of sickle cell disease complications.
Topics: Anemia, Sickle Cell; Antisickling Agents; Humans; Hydroxyurea | 2022 |
Prognostic factors associated with COVID-19 related severity in sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; beta-Thalassemia; Child; COVID-19; Female; Genotype; Health Personnel; H | 2021 |
Hepatobiliary Findings in Nigerian Children with Sickle Cell Anaemia.
Topics: Aged; Anemia, Sickle Cell; Blood Transfusion; Humans; Hydroxyurea; Male; Nigeria; Ultrasonography | 2021 |
Impact of hydroxyurea on lymphocyte subsets in children with sickle cell anemia.
Topics: Anemia, Sickle Cell; Child; Humans; Hydroxyurea; Prospective Studies; T-Lymphocyte Subsets; Th1 Cell | 2023 |
Patient-focused inquiry on hydroxyurea therapy adherence and reasons for discontinuation in adults with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Female; Humans; Hydroxyurea; Male; Medication Adherence | 2022 |
Spirometric Changes After Initiation of Hydroxyurea in Children With Sickle Cell Anemia.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Female; Humans; Hydroxyurea; Male; Retr | 2022 |
VCAM1, HMOX1 and NOS3 differential endothelial expression may impact sickle cell anemia vasculopathy.
Topics: Anemia, Sickle Cell; Child; Haplotypes; Heme Oxygenase-1; Hemolysis; Humans; Hydroxyurea; Nitric Oxi | 2022 |
Hydroxyurea and fetal hemoglobin effect on leg ulcers in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Female; Fetal Hemoglobin; Humans; Hydroxyurea; Inci | 2022 |
Reduced blood pressure in sickle cell disease is associated with decreased angiotensin converting enzyme (ACE) activity and is not modulated by ACE inhibition.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; An | 2022 |
Pregnancy outcomes with hydroxyurea use in women with sickle cell disease.
Topics: Abortion, Spontaneous; Anemia, Sickle Cell; Female; Humans; Hydroxyurea; Infant; Infant, Newborn; Li | 2022 |
Spotlight Commentary - Voxelotor: A new kid on the block in the treatment of sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Benzaldehydes; Humans; Hydroxyurea; Pyrazines; Pyrazoles | 2022 |
Introduction of Hydroxyurea Therapy to a Cohort of Sickle Cell Patients in Northern Haiti.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Haiti; Hospitalization; Humans; Hydroxyurea; Young | 2022 |
Growth Hormone/Insulin-like Growth Factor 1 Axis Associated with Modifier Factors in Children with Sickle Cell Anemia.
Topics: alpha-Thalassemia; Anemia, Sickle Cell; Child; Cross-Sectional Studies; Fetal Hemoglobin; Growth Hor | 2022 |
Risk and protective factors for severe COVID-19 infection in a cohort of patients with sickle cell disease.
Topics: Anemia, Sickle Cell; COVID-19; Humans; Hydroxyurea; Protective Factors; Retrospective Studies | 2022 |
An Immersive Virtual Reality Curriculum for Pediatric Hematology Clinicians on Shared Decision-making for Hydroxyurea in Sickle Cell Anemia.
Topics: Anemia, Sickle Cell; Child; Curriculum; Hematology; Humans; Hydroxyurea; Virtual Reality | 2022 |
[Disease genotype, haplotypes, diagnosis and associated studies in sickle cell anemia].
Topics: Anemia, Sickle Cell; Haplotypes; Humans; Hydroxyurea; Hypoxia | 2021 |
Impact of hydroxyurea dose and adherence on hematologic outcomes for children with sickle cell anemia.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Female; Fetal Hemoglo | 2022 |
Evolution of Extracranial Internal Carotid Artery Disease in Children With Sickle Cell Anemia.
Topics: Anemia, Sickle Cell; Carotid Artery Diseases; Carotid Artery, Internal; Carotid Stenosis; Cerebral I | 2022 |
Factors associated with left ventricular hypertrophy in children with sickle cell disease: results from the DISPLACE study.
Topics: Anemia, Sickle Cell; Biomarkers; Child; Erythrocyte Transfusion; Female; Humans; Hydroxyurea; Hypert | 2022 |
Real-world data on voxelotor to treat patients with sickle cell disease.
Topics: Adolescent; Adult; Aged; Anemia, Sickle Cell; Benzaldehydes; Bilirubin; Child; Female; Humans; Hydro | 2022 |
Risk of vaso-occlusive episode after exposure to corticosteroids in patients with sickle cell disease.
Topics: Adrenal Cortex Hormones; Adult; Anemia, Sickle Cell; Child; Cohort Studies; Hospitalization; Humans; | 2022 |
Comment on: Effects of hydroxyurea on brain function in children with sickle cell anemia.
Topics: Anemia, Sickle Cell; Antisickling Agents; Brain; Child; Humans; Hydroxyurea | 2022 |
Pharmacogenomics of hydroxyurea therapy and fetal hemoglobin levels in sickle cell anemia.
Topics: Anemia, Sickle Cell; Antisickling Agents; Fetal Hemoglobin; Humans; Hydroxyurea; Pharmacogenetics | 2022 |
Bringing Sickle Cell Disease Care Closer to Home: Feasibility and Efficacy of a Quality Improvement Initiative at a Community Hospital.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Child; Feasibility Studies; Hospitals, Community; H | 2022 |
Influence of hydroxyurea on the severity of acute chest syndrome in patients with sickle cell disease.
Topics: Acute Chest Syndrome; Anemia, Sickle Cell; Humans; Hydroxyurea | 2022 |
Epicatechin exerts dual action to shield sickling and hydroxyurea-induced myelosuppression: Implication in sickle cell anemia management.
Topics: Anemia, Sickle Cell; Animals; Catechin; Cytokines; Erythrocyte Membrane; Hydroxyurea; Rats | 2022 |
Longitudinal study of glomerular hyperfiltration in adults with sickle cell anemia: a multicenter pooled analysis.
Topics: Adult; Anemia, Sickle Cell; Female; Glomerular Filtration Rate; Humans; Hydroxyurea; Longitudinal St | 2022 |
Ten-year longitudinal analysis of hydroxyurea implementation in a pediatric sickle cell program.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Child; Erythrocytes, Abnormal; Fetal He | 2022 |
Safe use of hydroxycarbamide in sickle cell disease patients hospitalized for painful vaso-occlusive episodes during the randomized, open-label HELPS study.
Topics: Anemia, Sickle Cell; Humans; Hydroxyurea; Pain | 2022 |
Early hydroxyurea use is neuroprotective in children with sickle cell anemia.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Humans; Hydroxyurea | 2022 |
Pediatric hematology providers' contraceptive practices for female adolescents and young adults with sickle cell disease: A national survey.
Topics: Adolescent; Anemia, Sickle Cell; Child; Contraception; Contraceptive Agents; Female; Hematology; Hum | 2022 |
Age- and sex-specific rates of gall bladder disease in children with sickle cell disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Child; Child, Preschool; Female; Gallbladder Diseases; Galls | 2022 |
How Hydroxyurea Alters the Gut Microbiome: A Longitudinal Study Involving Angolan Children with Sickle Cell Anemia.
Topics: Anemia, Sickle Cell; Child; Gastrointestinal Microbiome; Humans; Hydroxyurea; Longitudinal Studies; | 2022 |
Neurocognitive functioning in children with sickle cell anemia and history of abnormal transcranial doppler ultrasonography.
Topics: Adolescent; Anemia, Sickle Cell; Blood Flow Velocity; Blood Transfusion; Child; Female; Humans; Hydr | 2022 |
Advanced clinical parameters: A complementary hydroxyurea adherence evaluation in sickle cell anemia treatment.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Cell Count; Child; Cross-Sectiona | 2022 |
The significance of spleen size in children with sickle cell anemia.
Topics: Anemia, Sickle Cell; Child; Child, Preschool; Erythrocyte Count; Humans; Hydroxyurea; Spleen; Spleno | 2022 |
Iron Chelators, Such as Deferasirox, When Combined With Hydroxyurea, Provide an Additional Benefit of Iron Chelation in Patients Receiving Chronic Transfusion Therapy.
Topics: Alanine Transaminase; Anemia, Sickle Cell; Aspartate Aminotransferases; Chelation Therapy; Creatinin | 2022 |
Pulmonary hypertension screening in children with sickle cell disease.
Topics: Adolescent; Anemia, Sickle Cell; Child; Humans; Hydroxyurea; Hypertension, Pulmonary; Peptide Fragme | 2023 |
Prioritizing Sickle Cell Disease.
Topics: Anemia, Sickle Cell; Humans; Hydroxyurea | 2022 |
Phenotypic screening of the ReFRAME drug repurposing library to discover new drugs for treating sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Drug Repositioning; Hemoglobin, Sickle; Humans; Hydroxyure | 2022 |
Vital Signs: Use of Recommended Health Care Measures to Prevent Selected Complications of Sickle Cell Anemia in Children and Adolescents - Selected U.S. States, 2019.
Topics: Adolescent; Anemia, Sickle Cell; Child; Delivery of Health Care; Humans; Hydroxyurea; Ultrasonograph | 2022 |
Plasma immune mediators as laboratorial biomarkers for Sickle Cell Disease patients according to the hydroxyurea therapy and disease severity.
Topics: Anemia, Sickle Cell; Antisickling Agents; Biomarkers; Cytokines; Humans; Hydroxyurea; Severity of Il | 2023 |
Evaluation of pharmacological efficacy and safety of hydroxyurea in sickle cell disease: Study of a pediatric cohort from Chhattisgarh, India.
Topics: Anemia, Sickle Cell; beta-Thalassemia; Child; Drug-Related Side Effects and Adverse Reactions; Fetal | 2023 |
Impact of adherence to hydroxyurea on health outcomes among patients with sickle cell disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Child; Female; Humans; Hydroxyurea; Infant; Medication Adher | 2023 |
Creating an automated contemporaneous cohort in sickle cell anemia to predict survival after disease-modifying therapy.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Child; Humans; Hydroxyurea; Midd | 2023 |
Determinants of hydroxyurea use among doctors, nurses and sickle cell disease patients in Nigeria.
Topics: Anemia, Sickle Cell; Antisickling Agents; Humans; Hydroxyurea; Nigeria; Physicians | 2022 |
What does it mean to be affiliated with care?: Delphi consensus on the definition of "unaffiliation" and "specialist" in sickle cell disease.
Topics: Anemia, Sickle Cell; Blood Transfusion; Consensus; Delphi Technique; Humans; Hydroxyurea | 2022 |
Hydroxyurea treatment is associated with lower malaria incidence in children with sickle cell anemia in sub-Saharan Africa.
Topics: Africa South of the Sahara; Anemia, Sickle Cell; Child; Humans; Hydroxyurea; Incidence; Malaria; Spl | 2023 |
The impact of Hydroxyurea on the rates of Vaso-occlusive crises in patients with sickle cell disease in Saudi Arabia: a single-center study.
Topics: Anemia, Sickle Cell; Child; Cognition; Female; Humans; Hydroxyurea; Male; Retrospective Studies; Sau | 2022 |
The impact of Hydroxyurea on the rates of Vaso-occlusive crises in patients with sickle cell disease in Saudi Arabia: a single-center study.
Topics: Anemia, Sickle Cell; Child; Cognition; Female; Humans; Hydroxyurea; Male; Retrospective Studies; Sau | 2022 |
The impact of Hydroxyurea on the rates of Vaso-occlusive crises in patients with sickle cell disease in Saudi Arabia: a single-center study.
Topics: Anemia, Sickle Cell; Child; Cognition; Female; Humans; Hydroxyurea; Male; Retrospective Studies; Sau | 2022 |
The impact of Hydroxyurea on the rates of Vaso-occlusive crises in patients with sickle cell disease in Saudi Arabia: a single-center study.
Topics: Anemia, Sickle Cell; Child; Cognition; Female; Humans; Hydroxyurea; Male; Retrospective Studies; Sau | 2022 |
Pediatric Sickle Cell Disease Patients on Hydroxyurea Have Higher Rates of Surgical Splenectomy.
Topics: Anemia, Sickle Cell; Child; Cross-Sectional Studies; Hemoglobins; Humans; Hydroxyurea; Retrospective | 2023 |
Pediatric Sickle Cell Disease Patients on Hydroxyurea Have Higher Rates of Surgical Splenectomy.
Topics: Anemia, Sickle Cell; Child; Cross-Sectional Studies; Hemoglobins; Humans; Hydroxyurea; Retrospective | 2023 |
Pediatric Sickle Cell Disease Patients on Hydroxyurea Have Higher Rates of Surgical Splenectomy.
Topics: Anemia, Sickle Cell; Child; Cross-Sectional Studies; Hemoglobins; Humans; Hydroxyurea; Retrospective | 2023 |
Pediatric Sickle Cell Disease Patients on Hydroxyurea Have Higher Rates of Surgical Splenectomy.
Topics: Anemia, Sickle Cell; Child; Cross-Sectional Studies; Hemoglobins; Humans; Hydroxyurea; Retrospective | 2023 |
Evidence-Based Minireview: How to utilize new therapies for sickle cell disease.
Topics: Anemia, Sickle Cell; Humans; Hydroxyurea | 2022 |
Evidence-Based Minireview: How to utilize new therapies for sickle cell disease.
Topics: Anemia, Sickle Cell; Humans; Hydroxyurea | 2022 |
Evidence-Based Minireview: How to utilize new therapies for sickle cell disease.
Topics: Anemia, Sickle Cell; Humans; Hydroxyurea | 2022 |
Evidence-Based Minireview: How to utilize new therapies for sickle cell disease.
Topics: Anemia, Sickle Cell; Humans; Hydroxyurea | 2022 |
Impact of hydroxyurea on hospital stay & analgesic utilization in sickle cell anaemia with vaso-occlusive crises.
Topics: Analgesics; Anemia, Sickle Cell; Humans; Hydroxyurea; Length of Stay; Tramadol | 2022 |
Impact of hydroxyurea on hospital stay & analgesic utilization in sickle cell anaemia with vaso-occlusive crises.
Topics: Analgesics; Anemia, Sickle Cell; Humans; Hydroxyurea; Length of Stay; Tramadol | 2022 |
Impact of hydroxyurea on hospital stay & analgesic utilization in sickle cell anaemia with vaso-occlusive crises.
Topics: Analgesics; Anemia, Sickle Cell; Humans; Hydroxyurea; Length of Stay; Tramadol | 2022 |
Impact of hydroxyurea on hospital stay & analgesic utilization in sickle cell anaemia with vaso-occlusive crises.
Topics: Analgesics; Anemia, Sickle Cell; Humans; Hydroxyurea; Length of Stay; Tramadol | 2022 |
Clinical and laboratory characterization of adult sickle cell anemia patients in Kinshasa.
Topics: Anemia, Sickle Cell; Cross-Sectional Studies; Democratic Republic of the Congo; Female; Fetal Hemogl | 2022 |
Clinical and laboratory characterization of adult sickle cell anemia patients in Kinshasa.
Topics: Anemia, Sickle Cell; Cross-Sectional Studies; Democratic Republic of the Congo; Female; Fetal Hemogl | 2022 |
Clinical and laboratory characterization of adult sickle cell anemia patients in Kinshasa.
Topics: Anemia, Sickle Cell; Cross-Sectional Studies; Democratic Republic of the Congo; Female; Fetal Hemogl | 2022 |
Clinical and laboratory characterization of adult sickle cell anemia patients in Kinshasa.
Topics: Anemia, Sickle Cell; Cross-Sectional Studies; Democratic Republic of the Congo; Female; Fetal Hemogl | 2022 |
Trends in blood transfusion, hydroxyurea use, and iron overload among children with sickle cell disease enrolled in Medicaid, 2004-2019.
Topics: Adolescent; Anemia, Sickle Cell; Blood Transfusion; Child; Child, Preschool; Cross-Sectional Studies | 2023 |
Role of microRNA in hydroxyurea mediated HbF induction in sickle cell anaemia patients.
Topics: Anemia, Sickle Cell; Fetal Hemoglobin; gamma-Globins; Humans; Hydroxyurea; MicroRNAs | 2023 |
Assessing barriers and facilitators to transition in sickle cell disease care prior to implementation of a formalized program.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Child; Erythrocyte Transfusion; Hemoglobin, Sickle; Humans; | 2023 |
Comment on: Impact of telehealth visits on hydroxyurea response in sickle cell anemia.
Topics: Anemia, Sickle Cell; Antisickling Agents; Humans; Hydroxyurea; Telemedicine | 2023 |
Impact of Hydroxyurea Starting Dose on Pain Outcomes in Patients with Sickle Cell Disease.
Topics: Analgesics, Opioid; Anemia, Sickle Cell; Humans; Hydroxyurea; Pain; Practice Patterns, Physicians' | 2022 |
Most adults with severe HbSC disease are not treated with hydroxyurea.
Topics: Adult; Anemia, Sickle Cell; Cohort Studies; Hemoglobin SC Disease; Hemoglobin, Sickle; Humans; Hydro | 2023 |
Hydroxyurea: how much is enough?
Topics: Anemia, Sickle Cell; Child; Humans; Hydroxyurea; Nigeria; Secondary Prevention; Stroke | 2023 |
Lack of hydroxyurea-associated mutagenesis in pediatric sickle cell disease patients.
Topics: Anemia, Sickle Cell; Animals; Cisplatin; Cross-Sectional Studies; Humans; Hydroxyurea; Male; Mutagen | 2023 |
Screening for asthma in preschool children with sickle cell disease.
Topics: Aged; Anemia, Sickle Cell; Asthma; Child, Preschool; Dermatitis, Atopic; Humans; Hydroxyurea; Prospe | 2023 |
Hydroxyurea and stroke prevention in sickle cell anaemia: the challenge of application in sub-Saharan Africa.
Topics: Africa South of the Sahara; Anemia, Sickle Cell; Antisickling Agents; Humans; Hydroxyurea; Stroke | 2023 |
Real-world characteristics of patients with sickle cell disease who initiated crizanlizumab therapy.
Topics: Adult; Anemia, Sickle Cell; Antibodies, Monoclonal, Humanized; Female; Humans; Hydroxyurea; Male; Re | 2023 |
Longitudinal effect of disease-modifying therapy on left ventricular diastolic function in children with sickle cell anemia.
Topics: Adolescent; Anemia, Sickle Cell; Child; Child, Preschool; Echocardiography; Erythrocyte Transfusion; | 2023 |
A Rare Report of the Coexistence of Sickle Cell Disease, Neurofibromatosis Type 1, and Intracranial Hypertension in a Pediatric Patient.
Topics: Acetazolamide; Anemia, Sickle Cell; Child; Female; Humans; Hydroxyurea; Intracranial Hypertension; N | 2023 |
Severity and burden of sickle cell disease in France: a nationwide real-world study.
Topics: Anemia, Sickle Cell; Databases, Factual; France; Hematopoietic Stem Cell Transplantation; Humans; Hy | 2023 |
HU for SCA in Africa: associated malaria benefit.
Topics: Africa South of the Sahara; Anemia, Sickle Cell; Child; Humans; Hydroxyurea; Incidence; Malaria | 2023 |
Changes in Hydroxyurea Use Among Youths Enrolled in Medicaid With Sickle Cell Anemia After 2014 Revision of Clinical Guidelines.
Topics: Adolescent; Anemia, Sickle Cell; Cross-Sectional Studies; Humans; Hydroxyurea; Male; Medicaid; Strok | 2023 |
Successful quality improvement project to increase hydroxyurea prescriptions for children with sickle cell anaemia.
Topics: Anemia, Sickle Cell; Child; Humans; Hydroxyurea; Quality Improvement; Surveys and Questionnaires | 2023 |
Detrimental effects of sickle cell disease and hydroxycarbamide on ovarian reserve but uncertain impact on fertility.
Topics: Anemia, Sickle Cell; Female; Fertility; Humans; Hydroxyurea; Ovarian Reserve | 2023 |
Early detection of glomerular dysfunction and renal tubulopathy in children with sickle cell disease in India.
Topics: Albuminuria; Anemia, Sickle Cell; Child; Humans; Hydroxyurea; India; Kidney; Kidney Diseases; Water | 2023 |
Adherence to hydroxyurea and clinical outcomes among children with sickle cell anemia.
Topics: Acute Chest Syndrome; Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; | 2023 |
Desire for biological parenthood and patient counseling on the risk of infertility among adolescents and adults with hemoglobinopathies.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Child; Counseling; Cross-Sectional Studies; Female; Fertilit | 2023 |
Simultaneous adjunctive treatment of malaria and its coevolved genetic disorder sickle cell anemia.
Topics: Anemia, Sickle Cell; Blood Transfusion; Erythrocytes; Humans; Hydroxyurea; Malaria; Malaria, Falcipa | 2023 |
Efficacy, safety, and pharmacokinetics of a new, ready-to-use, liquid hydroxyurea in children with sickle cell anemia.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Humans; Hydroxyurea | 2023 |
Leveraging mathematical modeling to analyze nonadherence for hydroxyurea therapy in sickle cell disease.
Topics: Anemia, Sickle Cell; Humans; Hydroxyurea | 2023 |
Examining Mental Health, Education, Employment, and Pain in Sickle Cell Disease.
Topics: Adult; Anemia, Sickle Cell; Cross-Sectional Studies; Educational Status; Employment; Female; Humans; | 2023 |
An innovative intervention for the prevention of vaso-occlusive episodes in sickle cell disease.
Topics: Anemia, Sickle Cell; Hemoglobin, Sickle; Humans; Hydroxyurea; Pain; Pain Management | 2023 |
Are Genetic Modifiers the Answer to Different Responses to Hydroxyurea Treatment?-A Pharmacogenetic Study in Sickle Cell Anemia Angolan Children.
Topics: Anemia, Sickle Cell; Fetal Hemoglobin; Hemolysis; Humans; Hydroxyurea; Pharmacogenomic Testing | 2023 |
[Disease modifying treatments for sickle cell disease].
Topics: Anemia, Sickle Cell; Humans; Hydroxyurea; Patient Compliance | 2023 |
[Therapeutic approaches in sickle cell disease].
Topics: Adult; Anemia, Sickle Cell; Child; France; Genetic Therapy; Humans; Hydroxyurea; Tissue Donors | 2023 |
[What is your diagnosis? Inveterate anterior shoulder dislocation].
Topics: Adult; Anemia, Sickle Cell; Child; France; Genetic Therapy; Humans; Hydroxyurea; Shoulder Dislocatio | 2023 |
Comment on: "Adherence to hydroxyurea and clinical outcomes among children with sickle cell anemia".
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Humans; Hydroxyurea; Medication Adherence | 2023 |
Metabolic signatures of cardiorenal dysfunction in plasma from sickle cell patients as a function of therapeutic transfusion and hydroxyurea treatment.
Topics: Anemia, Sickle Cell; Bile Acids and Salts; Hemoglobin SC Disease; Hemoglobin, Sickle; Hemolysis; Hum | 2023 |
Determinants of splenic preservation among patients with sickle cell disease in North-Eastern Nigeria.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Child; Child, Preschool; Female; Fetal Hemoglobin; Humans; H | 2023 |
Cost-Effectiveness of Hydroxyurea for Sickle Cell Anemia in a Low-Income African Setting: A Model-Based Evaluation of Two Dosing Regimens.
Topics: Anemia, Sickle Cell; Child; Cost-Benefit Analysis; Humans; Hydroxyurea; Quality of Life; Uganda | 2023 |
Reply to: Comment on: "Adherence to hydroxyurea and clinical outcomes among children with sickle cell anemia".
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Humans; Hydroxyurea | 2023 |
Promoting access of hydroxyurea to sickle cell disease individuals: Time to make it an essential medicine.
Topics: Anemia, Sickle Cell; Commerce; Government; Humans; Hydroxyurea; National Health Programs | 2022 |
Effect of Hydroxyurea Therapy on Growth Parameters in Older Children (6-15 Year-Old) with Sickle Cell Disease: Low Dose Versus High Dose.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Humans; Hydroxyurea; Oman; Prospective | 2023 |
Intensive hydroxyurea dosing in very young children with sickle cell anemia.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Humans; Hydroxyurea | 2023 |
VWF-ADAMTS13 axis dysfunction in children with sickle cell disease treated with hydroxycarbamide vs blood transfusion.
Topics: ADAMTS13 Protein; Anemia, Sickle Cell; Blood Transfusion; Child; Hemolysis; Hemostatics; Humans; Hyd | 2023 |
New Insights into Clinical Management for Sickle Cell Disease: Uncovering the Significant Pathways Affected by the Involvement of Sickle Cell Disease.
Topics: Anemia, Sickle Cell; Antiviral Agents; Blood Transfusion; Child; Erythrocytes; Humans; Hydroxyurea; | 2024 |
Prevalence and cost of sickle cell disease in France: real-world analysis using data from the Echantillon Généraliste des Bénéficiaires.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Delivery of Health Care; Female; Humans; Hydroxyurea; Male; | 2023 |
Hydroxyurea does not reverse functional alterations of the nitric oxide-cGMP pathway associated with priapism phenotype in corpus cavernosum from sickle cell mouse.
Topics: Acetylcholine; Anemia, Sickle Cell; Animals; Hemoglobins; Humans; Hydroxyurea; Male; Mice; Mice, Inb | 2023 |
Further evidence supporting the global use of hydroxyurea.
Topics: Anemia, Sickle Cell; Humans; Hydroxyurea; Malaria | 2023 |
Assessment of menstrual health in adolescent and young adults with sickle cell disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Child; Cross-Sectional Studies; Dysmenorrhea; Female; Humans | 2024 |
Clinical events in a long-term prospective neonatal cohort of children with sickle cell disease: Evidence for a high disease burden without systematic preventive intensification with hydroxyurea.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Cost of Illness; Humans; Hydroxyurea; Infant, Newbo | 2023 |
[Sickle cell disease diagnosis over a decade in a pediatric hematology unit].
Topics: Anemia, Sickle Cell; Child; Child, Preschool; Female; Hematology; Hemoglobins; Humans; Hydroxyurea; | 2022 |
Pulmonary hypertension in sickle cell disease.
Topics: Anemia, Sickle Cell; Echocardiography; Heart Diseases; Humans; Hydroxyurea; Hypertension, Pulmonary | 2023 |
Use of Disease-Modifying Treatments in Patients With Sickle Cell Disease.
Topics: Acute Chest Syndrome; Adult; Anemia, Sickle Cell; Child; Cross-Sectional Studies; Female; Glutamine; | 2023 |
Adherence to Quality of Care Indicators and Location of Sickle Cell Care Within Indiana.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Humans; Hydroxyurea; Indiana; Inf | 2020 |
Real-world experience using hydroxyurea in children with sickle cell disease in Lilongwe, Malawi.
Topics: Absenteeism; Adolescent; Anemia, Sickle Cell; Blood Transfusion; Child; Child, Preschool; Combined M | 2019 |
A Multidimensional Electronic Hydroxyurea Adherence Intervention for Children With Sickle Cell Disease: Single-Arm Before-After Study.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Controlled Before-Aft | 2019 |
Allocation of Treatment Responsibility and Adherence to Hydroxyurea Among Adolescents With Sickle Cell Disease.
Topics: Adolescent; Anemia, Sickle Cell; Caregivers; Child; Female; Humans; Hydroxyurea; Male; Medication Ad | 2019 |
The Role of Patient-Physician Communication on the Use of Hydroxyurea in Adult Patients with Sickle Cell Disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Communication; Decision Making; Decision Making, Sh | 2019 |
Approximately 40 000 children with sickle cell anemia require screening with TCD and treating with hydroxyurea for stroke prevention in three states in northern Nigeria.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Female; Humans; Hydroxyurea; Infa | 2019 |
Occurrence of acute myeloid leukemia in hydroxyurea-treated sickle cell disease patient.
Topics: Adult; Anemia, Sickle Cell; Carcinogenesis; Chromosome Deletion; Chromosomes, Human, Pair 17; Chromo | 2019 |
Barriers to the use of hydroxyurea in the management of sickle cell disease in Nigeria.
Topics: Anemia, Sickle Cell; Antisickling Agents; Cross-Sectional Studies; Disease Management; Health Care S | 2019 |
Ischemic stroke in children and young adults with sickle cell disease in the post-STOP era.
Topics: Adolescent; Anemia, Sickle Cell; Brain Ischemia; Child; Child, Preschool; Combined Modality Therapy; | 2019 |
Rifaximin for sickle cell disease.
Topics: Adult; Analgesics, Opioid; Anemia, Sickle Cell; Anti-Bacterial Agents; beta-Thalassemia; Cellular Se | 2019 |
Hydroxycarbamide and white matter integrity in pediatric sickle cell disease: Commentary to accompany: Hydroxycarbamide treatment in children with sickle cell anaemia is associated with more intact white matter integrity: a quantitative MRI study.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Humans; Hydroxyurea; Magnetic Resonance Imaging; Wh | 2019 |
Effectiveness and Safety of Hydroxyurea in the Treatment of Sickle Cell Anaemia Children in Jos, North Central Nigeria.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Female; Hematocrit; H | 2020 |
Hydroxyurea alters circulating monocyte subsets and dampens its inflammatory potential in sickle cell anemia patients.
Topics: Adolescent; Anemia, Sickle Cell; Child; Female; Humans; Hydroxyurea; Inflammation Mediators; Leukocy | 2019 |
Treatment patterns and economic burden of sickle-cell disease patients prescribed hydroxyurea: a retrospective claims-based study.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Child; Child, Preschool; Comorbidity; Cost of Illness; Femal | 2019 |
Effect of N(Epsilon)-(carboxymethyl)lysine on Laboratory Parameters and Its Association with
Topics: Anemia, Sickle Cell; Antisickling Agents; Aspartate Aminotransferases; beta-Globins; Child; Creatini | 2019 |
Hydroxyurea to lower transcranial Doppler velocities and prevent primary stroke: the Uganda NOHARM sickle cell anemia cohort.
Topics: Anemia, Sickle Cell; Blood Flow Velocity; Humans; Hydroxyurea; Stroke; Uganda; Ultrasonography, Dopp | 2020 |
[Digestives diseases associated to sickle cell anemia in Lubumbashi: epidemiological and clinical aspects].
Topics: Abdominal Pain; Adolescent; Adult; Anemia, Sickle Cell; Child; Child, Preschool; Cross-Sectional Stu | 2019 |
[Advances in sickle cell disease treatments: Towards targeted therapies].
Topics: Anemia, Sickle Cell; Antioxidants; Cell Adhesion Molecules; Fetal Hemoglobin; Genetic Therapy; Hemat | 2020 |
Pro-inflammatory cytokines associate with NETosis during sickle cell vaso-occlusive crises.
Topics: Adult; Anemia, Sickle Cell; Cohort Studies; Cytokines; Extracellular Traps; Female; Humans; Hydroxyu | 2020 |
Sickle cell disease: current treatment and emerging therapies.
Topics: Anemia, Sickle Cell; Antisickling Agents; Erythrocyte Transfusion; Female; Humans; Hydroxyurea; Male | 2019 |
Clinical and laboratory parameters, risk factors predisposing to the development of priapism in sickle cell patients.
Topics: Adult; Anemia, Sickle Cell; Case-Control Studies; Child, Preschool; Disease Susceptibility; Hematolo | 2020 |
Cross-sectional analysis of adhesion in individuals with sickle cell disease using a standardized whole blood adhesion bioassay to VCAM-1.
Topics: Adult; Anemia, Sickle Cell; Biological Assay; Blood Cell Count; Cell Adhesion; Cross-Sectional Studi | 2020 |
Neutrophils remain detrimentally active in hydroxyurea-treated patients with sickle cell disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Sickle Cell; Antisickling Agents; Case-Control S | 2019 |
Higher oxygen saturation with hydroxyurea in paediatric sickle cell disease.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Female; Humans; Hydro | 2020 |
The role of hydroxyurea in decreasing the occurrence of vasso-occulusive crisis in pediatric patients with sickle cell disease at King Saud Medical City in Riyadh, Saudi Arabia.
Topics: Anemia, Sickle Cell; Child; Cohort Studies; Humans; Hydroxyurea; Retrospective Studies; Saudi Arabia | 2020 |
Treating sickle cell anemia: A new era dawns.
Topics: Anemia, Sickle Cell; Antibodies, Monoclonal, Humanized; Benzaldehydes; Child; Fetal Hemoglobin; Fore | 2020 |
Hydroxyurea for ALL children with sickle cell anemia: What can we learn from Africa?
Topics: Africa; Anemia, Sickle Cell; Antisickling Agents; Child; Humans; Hydroxyurea; Precursor Cell Lymphob | 2020 |
Pharmacy hydroxyurea education materials for patients with sickle cell disease: An environmental scan and assessment of accuracy.
Topics: Anemia, Sickle Cell; Female; Humans; Hydroxyurea; Male; Medication Adherence; Ontario; Pharmacies | 2020 |
Complement activation in sickle cell disease: Dependence on cell density, hemolysis and modulation by hydroxyurea therapy.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Cell Count; Complement Activation; Female; Hemolysis; Humans | 2020 |
Sickle cell disease: A distinction of two most frequent genotypes (HbSS and HbSC).
Topics: Adolescent; Anemia, Sickle Cell; Biomarkers; Child; Cross-Sectional Studies; Female; Folic Acid; Gen | 2020 |
Ghana takes on sickle-cell disease.
Topics: Anemia, Sickle Cell; Delivery of Health Care; Ghana; Humans; Hydroxyurea | 2020 |
Pediatric Hematologists Report Infrequent Prognosis Discussions in the Routine Care of Children with Sickle Cell Disease.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Disease Progression; Female; Health Car | 2020 |
An experimental erythrocyte rigidity index (Ri) and its correlations with Transcranial Doppler velocities (TAMMV), Gosling Pulsatility Index PI, hematocrit, hemoglobin concentration and red cell distribution width (RDW).
Topics: Adolescent; Adult; Aged; Anemia, Sickle Cell; Blood Flow Velocity; Child; Child, Preschool; Erythroc | 2020 |
Cognitive deficit in sickle cell disease: Is hydroxyurea part of the story?
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Cognition; Humans; Hydroxyurea | 2020 |
Sickle cell disease induces resistance to cutaneous carcinogenesis.
Topics: Adult; Anemia, Sickle Cell; Carcinogenesis; Cross-Sectional Studies; Humans; Hydroxyurea; Leg Ulcer; | 2020 |
Impact of Medicaid expansion on access and healthcare among individuals with sickle cell disease.
Topics: Adolescent; Adult; Age Factors; Anemia, Sickle Cell; California; Child; Databases, Factual; Drug Pre | 2020 |
Treating sickle cell anemia.
Topics: Anemia, Sickle Cell; Antisickling Agents; Genetic Therapy; Humans; Hydroxyurea; Stem Cell Transplant | 2020 |
Hydroxyurea Exposure in Lactation: a Pharmacokinetics Study (HELPS).
Topics: Adult; Anemia, Sickle Cell; Antineoplastic Agents; Antisickling Agents; Female; Humans; Hydroxyurea; | 2020 |
Understanding heterogeneity of fetal hemoglobin induction through comparative analysis of F and A erythroblasts.
Topics: Adult; Anemia, Sickle Cell; Cell Line; Cell Separation; Cells, Cultured; Erythroblasts; Erythroid Ce | 2020 |
Initiating adjunct low-dose hydroxyurea therapy for stroke prevention in children with SCA during the COVID-19 pandemic.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Donors; Blood Safety; Blood Transfusion; Child; Chil | 2020 |
Plasma microparticles of sickle patients during crisis or taking hydroxyurea modify endothelium inflammatory properties.
Topics: Adolescent; Anemia, Sickle Cell; Cell-Derived Microparticles; Endothelium, Vascular; Female; Humans; | 2020 |
American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults.
Topics: Adult; Anemia, Sickle Cell; Child; Hematology; Hemoglobin, Sickle; Humans; Hydroxyurea; Stroke; Unit | 2020 |
Sickle cell disease and malaria: decreased exposure and asplenia can modulate the risk from Plasmodium falciparum.
Topics: Adolescent; Anemia, Sickle Cell; Antimalarials; Antisickling Agents; Humans; Hydroxyurea; Malaria, F | 2020 |
Gene expression of HIF-1α and VEGF in response to hypoxia in sickle cell anaemia: Influence of hydroxycarbamide.
Topics: Adolescent; Adult; Aged; Anemia, Sickle Cell; Antisickling Agents; Case-Control Studies; Female; Gen | 2020 |
Development of the InCharge Health Mobile App to Improve Adherence to Hydroxyurea in Patients With Sickle Cell Disease: User-Centered Design Approach.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Female; Humans; Hydroxyurea; Male; Middle Aged; Mobile Appli | 2020 |
The role of pain rehabilitation in an adolescent sickle cell disease population: a case series.
Topics: Adolescent; Analgesics; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Chronic Pain; F | 2020 |
Effects of oxidative stress on liver, brain and spinal cord of rats using L-NAME and treated with hydroxyurea. A model of sickle cell complication.
Topics: Anemia, Sickle Cell; Animals; Brain; Disease Models, Animal; Hydroxyurea; Liver; Male; NG-Nitroargin | 2020 |
The Impact of Sickle Cell Anemia and Mental Health Diagnoses on Healthcare Use and Preventive Care among Children Enrolled in Medicaid, 2005-2012.
Topics: Anemia, Sickle Cell; Antibiotic Prophylaxis; Antisickling Agents; Child; Cross-Sectional Studies; De | 2020 |
Beneficial Effects of Soluble Guanylyl Cyclase Stimulation and Activation in Sickle Cell Disease Are Amplified by Hydroxyurea: In Vitro and In Vivo Studies.
Topics: Anemia, Sickle Cell; Animals; Benzoates; Biphenyl Compounds; Cell Line, Tumor; Disease Models, Anima | 2020 |
Sickle particulars of microparticles.
Topics: Anemia, Sickle Cell; Cell-Derived Microparticles; Endothelium; Humans; Hydroxyurea; Plasma | 2020 |
Computer Algorithm-Based Hydroxyurea Dosing Facilitates Titration to Maximum Tolerated Dose in Sickle Cell Anemia.
Topics: Adult; Algorithms; Anemia, Sickle Cell; Antisickling Agents; Dose-Response Relationship, Drug; Femal | 2021 |
Accidental hydroxyurea overdosage in a child with sickle cell anemia: An African experience.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child, Preschool; Dose-Response Relationship, Drug; Drug O | 2020 |
Post-translational modification as a response to cellular stress induced by hemoglobin oxidation in sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Case-Control Studies; Child; Erythrocytes; Female; Hemoglobins; Humans; | 2020 |
Long-term oxygen therapy in children with sickle cell disease and hypoxaemia.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Case-Control Studies; Child; Chronic Disease; | 2021 |
Acute chest syndrome in the setting of SARS-COV-2 infections-A case series at an urban medical center in the Bronx.
Topics: Acute Chest Syndrome; Adolescent; Anemia, Sickle Cell; Anti-Bacterial Agents; Antisickling Agents; C | 2020 |
Intentional and unintentional nonadherence to hydroxyurea among people with sickle cell disease: a qualitative study.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Humans; Hydroxyurea; Medication Adherence; Middle Aged; Trea | 2020 |
What are the key considerations when prescribing pharmacotherapy for sickle cell anemia?
Topics: Anemia, Sickle Cell; Antisickling Agents; Humans; Hydroxyurea | 2021 |
HRI depletion cooperates with pharmacologic inducers to elevate fetal hemoglobin and reduce sickle cell formation.
Topics: Anemia, Sickle Cell; Erythrocytes, Abnormal; Erythroid Cells; Fetal Hemoglobin; Humans; Hydroxyurea | 2020 |
Making hydroxyurea affordable for sickle cell disease in Tanzania is essential (HASTE): How to meet major health needs at a reasonable cost.
Topics: Anemia, Sickle Cell; Antisickling Agents; Costs and Cost Analysis; Female; Humans; Hydroxyurea; Male | 2021 |
Effect of hydroxyurea exposure before puberty on sperm parameters in males with sickle cell disease.
Topics: Acute Chest Syndrome; Adolescent; Age Factors; Anemia, Sickle Cell; Antisickling Agents; Arterial Oc | 2021 |
Tackling adherence in sickle cell disease with mHealth.
Topics: Anemia, Sickle Cell; Antisickling Agents; Humans; Hydroxyurea; Mobile Applications; Patient Complian | 2020 |
Characterization of Hematopoiesis in Sickle Cell Disease by Prospective Isolation of Stem and Progenitor Cells.
Topics: Adult; Anemia, Sickle Cell; Antigens, CD; Bone Marrow; Cell Movement; Cell Separation; Child; Female | 2020 |
HbF Levels in Sickle Cell Disease Are Associated with Proportion of Circulating Hematopoietic Stem and Progenitor Cells and CC-Chemokines.
Topics: ADP-ribosyl Cyclase 1; Anemia, Sickle Cell; Antigens, CD34; Becaplermin; Biomarkers; Chemokine CCL11 | 2020 |
Standardized microfluidic assessment of red blood cell-mediated microcapillary occlusion: Association with clinical phenotype and hydroxyurea responsiveness in sickle cell disease.
Topics: Anemia, Sickle Cell; Erythrocytes; Hemoglobins; Humans; Hydroxyurea; Microcirculation; Microfluidics | 2021 |
Hydroxyurea Pharmacokinetics in Pediatric Patients After Total Pancreatectomy With Islet Autotransplantation.
Topics: Adolescent; Anemia, Sickle Cell; Child; Child, Preschool; Female; Humans; Hydroxyurea; Islets of Lan | 2021 |
Repurposing pyridoxamine for therapeutic intervention of intravascular cell-cell interactions in mouse models of sickle cell disease.
Topics: Anemia, Sickle Cell; Animals; Cell Adhesion; Cell Communication; Endothelial Cells; Endothelium, Vas | 2020 |
SCAR: The high-prevalence antigen 013.008 in the Scianna blood group system.
Topics: Alleles; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Blood Group Antigens; Blood Tra | 2021 |
The association between hydroxyurea adherence and opioid utilization among Texas Medicaid enrollees with sickle cell disease.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Presc | 2020 |
Hydroxyurea treatment is associated with reduced degree of oxidative perturbation in children and adolescents with sickle cell anemia.
Topics: Adolescent; Anemia, Sickle Cell; Biomarkers; Brazil; Case-Control Studies; Child; Female; Humans; Hy | 2020 |
Regaining Control: Anxiety in Sickle Cell Disease.
Topics: Adolescent; Anemia, Sickle Cell; Antidepressive Agents; Antisickling Agents; Anxiety Disorders; Chro | 2020 |
Benserazide as a potential novel fetal hemoglobin inducer: an observational study in non-carriers of hemoglobin disorders.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Sickle Cell; Antiparkinson Agents; Antisickling Agents; Bens | 2021 |
Impact of renal function on hydroxyurea exposure in sickle-cell disease patients.
Topics: Anemia, Sickle Cell; Antisickling Agents; Humans; Hydroxyurea; Kidney; Prospective Studies | 2021 |
Quality of life assessments in a cohort of Mozambican children with sickle cell disease.
Topics: Adolescent; Analgesics, Opioid; Anemia, Sickle Cell; Caregivers; Child; Child, Preschool; Cohort Stu | 2020 |
Use of Wise Device Technology to Measure Adherence to Hydroxyurea Therapy in Youth With Sickle Cell Disease.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Feasibility Studies; | 2021 |
Hydroxyurea does not affect the spermatogonial pool in prepubertal patients with sickle cell disease.
Topics: Age Factors; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Humans; Hydroxyurea; | 2021 |
A conversation with Griffin Rodgers.
Topics: Anemia, Sickle Cell; History, 20th Century; History, 21st Century; Humans; Hydroxyurea; National Ins | 2021 |
Blood plasma metabolomics of children and adolescents with sickle cell anaemia treated with hydroxycarbamide: a new tool for uncovering biochemical alterations.
Topics: Acids; Acute Chest Syndrome; Adolescent; Amino Acids; Anemia, Sickle Cell; Antisickling Agents; Arte | 2021 |
Transcranial Doppler screening in Nigerian children with sickle cell disease: A 10-year longitudinal study on the SPPIBA cohort.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Female; Humans; Hydro | 2021 |
Haemoglobin response to senicapoc in patients with sickle cell disease: a re-analysis of the Phase III trial.
Topics: Acetamides; Anemia, Sickle Cell; Benzaldehydes; Clinical Trials, Phase III as Topic; Drug Therapy, C | 2021 |
Hydroyxurea improves cerebral oxygen saturation in children with sickle cell anemia.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Cerebrovascular Circulation; Child; Child, Pre | 2021 |
Tolerance and humoral immune response to the yellow fever vaccine in sickle cell disease children treated with hydroxyurea: a multicentre prospective study.
Topics: Adolescent; Africa; Anemia, Sickle Cell; Child; Child, Preschool; Female; Humans; Hydroxyurea; Immun | 2021 |
OCCURRENCE OF UNUSUAL HAEMOGLOBINOPATHIES IN BALOCHISTAN: HB SD AND HB SE - PRESENTATION WITH OSTEOMYELITIS.
Topics: Administration, Intravenous; Administration, Oral; Anemia, Sickle Cell; Anti-Bacterial Agents; Antis | 2021 |
Hydroxyurea: coming to conclusions on safety.
Topics: Anemia, Sickle Cell; Antisickling Agents; Humans; Hydroxyurea; Male; Puberty; Spermatozoa | 2021 |
There's safety in numbers.
Topics: Anemia, Sickle Cell; Humans; Hydroxyurea | 2021 |
Longitudinal effect of disease-modifying therapy on tricuspid regurgitant velocity in children with sickle cell anemia.
Topics: Adult; Anemia, Sickle Cell; Child; Humans; Hydroxyurea; Prospective Studies; Thalassemia; Tricuspid | 2021 |
Clinical predictors of poor outcomes in patients with sickle cell disease and COVID-19 infection.
Topics: Acute Chest Syndrome; Adult; Anemia, Sickle Cell; Antisickling Agents; COVID-19; Disease Progression | 2021 |
Chronic osteo-articular changes in patients with sickle cell disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Cross-Sectional Studies; Female; Hemogl | 2021 |
MRI detection of brain abnormality in sickle cell disease.
Topics: Anemia, Sickle Cell; Brain; Diffusion Tensor Imaging; Humans; Hydroxyurea; Magnetic Resonance Imagin | 2021 |
Hydroxyurea improves nitric oxide bioavailability in humanized sickle cell mice.
Topics: Anemia, Sickle Cell; Animals; Antisickling Agents; Arginase; Disease Models, Animal; Hemoglobin A; H | 2021 |
Chronic organ injuries in children with sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Child; Humans; Hydroxyurea; Stroke | 2021 |
Nephrotic syndrome on sickle cell disease: the impact of Hydroxyurea.
Topics: Adolescent; Albuminuria; Anemia, Sickle Cell; Child; Female; Humans; Hydroxyurea; Kidney Diseases; N | 2021 |
Hydroxyurea Use Associated with Nonverbal and Executive Skills in Sickle Cell Anemia.
Topics: Anemia, Sickle Cell; Child; Child, Preschool; Executive Function; Fetal Hemoglobin; Hemoglobin, Sick | 2021 |
Implementation of near-universal hydroxyurea uptake among children with sickle cell anemia: A single-center experience.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Biological Transport; Child; Child, Preschool; | 2021 |
Adherence to hydroxyurea, health-related quality of life domains and attitudes towards a smartphone app among Irish adolescents and young adults with sickle cell disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Female; Humans; Hydroxyurea; Male; Medication Adherence; Mob | 2022 |
Lucio Luzzatto: tackling blood disorders on multiple continents.
Topics: Anemia, Sickle Cell; Animals; Antisickling Agents; Bone Marrow; Bone Marrow Examination; Glucosephos | 2021 |
Hydroxyurea in children with sickle cell disease in a resource-poor setting: Monitoring and effects of therapy. A practical perspective.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Cross-Sectional Studi | 2021 |
Single laser trapping for optical folding and rotation of red blood cells in sickle cell disease in response to hydroxyurea treatment.
Topics: Anemia, Sickle Cell; Antisickling Agents; Biomarkers; Case-Control Studies; Erythrocyte Count; Eryth | 2021 |
Telomere length and telomere repeat-binding protein in children with sickle cell disease.
Topics: Anemia, Sickle Cell; Biomarkers; Child; Humans; Hydroxyurea; Leukocytes; Telomere-Binding Proteins | 2022 |
[Sickle cell disease in the Democratic Republic of the Congo: what are the barriers to treatment using hydroxyurea?]
Topics: Anemia, Sickle Cell; Antisickling Agents; Cross-Sectional Studies; Democratic Republic of the Congo; | 2021 |
Multifocal Osteonecrosis in a 3-Year-old Child With Sickle Beta Plus Thalassemia.
Topics: Anemia, Sickle Cell; beta-Thalassemia; Child, Preschool; Humans; Hydroxyurea; Male; Osteonecrosis; T | 2022 |
Clinical Features and Outcome of Sickle Cell Disease in a Tertiary Center in Northern Lebanon: A Retrospective Cohort Study in a Local, Hospital-Associated Registry.
Topics: Anemia, Sickle Cell; Cohort Studies; Hospitals; Humans; Hydroxyurea; Lebanon; Pain; Registries; Retr | 2021 |
Blood pressure, hematologic and biochemical changes following L-arginine supplementation in children with sickle cell anaemia already on hydroxyurea therapy.
Topics: Anemia, Sickle Cell; Arginine; Blood Pressure; Child; Dietary Supplements; Humans; Hydroxyurea | 2020 |
A Feasibility Pilot Study of Online Modules of Hydroxyurea and Sickle Cell Disease Care for Adolescents and Young Adults for Family Medicine Residents.
Topics: Adolescent; Anemia, Sickle Cell; Family Practice; Feasibility Studies; Humans; Hydroxyurea; Pilot Pr | 2022 |
Time to rethink haemoglobin threshold guidelines in sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Benzaldehydes; Blood Transfusion; Blood Viscosity; Genetic | 2021 |
Effect of lysed and non-lysed sickle red cells on the activation of NLRP3 inflammasome and LTB4 production by mononuclear cells.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Caspase 1; Cells, Cultured; Child; Erythrocyte | 2021 |
Hydroxyurea therapy decreases coagulation and endothelial activation in sickle cell disease: a Longitudinal Study.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Coagulation; Endothelium; Female; Humans; Hyd | 2021 |
Effects of hydroxyurea on brain function in children with sickle cell anemia.
Topics: Adolescent; Anemia, Sickle Cell; Brain; Child; Hemoglobins; Humans; Hydroxyurea; Oxygen Saturation; | 2021 |
Neuroprotection: further evidence for the early and universal use of hydroxyurea in children with sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Humans; Hydroxyurea; Neuroprotection | 2021 |
Patient-reported neurocognitive symptoms influence instrumental activities of daily living in sickle cell disease.
Topics: Activities of Daily Living; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Cognitive D | 2021 |
Mechanisms underlying the adaptive pulp and jaw bone trabecular changes in sickle cell anemia.
Topics: Anemia, Sickle Cell; Cross-Sectional Studies; Dental Pulp Diseases; Hemoglobins; Humans; Hydroxyurea | 2023 |
Alpha haemoglobin-stabilising protein concentration in the red blood cells of patients with sickle cell anaemia with and without hydroxycarbamide treatment.
Topics: Adult; Anemia, Sickle Cell; Biomarkers; Blood Proteins; Case-Control Studies; Enzyme-Linked Immunoso | 2022 |
Developmental screening of three-year-old children with sickle cell disease compared to controls.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child, Preschool; Family Characteristics; Female; Humans; | 2021 |
Effect of hydroxyurea therapy on intravascular hemolysis and endothelial dysfunction markers in sickle cell anemia patients.
Topics: ADAMTS13 Protein; Adolescent; Adult; Anemia, Sickle Cell; Antigens, CD; Antigens, Differentiation, M | 2021 |
Neuropathic pain in patients with sickle cell disease: a cross-sectional study assessing teens and young adults.
Topics: Adolescent; Adult; Analysis of Variance; Anemia, Sickle Cell; Antisickling Agents; Chi-Square Distri | 2017 |
Lactate Dehydrogenase: A Marker of the Severity of Vaso-Occlusive Crisis in Children with Sickle Cell Disease Presenting at the Emergency Department.
Topics: Adolescent; Analgesics, Opioid; Anemia, Sickle Cell; Arterial Occlusive Diseases; Child; Child, Pres | 2016 |
Bone Marrow as a Hematopoietic Stem Cell Source for Gene Therapy in Sickle Cell Disease: Evidence from Rhesus and SCD Patients.
Topics: Anemia, Sickle Cell; Animals; Antigens, CD34; Bone Marrow Cells; Cells, Cultured; Genetic Therapy; H | 2017 |
Measurements of red cell deformability and hydration reflect HbF and HbA
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Cell Count; Blood Transfusion; Erythrocyte De | 2017 |
Key Pharmacogenomic Considerations for Sickle Cell Disease Patients.
Topics: Anemia, Sickle Cell; Humans; Hydroxyurea; Pain Management; Pharmacogenetics | 2017 |
Clinic Attendance of Youth With Sickle Cell Disease on Hydroxyurea Treatment.
Topics: Adolescent; Ambulatory Care; Anemia, Sickle Cell; Child; Child, Preschool; Family Characteristics; F | 2017 |
Accelerated leukemic transformation after haplo-identical transplantation for hydroxyurea-treated sickle cell disease.
Topics: Acute Disease; Adult; Anemia, Sickle Cell; Antineoplastic Agents; Cell Transformation, Neoplastic; F | 2018 |
Changes in urine albumin to creatinine ratio with the initiation of hydroxyurea therapy among children and adolescents with sickle cell disease.
Topics: Adolescent; Albuminuria; Anemia, Sickle Cell; Child; Creatinine; Female; Humans; Hydroxyurea; Male; | 2017 |
Decrease of externalized phosphatidylserine density on red blood cell-derived microparticles in SCA patients treated with hydroxycarbamide.
Topics: Adult; Anemia, Sickle Cell; Cell-Derived Microparticles; Erythrocyte Indices; Erythrocytes; Humans; | 2018 |
Adherence to hydroxyurea, health-related quality of life domains, and patients' perceptions of sickle cell disease and hydroxyurea: a cross-sectional study in adolescents and young adults.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Cross-Sectional Studies; Emergency Serv | 2017 |
Proponent or collaborative: Physician perspectives and approaches to disease modifying therapies in sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Bone Marrow Transplantation; Chi | 2017 |
Effects of hydroxyurea on blood rheology in sickle cell anemia: A two-years follow-up study.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Female; Follow-Up Studies; Humans; Hydroxyurea; Mal | 2017 |
Study of Seminal Fluid Parameters and Fertility of Male Sickle Cell Disease Patients and Potential Impact of Hydroxyurea Treatment.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Azoospermia; Fertility; Humans; Hydroxy | 2017 |
An age dependent response to hydroxyurea in pediatric sickle cell anemia patients with alpha thalassemia trait.
Topics: Adolescent; Age Factors; alpha-Thalassemia; Anemia, Sickle Cell; Arterial Occlusive Diseases; Child; | 2017 |
Twenty-Nail Transverse Melanonychia Induced by Hydroxyurea: Case Report and Review of the Literature.
Topics: Anemia, Sickle Cell; Diagnosis, Differential; Female; Humans; Hydroxyurea; Hyperpigmentation; Middle | 2017 |
Associations between endothelial dysfunction and clinical and laboratory parameters in children and adolescents with sickle cell anemia.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Bilirubin; C-Reactive Protein; Case-Control St | 2017 |
Hydroxyurea prescription, availability and use for children with sickle cell disease in Italy: Results of a National Multicenter survey.
Topics: Adolescent; Anemia, Sickle Cell; Child; Child, Preschool; Drug Prescriptions; Emigrants and Immigran | 2018 |
Skeletal and myocardial microvascular blood flow in hydroxycarbamide-treated patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Case-Control Studies; Coronary Circulation; Fetal Hemoglobin; Humans; Hy | 2017 |
A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapy.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Blood Cell Count; Child; Child, Preschool; Dos | 2017 |
Determination of hydroxyurea in human plasma by HPLC-UV using derivatization with xanthydrol.
Topics: Anemia, Sickle Cell; Chromatography, High Pressure Liquid; Humans; Hydroxyurea; Linear Models; Repro | 2017 |
Hydroxyurea differentially modulates activator and repressors of γ-globin gene in erythroblasts of responsive and non-responsive patients with sickle cell disease in correlation with Index of Hydroxyurea Responsiveness.
Topics: Anemia, Sickle Cell; Cells, Cultured; Erythroblasts; Fetal Hemoglobin; gamma-Globins; Gene Expressio | 2017 |
Hydroxyurea therapy in adult Nigerian sickle cell disease: a monocentric survey on pattern of use, clinical effects and patient's compliance.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Cross-Sectional Studies; Health Knowled | 2017 |
Changes in Transcranial Doppler Flow Velocities in Children with Sickle Cell Disease: The Impact of Hydroxyurea Therapy.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Blood Flow Velocity; Cerebrovascular Circulati | 2018 |
Therapeutic advances in sickle cell disease in the last decade.
Topics: Anemia, Sickle Cell; beta-Globins; Blood Transfusion; Genetic Therapy; Hematopoietic Stem Cell Trans | 2017 |
A thalidomide-hydroxyurea hybrid increases HbF production in sickle cell mice and reduces the release of proinflammatory cytokines in cultured monocytes.
Topics: Anemia, Sickle Cell; Animals; Cytokines; Disease Models, Animal; Fetal Hemoglobin; Hydroxyurea; Infl | 2018 |
Technological Advances in Sickle Cell Disease.
Topics: Anemia, Sickle Cell; Genomics; Genotyping Techniques; Humans; Hydroxyurea; Magnetic Resonance Imagin | 2017 |
Clinical Features of β-Thalassemia and Sickle Cell Disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Erythrocyte Transfusion; Genetic Therapy | 2017 |
Reactivation of Fetal Hemoglobin for Treating β-Thalassemia and Sickle Cell Disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Globins; beta-Thalassemia; Erythroid Cells; Fe | 2017 |
Inflammatory molecule reduction with hydroxyurea therapy in children with sickle cell anemia.
Topics: Adolescent; Anemia, Sickle Cell; Anti-Inflammatory Agents; Child; Child, Preschool; Humans; Hydroxyu | 2018 |
Hydroxyurea for SCA in Africa: no malaria harm.
Topics: Africa; Anemia, Sickle Cell; Antisickling Agents; Humans; Hydroxyurea; Malaria | 2017 |
Hydroxyurea responses in clinically varied beta, HbE-beta thalassaemia and sickle cell anaemia patients of Eastern India.
Topics: Adolescent; Adult; Anemia, Sickle Cell; beta-Thalassemia; Child; Child, Preschool; Female; Follow-Up | 2018 |
Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Child; Child, Prescho | 2018 |
Hydroxyurea (hydroxycarbamide) genotoxicity in pediatric patients with sickle cell disease.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Case-Control Studies; Child; Child, Preschool; | 2018 |
Model-based dosing with concentration feedback as an integral part of personalized hydroxycarbamide management.
Topics: Anemia, Sickle Cell; Child; Feedback; Humans; Hydroxyurea | 2018 |
A Retrospective Analysis of Sociodemographic and Hematologic Characteristics Associated With Achieving Optimal Hydroxyurea Therapy in Children With Sickle Cell Disease.
Topics: Adolescent; Adult; Age Factors; Anemia, Sickle Cell; Child; Child, Preschool; Female; Humans; Hydrox | 2018 |
Prevalence and incidence of congenital anomalies amongst babies born to women with sickle cell disease and exposed to hydroxyurea during pregnancy: a systematic review protocol.
Topics: Anemia, Sickle Cell; Antisickling Agents; Congenital Abnormalities; Female; Humans; Hydroxyurea; Inc | 2018 |
Hydroxycarbamide adherence and cumulative dose associated with hospital readmission in sickle cell disease: a 6-year population-based cohort study.
Topics: Adolescent; Adult; Age Distribution; Aged; Anemia, Sickle Cell; Antisickling Agents; Child; Child, P | 2018 |
Annual stroke incidence in Nigerian children with sickle cell disease and elevated TCD velocities treated with hydroxyurea.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Blood Flow Velocity; Cerebrovascular Circulati | 2019 |
Sickle Cell Clinical Research and Intervention Program (SCCRIP): A lifespan cohort study for sickle cell disease progression from the pediatric stage into adulthood.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Biological Specimen Banks; Blood Transfusion; Body Fluids; C | 2018 |
Immunological role of CD4
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; CD28 Antigens; CD4-Positive T-Lymphocytes; Chi | 2018 |
From trust to skepticism: An in-depth analysis across age groups of adults with sickle cell disease on their perspectives regarding hydroxyurea.
Topics: Adolescent; Adult; Aged; Anemia, Sickle Cell; Antisickling Agents; Female; Health Care Surveys; Heal | 2018 |
Development of a Hydroxyurea Decision Aid for Parents of Children With Sickle Cell Anemia.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Child; Child, Preschool; Decision Making; Female; Humans; Hy | 2019 |
Spermatogonial quantity in human prepubertal testicular tissue collected for fertility preservation prior to potentially sterilizing therapy.
Topics: Anemia, Sickle Cell; Antineoplastic Agents, Alkylating; Case-Control Studies; Child; Child, Preschoo | 2018 |
New and experimental agents for sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Combined Modality Therapy; Drug Discovery; Erythrocyte Tra | 2018 |
Association between Participants' Characteristics, Patient-Reported Outcomes, and Clinical Outcomes in Youth with Sickle Cell Disease.
Topics: Adolescent; Anemia, Sickle Cell; Child; Cross-Sectional Studies; Female; Humans; Hydroxyurea; Male; | 2018 |
Combined hydroxyurea and ET
Topics: Anemia, Sickle Cell; Animals; Antisickling Agents; Disease Models, Animal; Drug Therapy, Combination | 2019 |
Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: The effect of hydroxyurea, fetal hemoglobin, and α-thalassemia.
Topics: alpha-Globins; alpha-Thalassemia; Anemia, Sickle Cell; Biomarkers; Erythrocyte Indices; Erythrocytes | 2018 |
Airlie House legend.
Topics: Anemia, Sickle Cell; Genetic Therapy; Group Processes; History, 20th Century; Humans; Hydroxyurea; N | 2018 |
Targeted Hydroxyurea Education after an Emergency Department Visit Increases Hydroxyurea Use in Children with Sickle Cell Anemia.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Emergency Service, Ho | 2018 |
Impact of ZBTB7A hypomethylation and expression patterns on treatment response to hydroxyurea.
Topics: Anemia, Sickle Cell; beta-Globins; beta-Thalassemia; Carrier Proteins; DNA Methylation; DNA-Binding | 2018 |
High inpatient dose of opioid at discharge compared to home dose predicts readmission risk in sickle cell disease.
Topics: Adult; Analgesia, Patient-Controlled; Analgesics, Opioid; Anemia, Sickle Cell; Antisickling Agents; | 2019 |
Sickle cell disease: a case report of renal amyloidosis.
Topics: Adult; Amyloidosis; Anemia, Sickle Cell; Angiotensin-Converting Enzyme Inhibitors; Antibodies; DNA; | 2018 |
Improving Uptake of Hydroxyurea in Patients with Sickle Cell Disease: A Retrospective Study of a Clinic-based Change in Consenting Practices.
Topics: Adolescent; Ambulatory Care; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Fema | 2019 |
Use of metformin in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Drug Evaluation; Drug Therapy, Combination; Female; | 2019 |
Increased Patient Activation Is Associated with Fewer Emergency Room Visits and Hospitalizations for Pain in Adults with Sickle Cell Disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Cross-Sectional Stud | 2019 |
Risk of avascular necrosis of the femoral head in children with sickle cell disease on hydroxyurea: MRI evaluation.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Female; Femur Head Necrosis; Humans; Hy | 2019 |
Hydroxyurea prevents onset and progression of albuminuria in children with sickle cell anemia.
Topics: Adolescent; Albuminuria; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Disease | 2019 |
Hemoglobin oxidation-dependent reactions promote interactions with band 3 and oxidative changes in sickle cell-derived microparticles.
Topics: Anemia, Sickle Cell; Animals; Antisickling Agents; Cell-Derived Microparticles; Endothelial Cells; E | 2018 |
Additive effect of sirolimus and hydroxycarbamide on fetal haemoglobin level in kidney transplant patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Female; Fetal Hemoglobin; Humans; Hydroxyurea; Kidney Transplantation; M | 2019 |
Elevated fetal haemoglobin levels are associated with decreased incidence of retinopathy in adults with sickle cell disease.
Topics: Adolescent; Adult; Aged; Anemia, Sickle Cell; Antisickling Agents; Cross-Sectional Studies; Female; | 2018 |
Hydroxyurea for Primary Stroke Prevention: The time draweth nigh.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Humans; Hydroxyurea; Incidence; Nigeria; Stroke | 2019 |
Developing a risk-based composite neurologic outcome for a trial of hydroxyurea in young children with sickle cell disease.
Topics: Anemia, Sickle Cell; Child; Clinical Trials as Topic; Cognitive Dysfunction; Endpoint Determination; | 2019 |
Shape oscillations of single blood drops: applications to human blood and sickle cell disease.
Topics: Anemia, Sickle Cell; Blood Viscosity; Erythrocytes, Abnormal; Fetal Hemoglobin; Humans; Hydroxyurea; | 2018 |
Increasing hydroxyurea use in children with sickle cell disease at Kamuzu Central Hospital, Malawi.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Female; Hospitals, Te | 2018 |
Is chronic use of hydroxyurea safe for patients with sickle cell anemia? An account of genotoxicity and mutagenicity.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Brazil; Cross-Sectional Studies; DNA Da | 2019 |
Characterization of natural killer cells expressing markers associated with maturity and cytotoxicity in children and young adults with sickle cell disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Biomarkers; Case-Control Studies; Child | 2019 |
Hydroxyurea - An Essential Medicine for Sickle Cell Disease in Africa.
Topics: Africa South of the Sahara; Anemia, Sickle Cell; Child; Humans; Hydroxyurea | 2019 |
Management of an adult patient with sickle cell disease and acute chest syndrome by veno-venous extracorporeal membrane oxygenation.
Topics: Acute Chest Syndrome; Anemia, Sickle Cell; Anticoagulants; Combined Modality Therapy; Dobutamine; Ex | 2019 |
Hydroxyurea use in young infants with sickle cell disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Child; Female; Follow-Up Studies; Humans; Hydroxyurea; Infan | 2019 |
Social media discussions provide new insight about perceptions of hydroxyurea in the sickle cell community.
Topics: Anemia, Sickle Cell; Antisickling Agents; Female; Humans; Hydroxyurea; Male; Perception; Social Medi | 2019 |
Hydroxyurea use among children with sickle cell anemia.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Female; Follow-Up Stu | 2019 |
Leg ulcer induced by hydroxycarbamide in sickle cell disease: What is the therapeutic impact?
Topics: Anemia, Sickle Cell; Antisickling Agents; Humans; Hydroxyurea; Leg Ulcer; Male; Middle Aged; Treatme | 2019 |
Pregnancy outcomes in women with sickle cell disease: a retrospective study from Eastern India.
Topics: Abortion, Induced; Abortion, Spontaneous; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusio | 2019 |
Implication of HMOX1 and CCR5 genotypes on clinical phenotype of Egyptian patients with sickle cell anemia.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Arabs; Case-Control Studies; Child; Chi | 2019 |
Hydroxyurea for children with sickle cell anemia: Prescribe it early and often.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Humans; Hydroxyurea; Infant | 2019 |
Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Area Under Curve; Child; Child, Preschool; Dos | 2019 |
Hydroxyurea Initiation Among Children With Sickle Cell Anemia.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Female; Hospitalizati | 2019 |
Acute hydroxyurea treatment reduces tubular damage following bilateral ischemia-reperfusion injury in a mouse model of sickle cell disease.
Topics: Acute Kidney Injury; Anemia, Sickle Cell; Animals; Antisickling Agents; Biomarkers; Creatinine; Dise | 2019 |
Perceived benefits and risks of participation in a clinical trial for Ugandan children with sickle cell anemia.
Topics: Anemia, Sickle Cell; Antisickling Agents; Caregivers; Child; Clinical Trials, Phase III as Topic; De | 2020 |
Brain O
Topics: Anemia, Sickle Cell; Brain; Hemoglobin, Sickle; Humans; Hydroxyurea; Stress, Physiological | 2019 |
A novel, highly potent and selective phosphodiesterase-9 inhibitor for the treatment of sickle cell disease.
Topics: Anemia, Sickle Cell; Animals; Fetal Hemoglobin; Humans; Hydroxyurea; K562 Cells; Mice; Phosphodieste | 2020 |
Prospective longitudinal follow-up of children with sickle cell disease treated with hydroxyurea since infancy.
Topics: Anemia, Sickle Cell; Blood Transfusion; Child; Child, Preschool; Female; Fetal Hemoglobin; Fever; Fo | 2019 |
Thyroid hemodynamic alterations in Egyptian patients with sickle cell disease: relation to disease severity, total body iron and thyroid function.
Topics: Adolescent; Anemia, Sickle Cell; Child; Cross-Sectional Studies; Egypt; Female; Hemodynamics; Humans | 2019 |
Longitudinal Trend in Emergency Department Reliance for Pain Among Sickle Cell Disease Patients in Wisconsin.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Cohort Studies | 2019 |
Hydroxyurea Use for Sickle Cell Disease Among Medicaid-Enrolled Children.
Topics: Acute Disease; Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Cross- | 2019 |
Pediatric to Adult Transition in Sickle Cell Disease: Survey Results from Young Adult Patients.
Topics: Adult; Anemia, Sickle Cell; Blood Transfusion; Cross-Sectional Studies; Female; Humans; Hydroxyurea; | 2020 |
National trends in hydroxyurea and opioid prescribing for sickle cell disease by office-based physicians in the United States, 1997-2017.
Topics: Adolescent; Age Factors; Analgesics, Opioid; Anemia, Sickle Cell; Child; Child, Preschool; Drug Pres | 2019 |
Liver Transplantation for Acute Liver Failure Secondary to Acute Sickle Intrahepatic Cholestasis.
Topics: Acute Disease; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Bradycardia; Budd-Chiari | 2020 |
Fetal hemoglobin and hydroxycarbamide moduate both plasma concentration and cellular origin of circulating microparticles in sickle cell anemia children.
Topics: Adolescent; Anemia, Sickle Cell; Blood Platelets; Cell-Derived Microparticles; Child; Child, Prescho | 2013 |
Candidate sequence variants and fetal hemoglobin in children with sickle cell disease treated with hydroxyurea.
Topics: Adolescent; Alleles; Anemia, Sickle Cell; Antisickling Agents; Child; Female; Fetal Hemoglobin; Geno | 2013 |
Low flow nocturnal oxygen therapy does not suppress haemoglobin levels or increase painful crises in sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Erythropoiesis; Erythropoietin; Female; Hemoglobins | 2013 |
Thrombin generation in children with sickle cell disease: relationship with age, hemolysis, transcranial Doppler velocity, and hydroxyurea treatment.
Topics: Adolescent; Age Factors; Anemia, Sickle Cell; Blood Platelets; Child; Child, Preschool; Female; Hemo | 2013 |
Does increased red blood cell deformability raise the risk for osteonecrosis in sickle cell anemia?
Topics: Aged; Anemia, Sickle Cell; Antisickling Agents; Erythrocyte Deformability; Female; Humans; Hydroxyur | 2013 |
Expression of regulatory platelet microRNAs in patients with sickle cell disease.
Topics: Adult; Aged; Anemia, Sickle Cell; Blood Platelets; Cell Line; Chromosomes, Human, Pair 14; Computati | 2013 |
Erythrocyte deformability and aggregation in homozygous sickle cell disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Erythrocyte Ag | 2014 |
Altered levels of pro-inflammatory cytokines in sickle cell disease patients during vaso-occlusive crises and the steady state condition.
Topics: Anemia, Sickle Cell; beta-Thalassemia; Case-Control Studies; Cytokines; Demography; Female; Humans; | 2013 |
Current management of sickle cell anemia.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Clinical Trials as Topic; Early Diagnosis; Evidence | 2013 |
Information exploration system for sickle cell disease and repurposing of hydroxyfasudil.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Anemia, Sickle Cell; Antisickling Agents; Data Mining | 2013 |
Efficacy of fixed low dose hydroxyurea in Indian children with sickle cell anemia: a single centre experience.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Cohort Studies; Femal | 2013 |
Cerebrovascular events in sickle cell-beta thalassemia treated with hydroxyurea: a single center prospective survey in adult Italians.
Topics: Adult; Aged; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Cerebral Infarction; Cerebr | 2013 |
Longitudinal study of echocardiography-derived tricuspid regurgitant jet velocity in sickle cell disease.
Topics: Adult; Aged; Anemia, Sickle Cell; Antisickling Agents; Echocardiography; Female; Humans; Hydroxyurea | 2013 |
A young adult Jehovah's Witness with severe anemia.
Topics: Adolescent; Anemia, Sickle Cell; Blood Transfusion; Combined Modality Therapy; Critical Care; Erythr | 2013 |
Hydroxyurea use and hospitalization trends in a comprehensive pediatric sickle cell program.
Topics: Adolescent; Anemia, Sickle Cell; Child; Child, Preschool; Erythrocyte Transfusion; Female; Hospitali | 2013 |
Prior exposure of endothelial cells to hydroxycarbamide alters the flow dynamics and adhesion of sickle red blood cells.
Topics: Anemia, Sickle Cell; Antisickling Agents; Cell Adhesion; Cell Line; Endothelial Cells; Endothelium, | 2014 |
Nontraumatic extradural hematoma in sickle cell anemia: a rare neurological complication not to be missed.
Topics: Anemia, Sickle Cell; Antisickling Agents; Brain; Child; Female; Hematoma, Epidural, Cranial; Humans; | 2014 |
Sickle cell disease: taking a multidisciplinary approach.
Topics: Analgesics; Anemia, Sickle Cell; Antisickling Agents; Erythrocyte Transfusion; Hematopoietic Stem Ce | 2013 |
Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies.
Topics: Anemia, Sickle Cell; Antisickling Agents; Cell Adhesion; Endothelium, Vascular; Humans; Hydroxyurea; | 2013 |
A retrospective study to assess the utility of frequent laboratory monitoring of pediatric patients with sickle cell disease on hydroxyurea.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Drug Monitoring; Fema | 2014 |
Hydroxyurea is associated with lower prevalence of albuminuria in adults with sickle cell disease.
Topics: Acute Chest Syndrome; Adolescent; Adult; Aged; Albuminuria; Anemia, Sickle Cell; Angiotensin-Convert | 2014 |
Genetic and biochemical markers of hydroxyurea therapeutic response in sickle cell anemia.
Topics: Adolescent; Adult; Aged; Anemia, Sickle Cell; Biomarkers; Child; Female; Fetal Hemoglobin; Follow-Up | 2013 |
Quantification of HBG mRNA in primary erythroid cultures: prediction of the response to hydroxyurea in sickle cell and beta-thalassemia.
Topics: Adult; Aged; Anemia, Sickle Cell; beta-Thalassemia; Erythroid Precursor Cells; Female; Fetal Hemoglo | 2014 |
Current sickle cell disease management practices in Nigeria.
Topics: Anemia, Sickle Cell; Delivery of Health Care; Health Care Surveys; Health Facilities; Health Resourc | 2014 |
Pain characteristics and age-related pain trajectories in infants and young children with sickle cell disease.
Topics: Age Factors; Anemia, Sickle Cell; Child, Preschool; Female; Follow-Up Studies; Health Services; Hosp | 2014 |
Treating sickle cell anaemia with hydroxycarbamide.
Topics: Anemia, Sickle Cell; Antisickling Agents; Humans; Hydroxyurea | 2014 |
Clinical and hematological effects of hydroxyurea therapy in sickle cell patients: a single-center experience in Brazil.
Topics: Adolescent; Adult; Analysis of Variance; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion | 2013 |
Neuropathic pain in patients with sickle cell disease.
Topics: Adolescent; Adult; Age Factors; Anemia, Sickle Cell; Cross-Sectional Studies; Female; Humans; Hydrox | 2014 |
Fetal hemoglobin in sickle cell anemia: a glass half full?
Topics: Adult; Anemia, Sickle Cell; Erythrocytes; Fetal Hemoglobin; Gene Deletion; Haplotypes; Hemoglobin, S | 2014 |
Fetal hemoglobin in sickle cell anemia: a glass half full?
Topics: Adult; Anemia, Sickle Cell; Erythrocytes; Fetal Hemoglobin; Gene Deletion; Haplotypes; Hemoglobin, S | 2014 |
Fetal hemoglobin in sickle cell anemia: a glass half full?
Topics: Adult; Anemia, Sickle Cell; Erythrocytes; Fetal Hemoglobin; Gene Deletion; Haplotypes; Hemoglobin, S | 2014 |
Fetal hemoglobin in sickle cell anemia: a glass half full?
Topics: Adult; Anemia, Sickle Cell; Erythrocytes; Fetal Hemoglobin; Gene Deletion; Haplotypes; Hemoglobin, S | 2014 |
Stroke recurrence in Nigerian children with sickle cell disease treated with hydroxyurea.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Disabled Children; Female; Humans | 2013 |
Chronic inflammatory state in sickle cell anemia patients is associated with HBB(*)S haplotype.
Topics: Adult; Aged; Anemia, Sickle Cell; beta-Globins; Case-Control Studies; Chromosomes, Human; Chronic Di | 2014 |
Alpha-thalassaemia and response to hydroxyurea in sickle cell anaemia.
Topics: Adult; alpha-Globins; alpha-Thalassemia; Anemia, Sickle Cell; Antisickling Agents; Female; Gene Dele | 2014 |
Hydroxycarbamide reduces eosinophil adhesion and degranulation in sickle cell anaemia patients.
Topics: Adolescent; Adult; Aged; Anemia, Sickle Cell; Antigens, CD; Antisickling Agents; Case-Control Studie | 2014 |
Serum angiogenin level in sickle cell disease and beta thalassemia patients.
Topics: Adolescent; Age of Onset; Anemia, Sickle Cell; beta-Thalassemia; Blood Transfusion; Case-Control Stu | 2014 |
Modulation of gamma globin genes expression by histone deacetylase inhibitors: an in vitro study.
Topics: Adult; Anemia, Sickle Cell; Antigens, CD34; Butyric Acid; Carbamates; Cell Differentiation; Cells, C | 2014 |
Hydroxycarbamide decreases sickle reticulocyte adhesion to resting endothelium by inhibiting endothelial lutheran/basal cell adhesion molecule (Lu/BCAM) through phosphodiesterase 4A activation.
Topics: Anemia, Sickle Cell; Antisickling Agents; Cell Adhesion; Cell Adhesion Molecules; Cyclic AMP; Cyclic | 2014 |
An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Anticoagulants; Antihypertensive Agents; Antisickling Agents; Cardiac Ca | 2014 |
Hematology clinic. Sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Erythrocyte Transfusion; Hematology; Hemoglobin, Sickle; H | 2014 |
Hydroxycarbamide modulates components involved in the regulation of adenosine levels in blood cells from sickle-cell anemia patients.
Topics: 5'-Nucleotidase; Adenosine; Adenosine Deaminase; Adolescent; Adult; Anemia, Sickle Cell; Antigens, C | 2014 |
Practice patterns of stroke screening and hydroxyurea use in children with sickle cell disease: a survey of health care providers.
Topics: Acute Chest Syndrome; Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; | 2014 |
Do difficulties in swallowing medication impede the use of hydroxyurea in children?
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Deglutition; F | 2014 |
In vitro and in vivo anti-angiogenic effects of hydroxyurea.
Topics: Anemia, Sickle Cell; Angiogenesis Inhibitors; Animals; Cell Movement; Cell Proliferation; Human Umbi | 2014 |
National trends in hospitalizations for sickle cell disease in the United States following the FDA approval of hydroxyurea, 1998-2008.
Topics: Adolescent; Adult; Aged; Anemia, Sickle Cell; Antisickling Agents; Black or African American; Child; | 2014 |
Proteinuria in adults with sickle-cell disease: the role of hydroxycarbamide(hydroxyurea) as a protective agent.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Brazil; Cohort Studies; Female; Glomerular Filtrati | 2014 |
Pulmonary hypertension of sickle cell disease: new guidelines.
Topics: Anemia, Sickle Cell; Antisickling Agents; Humans; Hydroxyurea; Hypertension, Pulmonary; Practice Gui | 2014 |
A rare disorder in an orphan disease: Kikuchi-Fujimoto disease in a young-adult patient with sickle cell anemia.
Topics: Anemia, Sickle Cell; Cytapheresis; Female; Histiocytic Necrotizing Lymphadenitis; Humans; Hydroxyure | 2014 |
Growth differentiation factor-15 in young sickle cell disease patients: relation to hemolysis, iron overload and vascular complications.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Blood Vessels; Case-Control | 2014 |
What are the most promising emerging therapies for sickle cell disease?
Topics: Anemia, Sickle Cell; Hemoglobins; Humans; Hydroxyurea; Nitric Oxide | 2014 |
Differences in quality of life between pediatric sickle cell patients who used hydroxyurea and those who did not.
Topics: Adolescent; Age Factors; Anemia, Sickle Cell; Antisickling Agents; Child; Cross-Sectional Studies; D | 2014 |
Improved hydroxyurea effect with the use of text messaging in children with sickle cell anemia.
Topics: Adolescent; Anemia, Sickle Cell; Cell Phone; Child; Child, Preschool; Female; Humans; Hydroxyurea; M | 2014 |
Hyperfiltration is associated with the development of microalbuminuria in patients with sickle cell anemia.
Topics: Adolescent; Adult; Age Factors; Albuminuria; Anemia, Sickle Cell; Biomarkers; Disease Progression; F | 2014 |
Hydroxycarbamide treatment in sickle cell disease: estimates of possible leukaemia risk and of hospitalization survival benefit.
Topics: Adolescent; Adult; Age Factors; Anemia, Sickle Cell; Antisickling Agents; Child; Databases, Factual; | 2014 |
Mast cell activation syndrome as a significant comorbidity in sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Caseins; Chromogranin A; Cohort Studies; Female; He | 2014 |
The challenge of creating an evidence-based guideline for sickle cell disease.
Topics: Anemia, Sickle Cell; Blood Transfusion; Humans; Hydroxyurea | 2014 |
Reduced plasma angiotensin II levels are reversed by hydroxyurea treatment in mice with sickle cell disease.
Topics: Anemia, Sickle Cell; Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; Disease Models, Anima | 2014 |
Hydroxyurea Improves Oxygen Saturation in Children With Sickle Cell Disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Female; Follow | 2015 |
Primary stroke in a woman with sickle cell anemia responsive to hydroxyurea therapy.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Brain Ischemia; Echocardiography, Transesophageal; | 2014 |
Shared decision making for hydroxyurea treatment initiation in children with sickle cell anemia.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Clinical Decision-Making; Decision Making; Humans; | 2015 |
Prominent role of platelets in the formation of circulating neutrophil-red cell heterocellular aggregates in sickle cell anemia.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Platelets; Cell Adhesion; Cell Adhesion Molecules; E | 2014 |
Pulmonary hypertension in sickle cell disease.
Topics: Anemia, Sickle Cell; Anticoagulants; Antisickling Agents; Echocardiography, Doppler; Erythrocyte Tra | 2014 |
Intensive management of high-utilizing adults with sickle cell disease lowers admissions.
Topics: Adolescent; Adult; Analgesics; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease | 2015 |
Modulation of pain in pediatric sickle cell disease: understanding the balance between endothelin mediated vasoconstriction and apelin mediated vasodilation.
Topics: Adolescent; Age Factors; Anemia, Sickle Cell; Antisickling Agents; Apelin; Biomarkers; Child; Child, | 2015 |
[Treatment with hydroxyurea has revolutionized the evolution of sickle cell disease ].
Topics: Anemia, Sickle Cell; Antisickling Agents; Humans; Hydroxyurea | 2014 |
Management of patients with sickle cell disease.
Topics: Anemia, Sickle Cell; Blood Transfusion; Humans; Hydroxyurea | 2015 |
Management of patients with sickle cell disease.
Topics: Anemia, Sickle Cell; Blood Transfusion; Humans; Hydroxyurea | 2015 |
Management of patients with sickle cell disease--reply.
Topics: Anemia, Sickle Cell; Blood Transfusion; Humans; Hydroxyurea | 2015 |
Serum IL-6, IL-10, and TNFα levels in pediatric sickle cell disease patients during vasoocclusive crisis and steady state condition.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Child; Child, Preschool; Female; Humans; Hydroxyurea; Infant | 2015 |
Evidence gaps in the management of sickle cell disease: A summary of needed research.
Topics: Anemia, Sickle Cell; Erythrocyte Transfusion; Evidence-Based Medicine; Humans; Hydroxyurea; Practice | 2015 |
Prospects for early investigational therapies for sickle cell disease.
Topics: Anemia, Sickle Cell; Animals; Drug Design; Drugs, Investigational; Humans; Hydroxyurea | 2015 |
Hydroxyurea for sickle-cell anaemia in Africa: mind the gap.
Topics: Adolescent; Africa; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Humans; Hydro | 2015 |
Is low dose hydroxyurea the solution to the global epidemic of sickle cell disease?
Topics: Adult; Anemia, Sickle Cell; Child; Humans; Hydroxyurea | 2015 |
Key endothelial cell angiogenic mechanisms are stimulated by the circulating milieu in sickle cell disease and attenuated by hydroxyurea.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Animals; Antisickling Agents; Endothelial Cells; Female; Hum | 2015 |
Myelodysplastic syndrome with clonal cytogenetic abnormalities followed by fatal erythroid leukemia after 14 years of exposure to hydroxyurea for sickle cell anemia.
Topics: Anemia, Sickle Cell; Antineoplastic Agents; Antisickling Agents; Chromosome Aberrations; Chromosomes | 2015 |
Severity of Brazilian sickle cell disease patients: severity scores and feasibility of the Bayesian network model use.
Topics: Adult; Age Factors; Aged; Anemia, Sickle Cell; Antisickling Agents; Bayes Theorem; Bilirubin; Brazil | 2015 |
Hydroxyurea lowers transcranial Doppler flow velocities in children with sickle cell anaemia in a Nigerian cohort.
Topics: Adolescent; Anemia, Sickle Cell; Blood Cell Count; Blood Flow Velocity; Blood Transfusion; Cerebral | 2015 |
Response to hydroxyurea among Kuwaiti patients with sickle cell disease and elevated baseline HbF levels.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Child; Child, Prescho | 2015 |
Proportion of adults with sickle cell anemia and pain crises receiving hydroxyurea.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Databases, Factual; Female; Humans; Hydroxyurea; In | 2015 |
Hydroxyurea use in prevention of stroke recurrence in children with sickle cell disease in a developing country: A cost effectiveness analysis.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Cost-Benefit Analysis; Developing Countries; Female | 2015 |
RN-1, a potent and selective lysine-specific demethylase 1 inhibitor, increases γ-globin expression, F reticulocytes, and F cells in a sickle cell disease mouse model.
Topics: Anemia, Sickle Cell; Animals; Disease Models, Animal; Drug Evaluation, Preclinical; Enzyme Inhibitor | 2015 |
Biological parameters predictive of percent dense red blood cell decrease under hydroxyurea.
Topics: Adult; Anemia, Sickle Cell; Erythrocytes, Abnormal; Female; Fetal Hemoglobin; Humans; Hydroxyurea; M | 2015 |
Higher nocturnal and awake oxygen saturations in children with sickle cell disease receiving hydroxyurea therapy.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Canada; Child; Child, Preschool; Cross-Section | 2015 |
The effects of hydroxyurea and bone marrow transplant on Anti-Müllerian hormone (AMH) levels in females with sickle cell anemia.
Topics: Adolescent; Anemia, Sickle Cell; Anti-Mullerian Hormone; Antisickling Agents; Biomarkers; Bone Marro | 2015 |
Pharmacological Induction of Human Fetal Globin Gene in Hydroxyurea-Resistant Primary Adult Erythroid Cells.
Topics: Adult; Anemia, Sickle Cell; Animals; Antineoplastic Agents; beta-Thalassemia; Blotting, Western; But | 2015 |
Efficacy of Rapamycin as Inducer of Hb F in Primary Erythroid Cultures from Sickle Cell Disease and β-Thalassemia Patients.
Topics: Adolescent; Adult; Aged; alpha-Globins; Anemia, Sickle Cell; beta-Globins; beta-Thalassemia; Cells, | 2015 |
Acute hemolytic vascular inflammatory processes are prevented by nitric oxide replacement or a single dose of hydroxyurea.
Topics: Anemia, Sickle Cell; Animals; Cell Movement; Cyclic N-Oxides; Disease Models, Animal; Free Radical S | 2015 |
Lactate dehydrogenase isoenzyme 3 and hemolysis in sickle cell anemia: a possible correlation?
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Biomarkers; Child, Preschool; Female; Hemolysis; Hu | 2015 |
Hydroxyurea treatment does not increase blood viscosity and improves red blood cell rheology in sickle cell anemia.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Viscosity; Erythrocyte Deformability; Female; | 2015 |
Intravenous infusion of haptoglobin for the prevention of adverse clinical outcome in Sickle Cell Disease.
Topics: Albuminuria; Anemia, Sickle Cell; Anti-Inflammatory Agents; Antigens, CD; Antigens, Differentiation, | 2015 |
Do not leave for tomorrow what you can do today.
Topics: Anemia, Sickle Cell; Antisickling Agents; Databases, Factual; Female; Humans; Hydroxyurea; Male | 2015 |
Survival among children and adults with sickle cell disease in Belgium: Benefit from hydroxyurea treatment.
Topics: Adolescent; Adult; Age Factors; Allografts; Anemia, Sickle Cell; Antisickling Agents; Belgium; Blood | 2015 |
Elevated Steady State WBC and Platelet Counts Are Associated with Frequent Emergency Room Use in Adults with Sickle Cell Anemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Sickle Cell; Blood Platelets; Demography; Emerge | 2015 |
Revisiting the hyperhemolysis paradigm.
Topics: Anemia, Sickle Cell; Animals; Blood Transfusion; Brachial Artery; Cyclic N-Oxides; Female; Free Radi | 2015 |
Hydroxyurea with AKT2 inhibition decreases vaso-occlusive events in sickle cell disease mice.
Topics: Anemia, Sickle Cell; Animals; E-Selectin; Hydroxyurea; Intercellular Adhesion Molecule-1; Mice; Phos | 2015 |
Hydroxyurea Therapy for Children With Sickle Cell Anemia in Sub-Saharan Africa: Rationale and Design of the REACH Trial.
Topics: Africa South of the Sahara; Anemia, Sickle Cell; Child; Child, Preschool; Humans; Hydroxyurea; Infan | 2016 |
Frequency of Hospitalizations for Pain and Association With Altered Brain Network Connectivity in Sickle Cell Disease.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Brain; Brain Mapping; Child; Female; Fetal Hem | 2015 |
Hydroxyurea therapy for children with sickle cell disease: describing how caregivers make this decision.
Topics: Activities of Daily Living; Adolescent; Anemia, Sickle Cell; Antisickling Agents; Caregivers; Child; | 2015 |
Does HbF induction by hydroxycarbamide work through MIR210 in sickle cell anaemia patients?
Topics: Anemia, Sickle Cell; Fetal Hemoglobin; Humans; Hydroxyurea; MicroRNAs; Transcriptional Activation | 2016 |
A predictable but life-threatening complication of hydroxyurea in a patient with sickle cell anaemia: an experience learned from a Jehovah's Witness.
Topics: Anemia, Sickle Cell; Blood Transfusion; Bone Marrow; Bone Marrow Diseases; Enzyme Inhibitors; Humans | 2015 |
Hydroxyurea: Clinical and Hematological Effects in Patients With Sickle Cell Anemia.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Child; Female; Hospitalizat | 2015 |
A Novel High-Content Immunofluorescence Assay as a Tool to Identify at the Single Cell Level γ-Globin Inducing Compounds.
Topics: Anemia, Sickle Cell; beta-Globins; beta-Thalassemia; Butyric Acid; Fetal Hemoglobin; gamma-Globins; | 2015 |
Hydroxyurea-Increased Fetal Hemoglobin Is Associated with Less Organ Damage and Longer Survival in Adults with Sickle Cell Anemia.
Topics: Adolescent; Adult; Aged; Anemia, Sickle Cell; Antisickling Agents; Female; Fetal Hemoglobin; Humans; | 2015 |
Six Months of Hydroxyurea Reduces Albuminuria in Patients with Sickle Cell Disease.
Topics: Adult; Albuminuria; Anemia, Sickle Cell; Antisickling Agents; Cohort Studies; Female; Humans; Hydrox | 2016 |
Widespread Natural Occurrence of Hydroxyurea in Animals.
Topics: Anemia, Sickle Cell; Animals; Antineoplastic Agents; Crustacea; HIV Infections; Humans; Hydroxyurea; | 2015 |
Hydroxyurea in Pediatric Patients With Sickle Cell Disease: What Nurses Need to Know.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Drug-Related Side Eff | 2016 |
Development of a pharmacokinetic-guided dose individualization strategy for hydroxyurea treatment in children with sickle cell anaemia.
Topics: Anemia, Sickle Cell; Antisickling Agents; Area Under Curve; Child; Clinical Trials as Topic; Compute | 2016 |
Effects of hydroxyurea treatment for patients with hemoglobin SC disease.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Female; Humans; Hydroxyurea; Male; Retr | 2016 |
Optimizing hydroxyurea therapy for sickle cell anemia.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Cerebrovascular Disorders; Drug Adminis | 2015 |
New option for primary stroke prevention in sickle cell anaemia.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Female; Humans; Hydroxyurea; Male | 2016 |
Placenta growth factor augments airway hyperresponsiveness via leukotrienes and IL-13.
Topics: Anemia, Sickle Cell; Animals; Asthma; Disease Models, Animal; Hydroxyurea; Interleukin-13; Leukotrie | 2016 |
Soluble Fas/FasL ratio as a marker of vasculopathy in children and adolescents with sickle cell disease.
Topics: Adolescent; Albuminuria; Anemia, Sickle Cell; Antisickling Agents; Apoptosis; Biomarkers; C-Reactive | 2016 |
Neonatal Screening and the Clinical Outcome in Children with Sickle Cell Disease in Central India.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child, Preschool; Female; Heterozygote; Homozygote; Humans | 2016 |
Serum apelin as a novel non-invasive marker for subclinical cardiopulmonary complications in children and adolescents with sickle cell disease.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Apelin; Arterial Pressure; Bilirubin; Biomarke | 2016 |
Genomic variants in the ASS1 gene, involved in the nitric oxide biosynthesis and signaling pathway, predict hydroxyurea treatment efficacy in compound sickle cell disease/β-thalassemia patients.
Topics: Anemia, Sickle Cell; Antisickling Agents; Argininosuccinate Synthase; beta-Thalassemia; Case-Control | 2016 |
Original Research: Parvovirus B19 infection in children with sickle cell disease in the hydroxyurea era.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Erythrocyte Transfusi | 2016 |
Inheritance of the Bantu/Benin haplotype causes less severe hemolytic and oxidative stress in sickle cell anemia patients treated with hydroxycarbamide.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Biomarkers; Child; Female; Genetic Asso | 2016 |
RX of sickle cell leg ulcers.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Sickle Cell; Female; Humans; Hydroxyurea; Leg Ulcer; Male; M | 2016 |
Sickle Cell Disease in Central India: A Potentially Severe Syndrome.
Topics: alpha-Thalassemia; Anemia, Sickle Cell; Child; Cross-Sectional Studies; Fetal Hemoglobin; Humans; Hy | 2016 |
Hydroxyurea for abnormal TCDs: safe to switch?
Topics: Anemia, Sickle Cell; Blood Transfusion; Cerebrovascular Circulation; Female; Humans; Hydroxyurea; Ma | 2016 |
Improvement of medical care in a cohort of newborns with sickle-cell disease in North Paris: impact of national guidelines.
Topics: Acute Chest Syndrome; Anemia, Sickle Cell; Child; Child, Preschool; Cohort Studies; Female; Follow-U | 2016 |
Heme changes HIF-α, eNOS and nitrite production in HUVECs after simvastatin, HU, and ascorbic acid therapies.
Topics: Anemia, Sickle Cell; Ascorbic Acid; Cells, Cultured; Dose-Response Relationship, Drug; Heme; Human U | 2016 |
Hydroxyurea and Pain History in Relation to Patient-Reported Outcomes Using PROMIS Measures and the Frequency of Assessments in Sickle Cell Disease Patients.
Topics: Anemia, Sickle Cell; Antisickling Agents; Humans; Hydroxyurea; Pain; Patient Reported Outcome Measur | 2017 |
Sickle cell disease severity: an introduction.
Topics: Anemia, Sickle Cell; Biomarkers; Fetal Hemoglobin; Hemoglobin, Sickle; Humans; Hydroxyurea; Polymorp | 2016 |
Sickle cell anemia in Brazil: personal, medical and endodontic patterns.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Brazil; Child; Child | 2016 |
Adherence to hydroxyurea medication by children with sickle cell disease (SCD) using an electronic device: a feasibility study.
Topics: Adolescent; Anemia, Sickle Cell; Child; Child, Preschool; Electrical Equipment and Supplies; Feasibi | 2016 |
Influence of βS-Globin Haplotypes and Hydroxyurea on Arginase I Levels in Sickle Cell Disease.
Topics: Adult; Anemia, Sickle Cell; Arginase; beta-Globins; Biomarkers; Case-Control Studies; Cross-Sectiona | 2016 |
Hydroxyurea Use in Young Children With Sickle Cell Anemia in New York State.
Topics: Anemia, Sickle Cell; Child, Preschool; Cohort Studies; Female; Humans; Hydroxyurea; Infant; Infant, | 2016 |
Study protocol for a randomized controlled trial to assess the feasibility of an open label intervention to improve hydroxyurea adherence in youth with sickle cell disease.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Community Health Workers; Feasibility S | 2016 |
Effect of Age on Blood Rheology in Sickle Cell Anaemia and Sickle Cell Haemoglobin C Disease: A Cross-Sectional Study.
Topics: Adolescent; Adult; Age Factors; Anemia, Sickle Cell; Blood Viscosity; Child; Child, Preschool; Cross | 2016 |
Dense red blood cell and oxygen desaturation in sickle-cell disease.
Topics: 2,3-Diphosphoglycerate; Adult; Aged; Aged, 80 and over; Anemia, Sickle Cell; Erythrocytes; Erythrocy | 2016 |
Fetal hemoglobin level and nutritional status in patients with sickle cell disease.
Topics: Anemia, Sickle Cell; Fetal Hemoglobin; Humans; Hydroxyurea; Nutritional Status | 2016 |
Cellular normoxic biophysical markers of hydroxyurea treatment in sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Biomarkers; Blood Cell Count; Blood Transfusion; Erythrocy | 2016 |
Substance P is increased in patients with sickle cell disease and associated with haemolysis and hydroxycarbamide use.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Biomarkers; Black or African American; | 2016 |
Substance P is increased in patients with sickle cell disease and associated with haemolysis and hydroxycarbamide use.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Biomarkers; Black or African American; | 2016 |
Substance P is increased in patients with sickle cell disease and associated with haemolysis and hydroxycarbamide use.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Biomarkers; Black or African American; | 2016 |
Substance P is increased in patients with sickle cell disease and associated with haemolysis and hydroxycarbamide use.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Biomarkers; Black or African American; | 2016 |
Reversible kidney iron accumulation in a patient with sickle cell disease treated with hydroxyurea.
Topics: Adult; Anemia, Sickle Cell; Humans; Hydroxyurea; Iron; Kidney; Male | 2016 |
Discontinuation of Folic Acid Supplementation in Young Patients With Sickle Cell Anemia.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Child; Child, Preschool; Dietary Supplements; Female; Folic | 2017 |
Sickle cell solutions in sight.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Clinical Trials, Phase III as Topic; Female; Hemogl | 2016 |
Decreased fetal hemoglobin over time among youth with sickle cell disease on hydroxyurea is associated with higher urgent hospital use.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Emergency Service, Hospital; Female; Fe | 2016 |
Medical Neglect by Underprescription and Underutilization of Hydroxyurea in Children with Sickle Cell Disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Drug Prescriptions; Health Services Misuse; Humans; | 2016 |
Hydroxyurea for Sickle Cell Disease: Now Is the Time!
Topics: Anemia, Sickle Cell; Antisickling Agents; Humans; Hydroxyurea | 2016 |
Hydroxycarbamide treatment and brain MRI/MRA findings in children with sickle cell anaemia.
Topics: Adolescent; Anemia, Sickle Cell; Asymptomatic Diseases; Brain Infarction; Child; Child, Preschool; F | 2016 |
Reply to comment on: Hydroxyurea and pain history in relation to patient-reported outcomes using PROMIS® measures and the frequency of assessments in sickle cell disease patients.
Topics: Anemia, Sickle Cell; Antisickling Agents; Humans; Hydroxyurea; Pain; Patient Reported Outcome Measur | 2017 |
Impact of a Clinical Pharmacy Service on the Management of Patients in a Sickle Cell Disease Outpatient Center.
Topics: Adult; Albuminuria; Ambulatory Care; Anemia, Sickle Cell; Antisickling Agents; Cross-Sectional Studi | 2016 |
Stable-Isotope Dilution HPLC-Electrospray Ionization Tandem Mass Spectrometry Method for Quantifying Hydroxyurea in Dried Blood Samples.
Topics: Anemia, Sickle Cell; Calibration; Chromatography, High Pressure Liquid; Dried Blood Spot Testing; Dr | 2016 |
Genetic Modifiers of White Blood Cell Count, Albuminuria and Glomerular Filtration Rate in Children with Sickle Cell Anemia.
Topics: Adolescent; Albuminuria; Anemia, Sickle Cell; Apolipoprotein L1; Apolipoproteins; Child; Duffy Blood | 2016 |
Associations of Prolonged QTc in Sickle Cell Disease.
Topics: Adult; Anemia, Sickle Cell; Aspartate Aminotransferases; Cohort Studies; Death, Sudden, Cardiac; Ech | 2016 |
Rationale and design of mDOT-HuA study: a randomized trial to assess the effect of mobile-directly observed therapy on adherence to hydroxyurea in adults with sickle cell anemia in Tanzania.
Topics: Anemia, Sickle Cell; Antisickling Agents; Cell Phone; Directly Observed Therapy; Humans; Hydroxyurea | 2016 |
ARQ 092, an orally-available, selective AKT inhibitor, attenuates neutrophil-platelet interactions in sickle cell disease.
Topics: Administration, Oral; Adult; Aminopyridines; Anemia, Sickle Cell; Animals; Biomarkers; Blood Platele | 2017 |
Hydroxyurea effectiveness in children and adolescents with sickle cell anemia: A large retrospective, population-based cohort.
Topics: Adolescent; Age Factors; Anemia, Sickle Cell; Antisickling Agents; Child; Cohort Studies; Female; Ho | 2017 |
Effects of hydroxyurea on F-cells in sickle cell disease and potential impact of a second fetal globin inducer.
Topics: Adult; Aged; Anemia, Sickle Cell; Erythrocytes, Abnormal; Female; Fetal Globulins; Humans; Hydroxyur | 2017 |
The role of BCL11A and HMIP-2 polymorphisms on endogenous and hydroxyurea induced levels of fetal hemoglobin in sickle cell anemia patients from southern Brazil.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Brazil; Carrier Proteins; Child; Child, Preschool; Female; F | 2016 |
Daily pain in adults with sickle cell disease-a different perspective.
Topics: Adult; Analgesics; Analgesics, Opioid; Anemia, Sickle Cell; Anti-Inflammatory Agents, Non-Steroidal; | 2017 |
Secondary benefit of maintaining normal transcranial Doppler velocities when using hydroxyurea for prevention of severe sickle cell anemia.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Blood Flow Velocity; Cerebrovascular Circulati | 2017 |
Hydroxyurea treatment effect on children with sickle cell disease and obstructive sleep apnea.
Topics: Adenoidectomy; Anemia, Sickle Cell; Child; Child, Preschool; Humans; Hydroxyurea; Male; Polysomnogra | 2017 |
Genetic modulation of fetal hemoglobin in hydroxyurea-treated sickle cell anemia.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Child; Child, Preschool; Chromosomes, Human, Pair 11; Chromo | 2017 |
Lifespan care in SCD: Whom to transition, the patients or the health care system?
Topics: Adolescent; Adult; Anemia, Sickle Cell; Developed Countries; Education, Medical, Continuing; Emergen | 2017 |
Effect of Hydroxyurea Therapy on Pulmonary Function in Children with Sickle Cell Anemia.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Female; Humans; Hydroxyurea; Lung; Male; Respirator | 2017 |
Barriers to hydroxyurea adherence and health-related quality of life in adolescents and young adults with sickle cell disease.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Cross-Sectional Studies; Female; Humans | 2017 |
Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Fertility; Heterozygote; Homozygote; Humans; Hydroxyurea; In | 2008 |
High expression of the cGMP-specific phosphodiesterase, PDE9A, in sickle cell disease (SCD) and the effects of its inhibition in erythroid cells and SCD neutrophils.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 3',5'-Cyclic-GMP Phosphodiesterases; Adolescent; Adult; Anemia, | 2008 |
Chemical and functional analysis of generic hydroxyurea formulations.
Topics: Anemia, Sickle Cell; Antisickling Agents; Drugs, Generic; Humans; Hydroxyurea; Pharmaceutical Prepar | 2008 |
[Edifying affair of hydroxycarbamid].
Topics: Anemia, Sickle Cell; Antisickling Agents; Humans; Hydroxyurea | 2008 |
Hydroxyurea for sickle cell anemia.
Topics: Anemia, Sickle Cell; Antisickling Agents; Fetal Hemoglobin; Hemoglobin A; Humans; Hydroxyurea | 2008 |
Hydroxyurea for sickle cell anemia.
Topics: Anemia, Sickle Cell; Antisickling Agents; Disclosure; Health Services Accessibility; Humans; Hydroxy | 2008 |
Hydroxyurea therapy lowers circulating DNA levels in sickle cell anemia.
Topics: Adolescent; Adult; Aged; Anemia, Sickle Cell; Biomarkers; Cell Death; DNA; Female; Humans; Hydroxyur | 2008 |
Ten-year review of hospital admissions among children with sickle cell disease in Kuwait.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Female; Hospitalizati | 2008 |
Provider barriers to hydroxyurea use in adults with sickle cell disease: a survey of the Sickle Cell Disease Adult Provider Network.
Topics: Anemia, Sickle Cell; Antisickling Agents; Attitude of Health Personnel; Drug Utilization Review; Eth | 2008 |
Venous sinus thrombosis leading to stroke in a patient with sickle cell disease on hydroxyurea and high hemoglobin levels: treatment with thrombolysis.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Brain Infarction; Dura Mater; Follow-Up Studies; He | 2008 |
The presence of alpha-thalassaemia trait blunts the response to hydroxycarbamide in patients with sickle cell disease.
Topics: Adolescent; Adult; alpha-Globins; Anemia, Sickle Cell; Antisickling Agents; Child; Drug Monitoring; | 2008 |
Arterial spin-labeled perfusion combined with segmentation techniques to evaluate cerebral blood flow in white and gray matter of children with sickle cell anemia.
Topics: Adolescent; Anemia, Sickle Cell; Blood Flow Velocity; Central Nervous System; Cerebrovascular Circul | 2009 |
Use of hydroxyurea from childhood to adult age in sickle cell disease: semen analysis.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Child; Fertility; Humans; Hydroxyurea; Infertility, Male; Ma | 2008 |
Hodgkin lymphoma in a sickle cell anaemia child treated with hydroxyurea.
Topics: Adolescent; Anemia, Sickle Cell; Hodgkin Disease; Humans; Hydroxyurea; Male | 2009 |
Altered levels of cytokines and inflammatory mediators in plasma and leukocytes of sickle cell anemia patients and effects of hydroxyurea therapy.
Topics: Adult; Anemia, Sickle Cell; Case-Control Studies; Cytokines; Female; Gene Expression Regulation; Hum | 2009 |
Hydroxycarbamide and erythropoietin in the preoperative management of children with sickle cell anaemia undergoing moderate risk surgery.
Topics: Anemia, Sickle Cell; Child; Child, Preschool; Erythropoietin; Female; Humans; Hydroxyurea; Preoperat | 2009 |
When should hydroxyurea be used for children with sickle cell disease?
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Chemical Analysis; Child; Child, Preschool; Dose-Res | 2008 |
The clinical care of adult patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Female; Genetic Testing; Heart Diseases; Humans; Hy | 2008 |
Hydroxyurea or chronic exchange transfusions in patients with sickle cell disease: role of transcranial Doppler ultrasound in stroke prophylaxis.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Flow Velocity; Cerebral Arteries; Cerebrovascular Ci | 2009 |
Limbal stem cell deficiency arising from systemic chemotherapy with hydroxycarbamide.
Topics: Anemia, Sickle Cell; Antisickling Agents; Conjunctival Diseases; Cornea; Female; Humans; Hydroxyurea | 2009 |
[Effect of hydroxyurea on adhesion proteins in sickle cell anemia].
Topics: Anemia, Sickle Cell; Antisickling Agents; Cell Adhesion Molecules; Humans; Hydroxyurea | 2009 |
DNA hypomethylation therapies and hemoglobin disorders. [An interview with Hassana Fathallah by H&O].
Topics: Anemia, Sickle Cell; Antineoplastic Agents; Azacitidine; beta-Thalassemia; Decitabine; DNA (Cytosine | 2008 |
Hematologic, biochemical, and cardiopulmonary effects of L-arginine supplementation or phosphodiesterase 5 inhibition in patients with sickle cell disease who are on hydroxyurea therapy.
Topics: Adult; Anemia, Sickle Cell; Arginase; Arginine; beta-Globins; Citrulline; Cyclic Nucleotide Phosphod | 2009 |
Development and evaluation of a patient empowerment video to promote hydroxyurea adoption in sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Communication; Focus Groups; Health Knowledge, Attitudes, | 2009 |
Hydroxycarbamide in sickle cell syndrome: new drug. For severe cases only.
Topics: Adult; Anemia, Sickle Cell; Child; Clinical Trials as Topic; Drug Approval; Europe; Humans; Hydroxyu | 2009 |
Bone marrow transplantation or hydroxyurea for sickle cell anemia: long-term effects on semen variables and hormone profiles.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Azoospermia; Follow-Up Studies; Hematop | 2009 |
Adverse effects of a clinically relevant dose of hydroxyurea used for the treatment of sickle cell disease on male fertility endpoints.
Topics: Anemia, Sickle Cell; Animals; Antisickling Agents; Disease Models, Animal; Hydroxyurea; Hypogonadism | 2009 |
Climatic and geographic temporal patterns of pain in the Multicenter Study of Hydroxyurea.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Atmospheric Pressure; Climate; Cold Temperature; Fe | 2009 |
Relationship of erythropoietin, fetal hemoglobin, and hydroxyurea treatment to tricuspid regurgitation velocity in children with sickle cell disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Erythropoietin | 2009 |
The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design.
Topics: Age Factors; Anemia, Sickle Cell; Antisickling Agents; Clinical Trials, Phase III as Topic; Double-B | 2010 |
Exposure to hydroxyurea during pregnancy in sickle-beta thalassemia: a report of 2 cases.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Female; Fetus; Humans; Hydroxyure | 2010 |
Pulmonary hypertension in children and young adults with sickle cell disease: evidence for familial clustering.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Echocardiograp | 2010 |
Decision analysis of treatment strategies in children with severe sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Child; Child, Preschool; Decision Suppo | 2009 |
Characterization of S-glutathionyl hemoglobin in homozygous sickle cell disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Child; Child, Preschool; Erythrocytes, Abnormal; Fetal Hemog | 2009 |
Adherence to study medication and visits: data from the BABY HUG trial.
Topics: Anemia, Sickle Cell; Antisickling Agents; Clinical Trials, Phase III as Topic; Female; Humans; Hydro | 2010 |
[Effect of low-dose hydroxyurea with sodium butyrate on globin gene expression in human erythroid progenitor cells].
Topics: Anemia, Sickle Cell; Butyrates; Cells, Cultured; Drug Therapy, Combination; Erythroid Precursor Cell | 2009 |
Adherence to hydroxyurea therapy in children with sickle cell anemia.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Attitude; Child; Child, Preschool; Female; Fet | 2010 |
Hydroxurea and sickle cell disease: Its been a long, long time coming.
Topics: Adolescent; Age Factors; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Drug-Rel | 2010 |
In vivo pharmaco-proteomic analysis of hydroxyurea induced changes in the sickle red blood cell membrane proteome.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Biomarkers, Pharmacological; Case-Contr | 2010 |
Hydroxyurea-induced expression of glutathione peroxidase 1 in red blood cells of individuals with sickle cell anemia.
Topics: Adult; Anemia, Sickle Cell; Cells, Cultured; Enzyme Induction; Enzyme-Linked Immunosorbent Assay; Er | 2010 |
Resolution of cerebral artery stenosis in a child with sickle cell anemia treated with hydroxyurea.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Flow Velocity; Cerebral Arterial Diseases; Cerebral | 2010 |
Treatment adherence in patients with sickle cell anemia.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Humans; Hydroxyurea; Medication Adherence | 2010 |
Examining the effectiveness of hydroxyurea in people with sickle cell disease.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Anemia, Sickle Cell; Antisickling Agents; Drug Utilization | 2010 |
Hydroxycarbamide stimulates the production of proinflammatory cytokines by endothelial cells: relevance to sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Cell Line; Chemokines, CC; Cytokines; Endothelial Cells; G | 2010 |
Low cobalamin levels associated with sickle cell disease: Contrasting origins and clinical meanings in two instructive patients.
Topics: Adult; Anemia, Pernicious; Anemia, Sickle Cell; Autoantibodies; Depression; Female; Folic Acid; Gast | 2010 |
Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model.
Topics: Anemia, Sickle Cell; Animals; Blood Cell Count; Disease Models, Animal; Fetal Hemoglobin; Genetic Th | 2010 |
[Orbital subperiosteal hematoma in child with sickle cell thalassemia. A case report].
Topics: Anemia, Sickle Cell; Antisickling Agents; Bone Diseases; Child; Eye; Functional Laterality; Hematoma | 2010 |
Association of G6PD with lower haemoglobin concentration but not increased haemolysis in patients with sickle cell anaemia.
Topics: Adolescent; Alleles; alpha-Thalassemia; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Pres | 2010 |
Hydroxyurea in sickle cell disease: What will it take to change practice?
Topics: Anemia, Sickle Cell; DNA Damage; Double-Blind Method; Drug Utilization; Early Termination of Clinica | 2010 |
Aggregation of mononuclear and red blood cells through an {alpha}4{beta}1-Lu/basal cell adhesion molecule interaction in sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Cell Adhesion Molecules; Cell Aggregation; Cells, C | 2010 |
Aggregation of mononuclear and red blood cells through an {alpha}4{beta}1-Lu/basal cell adhesion molecule interaction in sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Cell Adhesion Molecules; Cell Aggregation; Cells, C | 2010 |
Aggregation of mononuclear and red blood cells through an {alpha}4{beta}1-Lu/basal cell adhesion molecule interaction in sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Cell Adhesion Molecules; Cell Aggregation; Cells, C | 2010 |
Aggregation of mononuclear and red blood cells through an {alpha}4{beta}1-Lu/basal cell adhesion molecule interaction in sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Cell Adhesion Molecules; Cell Aggregation; Cells, C | 2010 |
Decreased sickle red blood cell adhesion to laminin by hydroxyurea is associated with inhibition of Lu/BCAM protein phosphorylation.
Topics: Anemia, Sickle Cell; Cell Adhesion; Cell Adhesion Molecules; Cyclic AMP; Erythrocytes, Abnormal; Hum | 2010 |
Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex, age, and geographical location.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Analgesics, Non-Narcotic; Anemia, Sickle Cell; Climat | 2010 |
Cost-effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease.
Topics: Acute Chest Syndrome; Adolescent; Anemia, Sickle Cell; Child; Child, Preschool; Cohort Studies; Cost | 2010 |
Hydroxyurea in children with sickle cell disease: practice patterns and barriers to utilization.
Topics: Anemia, Sickle Cell; Attitude of Health Personnel; Child; Contraception; Data Collection; Drug Monit | 2010 |
Prevalence of daily medication adherence among children with sickle cell disease: a 1-year retrospective cohort analysis.
Topics: Anemia, Sickle Cell; Anti-Asthmatic Agents; Antisickling Agents; Child; Cohort Studies; Folic Acid; | 2010 |
Hydroxyurea (therapeutics and mechanism): metabolism, carbamoyl nitroso, nitroxyl, radicals, cell signaling and clinical applications.
Topics: Anemia, Sickle Cell; Free Radicals; Gene Expression; HIV Infections; Humans; Hydroxyurea; Models, Th | 2011 |
Clinical complications in severe pediatric sickle cell disease and the impact of hydroxyurea.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Cardiovascular Diseases; Child; Child, Prescho | 2011 |
Combined effects of arginine and hydroxyurea on BFU-E derived colony growth and HbF synthesis in erythroid progenitors isolated from sickle cell blood.
Topics: Anemia, Sickle Cell; Arginine; Cell Proliferation; Erythroid Precursor Cells; Fetal Hemoglobin; Huma | 2010 |
Hydroxyurea use in sickle cell disease: the battle with low prescription rates, poor patient compliance and fears of toxicities.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Child; Drug Monitoring; Fea | 2010 |
Effect of hydroxyurea on physical fitness indices in children with sickle cell anemia.
Topics: Adolescent; Anemia, Sickle Cell; Body Height; Body Mass Index; Case-Control Studies; Child; Exercise | 2011 |
Neurocognitive function in sickle cell disease: have we been missing something?
Topics: Anemia, Sickle Cell; Cognitive Behavioral Therapy; Humans; Hydroxyurea; Neuropsychological Tests | 2010 |
Manual erythroexchange for chronic transfusion therapy in patients with sickle cell syndromes unresponsive to hydroxyurea: a long-term follow-up.
Topics: Anemia, Sickle Cell; Blood Transfusion, Autologous; Deferoxamine; Erythrocyte Transfusion; Humans; H | 2010 |
Expression patterns of fetal hemoglobin in sickle cell erythrocytes are both patient- and treatment-specific during childhood.
Topics: Adolescent; Anemia, Sickle Cell; Blood Transfusion; Child; Child, Preschool; Erythrocyte Count; Eryt | 2011 |
Sickle cell disease serum induces NADPH enzyme subunit expression and oxidant production in leukocytes.
Topics: Adult; Anemia, Sickle Cell; Biomarkers; Case-Control Studies; Female; Humans; Hydroxyurea; Leukocyte | 2010 |
Examining the characteristics and beliefs of hydroxyurea users and nonusers among adults with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Cross-Sectional Studies; Humans; Hydroxyurea; Surve | 2011 |
Caring for the adult with sickle cell disease: results of a multidisciplinary pilot program.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Chi-Square Distribution; Female; Humans; Hydroxyure | 2010 |
Comparing abstract numerical and visual depictions of risk in survey of parental assessment of risk in sickle cell hydroxyurea treatment.
Topics: Adolescent; Anemia, Sickle Cell; Child; Child, Preschool; Data Collection; Decision Making; Female; | 2011 |
Clinical follow-up of hydroxyurea-treated adults with sickle cell disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Child; Drug Evaluation; Female; Follow- | 2011 |
Differential modulation of adhesion molecule expression by hydroxycarbamide in human endothelial cells from the micro- and macrocirculation: potential implications in sickle cell disease vasoocclusive events.
Topics: Anemia, Sickle Cell; Antisickling Agents; Cell Adhesion Molecules; Cells, Cultured; Endothelial Cell | 2011 |
Fetal hemoglobin response to hydroxyurea in Yemeni sickle cell disease patients.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Biomarkers, Pharmacological; Child; Chi | 2011 |
Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Child; Data Collection; Drug Evaluation; Emergencies; Female | 2011 |
Soluble CD163 levels in children with sickle cell disease.
Topics: Adolescent; Anemia, Sickle Cell; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antisickli | 2011 |
The impact of the 2009 H1N1 influenza pandemic on pediatric patients with sickle cell disease.
Topics: Acute Chest Syndrome; Anemia, Sickle Cell; Antisickling Agents; Antiviral Agents; Blood Transfusion; | 2011 |
Long-term results using hydroxyurea/phlebotomy for reducing secondary stroke risk in children with sickle cell anemia and iron overload.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Child; Cohort Studies; Combined Modalit | 2011 |
The rationale for using hydroxycarbamide in the treatment of sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Humans; Hydroxyurea | 2011 |
Should we still be focused on red cell hemoglobin F as the principal explanation for the salutary effect of hydroxyurea in sickle cell disease?
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Child; Child, Preschool; Er | 2011 |
Relationship between oxidative stress, glutathione S-transferase polymorphisms and hydroxyurea treatment in sickle cell anemia.
Topics: Adolescent; Adult; Aged; Anemia, Sickle Cell; Antisickling Agents; Child; Female; Gene Frequency; Ge | 2011 |
Differences in health-related quality of life in children with sickle cell disease receiving hydroxyurea.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Cross-Sectional Studi | 2011 |
Sickle cell disease from Africa to Belgium, from neonatal screening to clinical management.
Topics: Adolescent; Africa; Anemia, Sickle Cell; Antisickling Agents; Belgium; Bone Marrow Transplantation; | 2010 |
Protective role of hemoglobin and fetal hemoglobin in early kidney disease for children with sickle cell anemia.
Topics: Adolescent; Albuminuria; Anemia, Sickle Cell; Biomarkers; Blood Transfusion; Child; Early Diagnosis; | 2011 |
Pomalidomide augments fetal hemoglobin production without the myelosuppressive effects of hydroxyurea in transgenic sickle cell mice.
Topics: Anemia, Sickle Cell; Animals; Antisickling Agents; Bone Marrow; Disease Models, Animal; Erythropoies | 2011 |
Chromosome damage and repair in children with sickle cell anaemia and long-term hydroxycarbamide exposure.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Cells, Cultured; Child; Child, Preschoo | 2011 |
Hydroxycarbamide for sickle-cell anaemia in infancy.
Topics: Anemia, Sickle Cell; Antisickling Agents; Fetal Hemoglobin; Humans; Hydroxyurea; Infant; Neutropenia | 2011 |
Is it time to SWiTCH to composite primary endpoints?
Topics: Anemia, Sickle Cell; Erythrocyte Transfusion; Humans; Hydroxyurea; Iron Overload; Stroke | 2011 |
The rationale for using hydroxycarbamide in the treatment of sickle cell disease" (Haematologica 2011;96:488-491). Reply.
Topics: Anemia, Sickle Cell; Antisickling Agents; Humans; Hydroxyurea | 2011 |
Pain in sickle cell disease: the future of acute treatment.
Topics: Acute Disease; Anemia, Sickle Cell; Biomarkers; Humans; Hydroxyurea; Pain; Vascular Diseases | 2011 |
Antiradical, chelating and antioxidant activities of hydroxamic acids and hydroxyureas.
Topics: Anemia, Sickle Cell; beta Carotene; Biphenyl Compounds; Butylated Hydroxyanisole; Butylated Hydroxyt | 2011 |
Monitoring toxicity, impact, and adherence of hydroxyurea in children with sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Cross-Sectional Studies; Drug Monitoring; Electroni | 2011 |
Increased prevalence of osteonecrosis of the femoral head in children and adolescents with sickle-cell disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Child; Cohort Studies; Cross-Sectional | 2011 |
Stroke recurrence in children with sickle cell disease treated with hydroxyurea following first clinical stroke.
Topics: Anemia, Sickle Cell; Child; Cohort Studies; Female; Humans; Hydroxyurea; Male; Recurrence; Stroke | 2011 |
Study of correlation of nitrite levels with malonaldehyde and the prognosis of patients with sickle cell disease on hydroxyurea, Ceará-Brazil.
Topics: Adult; Anemia, Sickle Cell; Blood Transfusion; Brazil; Cohort Studies; Female; Humans; Hydroxyurea; | 2011 |
Hydroxyurea use in patients with sickle cell disease in a Medicaid population.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Cohort Studies; Female; Florida; Humans | 2011 |
Impact of hydroxyurea on perioperative management and outcomes in children with sickle cell anemia.
Topics: Anemia, Sickle Cell; Child; Female; Humans; Hydroxyurea; Male; Perioperative Care; Retrospective Stu | 2011 |
Fetal hemoglobin levels in African American and Hispanic children with sickle cell disease at baseline and in response to hydroxyurea.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Black or African American; Child; Child, Preschool; Female; | 2011 |
The proinflammatory cytokine GM-CSF downregulates fetal hemoglobin expression by attenuating the cAMP-dependent pathway in sickle cell disease.
Topics: Anemia, Sickle Cell; Cell Line; Cells, Cultured; Cyclic AMP; Down-Regulation; Erythroid Cells; Fetal | 2011 |
Feasibility and benefit of hydroxycarbamide as a long-term treatment for sickle cell disease patients: results from the North West London Sickle Cell Disease Registry.
Topics: Acute Chest Syndrome; Adolescent; Adult; Anemia, Sickle Cell; Blood Transfusion; Child; Child, Presc | 2011 |
Limitations of Hb F as a phenotypic modifier in sickle cell disease: study of Kuwaiti Arab patients.
Topics: alpha-Thalassemia; Anemia, Sickle Cell; Arabs; Femur Head Necrosis; Fetal Hemoglobin; Genetic Associ | 2011 |
Therapy-related acute myelogenous leukemia in a hydroxyurea-treated patient with sickle cell anemia.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Male | 2011 |
Hydroxycarbamide use in young children with sickle-cell anaemia.
Topics: Anemia, Sickle Cell; Antisickling Agents; Female; Humans; Hydroxyurea; Male | 2011 |
Hydroxycarbamide use in young children with sickle-cell anaemia.
Topics: Anemia, Sickle Cell; Antisickling Agents; Female; Humans; Hydroxyurea; Male | 2011 |
Hydroxyurea therapy of a murine model of sickle cell anemia inhibits the progression of pneumococcal disease by down-modulating E-selectin.
Topics: Anemia, Sickle Cell; Animals; Antisickling Agents; Child; Disease Models, Animal; E-Selectin; Female | 2012 |
In vitro modeling of the microvascular occlusion and thrombosis that occur in hematologic diseases using microfluidic technology.
Topics: Anemia, Sickle Cell; Eptifibatide; Hematologic Diseases; Hemolytic-Uremic Syndrome; Hemorheology; Hu | 2012 |
Inpatient management of sickle cell pain: a 'snapshot' of current practice.
Topics: Acute Chest Syndrome; Adolescent; Adult; Aged; Analgesia, Patient-Controlled; Anemia, Sickle Cell; B | 2012 |
Plasma thrombospondin-1 is increased during acute sickle cell vaso-occlusive events and associated with acute chest syndrome, hydroxyurea therapy, and lower hemolytic rates.
Topics: Acute Chest Syndrome; Adult; Anemia, Sickle Cell; Antisickling Agents; Biomarkers; Cohort Studies; F | 2012 |
Hydroxyurea makes inflammation "just right"?
Topics: Anemia, Sickle Cell; Animals; E-Selectin; Female; Humans; Hydroxyurea; Pneumonia, Pneumococcal | 2012 |
Sickle cell disease in children.
Topics: Anemia, Sickle Cell; Child; Clinical Trials, Phase III as Topic; Humans; Hydroxyurea; Research; Trea | 2011 |
The acceleration of the propagation phase of thrombin generation in patients with steady-state sickle cell disease is associated with circulating erythrocyte-derived microparticles.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Coagulation; Blood Coagulation Te | 2012 |
Decades after the cooperative study: a re-examination of systemic blood pressure in sickle cell disease.
Topics: Adolescent; Adult; Age Distribution; Aged; Anemia, Sickle Cell; Bilirubin; Blood Pressure; Body Mass | 2012 |
Elevated plasma levels and platelet-associated expression of the pro-thrombotic and pro-inflammatory protein, TNFSF14 (LIGHT), in sickle cell disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Biomarkers; Blood Platelets; Endothelium, Vascular; Female; | 2012 |
Hydroxyurea is associated with reductions in hypercoagulability markers in sickle cell anemia.
Topics: Anemia, Sickle Cell; Biomarkers; Enzyme-Linked Immunosorbent Assay; Humans; Hydroxyurea; Real-Time P | 2012 |
Hydroxyurea and a cGMP-amplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease mice.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Acute Disease; Anemia, Sickle Cell; Animals; Antisickling Agent | 2012 |
Low dose hydroxyurea is effective in reducing the incidence of painful crisis and frequency of blood transfusion in sickle cell anemia patients from eastern India.
Topics: Acute Pain; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Child; C | 2012 |
Sickle cell disease and leg ulcers.
Topics: Anemia, Sickle Cell; Blood Transfusion; Compression Bandages; Debridement; Hemoglobins; Humans; Hydr | 2012 |
DNA damage in leukocytes of sickle cell anemia patients is associated with hydroxyurea therapy and with HBB*S haplotype.
Topics: Adult; Aged; Anemia, Sickle Cell; DNA Damage; Female; Hemoglobin, Sickle; Hemoglobins; Humans; Hydro | 2012 |
Sickle cell disease: What all PAs should know.
Topics: Anemia, Sickle Cell; Antisickling Agents; Fluid Therapy; Humans; Hydroxyurea; Pain Management | 2012 |
HU for acute treatment of sickle VOC?
Topics: Anemia, Sickle Cell; Animals; Antisickling Agents; Cyclic GMP; Female; Humans; Hydroxyurea; Male; Py | 2012 |
KLF10 gene expression is associated with high fetal hemoglobin levels and with response to hydroxyurea treatment in β-hemoglobinopathy patients.
Topics: 3' Untranslated Regions; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Early Gr | 2012 |
Two assays to evaluate potential genotoxic effects of hydroxyurea in sickle cell disease patients.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Pre | 2012 |
Combined blood transfusion and hydroxycarbamide in children with sickle cell anaemia.
Topics: Adolescent; Anemia, Sickle Cell; Blood Transfusion; Brain Ischemia; Cerebral Infarction; Cerebral Re | 2013 |
Parental and other factors associated with hydroxyurea use for pediatric sickle cell disease.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Cross-Sectional Studi | 2013 |
Characteristics of sickle cell anemia in Yemen.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Female; Fetal | 2013 |
Hydroxyurea therapy in sickle cell anemia patients aids to maintain oral fungal colonization balance.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antifungal Agents; Antisickling Agents; Candida; Candida gla | 2013 |
A method of HbF determination for potential use in underdeveloped countries.
Topics: Anemia, Sickle Cell; Developing Countries; Fetal Hemoglobin; Hemoglobin A; Humans; Hydroxyurea; Repr | 2012 |
Age-related treatment patterns in sickle cell disease patients and the associated sickle cell complications and healthcare costs.
Topics: Adolescent; Adult; Age Factors; Anemia, Sickle Cell; Blood Transfusion; Chelation Therapy; Child; Ch | 2013 |
Protection from sickle cell retinopathy is associated with elevated HbF levels and hydroxycarbamide use in children.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Drug Evaluation; Female; Fetal Hemoglob | 2013 |
Hydroxyurea treatment of sickle cell anemia in hospital-based practices.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Female; Hospitalization; Hospita | 2002 |
Summary of symposium: the future of stem cell transplantation for sickle cell disease.
Topics: Anemia, Sickle Cell; Child; Child, Preschool; Clinical Trials as Topic; Female; Humans; Hydroxyurea; | 2002 |
Hydroxyurea (HU) for prevention of recurrent stroke in sickle cell anemia (SCA).
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Female; Fetal Hemoglo | 2002 |
Nitric oxide and cyclic GMP levels in sickle cell patients receiving hydroxyurea.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Cyclic GMP; Female; Fetal Hemoglobin; Humans; Hydro | 2002 |
Pain at home in sickle cell disease: an underrecognized problem.
Topics: Absenteeism; Adolescent; Adult; Analgesia; Anemia, Sickle Cell; Biomarkers; Child; Home Nursing; Hum | 2002 |
Home management of pain in sickle cell disease: a daily diary study in children and adolescents.
Topics: Absenteeism; Adolescent; Adult; Analgesics, Non-Narcotic; Anemia, Sickle Cell; Biomarkers; Child; Ch | 2002 |
Are we underestimating the leukemogenic risk of hydroxyurea.
Topics: Anemia, Sickle Cell; Antisickling Agents; Humans; Hydroxyurea; Leukemia, Myeloid, Acute | 2002 |
Concordant fetal hemoglobin response to hydroxyurea in siblings with sickle cell disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Erythrocyte Indices; Family Health; Female; Fetal Hemoglobin | 2003 |
Colonic pseudo-obstruction in sickle cell disease.
Topics: Acute Disease; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Colonic Pseudo-Obs | 2003 |
Decreased exhaled nitric oxide in sickle cell disease: relationship with chronic lung involvement.
Topics: Adult; Anemia, Sickle Cell; Breath Tests; Chronic Disease; Dyspnea; Female; Hemoglobins; Humans; Hyd | 2003 |
Resolution of chronic hepatic sequestration in a patient with homozygous sickle cell disease receiving hydroxyurea.
Topics: Adolescent; Anemia, Sickle Cell; Chronic Disease; Hepatomegaly; Humans; Hydroxyurea; Male | 2003 |
Long-term outcomes in patients with sickle cell disease and frequent vaso-occlusive crises.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Cause of Death; Female; Follow-Up Studies; Hospital | 2003 |
Reticulocyte parameters and hemoglobin F production in sickle cell disease patients undergoing hydroxyurea therapy.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Fetal Hemoglobin; Humans; Hydroxyurea; Neutrophils; | 2003 |
Optical tweezers for measuring red blood cell elasticity: application to the study of drug response in sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Elasticity; Erythrocyte Deformability; Hematologic Tests; Humans; Hydrox | 2003 |
Hydroxyurea and sickle cell disease: a chance for every patient.
Topics: Anemia, Sickle Cell; Antisickling Agents; Fetal Hemoglobin; Humans; Hydroxyurea | 2003 |
[Effect of hydroxyurea on hemoglobin S].
Topics: Anemia, Sickle Cell; Antisickling Agents; Arterial Occlusive Diseases; Blood Transfusion; Child; Hem | 2003 |
[Abnormalities of myocardial perfusion in sickle cell disease in childhood: a study of myocardial scintigraphy].
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Cohort Studies | 2003 |
In vitro induction of fetal hemoglobin in human erythroid progenitor cells.
Topics: Anemia, Sickle Cell; Child; Chromatography, High Pressure Liquid; Erythroid Precursor Cells; Fetal H | 2003 |
Long-term use of hydroxyurea for sickle cell anemia.
Topics: Anemia, Sickle Cell; Antisickling Agents; Humans; Hydroxyurea; Leukemia; Myelodysplastic Syndromes | 2003 |
Long-term use of hydroxyurea for sickle cell anemia.
Topics: Anemia, Sickle Cell; Antisickling Agents; Humans; Hydroxyurea; Immune Tolerance; Lymphocyte Count; O | 2003 |
Long-term use of hydroxyurea for sickle cell anemia.
Topics: Anemia, Sickle Cell; Antisickling Agents; Fetal Hemoglobin; Humans; Hydroxyurea; Leukocyte Count; Re | 2003 |
Long-term use of hydroxyurea for sickle cell anemia.
Topics: Anemia, Sickle Cell; Antisickling Agents; Humans; Hydroxyurea; Survival Analysis | 2003 |
Hydroxyurea downregulates endothelin-1 gene expression and upregulates ICAM-1 gene expression in cultured human endothelial cells.
Topics: Anemia, Sickle Cell; Antisickling Agents; Cell Line; Dose-Response Relationship, Drug; Down-Regulati | 2003 |
Effect of hydroxyurea on G gamma chain fetal hemoglobin synthesis by sickle-cell disease patients.
Topics: Anemia, Sickle Cell; Antisickling Agents; Case-Control Studies; Fetal Hemoglobin; Globins; Humans; H | 2003 |
Hydroxyurea-induced splenic regrowth in an adult patient with severe hemoglobin SC disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Female; Humans; Hydroxyurea; Splenomegaly | 2003 |
Malignancies in sickle cell disease patients treated with hydroxyurea.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Female; Humans; Hydroxyurea; Leukemia, Promyelocyti | 2003 |
The effect of hydroxyurea on the coagulation system in sickle cell anemia and beta-thalassemia intermedia patients: a preliminary study.
Topics: Adolescent; Adult; Anemia, Sickle Cell; beta-Thalassemia; Blood Coagulation; Blood Proteins; Child; | 2003 |
Malignancy in patients with sickle cell disease.
Topics: Adolescent; Adult; Age of Onset; Anemia, Sickle Cell; Child; Child, Preschool; Data Collection; Huma | 2003 |
Arterialization of venous blood for differentiation of sickle cell subjects in vaso-occlusive crisis.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Arterial Occlusive Diseases; Blood Specimen Collection; Cath | 2003 |
Zileuton induces hemoglobin F synthesis in erythroid progenitors: role of the L-arginine-nitric oxide signaling pathway.
Topics: Anemia, Sickle Cell; Arginine; Case-Control Studies; Cells, Cultured; Cyclic GMP; Dose-Response Rela | 2004 |
Hydroxyurea treatment for sickle cell disease: impact on haematopoietic stem cell transplantation's outcome.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Female; Graft Survival; Graft vs | 2004 |
Plasma levels of TNF-alpha in sickle cell patients receiving hydroxyurea.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Arterial Occlusive Diseases; Case-Control Studies; Drug Eval | 2004 |
Increased soluble guanylate cyclase activity in the red blood cells of sickle cell patients.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Child; Cyclic GMP; Erythrocytes; Female; Fetal Hemo | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Pressure; Cause of Death; Drug Resistance; Ec | 2004 |
Circulating endothelin-3 levels in patients with sickle cell disease during hydroxyurea treatment.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Endothelin-3; Female; Humans; Hydroxyurea; Male; Mi | 2004 |
Chemical and functional analysis of hydroxyurea oral solutions.
Topics: Administration, Oral; Anemia, Sickle Cell; Drug Stability; Humans; Hydroxyurea; Infant; Solutions; T | 2004 |
Increased levels of soluble ICAM-1 in the plasma of sickle cell patients are reversed by hydroxyurea.
Topics: Adult; alpha-Thalassemia; Anemia, Sickle Cell; Cell Adhesion; Child; Female; Fetal Hemoglobin; Human | 2004 |
Expanding the role of hydroxyurea in children with sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Humans; Hydroxyurea; Stroke; Transfusion Reaction; | 2004 |
Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Female; Humans; Hydro | 2004 |
Mortality in sickle cell patients on hydroxyurea therapy.
Topics: Acute Disease; Adolescent; Adult; Aged; Anemia, Sickle Cell; Antisickling Agents; Female; Humans; Hy | 2005 |
Pathways of innovation: a history of the first effective treatment for sickle cell anemia.
Topics: Anemia, Sickle Cell; Antisickling Agents; Biomedical Research; History, 20th Century; Humans; Hydrox | 2004 |
Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events: the Belgian experience.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Belgium; Child; Child, Preschool; Femal | 2005 |
Acute myocardial infarction in sickle cell disease: a possible complication of hydroxyurea treatment.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Viscosity; Hematocrit; Hemoglobins; Humans; H | 2005 |
Enalapril and hydroxyurea therapy for children with sickle nephropathy.
Topics: Adolescent; Albuminuria; Anemia, Sickle Cell; Antihypertensive Agents; Antisickling Agents; Child; C | 2005 |
Effects of hydroxyurea in a population of Brazilian patients with sickle cell anemia.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Brazil; Female; Fetal Hemoglobin; Follo | 2005 |
Decreased plasma endothelin-1 levels in children with sickle cell disease treated with hydroxyurea.
Topics: Anemia, Sickle Cell; Case-Control Studies; Child; Endothelin-1; Fetal Hemoglobin; Humans; Hydroxyure | 2005 |
Differential effects of hydroxyurea and zileuton on interleukin-13 secretion by activated murine spleen cells: implication on the expression of vascular cell adhesion molecule-1 and vasoocclusion in sickle cell anemia.
Topics: Anemia, Sickle Cell; Animals; Cell Proliferation; Cells, Cultured; Culture Media, Conditioned; Femal | 2005 |
Hydroxyurea therapy for sickle cell disease in community-based practices: a survey of Florida and North Carolina hematologists/oncologists.
Topics: Anemia, Sickle Cell; Antisickling Agents; Community Medicine; Cross-Sectional Studies; Florida; Hema | 2005 |
The measurement of urinary hydroxyurea in sickle cell anaemia.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Biomarkers; Child; Creatinine; Drug Therapy, C | 2005 |
Clinical and laboratory effects of hydroxyurea in children and adolescents with sickle cell anemia: a Portuguese hospital study.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Child; Female; Fetal Hemogl | 2005 |
Levels of soluble endothelium-derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality.
Topics: Adolescent; Adult; Aged; Anemia, Sickle Cell; Biomarkers; Cell Adhesion Molecules; E-Selectin; Endot | 2005 |
Approaches to the reactivation of hemoglobin F as a treatment for sickle cell disease.
Topics: Acetylation; Anemia, Sickle Cell; Azacitidine; Clinical Trials as Topic; CpG Islands; Decitabine; Di | 2004 |
Hydroxyurea and new agents for the treatment of sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Humans; Hydroxyurea; Prognosis; Treatment Outcome | 2004 |
Modulation of erythrocyte arginase activity in sickle cell disease patients during hydroxyurea therapy.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Arginase; Child; Erythrocytes; Fetal He | 2005 |
Hydroxyurea as secondary prevention for stroke in children with sickle cell anemia.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Humans; Hydroxyurea; Incidence; Secondary Preventio | 2005 |
Brief comment on the case report by Fattori et al. 2005 (5) 589-590.
Topics: Adult; Anemia, Sickle Cell; Biopolymers; Erythrocyte Aggregation; Erythrocyte Indices; Hemoglobin, S | 2005 |
Myths and facts...about sickle-cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Clotrimazole; Hemoglobin, Sickle; Humans; Hydroxyurea; Nit | 2005 |
Parents' assessment of risk in sickle cell disease treatment with hydroxyurea.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Child; Chi | 2005 |
Current therapy of sickle cell disease.
Topics: Acetamides; Anemia, Sickle Cell; Azacitidine; Butyrates; Decitabine; Erythrocyte Transfusion; Humans | 2006 |
Is the group of older sickle cell disease patients from Trinidad and Tobago different?
Topics: Adult; Aged; Aging; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Female; Foot Ulcer; | 2006 |
Hydroxyurea therapy lowers TCD velocities in children with sickle cell disease.
Topics: Adolescent; Anemia, Sickle Cell; Blood Flow Velocity; Child; Child, Preschool; Female; Hemoglobins; | 2006 |
Cytotoxic and genotoxic monitoring of sickle cell anaemia patients treated with hydroxyurea.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Case-Control Studies; Child; Chromosome | 2006 |
Hydroxyurea treatment in children with sickle cell anemia in Central America and the Caribbean countries.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Dose-Response Relatio | 2006 |
Activated neutrophil-mediated sickle red blood cell adhesion to lung vascular endothelium: role of phosphatidylserine-exposed sickle red blood cells.
Topics: Anemia, Sickle Cell; Animals; Annexin A5; Arachidonate 5-Lipoxygenase; Cell Adhesion; Endothelium, V | 2006 |
Pulmonary hypertension in patients with sickle cell disease: a longitudinal study.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Urea Nitrogen; Chi-Square Distribution; Echoc | 2006 |
Quantum chemical design of hydroxyurea derivatives for the treatment of sickle-cell anemia.
Topics: Anemia, Sickle Cell; Antisickling Agents; Free Radicals; Humans; Hydroxyurea; Nitric Oxide Donors; Q | 2005 |
The effect of fetal hemoglobin on the survival characteristics of sickle cells.
Topics: Anemia, Sickle Cell; Biotinylation; Cell Survival; Erythrocyte Aging; Erythrocytes, Abnormal; Fetal | 2006 |
Primary hyperparathyroidism mimicking vaso-occlusive crises in sickle cell disease.
Topics: Adenoma; Adolescent; Analgesics, Opioid; Anemia, Sickle Cell; Arthralgia; Back Pain; Bone Resorption | 2006 |
Treatment for children with severe aplastic anemia and sickle cell disease in low income countries in Latin America: a report on the recent meetings of the Monza International School of Pediatric Hematology/Oncology (MISPHO): Part III.
Topics: Anemia, Aplastic; Anemia, Sickle Cell; Antilymphocyte Serum; Child; Cyclosporine; Developing Countri | 2007 |
Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review.
Topics: Anemia, Sickle Cell; Darbepoetin alfa; Drug Therapy, Combination; Erythropoietin; Hematocrit; Humans | 2006 |
Hospitalization rates and costs of care of patients with sickle-cell anemia in the state of Maryland in the era of hydroxyurea.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Costs and Cost | 2006 |
Prognostic significance of early vaso-occlusive complications in children with sickle cell anemia.
Topics: Acute Disease; Anemia, Sickle Cell; Arterial Occlusive Diseases; beta-Thalassemia; Blood Transfusion | 2007 |
Prognostic significance of early vaso-occlusive complications in children with sickle cell anemia.
Topics: Acute Disease; Anemia, Sickle Cell; Arterial Occlusive Diseases; beta-Thalassemia; Blood Transfusion | 2007 |
Prognostic significance of early vaso-occlusive complications in children with sickle cell anemia.
Topics: Acute Disease; Anemia, Sickle Cell; Arterial Occlusive Diseases; beta-Thalassemia; Blood Transfusion | 2007 |
Prognostic significance of early vaso-occlusive complications in children with sickle cell anemia.
Topics: Acute Disease; Anemia, Sickle Cell; Arterial Occlusive Diseases; beta-Thalassemia; Blood Transfusion | 2007 |
Disseminated nontuberculous mycobacterial infections in sickle cell anemia patients.
Topics: Acetamides; Adolescent; Amikacin; Anemia, Sickle Cell; Anti-Bacterial Agents; Cefoxitin; Ciprofloxac | 2006 |
Adherent leukocytes capture sickle erythrocytes in an in vitro flow model of vaso-occlusion.
Topics: Anemia, Sickle Cell; Antisickling Agents; Cell Adhesion; Endothelial Cells; Erythrocytes, Abnormal; | 2007 |
Effects of hydroxyurea on malaria, parasite growth and adhesion in experimental models.
Topics: Anemia, Sickle Cell; Animals; Antisickling Agents; Apoptosis; Cell Adhesion; Endothelial Cells; Endo | 2006 |
Gene expression profiles of erythroid precursors characterise several mechanisms of the action of hydroxycarbamide in sickle cell anaemia.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Bone Marrow Cells; Cell Line; ERG1 Potassium Channe | 2007 |
Effects of hydroxyurea and L-arginine on the production of nitric oxide metabolites in cultures of normal and sickle erythrocytes.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Arginine; Cells, Cultured; Erythrocytes; Erythrocytes, Abnor | 2006 |
Leukocyte numbers correlate with plasma levels of granulocyte-macrophage colony-stimulating factor in sickle cell disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Case-Control Studies; Child; Eosinophils; Female; Granulocyt | 2007 |
Therapy with hydroxyurea is associated with reduced adhesion molecule gene and protein expression in sickle red cells with a concomitant reduction in adhesive properties.
Topics: Adult; Anemia, Sickle Cell; CD36 Antigens; Cell Adhesion; Cell Adhesion Molecules; Drug Evaluation; | 2007 |
Effect of hydroxyurea on sperm count, motility and morphology in adult men with sickle cell or myeloproliferative disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Azoospermia; Humans; Hydroxyurea; Male; Myeloprolif | 2007 |
[Physiopathology and treatment of sickle cell anemia].
Topics: Analgesics; Anemia, Sickle Cell; Blood Transfusion; Bone Marrow Transplantation; Fluid Therapy; Foli | 2007 |
Steroid treatment in children with sickle-cell disease.
Topics: Adolescent; Anemia, Sickle Cell; Arthritis; Autoimmune Diseases; Blood Transfusion; Child; Child, Pr | 2007 |
[Two splenic sequestrations in an infant with homozygous sickle cell anemia].
Topics: Anemia, Sickle Cell; Antisickling Agents; Folic Acid; Homozygote; Humans; Hydroxyurea; Infant; Male; | 2007 |
Prevalence, prevention, and treatment of microalbuminuria and proteinuria in children with sickle cell disease.
Topics: Adolescent; Adult; Age of Onset; Albuminuria; Anemia, Sickle Cell; Angiotensin-Converting Enzyme Inh | 2007 |
The association of oral hydroxyurea therapy with improved cognitive functioning in sickle cell disease.
Topics: Administration, Oral; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Aptitude; Child; | 2007 |
Sodium phenyl butyrate downregulates endothelin-1 expression in cultured human endothelial cells: relevance to sickle-cell disease.
Topics: Anemia, Sickle Cell; Cell Line, Transformed; Drug Evaluation, Preclinical; Drug Synergism; Endotheli | 2007 |
The effect of CYP2D6 polymorphisms on the response to pain treatment for pediatric sickle cell pain crisis.
Topics: Adolescent; Analgesics, Opioid; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; C | 2007 |
Pulmonary hypertension in patients with sickle cell/beta thalassemia: incidence and correlation with serum N-terminal pro-brain natriuretic peptide concentrations.
Topics: Adult; Anemia, Sickle Cell; beta-Thalassemia; Case-Control Studies; Female; Ferritins; Humans; Hydro | 2007 |
Sickle cell disease caused by Hb S/Québec-CHORI: treatment with hydroxyurea and response.
Topics: Abdominal Pain; Acute Disease; Anemia, Sickle Cell; Cholecystectomy; Cholecystitis; Exchange Transfu | 2007 |
Preservation of spleen and brain function in children with sickle cell anemia treated with hydroxyurea.
Topics: Adolescent; Anemia, Sickle Cell; Brain; Child; Child, Preschool; Female; Humans; Hydroxyurea; Male; | 2008 |
Role for cAMP-protein kinase A signalling in augmented neutrophil adhesion and chemotaxis in sickle cell disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Carbazoles; Cell Adhesion; Chemotaxis; | 2007 |
Inhibition of caspase-dependent spontaneous apoptosis via a cAMP-protein kinase A dependent pathway in neutrophils from sickle cell disease patients.
Topics: Adult; Anemia, Sickle Cell; Annexin A5; Antisickling Agents; Apoptosis; Biomarkers; Carbazoles; Case | 2007 |
Treatment and prevention of pain due to vaso-occlusive crises in adults with sickle cell disease: an educational void.
Topics: Acute Disease; Analgesics, Opioid; Anemia, Sickle Cell; Clinical Competence; Humans; Hydroxyurea; Op | 2008 |
Effect of hydroxyurea on immature reticulocyte fraction in sickle cell anemia.
Topics: Adolescent; Adult; alpha-Thalassemia; Anemia, Sickle Cell; Antisickling Agents; Case-Control Studies | 2007 |
DNA damage in blood leukocytes of individuals with sickle cell disease treated with hydroxyurea.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Comet Assay; D | 2008 |
Hydroxyurea attenuates activated neutrophil-mediated sickle erythrocyte membrane phosphatidylserine exposure and adhesion to pulmonary vascular endothelium.
Topics: Anemia, Sickle Cell; Animals; Antisickling Agents; Cell Adhesion; Endothelium, Vascular; Erythrocyte | 2008 |
Plasma and urine hydroxyurea levels might be useful in the management of adult sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Chromatography, High Pressure Liquid; Female; Fetal | 2007 |
Periodic erythroexchange is an effective strategy for high risk paediatric patients with sickle-cell disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Costs and Cost | 2007 |
Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells.
Topics: Anemia, Sickle Cell; Antigens, CD34; Antineoplastic Agents; Antisickling Agents; beta-Thalassemia; B | 2008 |
[The use of hydroxyurea in severe forms of sickle cell disease: study of 47 Tunisian paediatric cases].
Topics: Anemia, Sickle Cell; Child; Heterozygote; Homozygote; Hospitalization; Humans; Hydroxyurea; Length o | 2008 |
Characteristics and outcome of connective tissue diseases in patients with sickle-cell disease: report of 30 cases.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Arthritis, Rheumatoid; Blood Transfusion; Drug Ther | 2008 |
Use of hydroxyurea in prevention of stroke in children with sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Flow Velocity; Blood Transfusion; Child; Child, Pres | 2008 |
Strides made in red blood cell disorders, but substantial barriers to care remain.
Topics: Anemia, Sickle Cell; Antisickling Agents; Benzoates; Brain Diseases; Chelation Therapy; Deferasirox; | 2008 |
Resolution of chronic hypoxemia in pediatric sickle cell patients after treatment with hydroxyurea.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Chronic Disease; Female; Humans; Hydroxyurea; Hypox | 2008 |
Prevalence and risk factors for pulmonary artery systolic hypertension among sickle cell disease patients in Nigeria.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Case-Control Studies; Female; Humans; Hydroxyurea; Hypertens | 2008 |
Fetal haemoglobin response to hydroxycarbamide treatment and sar1a promoter polymorphisms in sickle cell anaemia.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Fetal Hemoglobin; Humans; Hydroxyurea; Infant, Newb | 2008 |
Modulation of erythroid adhesion receptor expression by hydroxyurea in children with sickle cell disease.
Topics: Africa South of the Sahara; Anemia, Sickle Cell; Arterial Occlusive Diseases; Basigin; CD36 Antigens | 2008 |
Increased adhesive properties of neutrophils in sickle cell disease may be reversed by pharmacological nitric oxide donation.
Topics: Adult; alpha-Thalassemia; Anemia, Sickle Cell; CD11a Antigen; CD11b Antigen; Cell Adhesion; Cyclic G | 2008 |
Experts urge wider use of hydroxyurea for sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Humans; Hydroxyurea | 2008 |
Adhesion molecules and hydroxyurea in the pathophysiology of sickle cell disease.
Topics: Anemia, Sickle Cell; Antigens, CD; Arterial Occlusive Diseases; Blood Platelets; Cell Adhesion; Cell | 2008 |
National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Biomedical Research; Child; Delivery of | 2008 |
Increasing fetal hemoglobin in sickle cell disease: comparisons of 5-azacytidine (subcutaneous or oral) with hydroxyurea.
Topics: Adult; Anemia, Sickle Cell; Azacitidine; Fetal Hemoglobin; Humans; Hydroxyurea; Middle Aged; Reticul | 1984 |
Hydroxyurea increases fetal hemoglobin production in sickle cell anemia.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Female; Fetal Hemoglobin; Humans; Hydroxyurea; Reticulocytes | 1984 |
Globin gene studies create a puzzle.
Topics: Anemia, Sickle Cell; Azacitidine; Cell Differentiation; Cytarabine; DNA; Erythropoiesis; Fetal Hemog | 1984 |
Hemoglobin--from F to A, and back.
Topics: Anemia, Sickle Cell; Azacitidine; DNA; Fetal Hemoglobin; Humans; Hydroxyurea; Methylation; Thalassem | 1984 |
Pathophysiology and management of sickle cell pain crisis. Report of a Meeting of Physicians and Scientists, University of Texas Health Science Center at Houston, Texas.
Topics: Adult; Anemia, Sickle Cell; Cell Adhesion; Chronic Disease; Endothelium, Vascular; Erythrocytes; Ery | 1995 |
A cautionary note regarding hydroxyurea in sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Blood Transfusion; Cerebral Hemorrhage; Cerebrovascular Disorders; Femal | 1994 |
Relationship of burst-forming-unit-erythroid progenitors and their DNA-synthesis stage to fetal hemoglobin levels in hydroxyurea-treated patients with sickle cell anemia.
Topics: Adolescent; Adult; Anemia, Sickle Cell; DNA; Dose-Response Relationship, Drug; Erythroid Precursor C | 1994 |
Sickle cell anemia--basic research reaches the clinic.
Topics: Adult; Anemia, Sickle Cell; Fetal Hemoglobin; Humans; Hydroxyurea; Infant, Newborn | 1995 |
Hemin-induced acceleration of hemoglobin production in immature cultured erythroid cells: preferential enhancement of fetal hemoglobin.
Topics: Anemia, Sickle Cell; beta-Thalassemia; Cell Division; Cells, Cultured; Drug Synergism; Erythroid Pre | 1995 |
The pharmacological manipulation of fetal haemoglobin: trials using hydroxyurea and recombinant human erythropoietin.
Topics: Adult; Anemia, Sickle Cell; Bilirubin; Blood Cell Count; Drug Evaluation; Drug Synergism; Erythropoi | 1995 |
Hydroxyurea: an alternative to transfusion therapy for stroke in sickle cell anemia.
Topics: Adult; Anemia, Sickle Cell; Blood Group Incompatibility; Blood Transfusion; Cerebrovascular Disorder | 1995 |
Sickle cell paths converge on hydroxyurea.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Azacitidine; Child; Fetal Hemoglobin; Hemoglobin, S | 1995 |
Frequency of sickle cell crises cut by hydroxyurea use.
Topics: Anemia, Sickle Cell; Controlled Clinical Trials as Topic; Humans; Hydroxyurea; Time Factors | 1995 |
Hydroxyurea and sickle cell crisis.
Topics: Anemia, Sickle Cell; Humans; Hydroxyurea; Leukemia; Randomized Controlled Trials as Topic | 1995 |
Hydroxyurea and sickle cell crisis.
Topics: Anemia, Sickle Cell; Humans; Hydroxyurea; Leukemia; Pain; Polycythemia Vera | 1995 |
Reversing ontogeny.
Topics: Anemia, Sickle Cell; Arginine; beta-Thalassemia; Butyrates; Fetal Hemoglobin; Globins; Humans; Hydro | 1993 |
Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; beta-Thalassemia; Drug Synergism; Drug Therapy, Combination; Erythrocyte | 1993 |
Hydroxyurea increases fetal hemoglobin in cultured erythroid cells derived from normal individuals and patients with sickle cell anemia or beta-thalassemia.
Topics: Anemia, Sickle Cell; beta-Thalassemia; Cells, Cultured; Erythroid Precursor Cells; Fetal Hemoglobin; | 1993 |
Enhanced fetal hemoglobin production by phenylacetate and 4-phenylbutyrate in erythroid precursors derived from normal donors and patients with sickle cell anemia and beta-thalassemia.
Topics: Anemia, Sickle Cell; Azacitidine; beta-Thalassemia; Blotting, Northern; Butyrates; Butyric Acid; Cel | 1993 |
Trial halted as sickle cell treatment proves itself.
Topics: Anemia, Sickle Cell; Clinical Trials as Topic; Drug Approval; Humans; Hydroxyurea; Multicenter Studi | 1995 |
US announces drug treatment for sickle cell anaemia.
Topics: Anemia, Sickle Cell; Clinical Trials as Topic; Humans; Hydroxyurea; Multicenter Studies as Topic | 1995 |
[A sickle cell homozygote with transfusion deadlock. Favorable outcome with hydroxyurea treatment].
Topics: Adult; Anemia, Sickle Cell; Blood Transfusion; Female; Homozygote; Humans; Hydroxyurea; Isoantibodie | 1993 |
Hydroxyurea in sickle cell disease.
Topics: Anemia, Sickle Cell; Fetal Hemoglobin; Humans; Hydroxyurea | 1996 |
Hydroxyurea in sickle cell disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Female; Humans; Hydroxyurea; Male; Melanosis; Middle Aged; N | 1996 |
Sickle cell pain crisis.
Topics: Anemia, Sickle Cell; Antisickling Agents; Erythropoietin; Female; Hemoglobins; Humans; Hydroxyurea; | 1996 |
Fetal hemoglobin in sickle cell anemia: relation to regulatory sequences cis to the beta-globin gene. Multicenter Study of Hydroxyurea.
Topics: Anemia, Sickle Cell; Base Sequence; DNA Primers; Fetal Hemoglobin; Gene Expression Regulation; Globi | 1996 |
Hydroxyurea therapy in children severely affected with sickle cell disease.
Topics: Adolescent; alpha-Thalassemia; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Child; Do | 1996 |
New treatments of sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Bone Marrow Transplantation; Genetic Th | 1996 |
Monoclonal antibody-based methods for quantitation of hemoglobins: application to evaluating patients with sickle cell anemia treated with hydroxyurea.
Topics: Anemia, Sickle Cell; Antibodies, Monoclonal; Enzyme-Linked Immunosorbent Assay; Fetal Hemoglobin; Fl | 1996 |
First report of reversal of organ dysfunction in sickle cell anemia by the use of hydroxyurea: splenic regeneration.
Topics: Adult; Anemia, Sickle Cell; Female; Humans; Hydroxyurea; Male; Regeneration; Spleen; Splenomegaly | 1996 |
[Study of hemoglobinopathies found in Belgium].
Topics: Anemia, Sickle Cell; Antisickling Agents; Belgium; beta-Thalassemia; Bone Marrow Transplantation; Ch | 1995 |
Clinical and hematologic effects of hydroxyurea in children with sickle cell anemia.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Female; Fetal Hemoglobin; Follow-Up Stu | 1996 |
[Pharma clinics. How I treat... Falciform anemia in children].
Topics: Adolescent; Adult; Analgesics; Anemia, Sickle Cell; Blood Transfusion; Bone Marrow Transplantation; | 1996 |
Hydroxyurea, sickle cell disease and renal transplantation.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Fetal Hemoglobin; Hematocrit; Hemoglobin, Sickle; H | 1997 |
Decrease of very late activation antigen-4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; CD36 Antigens; Cell Adhesion; Cell Adhesion Mo | 1997 |
Hydroxyurea-induced denaturation of normal and sickle cell hemoglobins in vitro.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Hemoglobin A; Hemoglobin, Sickle; Hemog | 1997 |
Valproic acid and augmentation of fetal hemoglobin in individuals with and without sickle cell disease.
Topics: Anemia, Sickle Cell; Anticonvulsants; Antisickling Agents; Blood Transfusion; Carbamazepine; Child; | 1997 |
Reticulocyte hemoglobin: an integrated parameter for evaluation of erythropoietic activity.
Topics: Administration, Oral; Anemia, Iron-Deficiency; Anemia, Sickle Cell; Antisickling Agents; Erythropoie | 1997 |
Cellular effects of hydroxyurea in Hb SC disease.
Topics: Anemia, Sickle Cell; Cations; Erythrocyte Count; Erythrocyte Indices; Erythrocytes; Fetal Hemoglobin | 1997 |
[Sickle cell anemia in children: value of hydroxyurea in severe forms].
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Drug Administration S | 1997 |
Minimal doses of hydroxyurea for sickle cell disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Humans; Hydroxyurea; Thalassemia | 1997 |
BFU-E colony growth in response to hydroxyurea: correlation between in vitro and in vivo fetal hemoglobin induction.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Cell Death; Cells, Cultured; Dose-Respo | 1997 |
Time resolved absorption study of the reaction of hydroxyurea with sickle cell hemoglobin.
Topics: Anemia, Sickle Cell; Antisickling Agents; Hemeproteins; Hemoglobin, Sickle; Humans; Hydroxyurea; In | 1998 |
Sickling of nucleated erythroid precursors from patients with sickle cell anemia.
Topics: Anemia, Sickle Cell; Bone Marrow Cells; Butyrates; Butyric Acid; Cell Hypoxia; Cell Nucleus; Cells, | 1998 |
Hydroxyurea marketed for sickle cell anemia.
Topics: Anemia, Sickle Cell; Antisickling Agents; Humans; Hydroxyurea; United States | 1998 |
Hydroxyurea therapy for sickle cell disease in Britain. Disappointing recruitment despite promising results.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Humans; Hydroxyurea; Patient Sele | 1998 |
Fetal hemoglobin and F-cell responses to long-term hydroxyurea treatment in young sickle cell patients. The French Study Group on Sickle Cell Disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Female; Fetal | 1998 |
Cytokines and soluble adhesion molecules in sickle cell anemia patients during hydroxyurea therapy.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Cell Adhesion Molecules; Cytokines; Female; Humans; | 1998 |
European register of patients with sickle cell disease treated with hydroxyurea is being set up.
Topics: Anemia, Sickle Cell; Antisickling Agents; Europe; Humans; Hydroxyurea; Registries | 1998 |
Successful hydroxyurea treatment of a patient with SD hemoglobinopathy.
Topics: Anemia, Sickle Cell; Female; Hemoglobin SC Disease; Hemoglobins, Abnormal; Humans; Hydroxyurea; Midd | 1999 |
[Results and current indications of bone marrow allograft in sickle cell disease].
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Bone Marrow Transplantation; Butyrates; | 1999 |
Comparison of radial immunodiffusion and alkaline cellulose acetate electrophoresis for quantitating elevated levels of fetal hemoglobin (HbF): application to evaluating patients with sickle cell disease treated with hydroxyurea.
Topics: Adult; Anemia, Sickle Cell; Electrophoresis, Cellulose Acetate; Fetal Hemoglobin; Hemoglobin, Sickle | 1999 |
Detection of nitrosyl hemoglobin in venous blood in the treatment of sickle cell anemia with hydroxyurea.
Topics: Adult; Anemia, Sickle Cell; Electron Spin Resonance Spectroscopy; Hemoglobins; Humans; Hydroxyurea; | 1999 |
Sickle cell patients find a brand New World.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Female; Humans | 1999 |
Preliminary report of a toxicity study of hydroxyurea in sickle cell disease. French Study Group on Sickle Cell Disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Cohort Studies | 1999 |
Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease.
Topics: Administration, Oral; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion | 1999 |
Hydroxyurea in two pregnant women with sickle cell anemia.
Topics: Adult; Anemia, Sickle Cell; Antineoplastic Agents; Female; Humans; Hydroxyurea; Pregnancy; Pregnancy | 1999 |
Predicting the effectiveness of hydroxyurea in individual sickle cell anemia patients.
Topics: Adolescent; Anemia, Sickle Cell; Erythrocyte Volume; Female; Fetal Hemoglobin; Humans; Hydroxyurea; | 2000 |
Clinical potential of in vitro measured red cell deformability, a myth?
Topics: Adult; Age Factors; Anemia, Sickle Cell; Cell Count; Child, Preschool; Cyclosporine; Elliptocytosis, | 1999 |
Pathogenesis and treatment of acute chest syndrome of sickle-cell anaemia.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Humans; Hydroxyurea; Nitric Oxid | 2000 |
Acquired DNA mutations associated with in vivo hydroxyurea exposure.
Topics: Adult; Anemia, Sickle Cell; Antineoplastic Agents; Antisickling Agents; Child; DNA; Humans; Hydroxyu | 2000 |
2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Azacitidine; Blood Cell Count; Cohort Studies; Decitabine; E | 2000 |
Azoospermia in a patient with sickle cell disease treated with hydroxyurea.
Topics: Adult; Anemia, Sickle Cell; Follow-Up Studies; Humans; Hydroxyurea; Male; Oligospermia | 2000 |
Mechanism for fetal hemoglobin induction by hydroxyurea in sickle cell erythroid progenitors.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Cell Division; Child; Erythroid Precursor Cells; Female; Fet | 2000 |
Successful treatment of hepatitis C in sickle-cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Antiviral Agents; Drug Therapy, Combination; Female | 2000 |
Acute leukemia in a patient with sickle-cell anemia treated with hydroxyurea.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Female; Humans; Hydroxyurea; Leukemia, Myeloid, Acu | 2000 |
Stroke in hemoglobin (SD) sickle cell disease with moyamoya: successful hydroxyurea treatment after cerebrovascular bypass surgery.
Topics: Anemia, Sickle Cell; Aphasia; Blood Flow Velocity; Blood Transfusion; Brain Damage, Chronic; Brain I | 2001 |
Cutaneous adverse reactions to hydroxyurea in patients with sickle cell disease.
Topics: Adult; Age Factors; Anemia, Sickle Cell; Antisickling Agents; Female; Humans; Hydroxyurea; Leg Ulcer | 2001 |
Hydroxyurea promotes the reduction of spontaneous BFU-e to normal levels in SS and S/beta thalassemic patients.
Topics: Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Blood Cell Count; Cell Differentiation; | 2001 |
Skin and nail changes in children with sickle cell anemia receiving hydroxyurea therapy.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Female; Humans; Hydroxyurea; Hyperpigme | 2001 |
Five years of experience with hydroxyurea in children and young adults with sickle cell disease.
Topics: Acute Disease; Adolescent; Adult; Anemia, Aplastic; Anemia, Sickle Cell; Antisickling Agents; Arteri | 2001 |
Resveratrol, a natural dietary phytoalexin, possesses similar properties to hydroxyurea towards erythroid differentiation.
Topics: Anemia, Sickle Cell; Antioxidants; Blotting, Western; Cell Differentiation; Cell Division; Cell Line | 2001 |
In vitro exposure to hydroxyurea reduces sickle red blood cell deformability.
Topics: Anemia, Sickle Cell; Erythrocyte Deformability; Erythrocyte Membrane; Erythrocytes, Abnormal; Fetal | 2001 |
Sickle cell disease: a chronic inflammatory condition.
Topics: Anemia, Sickle Cell; Animals; Chronic Disease; Humans; Hydroxyurea; Inflammation; Mice; Mice, Transg | 2001 |
Flow cytometric method for simultaneous assay of foetal haemoglobin containing red cells, reticulocytes and foetal haemoglobin containing reticulocytes.
Topics: Anemia, Sickle Cell; Anticoagulants; Erythrocyte Indices; Erythrocytes; Fetal Hemoglobin; Flow Cytom | 2001 |
Hodgkin's disease in a child with sickle cell disease treated with hydroxyurea.
Topics: Anemia, Sickle Cell; beta-Thalassemia; Bone Marrow Transplantation; Child; Combined Modality Therapy | 2001 |
Is hydroxyurea leukemogenic in children with sickle cell disease?
Topics: Adolescent; Anemia, Sickle Cell; Child; Humans; Hydroxyurea; Leukemia | 2001 |
Hydroxyurea in very young children with sickle cell anemia is not a cure-all.
Topics: Age Factors; Anemia, Sickle Cell; Antisickling Agents; Child, Preschool; Hematologic Diseases; Human | 2001 |
Hydroxyurea and sickle cell leg ulcers.
Topics: Anemia, Sickle Cell; Female; Humans; Hydroxyurea; Leg Ulcer; Middle Aged | 2001 |
Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Female; Glutathione; Hemoglobins; Humans; Hydroxyurea; Lumin | 2002 |
Effect of hydroxyurea on growth in children with sickle cell anemia: results of the HUG-KIDS Study.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Clinical Trials, Phas | 2002 |
Hydroxyurea corrects the dysregulated L-selectin expression and increased H(2)O(2) production of polymorphonuclear neutrophils from patients with sickle cell anemia.
Topics: Adolescent; Africa South of the Sahara; Anemia, Sickle Cell; Antisickling Agents; Black People; Cell | 2002 |
Effect of hydroxyurea therapy on resting energy expenditure in children with sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Basal Metabolism; Child; Child, Preschool; Energy Intake; | 2001 |
Increased erythropoietin level induced by hydroxyurea treatment of sickle cell patients.
Topics: Adolescent; Adult; Anemia, Sickle Cell; beta-Thalassemia; Erythroid Precursor Cells; Erythropoietin; | 2000 |
A patient on hydroxyurea for sickle cell disease who developed an opportunistic infection.
Topics: Adult; Anemia, Sickle Cell; Animals; Cryptosporidium; Female; Humans; Hydroxyurea; Opportunistic Inf | 2002 |
Hydroxyurea for the treatment of sickle cell disease.
Topics: Administration, Oral; Adolescent; Adult; Anemia, Sickle Cell; Drug Evaluation; Female; Humans; Hydro | 1992 |
Spectrum of fetal hemoglobin responses in sickle cell patients treated with hydroxyurea: the National Institutes of Health experience.
Topics: Anemia, Sickle Cell; Drug Administration Schedule; Erythropoiesis; Fetal Hemoglobin; Hemoglobin, Sic | 1992 |
Sickle cell problems continue to challenge medical science, but some progress is noted.
Topics: Anemia, Sickle Cell; Female; Fetal Hemoglobin; Hemoglobinopathies; Humans; Hydroxyurea; Sickle Cell | 1990 |
Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea.
Topics: Adult; Anemia, Sickle Cell; Blood Cell Count; Bone Marrow; Female; Fetal Hemoglobin; Hematopoiesis; | 1990 |
Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea.
Topics: Adult; Anemia, Sickle Cell; Blood Cell Count; Bone Marrow; Female; Fetal Hemoglobin; Hematopoiesis; | 1990 |
Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea.
Topics: Adult; Anemia, Sickle Cell; Blood Cell Count; Bone Marrow; Female; Fetal Hemoglobin; Hematopoiesis; | 1990 |
Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea.
Topics: Adult; Anemia, Sickle Cell; Blood Cell Count; Bone Marrow; Female; Fetal Hemoglobin; Hematopoiesis; | 1990 |
Treatment of sickle cell anemia with hydroxyurea and erythropoietin.
Topics: Administration, Oral; Anemia, Sickle Cell; Drug Administration Schedule; Drug Evaluation; Drug Thera | 1990 |
Effects of hydroxyurea on hemoglobin F and water content in the red blood cells of dogs and of patients with sickle cell anemia.
Topics: Administration, Oral; Anemia, Sickle Cell; Animals; Dogs; Erythrocyte Count; Erythrocytes; Fetal Hem | 1991 |
Regulation of fetal hemoglobin synthesis in the hemoglobinopathies.
Topics: Anemia, Sickle Cell; Animals; Cells, Cultured; Erythropoiesis; Fetal Hemoglobin; Haplorhini; Hematop | 1985 |
Pharmacologic manipulation of fetal hemoglobin synthesis.
Topics: Anemia, Sickle Cell; Azacitidine; DNA Replication; Erythropoiesis; Fetal Hemoglobin; Gene Expression | 1985 |
Stimulation of F-cell production in patients with sickle-cell anemia treated with cytarabine or hydroxyurea.
Topics: Adult; Anemia, Sickle Cell; Cytarabine; Dose-Response Relationship, Drug; Erythrocyte Count; Erythro | 1985 |
Chemotherapy to increase fetal hemoglobin in patients with sickle cell anemia.
Topics: Anemia, Sickle Cell; Azacitidine; Cytarabine; Fetal Hemoglobin; Humans; Hydroxyurea; Kinetics; Thala | 1985 |
Hydroxyurea induction of hemoglobin F production in sickle cell disease: relationship between cytotoxicity and F cell production.
Topics: Anemia, Sickle Cell; Azacitidine; Erythropoiesis; Fetal Hemoglobin; Hematopoietic Stem Cells; Humans | 1986 |
Hydroxyurea-induced augmentation of fetal hemoglobin production in patients with sickle cell anemia.
Topics: Adult; Anemia, Sickle Cell; Chromosomes; DNA Damage; Dose-Response Relationship, Drug; Female; Fetal | 1987 |
The effect of increased fetal hemoglobin production on the frequency of vaso-occlusive crisis in sickle cell disease.
Topics: Anemia, Sickle Cell; Azacitidine; Centrifugation, Density Gradient; Erythrocytes; Fetal Hemoglobin; | 1987 |
Influence of hydroxyurea on fetal hemoglobin production in vitro.
Topics: Anemia, Sickle Cell; Animals; Azacitidine; Cells, Cultured; Erythroblasts; Erythropoiesis; Fetal Hem | 1987 |
Increasing fetal hemoglobin production in sickle cell disease: results of clinical trials.
Topics: Anemia, Sickle Cell; Azacitidine; DNA; Fetal Hemoglobin; Hematopoietic Stem Cells; Humans; Hydroxyur | 1987 |
Induction of fetal hemoglobin in sickle cell patients by hydroxyurea: the N.I.H. experience.
Topics: Adult; Anemia, Sickle Cell; Drug Administration Schedule; Erythrocyte Count; Female; Fetal Hemoglobi | 1989 |
Promising drug combination for sickle cell anemia.
Topics: Anemia, Sickle Cell; Drug Therapy, Combination; Erythropoietin; Humans; Hydroxyurea | 1989 |
Effect of hydroxyurea on the rheological properties of sickle erythrocytes in vivo.
Topics: Anemia, Sickle Cell; Erythrocyte Deformability; Erythrocyte Indices; Erythrocyte Membrane; Genotype; | 1989 |